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Background: Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing
weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If
drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate
metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment.
This review appraises three of the newest class of drugs for monotherapy when metformin cannot be
used, the sodium–glucose co-transporter 2 (SGLT2) inhibitors.
Objective: To review the clinical effectiveness and cost-effectiveness of dapagliflozin (Farxiga, Bristol-Myers
Squibb, Luton, UK), canagliflozin (Invokana, Janssen, High Wycombe, UK) and empagliflozin (Jardiance,
Merck & Co., Darmstadt, Germany), in monotherapy in people who cannot take metformin.
Sources: MEDLINE (1946 to February 2015) and EMBASE (1974 to February 2015) for randomised
controlled trials lasting 24 weeks or more. For adverse events, a wider range of studies was used. Three
manufacturers provided submissions.
Methods: Systematic review and economic evaluation. A network meta-analysis was carried out involving
the three SGLT2 inhibitors and key comparators. Critical appraisal of submissions from three manufacturers.
Results: We included three trials of dapagliflozin and two each for canagliflozin and empagliflozin.
The trials were of good quality. The canagliflozin and dapagliflozin trials compared them with placebo,
but the two empagliflozin trials included active comparators. All three drugs were shown to be effective in
improving glycaemic control, promoting weight loss and lowering blood pressure (BP).
Limitations: There were no head-to-head trials of the different flozins, and no long-term data on
cardiovascular outcomes in this group of patients. Most trials were against placebo. The trials were done in
patient groups that were not always comparable, for example in baseline glycated haemoglobin or body
mass index. Data on elderly patients were lacking.
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Conclusions: Dapagliflozin, canagliflozin and empagliflozin are effective in improving glycaemic control,
with added benefits of some reductions in BP and weight. Adverse effects are urinary and genital tract
infections in a small proportion of users. In monotherapy, the three drugs do not appear cost-effective
compared with gliclazide or pioglitazone, but may be competitive against sitagliptin (Januvia, Boehringer
Ingelheim, Bracknell, UK).
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
In type 2 diabetes, it is important to get blood glucose levels back down to as near normal as possible toreduce the risk of long-term complications such as damage to eyesight and kidneys. The flozins are the
newest type of oral drugs. They work by increasing the amount of glucose lost in the urine, which leads to
calorie loss and some weight loss. However, they are much more expensive than older drugs.
Treatments for diabetes may increase or decrease a patient’s weight. One of the main uncertainties is how
large are any patient benefits from the direct impact of weight changes.
If a few kilograms gained or lost have little or no impact upon a patient’s day-to-day living, there are few if
any patient benefits from the flozins and sitagliptin over the more traditional treatments of pioglitazone
and sulfonylureas (SUs) such as gliclazide. The flozins and sitagliptin cost around £400 more each year
than the traditional treatments. So in monotherapy compared with gliclazide, pioglitazone or repaglinide,
the flozins represent poor value.
Not everyone can take the older drugs because of hypoglycaemia (with SUs) or risks of heart failure and
fracture (with pioglitazone). If patients who would receive flozins would otherwise be treated with
sitagliptin or similar drugs, the additional cost of the flozins is only around £40 more each year. This means
that fewer treatments elsewhere need to be reduced to fund the flozins, and that the flozins are good
value for patients as a whole.
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Scientific summary
The prevalence of type 2 diabetes has been increasing in the UK, and over 3.5 million people in Englandhave the disease. People with type 2 diabetes are at risk of the complications of diabetes, including
visual loss, renal failure and neuropathy, and an excess risk of cardiovascular disease (CVD).
Most people with type 2 diabetes are overweight, so treatment starts with lifestyle advice, aimed at reducing
weight and increasing physical activity. Even modest amounts of weight loss can improve glycaemic control.
If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot
tolerate metformin. It causes troublesome diarrhoea in 5–10% of people. It is not used in people with
renal impairment.
If drug treatment is required to control high blood glucose levels when metformin cannot be used, the
other options include:
l sulfonylureas (SUs)
l pioglitazone
l the dipeptidyl peptidase-4 (DPP-4) inhibitors
l repaglinide.
All are oral medications, licensed for use in monotherapy. The SUs have been used for decades and are
available in inexpensive generic forms. Gliclazide costs around £30 a year, or around £60–80 a year for the
modified-release form. Their safety record is well known. They can cause weight gain and hypoglycaemia.
Pioglitazone is also available in generic form, costing around £21 a year. It has adverse effects (AEs) of
weight gain, oedema, heart failure and fractures. There has been concern over an increased risk of bladder
cancer but recent research is reassuring.
The DPP-4 inhibitors, such as sitagliptin (Januvia, Boehringer Ingelheim, Bracknell, UK), are a more recent
group, with no generic forms, and cost around £430 a year. They are well tolerated, and do not cause
weight increase.
The newest group of drugs are the sodium–glucose co-transporter 2 (SGLT2) inhibitors. These inhibit a
mechanism in the kidney that conserves glucose by reabsorbing it from the urine. So glucose is lost in the urine,
which reduces the blood glucose level and also leads to a loss of calories, which leads to weight loss. They have
a mild diuretic effect and a modest blood pressure (BP)-lowering effect. They cost around £470 a year.
This report reviews the clinical effectiveness and cost-effectiveness of three SGLT2 inhibitors – dapagliflozin
(Farxiga, Bristol-Myers Squibb, Luton, UK), canagliflozin (Invokana, Janssen, High Wycombe, UK) and
empagliflozin (Jardiance, Merck and Co, Darmstadt, Germany) – in monotherapy in people who cannot
take metformin.
Methods
We searched MEDLINE and EMBASE for randomised controlled trials lasting 24 weeks or more. The trials
were then critically appraised and summarised. For adverse events, a wider range of studies was used.
A network meta-analysis (NMA) was carried out involving the three SGLT2 inhibitors and key comparators.
Cost-effectiveness modelling was done using the United Kingdom Prospective Diabetes Study (UKPDS)
outcome model, version 1.
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Results
Seven trials were obtained, three of dapagliflozin and two each for canagliflozin and empagliflozin. All
were of good quality. The canagliflozin and dapagliflozin trials compared them with placebo, but the two
empagliflozin trials included active comparators, one sitagliptin and one linagliptin (Trajenta, Boehringer
Ingelheim, Bracknell, UK). All three drugs were effective in improving glycaemic control, promoting weight
loss and lowering BP. The main outcome was glycaemic control as reflected in reductions in glycated
haemoglobin (HbA1c), where a reduction of 0.5% or more is regarded as clinically useful.
In the three trials of dapagliflozin 10 mg daily, HbA1c was reduced by 0.39%, 0.66% and 0.82% more
than on placebo. The trial with the smallest reduction had the lowest baseline HbA1c of 7.5%. Generally
speaking, the higher the baseline HbA1c in trials, the greater the reduction seen. Patients lost between
1.1 kg and 2 kg more than in the placebo groups, though it is worth noting that two trials were carried
out in China and Japan where starting body mass indices (BMIs) were around 26 kg/m2. The placebo
groups lost between 0.27 kg and 2.2 kg, and improved HbA1c (by 0.23%, 0.29% and 0.06%). Systolic
blood pressure (SBP) fell by 2.7 to 3.1 mmHg.
One canagliflozin trial was carried out in Japan and the other in 17 countries. On canagliflozin 100 mg
daily, HbA1c was reduced in the two trials by 0.91% and 1.01% more than on placebo, from baselines of
8.0%. One trial also used a dose of 300 mg, which reduced HbA1c by 1.17%. On 100 mg daily, weight
loss was around 2 kg, and SBP was reduced by 3.7 and 5.2 mmHg. On 300 mg daily, weight loss was
2.9 kg. In both the canagliflozin trials, the placebo group HbA1c rose (by 0.14% and 0.29%).
One trial compared empagliflozin with linagliptin in 197 centres in 22 countries. The other compared
empagliflozin with placebo and sitagliptin in 124 centres in nine countries, mainly Western countries but
including China, India and Japan. Compared with placebo, empagliflozin 10 mg reduced HbA1c by 0.74%
and empagliflozin 25 mg by 0.86%. Weight loss was about 2 kg, and SBP was reduced by 2.6 and
3.4 mmHg.
The only significant AEs reported in the seven trials were increases in urinary and genital tract infections
(GTIs), mainly in women, in about 4% to 9%.
Long-term cardiovascular outcome studies are being carried out on all three drugs, but the only one to
report is the empagliflozin outcomes trial. All-cause mortality at a median of 3 years was 8.3% in the
placebo group and 5.7% in the pooled empagliflozin group. This was mainly due to differences in
cardiovascular deaths – 5.9% and 3.7%. The difference in cardiovascular mortality was mainly due to
sudden death (1.6% and 1.1%), heart failure (0.8% and 0.2%) and an ill-defined category of ‘other
cardiovascular deaths’ (2.4% and 1.6%). However, nearly all patients were on combination diabetes
therapy. Half were on insulin-containing regimens. They are not comparable with patients being
considered for monotherapy. They were selected as being at very high risk of CVD.
Network meta-analysis
We included the three SGLT2 inhibitors, pioglitazone, gliclazide, sitagliptin, vildagliptin (Galvus, Novartis
Frimley, UK) and linagliptin in a NMA using placebo as a common comparator as far as possible.
Compared with placebo, reductions in HbA1c were:
l canagliflozin 300 mg: 1.19%
l canagliflozin 100 mg: 0.95%
l empagliflozin 25 mg: 0.88%
l empagliflozin 10 mg: 0.76%
l dapagliflozin 10 mg: 0.59%.
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A caveat is necessary regarding the effects of the larger doses of canagliflozin and empagliflozin, which is
that, according to the licences, the larger doses should only be used in people who have tolerated the
starting doses but have had an insufficient response. Those who do not respond well to the starting dose
might not achieve the same effects as did people in the trials randomised to the larger dose from the start.
In considering the smaller effect size with dapagliflozin 10 mg, the improvements in the placebo groups in
the dapagliflozin trials should be noted, in contrast to the canagliflozin trials where HbA1c rose in the
placebo groups.
The reductions in HbA1c with pioglitazone, gliclazide and sitagliptin were 1.13%, 0.95% and 0.76%,
respectively.
Another caveat is that some trials recruit patients with quite high HbA1c levels, and the reductions seen in
HbA1c may be much larger than would be seen in patients managed according to National Institute for
Health and Care Excellence (NICE) guidelines with frequent monitoring and prompt intensification once
their HbA1c exceeded 7.5%.
Cost-effectiveness: manufacturer modelling
Janssen, AstraZeneca and Boehringer Ingelheim submitted cost-effectiveness modelling exercises.
All the company submissions applied an annual cost of £608 for canagliflozin 300 mg, being submitted
before the price reduction in August 2015 to the same £477 annual price for canagliflozin 100 mg. So the
summary of cost-effectiveness results of the companies concentrates upon the canagliflozin 100 mg results.
Janssen used the Economic and Health Outcomes Model for Type 2 Diabetes Mellitus (ECHO-T2DM)
model. AstraZeneca, Boehringer Ingelheim and the Assessment Group (AG) used models based upon
either the UKPDS68 or upon a combination of the UKPDS68 and the UKPDS82.
The Janssen model assumed that after an initial treatment effect HbA1c would increase at a constant rate.
This rate was treatment specific. The annual rate of increase in HbA1c associated with a treatment could be
as important as the initial treatment effect upon HbA1c.
Janssen estimated that pioglitazone has the lowest total lifetime costs of £20,264 and yields an average 9.998
quality-adjusted life-years (QALYs). Gliclazide was estimated to be somewhat more expensive than pioglitazone,
with total costs of £20,956 and to yield 9.949 QALYs, so is dominated by pioglitazone. Sitagliptin was also
more expensive, with a total cost of £23,442 and to yield a total of 9.981 per QALY, so was dominated by
pioglitazone, though has a cost-effectiveness estimate compared with gliclazide of £6969 per QALY.
Janssen estimated that canagliflozin 100 mg has total costs of £23,525 and yields 10.039 QALYs, which
implies a cost-effectiveness estimate of £79,537 per QALY compared with pioglitazone. The cost-
effectiveness estimate compared with gliclazide was £3377 per QALY, this being largely due to the higher
costs in the gliclazide arm (using the modified-release form) compared with pioglitazone. Canagliflozin
100 mg was estimated to dominate empagliflozin 10 mg, empagliflozin 25 mg and dapagliflozin 10 mg.
The Janssen cost-effectiveness estimates for the flozins compared with sitagliptin were £1414 per QALY for
canagliflozin 100 mg, £1977 per QALY for empagliflozin 25 mg, £4724 per QALY for empagliflozin 10 mg
and £6040 per QALY for sitagliptin.
The AstraZeneca submission used the Cardiff Diabetes Model (CDM), which has been revised to use
the equations of UKPDS68 to evolve the risk factors and the equations of UKPDS82 to calculate the
probabilities of events and death.
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AstraZeneca pooled the flozins into a class effect. Given this, pioglitazone was estimated to be the least
costly with total costs of £26,067 and to yield 13.111 QALYs. The SUs were estimated to have a total cost
of £26,582, so £515 higher than pioglitazone, and to yield 13.179 QALYs, so have a cost-effectiveness
estimate of £7574 per QALY compared with pioglitazone. The gliptins were estimated to have a total
cost of £27,873 and to yield 13.188 QALYs or only 0.009 QALYs more than the SUs, hence have a
cost-effectiveness compared with the SUs of £143,000 per QALY. The flozins were only £106 more
expensive than the gliptins and yielded an additional 0.018 QALYs, so had a cost-effectiveness compared
with the gliptins of £5904 per QALY. But the flozins cost-effectiveness compared with the SUs was poor at
£52,047 per QALY.
AstraZeneca sensitivity analyses showed that results were sensitive to the HbA1c intensification threshold
and the assumptions around the evolution of weight.
The Boehringer Ingelheim submission built a visual basic front and back end to the UKPDS Outcomes
Model v1 (OM1) model. The OM1 model uses the UKPDS68 equations for the evolution of the risk factors
and the calculation of the probability of events.
Some Boehringer Ingelheim figures were classed as confidential, so are not reported in this monograph.
The Boehringer Ingelheim modelling estimated that pioglitazone was the least expensive treatment.
Only repaglinide was close to being cost-effective compared with pioglitazone, with a cost-effectiveness
estimate of £25,349 per QALY. Boehringer Ingelheim included costs (£52.64) of self-monitoring of blood
glucose (SMBG) for both repaglinide and pioglitazone, whereas it would be unnecessary with pioglitazone.
Empagliflozin 25 mg and empagliflozin 10 mg were estimated to be more expensive than pioglitazone but
to yield additional QALYs, giving cost-effectiveness estimates of £46,480 per QALY and £50,892 per
QALY compared with pioglitazone. The cost-effectiveness estimates for empagliflozin 25 mg and 10 mg
compared with sitagliptin were somewhat better, resulting in cost-effectiveness estimates of around £7333
per QALY and £8325 per QALY, respectively.
Cost-effectiveness: assessment group modelling
The AG modelling suggests that gliclazide is the least expensive, with total costs of £27,314. Repaglinide
and pioglitazone have similar total costs of £27,413 and £27,543, respectively. The increased costs for
pioglitazone are due in part to the AG including annual brain natriuretic peptide monitoring, which is not
standard practice. Costs increase quite markedly with sitagliptin at a total cost of £32,358, and increase
further with the flozins being clustered between £32,676 and £32,866. Sitagliptin is estimated to be
£5045 more expensive than gliclazide, and the flozins between £5362 and £5553 more expensive
than gliclazide.
If there are no direct quality-of-life (QoL) impacts from weight changes, gliclazide is estimated to yield
10.392 QALYs. This is the highest total QALYs for this BMI scenario and, as a consequence, gliclazide
dominates all the other treatments.
Including direct QoL impacts from weight changes, and assuming that the weight changes associated with
the monotherapies persist indefinitely, results in repaglinide now being superior to gliclazide by 0.030
QALYs and so having a cost-effectiveness estimate of £3331 per QALY. Repaglinide formally dominates
pioglitazone and sitagliptin, but canagliflozin yields an additional 0.177 QALYs at an additional cost of
£5262, so has a cost-effectiveness estimate of £44,994 per QALY compared with repaglinide. If weight
losses associated with treatment tend to rebound at either 1 year or at treatment intensification, the
cost-effectiveness estimate for canagliflozin compared with repaglinide worsens to £192,000 per QALY
and £119,000 per QALY, respectively.
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Over a lifetime, canagliflozin is estimated to be around £100 less expensive than empagliflozin and £200
less expensive than dapagliflozin. With no direct QoL effects from weight changes, it is estimated to be
marginally more effective by 0.002 QALYs than empagliflozin and more effective by 0.013 QALYs than
dapagliflozin. Including the effects of weight upon QoL increases these net gains to 0.034 QALYs and
0.046 QALYs if weight changes persist indefinitely. If they rebound after 1 year then these gains fall to
0.007 QALYs and 0.019 QALYs, whereas if they rebound at treatment change they fall to 0.014 QALYs
and 0.026 QALYs.
These very small differences in QALY gains lead to incremental cost-effectiveness ratio (ICERs) that can
vary widely.
Both canagliflozin and empagliflozin have reasonable cost-effectiveness estimates compared with
sitagliptin of £12,623 per QALY and £18,341 per QALY, even if there are no QoL impacts from weight
changes. Including these effects improves their cost-effectiveness estimates compared with sitagliptin.
Dapagliflozin fares slightly worse compared with sitagliptin. It costs an additional £508, but yields only an
additional 0.013 QALYs if there are no direct QoL impacts from weight changes, so has a cost-effectiveness
estimate of £40,383 per QALY compared with sitagliptin. This improves to £6632 per QALY if weight
changes have a QoL impact and are assumed to persist indefinitely.
The base case applied the baseline HbA1c of 8.4% values for those starting monotherapy from the NICE
clinical guideline. This differs from some of the companies’ modelling, which assumed a common baseline
HbA1c of 7.5%. As would be expected, this both improved patient outcomes and lowered total costs. It did
not alter the patterns of dominance.
Of more interest was that the cost-effectiveness estimates of the flozins compared with sitagliptin worsened.
With no direct QoL impacts from weight, these worsened to £24,939 per QALY for canagliflozin, £30,150 per
QALY for empagliflozin and £54,863 per QALY for dapagliflozin. If the monotherapy BMI effects persist for
the patient lifetime then these cost-effectiveness estimates improve to £3717 per QALY, £6042 per QALY and
£7442 per QALY, respectively. Weight loss rebound after 1 year reduces the improvements to £14,961 per
QALY, £21,643 per QALY and £38,256 per QALY.
Making the HbA1c treatment effect a function of patients’ baseline HbA1c had little practical impact upon
the cost-effectiveness estimates for the flozins compared with gliclazide, repaglinide and pioglitazone.
But it improved the cost-effectiveness estimates for canagliflozin compared with sitagliptin by around
one-third. The impact for empagliflozin is less, and there was little impact for dapagliflozin. This is as
would be expected given the greater HbA1c effect for canagliflozin compared with sitagliptin, the slightly
greater effect for empagliflozin and broad equivalence between dapagliflozin and sitagliptin.
Janssen applied linear evolutions of HbA1c with the annual rate of change being treatment specific, and
slower on pioglitazone. Applying the same annual rates of change within the AG modelling reduced total
costs and increased total QALYs quite considerably. It also caused pioglitazone to be estimated as the
cheapest treatment, with it dominating gliclazide.
The linear HbA1c evolutions still saw the flozins dominated unless there were direct QoL impacts from
weight changes.
Assuming that adding gliclazide at the first intensification causes only a 0.47% reduction in HbA1c (based
on starting it at HbA1c of just over 7.5%) compared with the 1.01% reduction of the base case has little
to no impact for gliclazide and repaglinide, as patients will not use this intensification. But it increases
costs and reduces QALYs in the other arms, so worsening the cost-effectiveness estimates for the flozins.
The cost-effectiveness estimates for the flozins compared with sitagliptin are not particularly affected,
though those for dapagliflozin do worsen slightly.
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Overall, the flozins are not cost-effective compared with gliclazide, pioglitazone and repaglinide, but can
compete with sitagliptin.
The average costs per QALY will apply to the ‘average patient’ and there will be instances when patients
may be more susceptible to AEs. For example, the risks of fracture with pioglitazone will be greater in
women with reduced bone density. In some people, especially the elderly, the risks of hypoglycaemia with
SUs may be deemed unacceptable. In others, SU or repaglinide use may require SMBG for driving.
Research needs
The main research need is for long-term data on cardiovascular outcomes for canagliflozin and
dapagliflozin. Large studies are under way.
Research is also needed in elderly patients, and in those who develop type 2 diabetes at younger ages.
Conclusions
Dapagliflozin, canagliflozin and empagliflozin are effective in reducing hyperglycaemia and improving
glycaemic control, with added benefits of some reductions in BP and weight. The only common AEs are
increases in urinary and GTIs, but in a small proportion of users. In monotherapy, the three drugs do not
appear cost-effective compared with gliclazide, pioglitazone or repaglinide, but may be competitive
against sitagliptin.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
The York and Humber Public Health Observatory (YHPHO) estimates that, in 2015, around 3.5 millionpeople in England had type 2 diabetes, with a prevalence of about 8%.1 The prevalence has been
increasing, partly due to demographic change, partly due to better detection, but mainly due to increased
prevalence of overweight and obesity. Diabetes is costly to the UK NHS, with a recent study estimating
that 10% of all NHS expenditure is on diabetes.2
The report, Prescribing for Diabetes, from the Health and Social Care Information Centre estimated that in
2013–14, 9.5% of prescribing costs were for diabetes, including drugs and blood glucose testing strips.3
There are two characteristics of type 2 diabetes: insulin resistance and a loss of insulin-producing capacity
in the pancreas. Insulin resistance is the initial state, which the pancreas initially copes with by increased
production of insulin from its beta cells. Over time, pancreatic insulin production falls. It is generally accepted
that by the time type 2 diabetes is diagnosed, the pancreas has lost half of its insulin-producing capacity.
Type 2 diabetes is regarded as a progressive disease. The United Kingdom Prospective Diabetes Study
(UKPDS) trial showed a deterioration in glycated haemoglobin (HbA1c) of about 0.2% a year.4 The
UKPDS495 paper reported that, by 3 years, only 50% could maintain HbA1c under 7% on monotherapy
and that this proportion fell to 25% after 9 years.
However, some people with early type 2 diabetes, who manage to lose weight and increase physical
activity, may then have enough beta cell capacity to remain well controlled on diet alone or on diet plus
monotherapy. They are probably a small minority, though a study in Trent region in 2003 found that 31% of
people with type 2 diabetes were being managed on diet alone with over 80% achieving HbA1c of 7.5% or
under.6 Most patients do not lose sufficient weight and so their diabetes is expected to progress over time.
They will require additional drug therapies, with about one-third progressing to requiring insulin injections to
try to control blood glucose levels. Progression may be slow. In a population-based study in Denmark, 79%
of people with type 2 diabetes who started metformin were still on metformin monotherapy 3 years later.7
National Institute for Health and Care Excellence clinical guideline 2015
The updated National Institute for Health and Care Excellence (NICE) clinical guideline (CG) for type 2
diabetes (CG28)8 was issued in December 2015. The recommendations include:
l Start drug treatment with metformin in patients who are overweight or obese, and whose control is
inadequate with lifestyle measures (diet and physical activity) alone.
l If metformin is contraindicated or not tolerated, consider monotherapy with one of a dipeptidyl
peptidase-4 (DPP-4) inhibitor, pioglitazone or a sulfonylurea (SU).
l Do not use pioglitazone in patients who have heart failure, hepatic impairment, a history of bladder
cancer or haematuria.
l When glycaemic control becomes unsatisfactory on metformin, consider dual therapy by adding a SU,
pioglitazone or a DPP-4 inhibitor.
l In patients who cannot take metformin, and if monotherapy does not control HbA1c, consider dual
therapy with two of a DPP-4 inhibitor, pioglitazone or a SU.
l Consider a DPP-4 inhibitor or pioglitazone in triple therapy with metformin and a SU when dual
therapy was insufficient to achieve adequate control.
l Addition of another drug, referred to as intensification of treatment, was recommended when HbA1c
was 7.5% or over (though with a recommendation that targets be adjusted for individual circumstances).
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The guideline dealt only briefly with the sodium–glucose co-transporter 2 (SGLT2) inhibitors, mentioning
that they may be appropriate for some people and referring readers to the guidances on canagliflozin
(Invokana, Janssen, High Wycombe, UK), dapagliflozin (Farxiga, Bristol-Myers Squibb, Luton, UK) and
empagliflozin (Jardiance, Merck and Co, Darmstadt, Germany) in combination therapy.
We prefer to use the terms ‘dual therapy’ and ‘triple therapy’ to ‘second-line’ and ‘third-line’ because
these last terms could cover substitution as well as addition.
Drugs for type 2 diabetes
We now have nine classes of glucose-lowering drugs for type 2 diabetes, though some contain only a
single drug. Those that are used in monotherapy are:
l Metformin.
l SUs: usually second- or third-generation drugs – gliclazide, glimepiride and glipizide.
l Pioglitazone.
l Acarbose.
l Meglitinides: nateglinide and repaglinide, though only the latter is licensed for monotherapy.
These drugs act in the same way as the SUs, promoting release of insulin.
l The DPP-4 inhibitors, also known as the ‘gliptins’, not currently recommended by NICE8 for
monotherapy (because of cost). There are now five available: sitagliptin, vildagliptin (Galvus, Novartis
Frimley, UK), saxagliptin (Onglyza, Bristol-Myers Squibb, Luton, UK), alogliptin (Vipidia, Takeda
Pharmaceutical Company, High Wycombe, UK) and linagliptin (Trajenta, Boehringer Ingelheim,
Bracknell, UK).
l The SGLT2 receptor inhibitors. In the UK, dapagliflozin, empagliflozin and canagliflozin have been
approved by NICE9–11 in combination therapy.
There are two classes that are injectable treatments. Neither is commonly used in monotherapy. Because
of both cost and the need to be injected, they appear later in the treatment pathway:
l The glucagon-like peptide-1 (GLP-1) analogues exenatide (Bydureon, AstraZeneca, Luton, UK),
albiglutide (Eperzan, GlaxoSmithKline, Brentford UK) and dulaglutide (Trulicity, Eli Lilly, Basingstoke, UK)
given once weekly, and liraglutide (Victoza, Novo Nordisk, Crawley, UK) and lixisenatide (Lixilan, Sanofi,
Guildford, UK) given once daily. There is also a form of exenatide given twice daily. Exenatide,
liraglutide and lixisenatide were covered in the update of the NICE guideline on type 2 diabetes,8 but
dulaglutide and albiglutide were not. Both dulaglutide and albiglutide are licensed in Europe for use in
monotherapy, when metformin cannot be used, as well as for combination therapy.12,13
l Insulins In type 2 diabetes, insulin treatment starts with once-daily basal insulin [NICE recommends
neutral protamine Hagedorn (NPH) insulin as first choice8], but if intensification is needed, short-acting
insulins may be added at mealtimes, or twice-daily biphasic insulin may be used.
There are now combinations of GLP-1 analogues with basal insulins, such as insulin degludec combined
with liraglutide, and insulin glargine and lixisenatide.
There are quite marked differences in costs of GLP-1 analogues, ranging from daily lixisenatide at around
£690 to weekly dulaglutide at almost £1200. Patients may prefer to inject once a week. There may be
differences in adverse effects (AEs). Longer-acting drugs increase heart rate more than shorter-acting ones,
though the importance of this is, as yet, uncertain.14
Despite the number of classes, there is still a need for drugs that that will lower glucose without causing
hypoglycaemia or weight gain, and that can improve cardiovascular outcomes. The SUs, repaglinide and
insulin cause varying degrees of weight gain, which may worsen insulin resistance. They can cause
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hypoglycaemia. The gliptins do not cause weight gain or hypoglycaemia, but have not been shown to
improve cardiovascular outcomes.
The 2015 NICE guideline first draft recommended that patients who cannot take or tolerate metformin should
take repaglinide, a meglitinide analogue (NICE Internal Clinical Guidelines Team. Type 2 Diabetes in Adults.
URL: www.nice.org.uk/guidance/NG28/documents/type-2-diabetes-guideline2). The meglitinide analogues are
insulin secretagogues, shorter acting than the SUs.15 They have not been widely used in the UK.
Pioglitazone is recognised as causing weight gain and oedema, with a risk of heart failure and fractures,
but does not cause hypoglycaemia. Metformin does not cause either weight gain or hypoglycaemia.
Box 1 shows the flow chart from the NICE guideline.16
The rational for including repaglinide was twofold:
l a network meta-analysis (NMA) showed that repaglinide reduced HbA1c more than SUs, by 0.19%,
and was non-significantly safer than SUs in terms of hypoglycaemia. However, the NICE modelling
included a mixture of SUs, including tolbutamide, glibenclamide, glipizide, glimepiride and gliclazide.
The largest number of trials comparing repaglinide with SUs featured glibenclamide. Gliclazide has
been reported to cause less hypoglycaemia than other SUs, so a direct comparison of repaglinide with
gliclazide might not have given the same results. Gliclazide is the SU that is preferred by clinicians in
the UK.
l costing that assumed self-monitoring of blood glucose (SMBG) was required because of risk of
hypoglycaemia on SUs and pioglitazone, but not for repaglinide, which is odd, given that repaglinide
causes hypoglycaemia and pioglitazone does not. If this assumption is reversed, pioglitazone becomes
the choice if metformin cannot be taken, though only just.
One drawback to using repaglinide in monotherapy in people who cannot take metformin is that it is
licensed only in dual therapy with metformin. So if repaglinide monotherapy was insufficient, dual therapy
would mean starting two new drugs.
Sulfonylureas
The SUs are insulin secretagogues, which means that they work largely by stimulating insulin release by
the beta cells in the pancreas. Once the beta cell capacity falls, the SUs become less effective. There is
some evidence that the duration of effectiveness is longer with gliclazide than glibenclamide.17
The main AEs of the SUs are weight gain and hypoglycaemia. A population-based study from Tayside
found an incidence of severe hypoglycaemia amongst people on SUs of 0.9 per 100 patient-years.18
This rate is similar to the 0.8% seen in the meta-analysis by Schopman et al.19 Monami et al.,20 in a
good-quality meta-analysis of 69 trials involving SUs, reported a cumulative incidence of at least one
episode of severe hypoglycaemia of 1.2%, but this was based on 24 trials because the others did not
report any severe hypoglycaemia. There was some evidence that hypoglycaemia was less common with
gliclazide than with other SUs.20 Schopman et al.19 reported that 0.1% of patients on gliclazide had severe
hypoglycaemia and that 1.4% had plasma glucose (PG) under 3.1 mmol/l at some point in trials that
ranged in duration from 24 to 104 weeks. Schernthaner et al.21 from the 27-week GUIDE (GlUcose control
in type 2 diabetes: Diamicron MR vs. glimEpiride trial), using modified-release (MR) gliclazide, reported that
3.7% of patients had at least one PG of < 3 mmol/l, but that none needed assistance. Compared with the
glimepiride arm, there were about 50% fewer hypoglycaemic episodes, despite a reduction in HbA1c of
1.2% on gliclazide and 1.0% on glimepiride.
The Schopman meta-analysis19 reported that, overall, 0.8% of patients on SUs had a severe hypoglycaemic
episode, but the proportions ranged from 0.1% for gliclazide to 2.1% for glipizide. In the ORIGIN trial,
75% of patients on standard treatment (25% of whom were on SUs) never had any hypoglycaemia.22
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In the very large (11,140 patients) ADVANCE (Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation) trial, gliclazide MR was used in two arms, intensive
and standard. In the intensive arm, the aim was to achieve HbA1c of 6.5% or less.23 This was achieved in
65% in the intensive arm and 29% in the standard arm. Severe hypoglycaemia event rates were 0.07 per
1000 patient-years in the intensive arm and 0.04 per 1000 patient-years in the standard arm. Minor
hypoglycaemic events occurred at rates of 12 and 9 per 1000 patient-years in intensive and standard
arms, respectively.
These rates of hypoglycaemia on SUs are much lower than the 7% reported for severe hypoglycaemia by
the UK Hypoglycaemia Study Group,24 but the patients in that study were recruited only from secondary
care clinics.
In the Netherlands, the guideline for the management of type 2 diabetes advises that gliclazide is the SU
of choice, partly because of its safety in renal failure.25,26 A meta-analysis of SU trials concluded that severe
hypoglycaemia was rare with gliclazide, especially if the dose does not exceed 240 mg daily. Non-severe
hypoglycaemia was seen mainly in those on 320 mg daily.25
Simpson et al.27 argued that as different SUs had different tissue selectivity and risk of hypoglycaemia, the
cardiovascular risk might also vary. They carried out a systematic review and NMA, and used glibenclamide
as the reference risk. Compared with people taking glibenclamide, those on gliclazide had a relative risk
for total mortality of 0.65 [95% credible interval (CrI) 0.53 to 0.79]. For cardiovascular mortality, the risk
ratio (RR) for gliclazide was 0.60 (95% CrI 0.45 to 0.84), whereas other SUs showed no significant
difference from glibenclamide.
Schramm et al.28 used Danish record linkage data to compare the mortality and cardiovascular risks
amongst patients on monotherapy with SUs and repaglinide, with those on metformin. The risks were
higher on most SUs, but not for gliclazide or repaglinide.
The risk of severe hypoglycaemia with SUs may have been overestimated, but it remains a problem that
can lead to hospital admission, as well causing anxiety and interrupting usual activities.
The Scottish Intercollegiate Guidelines Network (SIGN) recommends that SUs should be considered as first
line in patients who cannot take metformin.29 The 2015 American Diabetes Association (ADA) position
statement expresses no preference amongst SUs, pioglitazone, flozins and gliptins in people who cannot
take metformin.30
If SUs were the same price as the newer drugs such as the gliptins or the flozins, they would probably be
superceded. But they are very cheap, and have been used for so long that all their AEs are known.
In this report, based on the evidence reported above, we use gliclazide as the SU of choice. There are two
forms of gliclazide, standard and MR. The Diamicron Study Group reported these to be clinically equivalent
in a 10-month study in 800 patients.31 The MR form was given once a day, and 30–120 mg was equivalent
to 80–320 mg of the standard form taken twice daily. No severe hypoglycaemia occurred. Mild or
moderate hypoglycaemia was seen in 5% of those on the MR form. Once-daily administration may help
adherence, but the MR form costs more – £62 a year at 60 mg a day, £89 at 90 mg. The standard form
costs about £28 a year.
Pioglitazone
Pioglitazone, the only glitazone used in the UK, can cause oedema, which can precipitate congestive heart
failure (CHF) and fractures. CHF is a common cause of admission to hospital, and the second commonest
first presentation of cardiovascular disease (CVD) (after peripheral arterial disease).32 A fivefold risk of
macular oedema (MO) has also been reported.33
There is an increased risk of fractures amongst people taking pioglitazone. The fractures were originally
reported as being atypical fractures of long bones,34 but Scottish data also show an increase in hip fractures.35
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More recently there has been concern over bladder cancer. Pioglitazone use has now been discontinued
in France.
However, the evidence is inconsistent. A Canadian study using UK data36 reported an increased risk of
1.83 (95% confidence interval (CI) 1.10 to 3.05). A French study37 reported a doubling of a very small risk
of bladder cancer. The large Kaiser Permanente study from the USA reported an increase in risk with
pioglitazone with RR of 1.18 but this was not statistically significant.38 The PrOactive (PROspective
pioglitAzone Clinical Trial In macroVascular Events) trial reported a RR of 2.83 (p = 0.04) but once cases of
bladder cancer diagnosed in the first year were excluded there was no difference.39 It was argued that
cancers diagnosed within a year of starting the drug must have been there before. However, Gale has
argued that pioglitazone could be acting as a growth promoter in latent tumours.40
A very large study by Levin et al.,41 mainly in the UK, Finland and British Columbia (one million people with
type 2 diabetes, almost 6 million person-years of observation), found no increased risk of bladder cancer,
providing further reassurance.
It should be noted that diabetes itself has been reported in a very large meta-analysis to increase the risk
of bladder cancer with RR 1.35 (95% CI 1.17 to 1.56), though this applied only to those within 5 years of
diagnosis.42 Amongst those with duration of over 5 years, the RR was 1.08.
The European Medicines Agency (EMA) issued a statement in 2011 saying that there was a small increased
risk of bladder cancer, but that, on balance, pioglitazone could still be used as a second- and third-line
treatment.43 The Medicines & Healthcare products Regulatory Agency (MHRA) concurred.44
Patients should be screened for haematuria before starting pioglitazone and then at least annually
afterwards.
There are some cardiovascular benefits from pioglitazone (the reverse of what was seen with rosiglitazone)
with a reported reduced risk of myocardial infarction (MI), but there is clearly an increased risk of heart
failure,34,39 and regular monitoring with B-type natriuretic peptide (BNP) seems advisable for the safest use
of this drug.45 Patients are advised of possible side effects and advised to stop if oedema or shortness of
breath develops. If there are concerns regarding heart failure, echocardiography is often carried out, to
check that left ventricular function is satisfactory, before starting pioglitazone.
Despite its side effects, including progressive weight gain by as much as 5 kg, pioglitazone can be a
valuable diabetes therapy, as it is an insulin sensitiser and allows reduction in insulin resistance, still known
to be a major factor in the pathogenesis of type 2 diabetes and glucose intolerance. Early studies using
genetic profiling showed that the Pro12Ala of the peroxisome proliferator-activated receptor gamma
(PPARG) gene showed a population attributable risk of approximately 50% and, taken together with
clinical risk factors, might define those most at risk of renal sodium retention and oedema. Unfortunately,
probably because of the fact that the PPARG agonists also show greater metabolic efficacy in those with
the Pro12Ala variant, this approach has not been developed in clinical practice, as those who would
benefit most would have to be excluded.46
Many people with type 2 diabetes are considerably overweight and may develop non-alcoholic fatty liver
disease (NAFLD). Pioglitazone has been reported to improve NAFLD,47 so if attempts at weight loss are
unsuccessful and the NAFLD is progressing, pioglitazone may need to be considered for this group of
patients. NAFLD is a spectrum of disease ranging from an increased fat content in the liver (steatosis) to
inflammation (non-alcoholic steatohepatitis) and possibly on to cirrhosis. NAFLD is strongly associated with
insulin resistance.
Despite its AEs, pioglitazone is still widely used, though its use may be declining, with new initiations
falling in recent years. The Health and Social Care Information Centre Report gives figures for items
prescribed in 2013–143 (Table 1).
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The strongest argument for using pioglitazone is the very low cost, but the costs of AEs need to
be considered.
Dipeptidyl peptidase-4 inhibitors
The first two of these to reach the market, sitagliptin and vildagliptin, were appraised for NICE CG87, and
recommended for use in combination therapy.8 There are now five DPP-4 inhibitors with slightly different
licensed indications. Others are coming, including two that are taken only once a week, trelagliptin and
omarigliptin, both now licensed in Japan.
The CG87 guidance8 is reproduced in Box 2.
Repaglinide
Repaglinide acts on the same receptor in the pancreas as the SUs (and another receptor) but is shorter-acting
and was therefore thought to be particularly useful in controlling hyperglycaemia after meals. Like the SUs,
its AEs include significant weight gain and hypoglycaemia.
The relevant recommendation in CG878 was ‘to consider offering a rapid-acting insulin secretagogue to a
person with an erratic lifestyle’. This presumably related to unpredictability of mealtimes, when there
would be a case for using a shorter-acting meglitinide analogue instead of a SU.
The cost of repaglinide treatment will depend on dosages used. It was designed to be taken to reduce
postprandial hyperglycaemia, which means it should be taken at mealtimes. The NICE guideline costing16
assumes a total daily dose of 4 mg. If that comprised 2 × 2-mg tablets twice a day, the annual cost would
be about £48. However, that assumes that people take it at only two meals. If a third 2-mg dose was
added, the annual cost would be £72. But if the third dose was only 1 mg (say to cover a small breakfast
or lunch), the annual cost would be £92, because the 1-mg tablets are almost double the price of the
2-mg ones. The variability in doses used in the repaglinide studies makes comparison with the SUs difficult.
Sodium–glucose co-transporter 2 inhibitors
The SGLT2 inhibitors, hereafter referred to as the flozins, have a unique mechanism of action. In the
non-diabetic state glucose is allowed through the filter in the renal glomeruli but is fully reabsorbed in the
renal tubules through sodium–glucose co-transporter mechanisms. Glycosuria (glucose in the urine) occurs
when the renal threshold for glucose (blood glucose of approximately 10 mmol/l) is exceeded. The main
transport mechanism responsible for glucose reabsorption, SGLT2, is found in the proximal kidney tubule.
This is encoded by the gene for the solute carrier family 5 (sodium–glucose co-transporter), member 2
(SLC5A2). Some people have a mutation in the SLC5A2 gene that causes a defective SGLT2 protein,
resulting in glycosuria. Individuals who have this mutation do not have significant problems related to the
glycosuria, such as urinary tract infections (UTIs), and they have a normal life expectancy with no increase
TABLE 1 Prescriptions 2013–14
Drug No. of prescriptions
Metformin 18,100,000
SUs 8,400,000
Sitagliptin 2,020,100
Pioglitazone 1,408,600
Linagliptin 329,400
Vildagliptin 173,200
Repaglinide 83,800
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in cardiovascular mortality or urogenital cancers.48 This implies that blocking the transport mechanism
should not cause problems.
The flozins block the SGLT2 system and so mimic the effect of the SLC5A2 mutation and reduce the
reabsorption of renal filtered glucose back into the bloodstream, thereby lowering blood glucose levels.
Owing to their insulin-independent mode of action, they do this without weight gain or hypoglycaemia.49
For uncertain reasons, the SGLT2 inhibitors do not block all glucose reabsorption. Around 160–180 mg of
glucose is filtered into the urine each day, and the SGLT2 system reabsorbs 80–90% of that. The amount
blocked appears to vary amongst the different drugs, with dapagliflozin 10 mg blocking only about a third
of reabsorption.50,51 Even very large doses of dapagliflozin (such as 100 mg) do not block all glucose
reabsorption in people with type 2 diabetes.52 But none of the SGLT2 inhibitors block reabsorption of over
half of the filtered glucose load.
There is also a sodium–glucose co-transporter 1 (SGLT1) transport mechanism, which is present both in the
kidney and the gut. In the kidney, it is much less important than SGLT2. Inhibition of gut SGLT1 reduces
BOX 2 Clinical guideline 87 guidance8
1.6.1 DPP-4 inhibitors (sitagliptin, vildagliptin)
1.6.1.1 Consider adding a DPP-4 inhibitor (sitagliptin, vildagliptin) instead of a sulfonylurea as second-line
therapy to first-line metformin when control of blood glucose remains or becomes inadequate (HbA1c ≥ 6.5%,
or other higher level agreed with the individual) if:
l the person is at significant risk of hypoglycaemia or its consequences (for example, older people and people
in certain jobs [for example, those working at heights or with heavy machinery] or people in certain social
circumstances [for example, those living alone]), or
l the person does not tolerate a sulfonylurea or a sulfonylurea is contraindicated.
1.6.1.2 Consider adding a DPP-4 inhibitor (sitagliptin, vildagliptin) as second-line therapy to first-line
sulfonylurea monotherapy when control of blood glucose remains or becomes inadequate (HbA1c ≥ 6.5%, or
other higher level agreed with the individual) if:
l the person does not tolerate metformin, or metformin is contraindicated.
1.6.1.3 Consider adding sitagliptin5 as third-line therapy to first-line metformin and a second-line sulfonylurea
when control of blood glucose remains or becomes inadequate (HbA1c ≥ 7.5% or other higher level agreed
with the individual) and insulin is unacceptable or inappropriate.6
1.6.1.4 Only continue DPP-4 inhibitor therapy (sitagliptin, vildagliptin) if the person has had a beneficial
metabolic response (a reduction of at least 0.5 percentage points in HbA1c in 6 months).
A DPP-4 inhibitor (sitagliptin, vildagliptin) may be preferable to pioglitazone if:
l further weight gain would cause or exacerbate significant problems associated with a high body weight, or
l pioglitazone is contraindicated, or
l the person has previously had a poor response to, or did not tolerate, a TZD.
TZD, thiazolidinedione.
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absorption of glucose there, and it has been suggested that canagliflozin may have a dual action. This was
reported first in healthy volunteers53 but has since been reported in a study of people with type 2 diabetes.54
Because these drugs act through an insulin-independent mechanism, they can be effective when other
drugs that depend entirely (sulfonylureas and meglitinides) or in part (gliptins and GLP-1 analogues) on
stimulating insulin release have lost effectiveness. In type 2 diabetes, the capacity of the pancreatic beta
cells to produce insulin often falls over time.
In addition to improving glycaemic control, the SGLT2 inhibitors also reduce blood pressure (BP). In a
meta-analysis of 27 randomised controlled trials (RCTs) with 12,960 patients, Baker et al.55 reported a
mean reduction in systolic blood pressure (SBP) of 4 mmHg.
Marketing authorisations
The indications for the three flozins are similar – for adults with type 2 diabetes, when diet and physical
activity do not provide good control (or adherence is poor) and metformin cannot be tolerated or
is contraindicated.
The NICE recommendations differ slightly for the three flozins as shown in Box 3.
Renal impairment
The dapagliflozin, canagliflozin and empagliflozin guidances differ also in use in moderate renal impairment.
The guidance on dapagliflozin says that it should not be used in patients with glomerular filtration rates
(GFRs) of below 60 ml/minute, whereas the guidances on canagliflozin and empagliflozin say that if started
before renal function declined to an estimated glomerular filtration rate (eGFR) of 60 ml/minute, it may be
continued until eGFR falls below 45 ml/minute.
Age
Dapagliflozin is not recommended in people aged over 75 years but there is no such restriction for
canagliflozin or empagliflozin. However, empagliflozin is not recommended for people over 85 years due
to lack of data in this group.
Pioglitazone
Dapagliflozin is not licensed for use in combination with pioglitazone. Both canagliflozin and
empagliflozin are.
Dosages
There are two doses of canagliflozin and empagliflozin. Canagliflozin comes as 100 mg and 300 mg. The
licence states that the 300-mg dose may be used in those who tolerate the 100-mg dose – so ruling out
canagliflozin 300 mg as a starting dose. Similarly, with empagliflozin, the 25-mg dose is licensed for those
who can tolerate the 10 mg starting dose. A 5 mg starting dose of dapagliflozin is recommended for
patients with severe hepatic impairment.
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Newer SGLT2 inhibitors include luseogliflozin (Taisho Pharmaceutical, Tokyo, Japan, and Novartis),
ipragliflozin (Suglat®, Astella Pharma, Chertsey, UK), tofogliflozin (Sanofi, Guildford, UK; Takeda
Pharmaceutical Company, High Wycombe, UK) and remogliflozin (GlaxoSmithKline, Research Triangle Park,
NC, USA) but these are not included in the NICE scope. Some are still in pre-licensing trials.
Therapeutic pathway
Where should SGLT2 inhibitors fit into the therapeutic pathway? Factors to be considered include:
l Effect on glycaemic control as reflected in HbA1c reductions.
l Effect on weight, compared with other drugs, some of which cause marked weight gain.
BOX 3 The NICE recommendations for SGLT2 inhibitors
Dapagliflozin has been approved by NICE as follows9
l In a dual therapy regimen in combination with metformin, only if it is used as described for DPP-4 inhibitors
in Type 2 diabetes: The Management of Type 2 Diabetes (NICE CG87).
l Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an
option for treating type 2 diabetes.
Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea is not
recommended for treating type 2 diabetes, except as part of a clinical trial. This was because at the time of the
dapagliflozin appraisal, there was insufficient evidence on its use in triple therapy.
Canagliflozin has been approved by NICE, as follows10
l In a dual therapy regimen in combination with metformin is recommended as an option for treating type 2
diabetes, only if a sulfonylurea is contraindicated or not tolerated or the person is at significant risk of
hypoglycaemia or its consequences.
l Canagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in
combination with metformin and either a sulfonylurea or pioglitazone.
l Canagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an
option for treating type 2 diabetes.
Empagliflozin has been approved by NICE as follows11
1.1 Empagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for
treating type 2 diabetes, only if:
l A sulphonylurea is contraindicated or not tolerated.
l The person is at significant risk of hypoglycaemia or its consequences.
1.2 Empagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in
combination with:
l metformin and a sulphonylurea.
l metformin and pioglitazone.
1.3 Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an
option for treating type 2 diabetes.
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l Effect on cardiovascular risk, including on BP and lipid levels, and ideally as reflected in longer-term
cardiovascular outcomes.
l AEs, particularly increased genital and urinary infections.
l Duration of diabetes. In long-standing type 2 diabetes, the efficacy of the flozins will not be affected by
a fall in endogenous insulin production.
l Interactions with other drugs, especially in patients on treatment for comorbidities.
l Ease of use, by oral administration rather than injection.
l Cost.
Figure 1 shows the annual costs of the drugs for type 2 diabetes (drug costs only).
Decision problem
The objective of the appraisal as stated by NICE57 is:
To appraise the clinical and cost-effectiveness of canagliflozin, dapagliflozin and empagliflozin
monotherapy within their licensed indications for treating type 2 diabetes.
In PICO (Population, Intervention, Comparator, Outcomes) terms:
l The population is people with type 2 diabetes, not currently on glucose-lowering drugs, but requiring a
glucose-lowering agent, but who cannot take metformin.
l The interventions are the SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin.
l The comparators listed in the NICE scope are repaglinide, sulfonylureas, pioglitazone and the DPP-4
inhibitors, hereafter referred to as the gliptins.
l The outcomes would ideally be the rates of complications of diabetes, but most trials of new diabetes
drugs are short term, and rely on modelling changes in HbA1c, BP, weight and lipids to predict
longer-term outcomes.
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Repaglinide 2 mg b.i.d.
Alogliptin 25 mg
Saxagliptin 5 mg
Vildagliptin 50 mg b.i.d.
Linagliptin 5 mg
Sitagliptin 100 mg
Canagliflozin 100 mg
Canagliflozin 300 mg
Dapagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 25 mg
FIGURE 1 Costs of different pharmacological interventions for diabetes. Source: Drug Tariff;56 MS/ERG report on
canagliflozin. b.i.d., twice daily; MS, manufacturer submission. ERG, Evidence Review Group.
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As noted above, the NICE guideline CG878 recommends starting with diet and lifestyle, adding metformin
if lifestyle change is insufficient. However, 5–15% of people with type 2 diabetes cannot take metformin,
either because they cannot tolerate it, or because of contraindications to use. The intolerance is usually
because of gastrointestinal (GI) side effects such as diarrhoea, especially with higher doses. Faecal
incontinence can occur. Bailey and Turner58 reported that 5% of people could not tolerate any dose of
metformin, and Garber et al.59 also reported that 5% had to stop. Of those who could take it, over half
could manage the maximum dose (2250 mg/day). De Fronzo and Goodman60 reported that with gradual
dose escalation, 85% could take 2250 mg per day. The AEs are reduced by using slow-release metformin:
diarrhoea from 18% to 8%; any GI AEs from 26% to 12%.61 So the slow-release form should be tried
before abandoning metformin. Scarpello et al.62,63 reported that use of bile acid sequestrants could
improve tolerance to metformin, but many patients find these drugs unpalatable.
The main contraindication to metformin use is chronic renal impairment, and NICE recommends that
metformin should not be used once eGFR falls below 30 ml/minute, and used with caution if eGFR is in the
range of < 45 to > 30 ml/minute.
The guidance on contraindications may be overcautious, and are largely with lactic acidosis in mind.
Emslie-Smith et al.,64 using population-based data in Tayside, found 621 episodes of contraindications,
but in only 10% of patients was metformin stopped. Overall, 25% of people on metformin had
contraindications but AEs were rare. The fear of lactic acidosis with metformin use may be a carry-over
from problems with phenformin, the other biguanide, which increases lactate levels – metformin does
not.60 Phenformin was withdrawn from use in the UK many years ago because of the lactic acidosis risk.
The Cochrane review of metformin and lactic acidosis concluded that there was no increase in lactic
acidosis with metformin.65
For those who cannot tolerate metformin or in whom it is contraindicated, the usual next drug has been
a SU such as gliclazide. CG878 recommended that a sulfonylurea may be considered as first-line
monotherapy if the person is not overweight, or if
l metformin is not tolerated or is contraindicated, or
l a rapid therapeutic response is required because of hyperglycaemic symptoms.
It also listed acarbose as being considered if a person is unable to use other oral glucose-lowering agents.
Issues
The patients involved will be those who cannot take metformin. One issue is that trials of flozins and other
drugs as monotherapy have not been restricted to patients who have not been able to tolerate metformin.
A literature search found few studies comparing people who got diarrhoea on metformin with those who
did not. A study from Japan66 identified several factors that increased the incidence of diarrhoea (often
transient, in the first few days): female gender, initial dose of 750 mg, age under 65 years, and BMI of
over 25 kg/m2.
Given the lack of data, it is necessary to assume that the effectiveness of other drugs, and the effect on
long-term complications, is no different in those who get GI AEs with metformin than from those who can
tolerate it. However, some renal function restrictions also apply to other drugs such as the flozins.
Some previous appraisals of diabetes drugs have often found very little differences in lifetime quality-adjusted
life-year (QALY) gains and sometimes in lifetime costs. For example, table 38 of the Evidence Review Group
(ERG) report on empagliflozin in combination therapy noted a difference in lifetime cost of £40 and in QALYs
of 0.030 – which means 11 days. Another QALY difference noted was 0.003 – 1.1 days. There are two
problems with such differences. Firstly, they result in very unstable incremental cost-effectiveness ratios
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(ICERs). Secondly, and more importantly, such differences are effectively meaningless over a lifetime. It would
be useful if NICE could decide what the smallest meaningful difference in QALYs is. A QALY difference of
0.1 would equate to 36 days. If we are modelling over an average 20 years of expected life (most modelling
is done over a 40-year time span), those 36 days represent 0.5% of the lifespan. Any difference of 0.1 or
fewer QALYs could be regarded as no difference. Perhaps 0.1 QALY is too small and 0.2 or 0.3 would be
better, over a mean expected lifespan of 20 years. The meaningful difference should be expressed as a
proportion of expected life expectancy.
Similarly, small cost differences should be discarded, especially as many costs will change over the
modelling timescale, including drug prices. Current methods assume that drug prices remain constant for
the duration.
Targets
The NICE type 2 diabetes guideline update suggests that a HbA1c of 7.5% should be the switching
point for intensification (as in CG878) aiming at a target of 7.0% (see section 1.3.4). In section 1.5,
Recommendation 38, the target of 6.5% is suggested for most adults managed on the combination of
diet and a single drug not associated with hypoglycaemia. However, the draft notes the need for
individualised setting of targets.
These individual targets may take the following factors into account:67
l The duration of diabetes. Patients who have not developed complications such as retinopathy after
20 years’ duration are unlikely to do so, and have less to gain from tight control.
l Age and life expectancy, and hence time to develop complications. Intensification may be unnecessary
and possibly harmful in people over 75 years of age with no symptoms of diabetes.
l The risk of severe hypoglycaemia.
l Comorbidities.
l Patient preferences.
Glycaemic targets are based mainly on reducing the risk of microvascular disease. With a greater number
of younger people being diagnosed with type 2 diabetes, glycaemic control becomes increasingly
important to reduce the potential microvascular disease burden. There is less evidence that tight control
using existing treatments reduces macrovascular disease or overall mortality,68 though this may be because
trials are not long enough. In the UKPDS, there was no difference in macrovascular outcomes at study
end69 but with the longer-term follow-up, a significant difference emerged70 despite a considerable
narrowing of the difference in glycaemic control. However, neither the ACCORD (Action to Control
Cardiovascular Risk in Diabetes ) trial71 nor the ADVANCE trial72 showed that intensive control (HbA1c 6.4%
and 6.3%, respectively) reduced cardiovascular outcomes compared with standard therapy (HbA1c 7.5%
and 7.0%). A meta-analysis by Boussageon et al.73 showed no reduction in all-cause mortality or
cardiovascular death in trials of intensive versus standard regimens.
Targets also need to take account of potential benefits and harms. Vijan et al.74 used data from the UKPDS
to model probable benefits of improving glycaemic control at different ages and by different means
(metformin, insulin), taking into account the burden of treatment. For older people the benefits of
intensifying treatment could be outweighed by even minor AEs and other inconvenience. A reduction of
1% in HbA1c in a 45-year-old might gain 0.8 QALYs (10 months) but the same reduction in someone aged
75 years might gain 0.06 QALYs (22 days). If that was achieved using insulin, the AEs on quality of life
(QoL) from insulin treatment could mean that the net effect was a QALY loss.
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Chapter 2 Clinical effectiveness
Methods
Inclusion criteria
Types of studies
We included RCTs with a minimum duration of 24 weeks. Observational studies were included to assess
safety data. Some of these were open-label extensions of the trials, but we obtained other studies in two
ways. First, we checked the Food and Drug Administration (FDA) and EMA websites for alerts of possible
AEs. Second (and more productively), we had auto-alerts running throughout the review, which picked up
concerns about diabetic ketoacidosis (DKA) and fractures.
Types of participants
We included trials in people with type 2 diabetes on diet and exercise therapy only or in people on
monotherapy with a glucose-lowering agent after a washout period. The target group was patients with
type 2 diabetes, unable to take metformin, but this distinction was not made in the trials.
A search was carried out for studies comparing people who can and cannot tolerate metformin, looking
for any differences in factors that might affect the modelling, such as weight, BP and cholesterol. Nothing
significant was found.
Types of interventions
Only trials of monotherapy were included.
To be included, trials had to investigate canagliflozin (100 mg or 300 mg), dapagliflozin (10 mg) or
empagliflozin (10 mg or 25 mg). Eligible comparators were repaglinide, gliclazide as representative of the
sulfonylureas, pioglitazone, DPP-4 inhibitors (the gliptins) or placebo.
The three flozins were also compared with each other. As there were no head-to-head trials of the flozins,
data from a NMA were required.
Types of outcomes
Studies were eligible if they investigated at least one of the following outcomes:
l mortality
l complications of diabetes, including cardiovascular, renal and eye
l HbA1c /glycaemic control
l body mass index (BMI)
l frequency and severity of hypoglycaemia
l changes in cardiovascular risk factors
l AEs of treatment, including UTIs, genital infections and malignancies
l health-related QoL.
Search strategy
Searches were run in Ovid MEDLINE, EMBASE and Web of Science from the inception of the databases
until February 2015. Thereafter, weekly auto-alerts were run in PubMed in process and EMBASE until
September 2015 to check for newly emerging studies. The searches were not restricted by language or
publication type. The full search strategy is shown in Appendix 1.
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Selection of studies
Two reviewers independently checked titles and abstracts of the search results against the inclusion
criteria. Studies were retrieved in full if they appeared to fulfil the inclusion criteria or when eligibility could
not be determined from the search results alone.
Assessment of study quality
The quality of the RCTs was assessed using the Cochrane risk of bias tool, which included the following
items (rated as adequate, unclear, not reported or inadequate):
l method of randomisation
l allocation concealment
l blinding of participants and personnel
l blinding of outcome assessment
l incomplete outcome data (> 20% dropout regarded as inadequate)
l intention-to-treat (ITT) analysis
l selective reporting
l similarity at baseline
l other (e.g. power analysis).
Overall quality was expressed in terms of proportion of items rated as ‘adequate’.
Quality was assessed by one reviewer and checked by a second reviewer.
Data extraction
Data were extracted using a predesigned data extraction table, with one reviewer extracting and another
reviewer checking the data.
Results were expressed as means and standard deviations (SDs). Standard errors (SEs) and CIs were
converted to SDs using the equations provided in the Cochrane handbook.75 Results for lipids were
expressed as millimoles per litre (mmol/l). Cholesterol values expressed in milligrams per decilitre (mg/dl)
were converted to mmol/l by dividing by 38.67 and lipid values expressed in milligrams per decilitre were
converted to millimoles per litre by dividing by 88.57.
Data summary
Data were summarised using text and tables.
The following subgroup analyses were considered:
l BMI < 25, 25–29, 30 kg/m2 and over
l baseline HbA1c.
Results
Search results
Seven studies76–84 were included in the final analysis. We will usually refer to them by first author and year.
They were:
Canagliflozin:
l CANTATA-M (CANagliflozin Treatment and Trial Analysis – Monotherapy) 201384
l Inagaki 2014.76
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Dapagliflozin:
l Ferrannini 2010 (with Bailey et al. 2015)77,78
l Ji 201479
l Kaku 2014.80
Empagliflozin:
l Lewin 201581
l Roden 2013–14.82,83
A list of excluded studies, and reasons for exclusion, is in Appendix 2.
Characteristics of included studies
A summary of study characteristics is shown in Table 2.
Details can be found in Appendix 3.
TABLE 2 Summary study characteristics
Study Intervention n Age (years)
Diabetes duration
(years) HbA1c (%) BMI (kg/m2)
Canagliflozin
CANTATA-M
(Stenlöf 2013)84
Canagliflozin
100 mg/day
195 55.1, SD 10.8 4.5, SD 4.4 8.1, SD 1.0 31.3, SD 6.6
Quality 5/9 criteria
adequate
Canagliflozin
300 mg/day
197 55.3, SD 10.2 4.3, SD 4.7 8.0, SD 1.0 31.7, SD 6.0
Placebo 192 55.7, SD 10.9 4.2, SD 4.1 8.0, SD 1.0 31.8, SD 6.2
100 mg/day HbA1c
> 10%
47 49.7, SD 11.1 4.6, SD 4.6 10.6, SD 0.9 30.4, SD 7.1
300 mg/day HbA1c
> 10%
44 48.8, SD 10.8 5.2, SD 4.8 10.6, SD 0.6 30.5, SD 5.5
Inagaki 201476 Canagliflozin
100 mg/day
90 58.4, SD 10.4 4.7, SD 4.6 8.0, SD 0.7 25.6, SD 4.2
Quality 8/9 criteria
adequate
Placebo 93 58.2, SD 11.0 5.6, SD 5.8 8.0, SD 0.7 25.9, SD 4.4
Dapagliflozin
Ferrannini 2010/
Bailey 201577,78
Dapagliflozin
10 mg/day a.m.
70 50.6, SD 10.0 0.45 (0.1–3.4)
(median, IQR)
8.0, SD 0.9 33.6, SD 5.4
Quality 8/9
adequate
Dapagliflozin
10 mg/day p.m.
76 50.7, SD 9.7 0.40 (0.1–2.45) 8.0, SD 1.1 33.3, SD 5.6
Placebo 75 52.7, SD 10.3 0.5 (0.1–3.4) 7.8, SD 0.9 32.3, SD 5.5
Dapagliflozin
10 mg/day HbA1c
> 10%
39 47.9, SD 12.1 1.4 (0.2–3.5) 10.7, SD 0.9 31.1, SD 5.9
Ji 201479 Dapagliflozin
10 mg/day
133 51.2, SD 9.9 1.7, SD 2.8 8.3, SD 1.0 25.8, SD 3.4
Quality 9/9
adequate
Placebo 132 49.9, SD 10.9 1.3, SD 2.0 8.4, SD 1.0 25.9, SD 3.6
continued
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TABLE 2 Summary study characteristics (continued )
Study Intervention n Age (years)
Diabetes duration
(years) HbA1c (%) BMI (kg/m2)
Kaku 201480 Dapagliflozin
10 mg/day
88 57.5, SD 9.3 4.9, SD 4.5 7.5, SD 0.6 26.1, SD 4.5
Quality 6/9
adequate
Placebo 87 60.4, SD 9.7 5.3, SD 6.2 7.5, SD 0.6 25.2, SD 4.4
Empagliflozin
Lewin 201581 Empagliflozin
10 mg/day
132 53.9, SD 10.5 32.6% ≤ 1 year 8.1, SD 1.0 31.5, SD 5.7
45.5% > 1–5 years
11.4% > 5–10 years
10.6% > 10 years
Quality 6/9
adequate
Empagliflozin
25 mg/day
133 56.0, SD 9.3 36.1% ≤ 1 year 8.0, SD 1.0 31.2, SD 5.7
36.1% > 1–5 years
18.8% > 5–10 years
9.0% > 10 years
Linagliptin
5 mg/day
133 53.8, SD 11.5 37.6% ≤ 1 year 8.1, SD 0.9 31.9, SD 5.9
42.9% > 1–5 years
16.5% > 5–10 years
3.0% > 10 years
Roden
2013/1482,83
Empagliflozin
10 mg/day
224 56.2, SD 11.6 39% ≤ 1 year 7.9, SD 0.9 28.3, SD 5.5
41% 1–5 years
13% 5–10 years
7% > 10 years
Quality 9/9
adequate
Empagliflozin
25 mg/day
224 53.8, SD 11.6 41% ≤ 1 year 7.9, SD 0.9 28.2, SD 5.5
37% 1–5 years
17% 5–10 years
6% > 10 years
Sitagliptin
100 mg/day
223 55.1, SD 9.9 42% ≤ 1 year 7.9, SD 0.8 28.2, SD 5.2
39% 1–5 years
14% 5–10 years
5% > 10 years
Placebo 228 54.9, SD 10.9 32% ≤ 1 year 7.9, SD 0.8 28.7, SD 6.2
46% 1–5 years
15% 5–10 years
8% > 10 years
Empagliflozin
25 mg/day HbA1c
> 10%
87 50.2, SD 11.3 52% ≤ 1 year 11.5, SD 1.4 28.2, SD 5.5
25% 1–5 years
14% 5–10 years
8% > 10 years
IQR, interquartile range.
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Study design
The studies were all double-blind multicentre trials and only the two empagliflozin trials had active
comparators (Roden 2013/1482,83 and Lewin 201581). Four studies were carried out in centres around the
world (CANTATA-M 2013,84 Ferrannini 2010,77 Lewin 2015,81 Roden 2013/1482,83), while three (Inagaki
2014,76 Ji 2014,79 Kaku 201480) were in Asian populations. Primary end points were generally reported at
24 or 26 weeks, but four trials had extensions, following participants up to 52 weeks (CANTATA-M
2013,84 Lewin 201581) or 76–78 weeks (Ferrannini 2010,77 Roden 2013/1482,83). However, the CANTATA-M
study (2013)84 did not report results for the placebo group for the extension period, so results were not
considered here. All studies were sponsored by industry.
Participants
The studies included between 183 and 986 participants, with 70–228 participants in the main comparison
groups. Three studies77,82,84 included small exploratory groups of patients (n = 39–87) with HbA1c > 10%;
however, these were not randomised groups (it being unethical not to treat such high levels) and no
relevant comparison group existed. Between 34.1% and 58.7% of participants in the main comparison
groups were women and mean age was between 50 and 60 years. In most studies, the entry HbA1c of
patients was restricted to between 7% and 10% or 10.5%. Most participants had duration of diabetes of
less than 5 years. Mean baseline HbA1c was between 7.5% and 8.4% in the main comparison groups and
between 10.6% and 11.5% in the high HbA1c groups. BMI was between 25 and 34 kg/m2. Four studies had
ethnically mixed populations (CANTATA-M 2013,84 Ferrannini 2010,77 Lewin 2015,81 Roden 2013/14),82,83
while three studies included only Asian participants (Japanese in the Inagaki and Kaku studies,76,80 mainly
Chinese in Ji 201479).
Interventions
Two studies76,84 examined canagliflozin. The CANTATA-M (2013) study84 compared 100 or 300 mg/day
with placebo. After the main intervention period of 26 weeks, placebo was replaced with 100 mg/day of
sitagliptin (double blind) for another 26 weeks. Inagaki 201476 compared 100 mg/day of canagliflozin with
placebo. They also included a 200-mg/day group, but this is not considered here because it is not a
marketed dose.
Three studies77,79,80 examined dapagliflozin. Ferrannini 201077 compared 10 mg/day of dapagliflozin given
in the morning with the same amount given in the evening and with placebo. The trial also included
groups receiving 2.5 or 5 mg/day of dapagliflozin, but these were not included in the current analysis as
they are not recommended doses. After the main intervention period of 24 weeks, participants in the
placebo group were switched to low-dose metformin (500 mg/day, double blind). Both Ji 201479 and
Kaku80 compared 10 mg/day of dapagliflozin given in the morning with placebo. Both also included a
5-mg/day group which is not considered here.
Two trials studied empagliflozin. Lewin 201581 compared 10 or 25 mg/day of empagliflozin with 5 mg/day
of linagliptin. The trial also included groups receiving a fixed combination of empagliflozin and linagliptin
(10 or 25 mg/day of empagliflozin and 5 mg/day of linagliptin), but these were not considered here. Roden
2013/1482,83 compared 10 or 25 mg/day of empagliflozin with 100 mg/day of sitagliptin and with placebo.
Some studies included run-in periods for washout of previous medication (if required) and to establish a
diet/exercise regime.
Rescue therapy was provided as outlined in the detailed data tables (see Appendix 3).
Outcomes
The primary outcome in all trials was change in HbA1c from baseline to the end of the main intervention
period. Most studies also reported on body weight, blood lipids and BP, as well as on safety parameters
including hypoglycaemia. Outcomes with respect to complications of diabetes were not reported, and
neither was health-related QoL.
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Three trials defined hypoglycaemia as PG levels of ≤ 3.9 mmol/l with or without symptoms (CANTATA-M
2013,84 Lewin 2015,81 Roden 2013/147983). Inagaki 201476 distinguished between symptomatic (typical
hypoglycaemic symptoms irrespective of blood glucose levels) and asymptomatic (blood glucose
≤ 3.9 mmol/l without symptoms) hypoglycaemia. In Ji 201479 and Ferrannini 2010,77 hypoglycaemia was
defined as PG levels of ≤ 3.5 mmol/l. Only three trials defined major hypoglycaemia (CANTATA-M 2013,84
Ferrannini 2014,77 Ji 201479). All three trials defined major hypoglycaemia as requiring external assistance
and two specified associated blood glucose levels of < 3.0 mmol/l (Ferrannini 2014;77 Ji 201479). Kaku et al.
201480 did not define hypoglycaemia.
Note that the 3.9-mmol/l cut-off is above the lower end of the normal range for PG (3.5 mmol/l). It is the
threshold for action to avoid hypoglycaemia in people on drugs that may cause it.
Quality of included studies
Details of study quality can be found in Appendix 4.
Two studies fulfilled all the quality criteria (Ji 2014,79 Roden 2013/1482,83), two fulfilled eight of the nine
quality criteria (Inagaki 201476 and Ferrannini 201077), one only fulfilled six of nine criteria (Kaku 201480)
and two only fulfilled five (CANTATA-M 2013,84 Lewin 201581).
Two studies80,84 did not report on the method of randomisation and three studies80,81,84 did not report on
allocation concealment. All studies were double blind, but in three studies80,81,84 it was not clearly reported
whether or not outcome assessors were also blinded to study treatment. Rates of discontinuation were
reported by all studies and were between 7% and 20%. In most studies, rates of discontinuation were
lower than 20% and balanced between groups. In Inagaki 2014,76 only 7% discontinued in the
canagliflozin group, whereas 20% discontinued in the placebo group. Only one study77 did not clearly
carry out an ITT analysis, and studies gave no evidence of selective reporting, except that in two studies81,84
some results were shown only in graphs and numeric values were not provided. Baseline characteristics
were similar for the main comparison groups in all studies, and all studies reported on a power analysis.
Outcomes
A summary of results is shown in Table 3.
Glycated haemoglobin
Canagliflozin
Canagliflozin at 100 mg/day reduced HbA1c by between 0.74% (Inagaki76) and 0.77% (CANTATA-M84)
from baseline, which amounted to between 0.91 and 1.03% more than with placebo (p < 0.001 for both).
Between 31.5% and 44.6% reached HbA1c < 7%. With 300 mg/day, HbA1c was reduced by 1.03%, which
was 1.17% more than with placebo (p < 0.001). In this group, 62.4% reached HbA1c < 7%. In both
studies,76,84 reductions in HbA1c were significantly greater in participants with higher HbA1c values.
Dapagliflozin
Dapagliflozin at 10 mg/day reduced HbA1c by between 0.45% (Kaku80) and 1.11% (Ji:79 p < 0.0001) from
baseline, which amounted to between 0.39 and 0.82% more than with placebo. Between 48.8% and
51.4% of participants reached HbA1c < 7% compared with between 20.5% and 32.0% in the placebo
group. There was no significant difference in HbA1c results depending on whether dapagliflozin was given
in the morning or in the evening (Ferrannini 201077). Reductions in HbA1c were greater in the exploratory
group with HbA1c > 10% (Ferrannini 201077), as well as in higher HbA1c subgroups of the main study
cohorts (Ferrannini 2010,77 Ji 2014,79 Kaku 201480). In Ji 2014, results were similar for the exclusively
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Chinese cohort. In Ferrannini 2010,77 at 102 weeks, HbA1c reductions were still significantly greater with
10 mg/day dapagliflozin than with low-dose metformin (–0.61% compared with baseline and –0.44%
compared with placebo).
Empagliflozin
Empagliflozin at 10 mg/day reduced HbA1c by between 0.66 (Roden,82
,83 the monotherapy trial) and 0.83%
(Lewin,81 the fixed dose trial) from baseline, which amounted to 0.16% more than with linagliptin, no
difference to sitagliptin, and 0.58% more than with placebo. Empagliflozin at 25 mg/day reduced HbA1c by
between 0.78 (Roden82,83) and 0.95% (Lewin81) from baseline, which amounted to between 0.28% more
than with linagliptin, 0.12% more than with sitagliptin and 0.86% more than with placebo (p < 0.0001
for comparisons with placebo). Between 35.3% and 38.8% of participants reached HbA1c < 7% with
10 mg/day of empagliflozin, 41.5% to 43.6% with 25 mg/day of empagliflozin, 37.5% with sitaglipitin,
32.3% with linagliptin and 12.0% with placebo. Reductions in HbA1c were greater in the exploratory
group with HbA1c > 10% (Roden 2013/1482,83), as well as in higher HbA1c subgroups of the main study
cohorts (Roden 2013/14,82,83 Lewin 201581). In Lewin 2015,81 at 52 weeks, HbA1c was reduced by 1.01%
from baseline, which amounted to 0.5% more than with placebo.
Weight
Canagliflozin
Canagliflozin at 100 mg/day reduced weight by between 2.5 and 2.6 kg from baseline, which amounted
to between 1.9 and 2.1 kg more than with placebo (p < 0.001 for both). With 300 mg/day, weight was
reduced by 3.4 kg, which was 2.9 kg more than with placebo.
Dapagliflozin
Dapagliflozin at 10 mg/day reduced weight by between 2.2 and 3.2 kg from baseline, which amounted to
between 0.9 and 2.0 kg more than with placebo. In the study by Ji et al. 2014,79 results were similar for
the exclusively Chinese cohort. In Ferrannini 2010,77 at 102 weeks, weight reductions were still significantly
greater with 10 mg/day dapagliflozin than with low-dose metformin (–3.9 kg compared with baseline and
–2.6 kg compared with placebo).
Empagliflozin
Empagliflozin at 10 or 25 mg/day reduced weight by between 2.2 and 2.5 kg from baseline, which
amounted to 1.4–1.5 kg more than with linagliptin, 2.5–2.7 kg more than with sitagliptin, and 2.0 and
2.2 kg more than with placebo. In Lewin 2015,81 weight was reduced by 2.3 and 2.4 kg with 10 and
25 mg/day of empagliflozin after 52 weeks, which was 2.0 and 2.1 kg more than with linagliptin.
The weight loss on the SGLT2 inhibitors is less than might be expected from the glucose loss in the urine.
Rajeev et al.85 have reviewed possible explanations, such as a compensatory increase in food intake, but
the mechanism is uncertain. Ferrannini et al.86 reported that patients in an empagliflozin trial lost only 38%
of the weight loss predicted from the calories lost via glycosuria, and suggested that this was due to an
increase in food intake.
Lipids
Canagliflozin
Canagliflozin at 100 mg/day increased low-density lipoprotein cholesterol (LDL-C) levels by between 0 and
0.15 mmol/l from baseline, which amounted to between 0.07 and 0.16 mmol/l more than with placebo.
The corresponding high-density lipoprotein cholesterol (HDL-C) levels showed increases of between 0.07
and 0.11 mmol/l from baseline and 0.07–0.1 mmol/l of difference from placebo (p < 0.01). With 300 mg/
day, LDL-C was increased by 0.12 mmol/l, which was 0.19 mmol/l more than with placebo, and HDL-C was
increased by 0.11 mmol/l, which was 0.07 mmol/l different from placebo. The two studies76,84 did not
report total cholesterol (TC) levels.
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Dapagliflozin
Ferrannini 201077 did not report on lipid levels. In the other studies, TC changed by 0.01–0.06 mmol/l from
baseline in the 10-mg/day dapagliflozin groups, the difference from placebo was between –0.01 and
0.1 mmol/l. LDL-C changed by between 0.19 and –0.03 mmol/l from baseline (difference to placebo
between 2.2 and –0.15 mmol/l). HDL-C changed by between 0.16 and 0.3 mmol/l from baseline
(difference to placebo between 0.19 and 0.09 mmol/l).
Empagliflozin
Total cholesterol changed by 0.07–0.2 mmol/l from baseline in the 10- or 25-mg/day empagliflozin groups,
the difference from control was between 0.02 and 0.3 mmol/l. LDL-C changed by between 0.06 and
0.11 mmol/l from baseline (difference to control 0.02 mmol/l). HDL-C changed by between 0.10 and
0.13 mmol/l from baseline (difference to control between 0.07 and 0.1 mmol/l).
Systolic blood pressure
Canagliflozin
Canagliflozin at 100 mg/day reduced SBP by between 3.3 and 7.9 mmHg from baseline, which amounted
to between 3.7 and 5.2 mmHg more than with placebo (p < 0.001). With 300 mg/day, SBP was reduced
by 5.0 mmHg, which was 5.4 mmHg more than with placebo.
Dapagliflozin
Dapagliflozin at 10 mg/day reduced SBP by between 2.3 and 3.6 mmHg from baseline, which amounted to
between 1.4 and 3.1 mmHg more than with placebo. In Ji 2014,79 results were similar for the exclusively
Chinese cohort. In Ferrannini 2010,77 at 102 weeks, SBP was increased by 3.9 mmHg from baseline, which
was 1.8 mmHg more than with placebo/low-dose metformin.
Empagliflozin
In Roden 2013,83 empagliflozin at 10 or 25 mg/day reduced SBP by between 2.9 and 3.7 mmHg from
baseline, which amounted to between 2.6 and 3.3 mmHg more than in the placebo group. In patients
with previously uncontrolled hypertension, the reductions were greater at 3.9 and 5.0 mmHg.
Hypoglycaemia
The definition of hypoglycaemia varied amongst trials, with most using 4.0 mmol/l as the threshold, which
seems a little high, when the lower limit of normal is 3.5 mmol/l.87 The threshold of 4.0 mmol/l is used as
an indicator of the need for corrective action, and is also relevant for driving. The three dapagliflozin trials
used 3.5 mmol/l to define minor hypoglycaemic events.
Canagliflozin
Rates of hypoglycaemia were not substantially different between canagliflozin and placebo groups. The
CANTATA-M study (2013)84 defined hypoglycaemia as PG of under 4.0 mmol/l. They reported rates of
hypoglycaemia of 3.6% in the 100-mg/day canagliflozin group, 3.0% in the 300-mg/day group and 2.6%
in the placebo group. There were no cases of major hypoglycaemia.
In Inagaki 2014,76 there were two cases of symptomatic (2.2%) and four cases of asymptomatic (4.4%)
hypoglycaemia (PG under 4.0 mmol/l) in the 100-mg/day canagliflozin group, and one case of
asymptomatic (1.1%) and two cases of symptomatic (2.2%) hypoglycaemia in the placebo group.
Dapagliflozin
Rates of hypoglycaemia were not substantially different between the dapagliflozin and placebo groups.
Over 24 weeks, not more than two cases of hypoglycaemia occurred in any of the comparison groups.
There were no cases of major hypoglycaemia.
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Empagliflozin
In Roden 2013/14,82,83 there was one case of hypoglycaemia (defined as below 4.0 mmol/l or requiring
assistance) in each of the comparison groups over 24 weeks (none of them was symptomatic) and two
cases in each group at 76 weeks or more (only one of these in the 10-mg/day empagliflozin group was
symptomatic). In Lewin 2015,81 there was one case of hypoglycaemia (also defined as under 4.0 mmol/l)
in the linagliptin group and the 25-mg/day empagliflozin group, and four cases in the 10-mg/day
empagliflozin group. None of these required assistance.
Given the infrequency of reported hypoglycaemia, the similarities of the frequencies of hypoglycaemia in
active and placebo arms, and the cut-off level used, the Assessment Group (AG) considers that it would be
reasonable to assume that the flozins do not cause hypoglycaemia.
Tables 4 and 5 summarise the occurrence of UTIs and genital tract infections (GTIs), respectively, in the
studies considered for this review.
Adverse events
In this section, we include data from trials and other studies in combination therapy as well
as monotherapy.
Urogenital tract infections
Although most UTIs are mild and easily resolved with appropriate antibiotic treatment, more severe
infections can be devastating, resulting in bacteraemia, sepsis and death. Because of the frequency with
which they occur, UTIs also impose a substantial economic burden on health-care systems.88
Symptoms of UTI include dysuria (a burning feeling when urinating); frequency of urination; urgency
(a feeling of an intense urge to urinate); pain or pressure in the back or lower abdomen; nausea and/or
vomiting; cloudy, dark, bloody or strange-smelling urine; feeling tired or shaky; and fever or chills.
The presence of glucose in the urine (glycosuria) creates a suitable environment for the growth and
proliferation of bacteria. Glycosuria also promotes increased adherence of bacteria to uroepithelial cells, in
particular Escherichia coli.89 By blocking renal glucose reabsorption, SGLT2 inhibitors cause glycosuria, and
increase the risk of UTI in patients.89
Glycosuria in patients with type 2 diabetes predisposes these patients to develop GTIs, in particular genital
mycotic infections, that is vulvovaginal candidiasis in women and candida balanitis in men, as it provides a
favourable growth environment for otherwise commensal genital microorganisms. Candida albicans is the
most common cause, but Candida glabrata is also an important cause in women with type 2 diabetes.90
Symptoms of genital candidiasis can include itching; burning; genital discharge; pain during sexual
intercourse; soreness; redness in the genital area; and rash.
Both UTIs and GTIs are more common in females.91
Canagliflozin
In the Inagaki study of Japanese patients with type 2 diabetes,76 urogenital tract infections were
infrequent, mild, managed with standard treatments and did not recur in any of the patients. The low
incidence may be at least partly because patients with a history of such infections were excluded from the
trial. The incidence of UTIs was similar across all groups.76 GTIs were more frequent in the canagliflozin
groups compared with placebo, and mostly occurred in women.
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TABLE 4 Summary of UTIs
Inagaki 201476
Canagliflozin
100mg Canagliflozin 200mg Placebo
24 weeks 1/90 (1.1%) 1/89 (1.1%) 1/93 (1.1%)
Stenlöf 2013, 201484,92
Canagliflozin
100mg Canagliflozin 300mg Placebo
Canagliflozin
100mg
(high HbA1c)
26 weeks 14/195 (7.2%) 10/197 (5.1%) 8/192 (4.2%) 3/47 (6.4%)
52 weeks 16/195 (8.2%) 14/197 (7.1%) 12/192 (6.3%)
Kaku 201480
Dapagliflozin
10mg Placebo
24 weeks 2/88 (2.3%) 2/87 (2.3%)
Ji 201479
Dapagliflozin
10mg Placebo
24 weeks 7/133 (5.3%) 4/132 (3.0%)
24 weeks (Chinese) 6/110 (5.5%) 4/110 (3.6%)
Ferrannini/
Bailey 2010, 201577,78
Dapagliflozin
10mg (a.m.) Placebo
Dapagliflozin
10mg (p.m.)
24 weeks 4/70 (5.7%) 3/75 (4.0%) 5/76 (6.6%)
102 weeks 6/70 (8.6%) 3/75 (4.0%)
102 weeks (men) 2/34 (5.9%) 0/31 (0.0%)
102 weeks (women) 4/36 (11.1%) 3/44 (6.8%)
Roden 2013, 201482,83 Empagliflozin 10mg
Empagliflozin
25mg Placebo
Sitagliptin
100mg
24 weeks 15/224 (6.7%) 12/223 (5.4%) 12/229 (5.2%) 11/223 (4.9%)
24 weeks (men) 3/142 (2.1%) 2/144 (1.4%) 3/124 (2.4%) 4/141 (2.8%)
24 weeks (women) 12/82 (14.6%) 10/79 (12.7%) 9/105 (8.6%) 7/82 (8.5%)
≥ 76 weeks 21/224 (9.4%) 20/224 (8.9%) 25/228 (11.0%) 20/223 (9.0%)
Lewin 201381 Empagliflozin 10mg
Empagliflozin
25mg
Linagliptin
5mg
52 weeks 22/135 (16.3%) 14/135 (10.4%) 14/135 (10.4%)
52 weeks (men) 6/77 (9.2%) 3/64 (3.8%) 2/75 (2.7%)
52 weeks (women) 16/58 (22.9%) 11/71 (19.3%) 12/60 (20.0%)
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TABLE 5 Summary of GTIs
Inagaki 201476
Canagliflozin
100mg
Canagliflozin
200mg Placebo
24 weeks 2/90 (2.2%) 1/89 (1.1%) 1/93 (1.1%)
24 weeks (men) 0/59 (0.0%) 0/73 (0.0%) 1/60 (1.7%)
24 weeks (women) 2/31 (6.5%) 1/16 (6.3%) 0/33 (0.0%)
Stenlöf 2013;84 201492
Canagliflozin
100mg
Canagliflozin
300mg Placebo
Canagliflozin
100mg
(high HbA1c)
Canagliflozin
300mg
(high HbA1c)
26 weeks 12/195 (6.2%) 13/197 (6.6%) 4/192 (2.1%) 6/47 (12.8%) 2/44 (4.5%)
26 weeks (men) 2/195 (2.5%) 5/197 (5.6%) 0/192 (0.0%)
26 weeks (women) 10/195 (8.8%) 8/197 (7.4%) 4/192 (3.8%)
52 weeks 18/195 (9.2%) 18/197 (9.1%) 5/192 (2.6%)
52 weeks (men) 5/195 (6.2%) 8/197 (9.0%) 0/192 (0.0%)
52 weeks (women) 13/195 (11.4%) 10/197 (9.3%) 5/192 (4.8%)
Kaku 201480
Dapagliflozin
10mg Placebo
24 weeks 2/88 (2.3%) 1/87 (1.1%)
Ji 201479
Dapagliflozin
10mg Placebo
24 weeks 6/133 (4.5%) 1/132 (0.8%)
24 weeks (Chinese) 4/110 (3.6%) 0/110 (0.0%)
Ferrannini 201077/
Bailey 201578
Dapagliflozin
10mg (a.m.) Placebo
Dapagliflozin
10mg (p.m.)
Dapagliflozin
10mg
(high HbA1c)
24 weeks 9/70 (12.9%) 1/75 (1.3%) 2/76 (2.6%) 7/39 (17.9%)
102 weeks 11/70 (15.7%) 1/75 (1.3%)
102 weeks (men) 2/34 (5.9%) 0/31 (0.0%)
102 weeks (women) 9/36 (25.0%) 1/44 (2.3%)
Roden 2013/1482,83
Empagliflozin
10mg
Empagliflozin
25mg Placebo
Sitagliptin
100mg
Empagliflozin
25mg
(open-label)
24 weeks 7/224 (3.1%) 9/223 (4.0%) 0/229 (0.0%) 2/223 (0.9%) 1/87 (1.1%)
24 weeks (men) 4/142 (2.8%) 2/144 (1.4%) 0/124 (0.0%) 1/141 (0.7%) 1/64 (1.6%)
24 weeks (women) 3/82 (3.7%) 7/79 (8.9%) 0/105 (0.0%) 1/82 (1.2%) 0/23 (0.0%)
≥ 76 weeks 13/224 (5.8%) 14/24 (6.3%) 4/228 (1.8%) 2/223 (0.9%)
Lewin 201581
Empagliflozin
10mg
Empagliflozin
25mg
Linagliptin
5mg
52 weeks 7/135 (5.2%) 6/135 (4.4%) 4/135 (3.0%)
52 weeks (men) 2/77 (3.1%) 1/64 (1.3%) 1/75 (1.3%)
52 weeks (women) 5/58 (7.1%) 5/71 (8.8%) 3/60 (5.0%)
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In the Stenlöf study (CANTATA-M study) of predominantly white people,84,92 there were small increases in
UTIs with canagliflozin 100 mg (7.2% at 24 weeks, 8.2% at 52 weeks) and 300 mg (5.1% and 7.1%)
compared with placebo (4.2% and 6.3%). All UTIs were mild to moderate in severity and no patients
discontinued treatment because of a UTI.
Lavalle-González et al.93 examined the efficacy and safety of canagliflozin 100 mg and canagliflozin
300 mg versus placebo and sitagliptin, for 26 weeks, in patients with type 2 diabetes who were being
treated with background metformin; interestingly, the incidence of UTIs was higher only in the
canagliflozin-100 mg group. The incidence of genital mycotic infections was higher in females and males
with canagliflozin than with placebo, but all were mild to moderate in severity, and responded to standard
antifungal treatment. Once again, the incidence was higher in females than males, as expected;93
furthermore, the incidence of genital mycotic infections was higher in patients with high HbA1c.93 No
patients discontinued treatment because of a GTI.
In a separate 52-week, open-label study by Inagaki94 of canagliflozin alone or as add-on to other oral
antihyperglycaemic drugs in Japanese patients with diabetes, UTI was present in 2 out of 127 (1.6%) with
canagliflozin 100 mg and 5 out of 253 (2.0%) with canagliflozin 200 mg, and none was severe (9). GTIs
mostly occurred in females; most of the events were mild in severity and the patients recovered after
antifungal therapy.
Leiter et al.95 also compared canagliflozin 100 mg and canagliflozin 300 mg with glimepiride over 104
weeks in patients with type 2 diabetes that was inadequately controlled with metformin, and found the
incidence of UTIs to be higher in the canagliflozin groups.
Interestingly, Neal et al.96 looked at canagliflozin 100 mg and canagliflozin 300 mg when used together
with insulin treatment over a 52-week time period and found no increase in the incidence of UTIs.
Further, in a double-blind, Phase III clinical study,97 patients aged > 55 years to < 80 years inadequately
controlled with their current treatment regimen (n = 714) were randomised to receive canagliflozin
100 mg, canagliflozin 300 mg or placebo. Over 2 years, the incidence of GTIs was higher with canagliflozin
100 mg (23.9%) or canagliflozin 300 mg (18.7%) than placebo (4.3%) in women and men (5.6% and
10.9% vs. 1.4%, respectively). The largest number of events occurred within 6 months of treatment
initiation and declined with time. Most GTIs were mild to moderate in intensity and responded to
standard treatment.
In a pooled analysis by Nicolle et al.,98 the association between UTIs and canagliflozin treatment based on
data from patients with type 2 diabetes enrolled in Phase III clinical studies, and on data from individual
Phase III clinical studies in special patient populations, showed that the incidence of UTIs tended to be higher
with canagliflozin 100 mg and canagliflozin 300 mg than with placebo, but with no dose dependence.
Finally, a recent report99 based on pooled data from patients with type 2 diabetes enrolled in Phase III
clinical studies supports the notion of higher incidences of genital mycotic infections with canagliflozin
compared with control patients with type 2 diabetes, GTIs being generally mild to moderate in intensity
and responding to standard treatments.
In summary, canagliflozin treatment (≥ 24 weeks) is associated with a higher incidence of urogenital
tract infections, but there is no evidence of a dose-dependent response. UTIs were mild to moderate in
severity and were amenable to standard treatment with no recurrence. This was also true in patients on
pre-existing diabetic medication, that is metformin. GTIs were also more frequent in females, and in older
patients (> 55 years but < 80 years) – the risk of GTIs with canagliflozin use is increased mostly early after
treatment initiation, that is within the first 6 months. GTIs were also mild to moderate in severity and were
amenable to standard treatment.
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Dapagliflozin
Dapagliflozin has been shown to have a dose-dependent effect on glycosuria in patients with type 2
diabetes,50 and treatment with dapagliflozin 10 mg as add-on to metformin showed that increased
glycosuria with dapagliflozin was maintained for up to 102 weeks.100 However, there is no demonstrable
dose relationship between glycosuria and UTIs.101
In the Kaku monotherapy study in Japanese patients,80 after 24 weeks, two patients each in the
dapagliflozin 10 mg and placebo groups experienced at least one event suggestive of UTIs, but they were
mild to moderate in severity.80 Two patients in the dapagliflozin-10 mg group and one patient in the
placebo group experienced one or more GTI events, and GTIs were mild to moderate in severity.80
In a separate 52-week, open-label Phase III study by Kaku,102 consisting of a single treatment arm with no
comparator, dapagliflozin (initiated at 5 mg/day and titrated to 10 mg/day as required) was administered as
monotherapy (n = 249) or combination therapy (n = 479) with other antihyperglycaemic agents (AHAs:
sulfonylurea, glinides, metformin, alpha-glucosidase inhibitors, thiazolidinediones (TZDs), DPP-4 inhibitors,
or GLP-1 receptor agonists) in Japanese patients with type 2 diabetes with inadequate glycaemic control.102
Urogenital infections were rare, mild to moderate in intensity, and rates were similar in the monotherapy
and combination therapy groups.102
In the study by Ji et al.79 in predominantly Chinese patients, urogenital tract infections were few, with
higher incidence in the dapagliflozin group (5.3%) compared with placebo (3.0%). All reported events
were predominantly of mild or moderate intensity. One patient had urethritis of moderate intensity, which
resolved with antibiotic treatment; the patient continued with the study.
In the 24-week study by Ferrannini et al.,77 there was an increased incidence of urogenital tract infections
with dapagliflozin treatment compared with placebo. The incidence of urogenital tract infections in the
exploratory evening-dose cohort was similar to the morning-dose cohort. Urogenital tract infections
resolved with standard treatment and rarely led to discontinuation.77
In the 102-week Bailey study,100 which is an extension of the 24-week Ferrannini study,77 low-dose
metformin 500 mg/day was added to the placebo group.100 Once again, the incidence of urogenital tract
infections with dapagliflozin treatment was higher than with the placebo-plus-low-dose-metformin group.100
Urogenital tract infections occurred during the first 6 months of dapagliflozin therapy, were more common
in women, and most were single episodes of mild or moderate severity. All urogenital tract infections
responded to standard management.103 One patient on dapagliflozin discontinued the study because of UTI.
In triple therapy, dapagliflozin as add-on to metformin plus sulfonylurea, in a 24-week trial, was associated
with a higher incidence of urogenital tract infections than in the placebo group.104
Rosenstock et al.,105 in a 24-week trial against saxagliptin, reported that urogenital infections were more
frequent in the dapagliflozin/metformin arm than either saxagliptin/metformin or saxagliptin/dapagliflozin/
metformin groups.
In a recent report by Ptaszynska et al.,106 the association between urogenital tract infections and dapagliflozin
treatment based on pooled analyses from 12 placebo-controlled studies of Phase IIb or Phase III clinical
studies in patients with type 2 diabetes receiving comparator or dapagliflozin as monotherapy, add-on to
antidiabetic therapy or as initial combination with metformin, showed that urogenital tract infections
occurred more often with dapagliflozin treatment than with placebo, but were mild or moderate in severity.
Pyelonephritis was rare and balanced among treatments.
In summary, dapagliflozin monotherapies and combination therapies (≥ 24 weeks) are associated with a
higher incidence of urogenital tract infections. Urogenital infections were generally mild to moderate in
severity, tended to occur during the first 6 months of dapagliflozin therapy, were more common in women
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and were amenable to standard treatment. Urogenital infection rates were similar between monotherapy
and combination therapy groups in all studies, with the exception of combination therapies involving
saxagliptin.105
Empagliflozin
Roden et al.83,107 found that after 24 weeks UTIs were mild to moderate in intensity (only one patient in
the empagliflozin-25 mg group discontinued the study) and more common in women but similar in all
arms. After 76 weeks, the frequency of UTIs was again similar in all groups. However, the frequency of
GTIs was higher in the empagliflozin groups (3.1% and 4.0%) than the placebo (0%) and sitagliptin
(0.9%) groups. GTIs were once again more common in women. GTI events were of moderate intensity in
three patients in the empagliflozin-25 mg group (one patient discontinued the study); all other events
were mild.
Barnett et al.,108 in the EMPA-REG RENAL (Efficacy and Safety of Empagliflozin in Patients With Type 2
diabetes and Renal Impairment) study of empagliflozin versus placebo in patients with renal impairment,
found that both UTIs and GTIs were more frequent in patients with type 2 diabetes with stage 3 chronic
kidney disease (CKD) and stage 4 CKD, but not stage 2 CKD.
In the Lewin trial,81 after 52 weeks, urogenital infections were more common in women, and empagliflozin
treatment was usually associated with a higher incidence of urogenital infections compared with the
placebo group. The exceptions were empagliflozin 25 mg versus placebo for UTI, and empagliflozin 10 mg/
linagliptin 5 mg versus placebo for GTI. One patient (receiving empagliflozin 25 mg) had a UTI of severe
intensity, but which did not lead to discontinuation of the study drug, and one patient (receiving empagliflozin
10mg) had chronic pyelonephritis that was mild in intensity and was not considered to be related to the study
drug.81 There were no severe GTI events, but two patients (one patient on empagliflozin 25mg/linagliptin
5 mg and one patient on empagliflozin 10mg) discontinued the study because of GTIs.
DeFronzo et al.109 evaluated combinations of empagliflozin/linagliptin (empagliflozin 10 mg/linagliptin 5 mg
and empagliflozin 25 mg/linagliptin 5 mg) as second-line therapy in subjects with type 2 diabetes that was
inadequately controlled on metformin. They found that after 52 weeks, the incidence of UTIs was similar
across the empagliflozin-25 mg, empagliflozin-10 mg and linagliptin-5 mg groups. In contrast with UTIs,
the frequency of GTIs was higher in the empagliflozin-25 mg and empagliflozin-10 mg groups than with
the linagliptin-5 mg group; interestingly, the two combinations of empagliflozin/linagliptin therapies had a
lower frequency of urogenital infections compared with these three groups.
Similar findings were reported from the Rosenstock placebo-controlled trial in obese (BMI ≥ 30 kg/m2
and ≤ 45 kg/m2), inadequately controlled (HbA1c ≥ 7.5% to ≤ 10%) patients with type 2 diabetes, when
empagliflozin was added on to multiple daily injections (MDI) of insulin for 52 weeks, that is similar rates
of UTIs and higher rates of GTIs in the empagliflozin groups compared with the placebo group.110
However, in the EMPA-REG BASAL (Impact of empagliflozin added on to basal insulin in type 2 diabetes
inadequately controlled on basal insulin) study, which enrolled patients with type 2 diabetes with BMI
≤ 45 kg/m2, inadequately controlled (HbA1c > 7% to ≤ 10%), despite treatment with basal glargine or
detemir insulin (≥ 20 IU/day) or NPH insulin (≥ 14 IU/day), with or without metformin and/or sulfonylurea
use, Rosenstock et al.111 observed that both UTIs as well as GTIs were more frequent in the empagliflozin
groups than with the placebo group.
Häring et al.112 studied the effect of adding either empagliflozin 10 mg or empagliflozin 25 mg or placebo
for 24 weeks in patients with type 2 diabetes, inadequately controlled (HbA1c ≥ 7% to ≤ 10%), on
metformin and sulfonylurea [EMPA-REG METSU (Empagliflozin as add-on to metformin plus sulfonylurea in
patients with type 2 diabetes)] or on metformin alone [EMPA-REG MET].113 In both studies, the incidence
of UTIs was slightly higher and the incidence of GTIs higher in the empagliflozin groups than in the
placebo groups, respectively. 71.2% of patients of the EMPA-REG METSU study continued in a double-
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blind extension for ≥ 52 weeks, named the EMPA-REG EXTEND METSU study,114 and 72.7% of patients
of the EMPA-REG MET study continued in a double-blind extension study for ≥ 52 weeks, named the
EMPA-REG EXTEND MET study.115 Both of these studies demonstrated that UTIs were not more frequent in
the empagliflozin groups than the placebo groups, but GTIs were reported in more patients on empagliflozin
therapies than placebo.114,115 Similar findings were found in the 104-week randomised, active-controlled,
double-blind, parallel-group Phase III trial comparing empagliflozin and glimepiride as add-on therapy to
metformin treatment in patients with type 2 diabetes, the EMPA-REG H2H-SU study.116
The EMPA-REG PIOGLITAZONE study compared empagliflozin as add-on therapy to pioglitazone (≥ 30 mg/
day) with or without metformin (≥ 1500 mg/day), at unchanged doses for ≥ 12 weeks, in patients with
type 2 diabetes.117 Afterwards, 61.2% of patients who completed 24 weeks of treatment continued in a
double-blind extension trial for ≥ 52 weeks (total duration ≥ 76 weeks), the EMPA-REG EXTEND™ PIO
study.118 Both of these studies found that UTIs were not more frequent in the empagliflozin groups
compared with the placebo arms. However, GTIs were reported in more patients on empagliflozin
therapies than placebo.117,118
In summary, empagliflozin monotherapies and combination therapies (≥ 24 weeks) are associated with a
higher incidence of GTIs but not UTIs, as almost all studies reported similar rates of UTI across all treatment
and placebo groups. Urogenital infections were more common in women, generally mild to moderate in
severity and amenable to standard treatment.
Some trials show little difference in UTI results between the SGTL2 inhibitor and placebo arms. A possible
explanation is that the placebo group had glycosuria, due to poor diabetes control, leading to an increased
risk of UTI. We note that in a trial of dapagliflozin against an active comparator, glipizide, the difference in
UTI rates was greater than in most of the trials against placebo.119
Frequencies of urinary tract infections
The trials of different drugs reported different rates of UTIs, but a recent meta-analysis of 19 trials found
no significant differences in risk amongst the three drugs.120
When do urinary tract infections occur?
Several trials report cumulative incidence of UTIs. Kaku80 reports 2.3% at 24 weeks and 3.6% by 52 weeks.
So 1.3% of UTIs occur in months 7–12. Ferrannini77 reports 5.7% at 24 weeks and 8.6% at 102 weeks. So
2.9% occur from week 24 to week 102. Roden82,83 reports 6.7% at week 24 and 9.4% by week 76. So
2.7% occurred from week 24 to week 76.
Patients on SGLT2 inhibitors who have more than one UTI will be switched to another drug. For modelling
purposes, we will assume that:
l Sixty per cent of flozin-induced UTIs will occur in the first 6 months.
l All flozin-induced UTIs will occur in the first 2 years.
l Two UTIs will trigger a change of therapy.
Diabetic ketoacidosis
Diabetic ketoacidosis (DKA) is a serious complication of diabetes, seen predominantly, but not exclusively,
in type 1 diabetes. It is life-threatening. It requires admission to hospital for intensive treatment with
intravenous infusion and insulin. It is therefore costly to health care.
Cases of DKA have been reported associated with treatment with SGLT2 inhibitors. The EMA has
announced a review of the risk of DKA amongst people who are treated with these drugs.121 It notes that
101 cases of DKA had been reported worldwide in patients who are treated with SGLT2 inhibitors, which,
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based on an estimated 500,000 patient-years of use, would be a risk of 1 in 5000 patient-years. The EMA
also notes that in some cases the level of blood glucose was much lower than is usually seen in DKA
(‘euglycaemic DKA’) and expressed concern that this might lead to delays in diagnosis.
In the USA, the FDA has also announced a review and has issued a safety announcement.122 The FDA had
received notifications of DKA in patients treated with SGLT2 inhibitors.
The manufacturers of canagliflozin, Janssen, have reported that in their series of trials, the incidence of
DKA was very low – 0.5 per 1000 patient-years on canagliflozin 100 mg daily, 0.8 on canagliflozin 300 mg
daily and 0.2 per 1000 patient-years on placebo.123 The other manufacturers have yet to publish data, but
enquiries by Rosenstock and Ferrannini124 for a commentary in Diabetes Care elicited rates from the
manufacturer for dapagliflozin and empagliflozin of under 0.1%, though no details are given of time
period. Rosenstock and Ferrannini124 suggest that some of the cases reported in the USA may have been in
patients with type 1 diabetes.
With greater use of the SGLT2 inhibitors, rare adverse events can be expected. Acute pancreatitis has been
reported shortly after canagliflozin was started,125 but cause and effect is not proven. A case of severe
hypercalcaemia has been reported,126 possibly linked to the osmotic diuresis and ingestion of calcium-
containing indigestion tablets.
Late reporting of adverse events is not unusual. The FDA have also recently issued a safety alert on the
gliptins, the DPP-4 inhibitors, after reports of severe joint pain.127
What is becoming clearer as evidence accumulates, is that the SGLT2 inhibitors have actions beyond the
kidney, for example on the pancreas, with an increase in plasma glucagon levels, and effects on
blood lipids.128
Cardiovascular safety
All three of the SGLT2 inhibitors reviewed in this report are in large, long-term cardiovascular studies,
mandated by the FDA to satisfy the post-marketing requirements in the USA. The results of these
(CANVAS129 for canagliflozin and DECLARE130 for dapagliflozin) are awaited but there have been early
reports of reductions in cardiovascular events.131 The results of the empagliflozin study are reported below.
Bone health
The FDA has issued a warning on decreases in bone density and an increased risk of fractures in people
taking canagliflozin, possibly through effects on phosphate metabolism involving parathyroid hormone,
fibroblast growth factor 23 and vitamin D.132 Fractures have also been reported amongst people taking
dapagliflozin. Kohan et al.133 randomised 252 people with moderate renal impairment (94% in the range
30–59 ml/minute) to placebo or dapagliflozin. HbA1c fell by 0.44% on dapagliflozin 10 mg daily and by
0.32% on placebo, but there was good weight loss on dapagliflozin (reduction by 1.89 kg) and a useful
reduction in SBP (6.8 mmHg). However, 8 of 85 (9.4%) people on dapagliflozin 10 mg suffered fractures,
compared with none on placebo.
Kwon134 reviewed bone safety and canagliflozin for the FDA, using data from the canagliflozin Phase 3
programme, for 6177 patients on the drug and 3262 on other treatments. The proportions suffering
fractures were 2.1% and 1.6% for canagliflozin and others, respectively, with most of the difference being
in low trauma fractures (1.6% and 1.2%), with the main difference being in the upper limb (0.7% vs.
0.3%). The incidence per 1000 patient-years was 18.1 for canagliflozin regimens and 14.2 for other
regimens. So the risk of fracture is small but increased by around 30% in people taking canagliflozin.
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The mechanism by which canagliflozin increases fracture risk is uncertain.135 An important issue is that the
fracture rate is not increased in the first year of treatment, but appears later. So any increase in fracture
risk may not be detected in short trials (Taylor 2015135). (The FDA warning, however, states that fractures
can occur as early as 12 weeks after starting canagliflozin.)
EMPA-REG OUTCOME study
The results of this trial were published on 17 September 2015.136 The trial recruited 7020 patients at high
risk of CVD. High risk included having a history of MI or stroke, coronary artery stenosis of 50% or more,
previous coronary revascularisation and peripheral vascular disease (PVD). The trial scores quite well with
the Cochrane risk of bias score (see Appendix 5) with the deficiencies probably due to failure to provide
details rather than design or execution flaws.
Patients were randomised to placebo, and empagliflozin 10 mg or 25 mg. Patients were recruited from
590 sites in 42 countries, an average of 12 per site: 72% were white, 21% Asian and 5% black, including
African-Americans. Of the 21% Asian, 19% were from 10 countries with a mix of South and East Asian
centres, ranging from India to Japan and Korea. There were no centres in China except Hong Kong, but
there were centres in Taiwan and Singapore. Numbers are not given by country. There were 12 UK
centres, and 41% of all recruits were from Europe, including Russia. The mean HbA1c at baseline was just
under 8.1%. In 57% of patients, duration of diabetes was over 10 years. At baseline, 74% were on
metformin, 48% on insulin, 43% on sulfonylureas and 11% on DPP-4 inhibitors. About 29% were on
monotherapy, 2% on no drugs and 45% on dual therapy, implying that 24% were on more complex
regimens with three drugs or more. Discontinuation from trial medication occurred in 29% of the placebo
group and 23% of the empagliflozin group, with 13% and 11.5% being due to adverse events (which did
not include need for rescue therapy).
After 12 weeks, other glucose-lowering drugs could be adjusted or added. Targets were not specified
centrally but left to local guidelines. Changes were made in 31.5% of the placebo group and 19.5% of the
empagliflozin group. The changes in the empagliflozin group included the introduction of insulin (5.8%), a
DPP-4 inhibitor (5.4%), a sulfonylurea (3.8%), metformin (3.7%), a TZD (1.2%) or a GLP-1 analogue (1.4%).
This means that we cannot use the drift upwards of HbA1c of 0.1% per year in the empagliflozin group as a
guide to progression of diabetes. Despite the addition of other glucose-lowering drugs, the mean HbA1c at
week 206 was 7.81% in the empagliflozin group and 8.16% in the placebo group, a difference of 0.35%.
Being a high-risk group, at baseline 95% were on antihypertensive medications (81% on angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs); 65% on beta-blockers;
33% on calcium channel blockers). Seventy-seven per cent were on statins, 9% on fibrates and 4% on
ezetimibe. Forty-three per cent were on diuretics, unspecified, but loop diuretics are not recommended for
use with canagliflozin and dapagliflozin.
A range of subgroups was specified in the protocol.137 The results were analysed by staff from Boehringer
Ingelheim, who co-funded it with Eli Lilly. The two empagliflozin groups were pooled for the analysis,
because event rates were almost identical (CVD deaths 3.8% with 10 mg and 3.5% with 25 mg). When
the main outcomes were assessed for the 10- and 25-mg empagliflozin groups separately, the differences
were not significantly different from the placebo group.
The primary outcome was a composite of death from a cardiovascular cause, non-fatal MI and non-fatal
stroke. The primary outcome occurred in 10.5% of people on empagliflozin and in 12.1% of those on
placebo, giving a hazard ratio (HR) 0.86 (95% CI 0.74 to 0.99). Table 6 shows some of the outcomes.
The DKA rate in the empagliflozin was double that in the placebo group, but the excess risk was only
about 1 in 1500 per year, and numbers were very small.
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The proportion of fatal to non-fatal MIs looks odd – 5 deaths out of 126 MIs. Similarly, of 69 strokes, only
nine were fatal. This raises the question of where the 137 cardiovascular deaths come from.
Supplementary table S5 reports 11 deaths from acute MI in the placebo group and 15 in the pooled
empagliflozin group, but these figures do not match those in table 1 in the main paper. The figures for
fatal stroke also differ between main text and supplement, 11 versus 9 for placebo, 16 versus 14
for empagliflozin.
Supplementary table S5 gives cardiovascular deaths reproduced in Table 7.
Total mortality was 8.3% in the placebo group and 5.7% in the pooled empagliflozin, a difference
of 2.6%.
The ill-defined ‘other cardiovascular deaths’ constitute 41% and 44% of all cardiovascular deaths for
placebo and empagliflozin, respectively, and they account for 29% and 28% of all deaths, respectively.
Three causes account for 83% of the observed difference in mortality: sudden death, heart failure and
‘other cardiovascular deaths’.
The totals of proportions having the individual events in the composite primary outcomes exceeds the
primary outcome proportion, presumably because some patients had more than one event.
The Kaplan–Meier curves diverge after about 2 months, with curious accelerations in the placebo group
curves after 42 months.
TABLE 6 Results of EMPA-REG-OUTCOME trial136
Results Placebo Empagliflozin
No. of patients 2333 4687
All-cause mortality 8.3% 5.7%
Cardiovascular mortality 5.9% 3.7%
Non-cardiovascular mortality 2.4% 2.0%
Primary composite outcome 12.1% 10.5%
MI
Non-fatal 5.2% 4.5%
Fatal 0.2% 0.3%
Silent 1.2% 1.6%
Stroke 3.0% 3.5%
Fatal 0.4% 0.3%
Non-fatal 2.6% 3.2%
Hospital admission
Heart failure 4.1% 2.7%
Unstable angina 2.8% 2.8%
UTIs 18.1% 18.0%
GTIs 1.8% 6.4%
DKA 1 event 4 events
EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients.
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How were these cardiovascular benefits achieved?
Glycated haemoglobin was 0.57% lower in the empagliflozin group than the placebo arm at week 12,
but steadily narrowed thereafter to 0.35% at week 206. Given the weak relationship between glycaemic
control and CVD,68 this difference seems unlikely to have caused the difference.
Systolic blood pressure fell by about 5.5 mmHg in the empagliflozin group and by about 2 mmHg in the
placebo group by week 16, but the difference between the empagliflozin and placebo groups narrowed
thereafter to about 2 mmHg. There was no difference in BP lowering between doses. Diastolic blood
pressure (DBP) fell by about 2.5 mmHg in all three arms. By 206 weeks, there was no difference in DBP
between empagliflozin and placebo groups.
For some complications of diabetes, BP control is as important as glycaemic control, as was shown by the
UKPDS study, where ‘tight’ BP control (with a mean BP of 144/82 mmHg, it was not really tight) reduced
overall mortality by 32% (RR 0.68, 95% CI 0.49 to 0.94).138
Weight was reduced by 2 kg in the empagliflozin group and by 1.2 kg in the placebo group.
Changes in lipids were small. On empagliflozin 25 mg, LDL-C rose (placebo adjusted) from baseline
2.2 mmol/l to about 2.3 by 12 months, stayed there until about 136 weeks then fell to about 2.21 mmol/l,
just below the placebo level. On empagliflozin 25 mg, HDL-C rose by about 0.05 mmol/l then fell slightly.
The placebo level rose by about 0.01 mmol/l. (Figures derived from graph – data not provided in text.) The
baseline TC/high-density lipoprotein (HDL) ratio was 3.5, perhaps because so many were on statins and
other lipid-lowering drugs. These lipid changes seem insufficient to explain the mortality results.
However, the combination of factors might have more effect than the individual ones, and the reduction
in BP, though small, is similar to that seen in the Heart Outcomes Prevention Evaluation (HOPE) trial,139 in
which a reduction of 2–4 mmHg in BP from ramipril (an ACEI) was thought by the HOPE authors to be
sufficient to explain about one-quarter of the observed 25% reduction in cardiovascular events, in another
high-risk group with vascular disease and/or diabetes.
Discontinuation rates from study drugs due to adverse events are reported as 19.4% for placebo and
17.3% for empagliflozin in the paper but as 13.0% and 11.5% in appendix H.
Subgroup analysis for the primary composite outcome shows:
l Statistically significant benefit in Asians (a mixed group, with about 44% from North East Asia) but
not in white people, though death from cardiovascular causes is significantly reduced in white people.
This implies that white people gained less for non-fatal MI and stroke. The Asian group is rather
TABLE 7 Cardiovascular deaths in the EMPA-REG OUTCOME trial136
Cause Placebo (%) Empagliflozin (%) Difference (%)
Sudden death 1.6 1.1 0.5
Heart failure 0.8 0.2 0.6
Acute MI 0.5 0.3 0.2
Stroke 0.5 0.3 0.2
Cardiogenic shock 0.1 0.1 0
Other cardiovascular deaths 2.4 1.6 0.8
EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients.
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heterogeneous and no details are given of risks in East Asians versus South Asians. There are
differences in the balance of insulin deficiency and insulin resistance.
l Statistically significant benefit in those with baseline HbA1c under 8.5% but not in those above that.
l Statistically significant benefit in those with BMI of < 30 kg/m2 but not in those above that level.
l Statistically significant benefit in those on insulin but not in those on non-insulin regimens; 51% in
both groups were on insulin.
l Greater benefit in those aged over 65 years.
In a number of subgroups, reductions in cardiovascular death were statistically significant when reductions
in the primary outcome were not. To recall, the primary outcome was cardiovascular death, non-fatal MI
and non-fatal stroke. Of 282 primary outcome events in the placebo group, 49% were cardiovascular
deaths. Of 490 primary outcome events in the empagliflozin groups, 35% were cardiovascular deaths. So
a greater proportion of events in the empagliflozin group was of non-fatal events. The fact that in some
subgroups, cardiovascular death rates are significantly different when the composite primary outcome is
not, is explained by a lack of any statistically significant differences in non-fatal MI and non-fatal stroke.
Non-fatal MI was diagnosed on the basis of symptoms plus one or more of:
l troponin or creatine kinase-MB
l ECG changes
l imaging of new non-viable or non-motile myocardium.
This study has attracted worldwide interest. It contrasts with the equivalent studies with the DPP-4
inhibitors, which did not show any reduction in cardiovascular outcomes. They were:
l SAVOUR for saxagliptin (The Saxagliptin assessment Of Vascular Outcomes Recorded in patients with
diabetes mellitus).140
l EXAMINE for alogliptin (Examination of cardiovascular outcomes with alogliptin versus standard of care
in patients with type 2 diabetes mellitus and acute coronary syndrome).141
l TECOS for sitagliptin (Trial Evaluating Cardiovascular Outcomes with Sitagliptin).142
There was no difference in cardiovascular outcomes in SAVOUR except that more patients on saxagliptin than
on placebo (3.5% vs. 2.8%: HR 1.27, 95% CI 1.07 to 1.51) were admitted to hospital with heart failure.
The findings in EXAMINE were similar – no difference in end points – except an increase in heart failure in
a subgroup analysis of patients with no heart failure at baseline (2.2% on alogliptin, 1.3% on placebo;
HR 1.76, 95% CI 1.07 to 2.90).
The TECOS results were again similar – no differences in a composite primary end point of cardiovascular
death, non-fatal MI and non-fatal stroke nor in other end points including hospital admission for heart
failure and death from any cause.
These results were seen as providing reassurance, in the wake of the rosiglitazone story with an increase
in cardiovascular events.143 They could also be seen as disappointing in that they did not reduce the most
important complication of diabetes, the excess of CVD. However, as has been pointed out by Hirshberg
and Katz,144 these trials ran for only a few years and showed only small changes in HbA1c (reductions
of 0.27–0.36% compared with placebo), so reducing the chance of showing reductions in cardiovascular
events.
The subgroup analyses in EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in
Type 2 diabetes Mellitus Patients) trial are interesting.136 Younger, lighter, better-controlled patients did
better, as did the Asian group. There could be overlapping features here in that the East Asians tend to be
lighter. Further details will no doubt be released but with such a very large study, further analysis is bound
to take time.
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The differences observed do not seem sufficient to justify the very optimistic media coverage, such as
reports that ‘Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster’.145
It is worth noting that the EMPA-REG OUTCOME trial136 involved patients at high cardiovascular risk who
had had diabetes for many years and who were on complex regimens for their diabetes. The results are
not applicable to people starting monotherapy with empagliflozin.
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Chapter 3 Network meta-analysis of
sodium–glucose co-transporter 2 inhibitors and
comparators in monotherapy
One question is whether or not all of the three flozins in this appraisal should be regarded as equallypotent. In addition to the SGLT2 transport system in the kidney, there is also a related transport
system in the gut, SGLT1. Most SGLT2 inhibitors appear to be highly selective, with no significant effect on
SGLT1, but one of the class, canagliflozin, does affect SGLT1, and it has been suggested by Polidori et al.53
that canagliflozin may reduce blood glucose by a dual action in both gut and kidney. However, that
suggestion followed a very short-term study of canagliflozin in healthy individuals, and the gut effect was
seen only with higher doses, such as 300 mg, and not with the 100-mg dose.
A study by Stein et al.54 from Janssen Research and Development looked at the SGLT1 effect in people
with type 2 diabetes and found that canagliflozin 300 mg, but not 150 mg, reduced postprandial PG, by
about 0.5 mmol/l (from graph) for about 2 hours after administration, as it depends on an intestinal drug
action not a systemic one. Hence this reduction would occur only after the single daily dose.
If the SGLT1 effect is clinically significant in people with type 2 diabetes then one might expect
canagliflozin 300 mg to be more potent in reducing HbA1c levels than SGLT2 inhibitors without the
SGTL1 effect.
The CANTATA-M study 201384 did not report weight SDs for the two doses of canagliflozin so this study
could not be included in weight comparison. The weight data for canagliflozin 100 mg comes from the
Inagaki 2014 study,76 in which the 100- and 200-mg doses of canagliflozin were used. We excluded the
200-mg dose as this is not a standard dose.
For assessing the relative merits of the SGLT2 inhibitors in monotherapy, the first comparison is amongst
the usual starting doses: canagliflozin 100 mg, dapagliflozin 10 mg and empagliflozin 10 mg. By including
empagliflozin 25 mg and canagliflozin 300 mg, we can assess the effect of increasing the doses. However,
a caveat is necessary. The empagliflozin 25 mg and canagliflozin 300 mg are used in people who can
tolerate the starting dose, but have an insufficient HbA1c response. Such patients may not respond as well
to SGLT2 inhibition as the average patient, and the effect of increasing the doses may be less than that
seen in the trials.
The aim of our NMA was not only to compare canagliflozin, empagliflozin and dapagliflozin, but also to
assess their effects relative to active comparators.
Methods
Selection of trials
We applied the following selection criteria:
l Trials of 24–26 weeks, starting with placebo as the common comparator.
l Trials only of selected drugs. For example, we did not include all sulfonylureas but focused on
gliclazide, which should be the sulfonylurea for comparison in trials of newer agents.26 We did not
include all DPP-4 inhibitors, originally intending to focus on sitagliptin.
l Baseline HbA1c of 7.5% or more, based on the NICE guideline for treatment intensification.8 There are
some RCTs in patients with lower baseline HbA1c values, but they have less scope for lowering HbA1c.
l Dropout rates of no more than 20%.
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However, the first of these criteria had to be relaxed in order to include gliclazide, as we found no trials of
gliclazide against placebo. We had to indirectly link gliclazide with placebo via linagliptin and pioglitazone.
All of the other drugs included had trials against placebo. Unfortunately, we found no satisfactory trials
of repaglinide for inclusion.
We searched the lists of trials used for the NICE guideline group on type 2 diabetes, but carried out
additional searches specifically for gliclazide trials, as the guideline group pooled trials of sulfonylureas.
Evidence on repaglinide
The annex to the NICE guideline CG87 lists seven studies on repaglinide but only three gave 24-week data.16
Abbatecola et al.146 report a randomised trial comparing repaglinide and glibenclamide. The main outcome
measure was cognitive function, with the hypothesis being the tighter control of postprandial PG would
reduce cognitive decline, in patients aged 60–78 years, mean age 74 years. [Note that according to the
British National Formulary (BNF), repaglinide is ‘not recommended’ in people over 75 years.147]
The baseline HbA1c in patients in this trial was quite low – 7.25%. So it is an exclusion for our purposes. The
final HbA1c is not given in the text, but from the graph is about 6.6% with no difference between the drugs.
In the Jovanovic 2000 trial,148 patients were randomised to placebo, and repaglinide 1 mg or 4 mg daily.
Under 30% of patients were drug naive, and 10% had been on two glucose-lowering drugs. Baseline
HbA1c was 8.6% in the placebo group and rose to 10% at 24 weeks. In those who had been on previous
combination treatment, HbA1c rose by 1.8% on placebo, and fell by inconsequential 0.07% and 0.05% on
repaglinide 1 mg and 4 mg. Dropout rates were very high – 60% in the placebo group, of which half had
to start rescue treatment, and 23% and 31% in the repaglinide groups. Given that 70% had been on
prior drug therapy, the high proportion in the placebo group requiring rescue treatment is not surprising,
but it devalues any conclusions drawn from this study.
The third 24-week study used by NICE was by Saleem et al.149 from Lahore. This compared the effects on
HbA1c of repaglinide and glibenclamide. It says that 50 patients were ‘randomly selected’ for each group
but gives no details of how this was done, or on allocation concealment. Blinding was not feasible because
of different dosing frequencies – once or twice daily for glibenclamide, preprandially up to three times a
day for repaglinide. No patients are reported to have dropped out. The recruitment period in this study
(March 2006 to March 2007) overlaps with that for another paper by the same group (Shah et al. 2011150),
which reports only PG, in 200 patients. The changes in fasting plasma glucose (FPG) and 2-hour PG are
almost identical in the two studies.149,150 The Shah paper150 has no HbA1c data. Saleem et al. 2011149
report a reduction by 24 weeks in HbA1c of 0.6% on repaglinide and 0.4% on glibenclamide. The final
repaglinide dose was 4.27 mg daily, and the final glibenclamide dose was 8.8 mg (identical to the Shah
et al. article150). The Shah article150 states that dosages were reported as being adjusted based on glucose
levels, so it is not clear why the final glucose levels are so different, with a reduction in FPG in the
repaglinide group which is almost double that in the glibenclamide group. No details of source of funding
are given. We think that the patients in the Saleem study149 may be a subset of those in the Shah study.150
We also note the trial by Jibran et al.151 This paper is very similar to the Saleem et al. 2011149 paper, but
has no authors in common. The numbers of patients are the same, and values for baseline age, weight
and BMI have identical means and SDs. The result tables are identical in means and SDs. Much of the text
is the same. The patients are said to have been recruited in different time periods.
Glibenclamide is a first-generation SU and was not included in our NMA, so the Saleem149/Jibran151 and
Abbatecola146 trials are not included.
The NICE guideline group also considered evidence on repaglinide at 12 months, from four trials. These
included the Abbatecola and Saleem trials146,149 mentioned above, and two better-quality ones by Derosa
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et al.152 and Marbury et al.153 The Derosa trial152 compared repaglinide with glimepiride, in patients with
mean HbA1c of 8.0%, and showed a reduction of 1.2% at 12 months. We use the effect sizes from this
study in our modelling, for changes in HbA1c, SBP and weight. However, we prefer gliclazide to
glimepiride, so the Derosa trial152 is not included in our NMA. The Marbury trial153 recruited both patients
who had never had any glucose-lowering drugs (13%) and those who had previously been treated with
sulfonylureas and other drugs (87%). The reduction in HbA1c was much greater in the pharmacotherapy-
naive group – 1.3% at 12 months, similar to the Derosa152 results. In previously treated patients, the HbA1c
actually rose by 0.3%. Mean baseline HbA1c was quite high at 8.7% so the results may be less applicable
to patients treated according to the NICE guidelines with close monitoring and prompt intensification
when HbA1c exceeded 7.5%. The sulfonylurea comparator was glibenclamide, so the trial is not used in
our NMA.
The network diagram is shown in Figure 2. The included trials are listed in Table 8.
Summary measures
The primary measures of treatment effect were the mean differences (MDs) in change from baseline for
HbA1c, weight gain and SBP. A negative value indicates improvement in the outcome. In the case of
missing values for SD of change from baseline values, the SD was imputed as described in detail in the
Cochrane Handbook.75 In brief, we assumed a correlation of r = 0.5 between baseline and follow-up to
estimate SD for change from baseline.
Data synthesis and model implementation
We used a Bayesian NMA method to analyse all the data, preserving randomised treatment effects within
trials and accounting for correlation between comparisons with three arms or four arms using the freely
available software, WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, UK). The statistical heterogeneity
in treatment effect estimates was estimated using between-study variance (i.e. square root of the SD of
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underlying effects across trials) with 95% CrI.164 To estimate inconsistency in the networks of evidence,
we calculated the difference between indirect and direct estimates whenever indirect estimates could be
constructed with a single common comparator.164 Inconsistency was defined as disagreement between
direct and indirect evidence with a 95% CrI excluding 0 for MD.165 The model convergence was assessed
using trace plots and the Brooks–Gelman–Rubin statistic.166 The analysis was undertaken using two Markov
chains, which were run simultaneously. The model was found to be converging adequately after 20,000
samples for both chains. We ran the model further using 70,000 samples and the results presented in the
paper are based on these samples as we discarded the first 20,000 samples.
We used both the fixed- and random-effects models. The Bayesian deviance information criterion (DIC)
was used to compare the two models to see which was appropriate to compare treatment effects. The DIC
measures the fit of the model while penalising it for the number of effective parameters. The model with
the lowest DIC value was considered as the most appropriate NMA model. Based on DIC values obtained
from the two models and also because of small number of studies available for the NMA, a fixed-effects
model was chosen. Owing to small number of studies, it would have been difficult to estimate between
studies variance if a random-effects model was implemented.
All results are reported as posterior medians of MDs with corresponding 95% CrIs. CrIs are the Bayesian
equivalent of classic CIs. A 95% CrI can be interpreted as there being a 95% probability that the
parameter takes a value in the specified range. Drugs were not ranked, but were considered in terms
of effect sizes and uncertainties.
TABLE 8 Trials included in the NMA
Trial Drug Comparator Notes
Inclusions
Aschner 2006154 Sitagliptin 100 mg Placebo
Chen 2015155 Linagliptin Placebo
Dejager 2007156 Vildagliptin Placebo
Del Prato 2011157 Linagliptin Placebo
Erem 2014158 Pioglitazone Gliclazide
Ferranini 201077 Dapagliflozin Placebo
Foley 2009159 Gliclazide Vildagliptin
Haak 2012160 Linagliptin Placebo
Inagaki 201476 Canagliflozin 100 mg Placebo
Ji 201479 Dapagliflozin Placebo
Kaku 201480 Dapagliflozin Placebo
Kikuchi 2012161 Pioglitazone Placebo
Lawrence 2004162 Pioglitazone Gliclazide
Lewin 201581 Empagliflozin Placebo Linagliptin
Miyazaki 2002163 Pioglitazone Placebo
Roden 201383 Empagliflozin Placebo Sitagliptin
Stenlöf 201384 Canagliflozin 100 and 300mg Placebo Sitagliptin in extension
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Results
Glycated haemoglobin (haemoglobin A1c)
Networks of eligible comparisons for HbA1c are provided in Figure 3, showing predominantly pairwise
comparisons of drugs with placebo. There were eleven comparisons (ten drugs plus placebo).
Figure 4 and Table 9 display a caterpillar plot of the MD and 95% CrIs for all comparisons for mean
change in HbA1c (at 24 weeks) from baseline. All SGLT2 inhibitors were significantly more effective than
placebo in reducing mean change in HbA1c from baseline, with the reduction ranging from –1.19% to
–0.59%. Canagliflozin 100 mg and 300 mg and pioglitazone were significantly more effective in reducing
mean change in HbA1c from baseline than linagliptin 5 mg, dapagliflozin 10 mg and vildagliptin 50 mg. The
reductions in HbA1c from baseline were similar for linagliptin 5 mg and dapagliflozin 10 mg. The between-
study variance was small, suggesting no heterogeneity, but the CrIs were wide, which reflects the small
number of studies available for pairwise comparisons. Analyses based on direct versus indirect comparisons
showed no evidence of inconsistency between direct and indirect evidence in the network for HbA1c.
Weight gain
Networks of eligible comparisons for the weight gain are provided in Figure 5, showing predominantly
pairwise comparisons of drugs with placebo. There were 11 comparisons (10 active drugs plus placebo).
Figure 6 and Table 10 display a caterpillar plot of the MD and 95% CrIs for all comparisons for mean
change in weight gain from baseline. Sitagliptin 100 mg, vildagliptin 50 mg, gliclazide and pioglitazone
were associated with significant weight gain compared with placebo, with the weight gain ranging from
0.74 kg to as much as 3.79 kg. Compared with placebo, canagliflozin 300 mg, canagliflozin 100 mg,
empagliflozin 25 mg, empagliflozin 10 mg and dapagliflozin 10 mg were associated with significant weight
loss, ranging from –2.91 kg to –1.58 kg. Compared with all other drugs in the network, canagliflozin
300 mg was associated with significant weight reduction. The between-study variance was small,
suggesting no heterogeneity, but the CrIs were wide, which reflects the small number of studies available
for pairwise comparisons. Analyses based on direct versus indirect comparisons showed no evidence of
inconsistency between direct and indirect evidence in the network for weight gain.
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FIGURE 3 Network plot: HbA1c.
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Pairwise comparison
Compared with placebo
Canagliflozin 300 mg
Pioglitazone
Canagliflozin 100 mg
Gliclazide
Empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliptin 10 mg
Compared with canagliflozin 300 mg
Pioglitazone
Canagliflozin 100 mg
Gliclazide
Empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with pioglitazone
Canagliflozin 100 mg
Gliclazine
Empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with canagliflozin 100 mg
Gliclazide
Empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with gliclazide
Empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with empagliflozin 25 mg
Sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with sitagliptin 100 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with empagliflozin 10 mg
Vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with vildagliptin 50 mg
Linagliptin 5 mg
Dapagliflozin 10 mg
Compared with linagliptin 5 mg
Dapagliflozin 10 mg
–1.5
–1.19 (–1.34 to –1.04)
–1.13 (–1.49 to –0.78)
–0.95 (–1.06 to –0.84)
–0.95 (–1.27 to –0.64)
–0.88 (–0.99 to –0.77)
–0.76 (–0.87 to –0.65)
–0.76 (–0.87 to –0.65)
–0.72 (–0.98 to –0.46)
–0.61 (–0.71 to –0.51)
–0.59 (–0.70 to –0.48)
0.06 (–0.33 to 0.44)
0.24 (0.09 to 0.38)
0.24 (–0.11 to 0.58)
0.31 (0.13 to 0.50)
0.43 (0.24 to 0.61)
0.43 (0.25 to 0.62)
0.47 (0.17 to 0.77)
0.58 (0.40 to 0.76)
0.60 (0.42 to 0.79)
0.18 (–0.19 to 0.56)
0.18 (–0.16 to 0.53)
0.26 (–0.11 to 0.63)
0.37 (0.00 to 0.75)
0.38 (0.01 to 0.75)
0.42 (0.05 to 0.77)
0.53 (0.16 to 0.89)
0.55 (0.18 to 0.91)
–0.00 (–0.33 to 0.34)
0.07 (–0.08 to 0.23)
0.19 (0.03 to 0.35)
0.19 (0.04 to 0.35)
0.23 (–0.05 to 0.52)
0.34 (0.19 to 0.50)
0.36 (0.21 to 0.52)
0.08 (–0.26 to 0.40)
0.19 (–0.14 to 0.52)
0.20 (–0.14 to 0.52)
0.24 (0.01 to 0.47)
0.35 (0.01 to 0.68)
0.37 (0.03 to 0.70)
0.12 (–0.01 to 0.24)
0.12 (0.02 to 0.22)
0.16 (–0.12 to 0.44)
0.27 (0.16 to 0.38)
0.29 (0.13 to 0.45)
0.00 (–0.12 to 0.12)
0.04 (–0.24 to 0.32)
0.15 (0.02 to 0.28)
0.17 (0.01 to 0.33)
0.04 (–0.24 to 0.31)
0.15 (0.04 to 0.26)
0.17 (0.01 to 0.33)
0.11 (–0.16 to 0.39)
0.13 (–0.15 to 0.41)
0.02 (–0.13 to 0.17)
Effect (95% CI)
–0.5 0
Better than comparator Worse than comparator
0.5 1
FIGURE 4 Pairwise comparisons of all drugs for HbA1c.
NMA OF SODIUM–GLUCOSE CO-TRANSPORTER 2 INHIBITORS AND COMPARATORS IN MONOTHERAPY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 9 Pairwise comparisons of all drugs for HbA1c
Pairwise comparison MD (95% CrIs)
Compared with placebo
Canagliflozin 300 mg –1.19 (–1.34 to –1.04)
Pioglitazone –1.13 (–1.49 to –0.78)
Canagliflozin 100 mg –0.95 (–1.06 to –0.84)
Gliclazide –0.95 (–1.27 to –0.64)
Empagliflozin 25 mg –0.88 (–0.99 to –0.77)
Sitagliptin 100 mg –0.76 (–0.87 to –0.65)
Empagliflozin 10 mg –0.76 (–0.87 to –0.65)
Vildagliptin 50 mg –0.72 (–0.98 to –0.46)
Linagliptin 5 mg –0.61 (–0.71 to –0.51)
Dapagliflozin 10 mg –0.59 (–0.70 to –0.48)
Compared with canagliflozin 300mg
Pioglitazone 0.06 (–0.33 to 0.44)
Canagliflozin 100 mg 0.24 (0.09 to 0.38)
Gliclazide 0.24 (–0.11 to 0.58)
Empagliflozin 25 mg 0.31 (0.13 to 0.50)
Sitagliptin 100 mg 0.43 (0.24 to 0.61)
Empagliflozin 10 mg 0.43 (0.25 to 0.62)
Vildagliptin 50 mg 0.47 (0.17 to 0.77)
Linagliptin 5 mg 0.58 (0.40 to 0.76)
Dapagliflozin 10 mg 0.60 (0.42 to 0.79)
Compared with pioglitazone
Canagliflozin 100 mg 0.18 (–0.19 to 0.56)
Gliclazide 0.18 (–0.16 to 0.53)
Empagliflozin 25 mg 0.26 (–0.11 to 0.63)
Sitagliptin 100 mg 0.37 (0.00 to 0.75)
Empagliflozin 10 mg 0.38 (0.01 to 0.75)
Vildagliptin 50 mg 0.42 (0.05 to 0.77)
Linagliptin 5 mg 0.53 (0.16 to 0.89)
Dapagliflozin 10 mg 0.55 (0.18 to 0.91)
Compared with canagliflozin 100mg
Gliclazide –0.00 (–0.33 to 0.34)
Empagliflozin 25 mg 0.07 (–0.08 to 0.23)
Sitagliptin 100 mg 0.19 (0.03 to 0.35)
Empagliflozin 10 mg 0.19 (0.04 to 0.35)
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TABLE 9 Pairwise comparisons of all drugs for HbA1c (continued )
Pairwise comparison MD (95% CrIs)
Vildagliptin 50 mg 0.23 (–0.05 to 0.52)
Linagliptin 5 mg 0.34 (0.19 to 0.50)
Dapagliflozin 10 mg 0.36 (0.21 to 0.52)
Compared with gliclazide
Empagliflozin 25 mg 0.08 (–0.26 to 0.40)
Sitagliptin 100 mg 0.19 (–0.14 to 0.52)
Empagliflozin 10 mg 0.20 (–0.14 to 0.52)
Vildagliptin 50 mg 0.24 (0.01 to 0.47)
Linagliptin 5 mg 0.35 (0.01 to 0.68)
Dapagliflozin 10 mg 0.37 (0.03 to 0.70)
Compared with empagliflozin 25mg
Sitagliptin 100 mg 0.12 (–0.01 to 0.24)
Empagliflozin 10 mg 0.12 (0.02 to 0.22)
Vildagliptin 50 mg 0.16 (–0.12 to 0.44)
Linagliptin 5 mg 0.27 (0.16 to 0.38)
Dapagliflozin 10 mg 0.29 (0.13 to 0.45)
Compared with sitagliptin 100mg
Empagliflozin 10 mg 0.00 (–0.12 to 0.12)
Vildagliptin 50 mg 0.04 (–0.24 to 0.32)
Linagliptin 5 mg 0.15 (0.02 to 0.28)
Dapagliflozin 10 mg 0.17 (0.01 to 0.33)
Compared with empagliflozin 10mg
Vildagliptin 50 mg 0.04 (–0.24 to 0.31)
Linagliptin 5 mg 0.15 (0.04 to 0.26)
Dapagliflozin 10 mg 0.17 (0.01 to 0.33)
Compared with vildagliptin 50mg
Linagliptin 5 mg 0.11 (–0.16 to 0.39)
Dapagliflozin 10 mg 0.13 (–0.15 to 0.41)
Compared with linagliptin 5mg
Dapagliflozin 10 mg 0.02 (–0.13 to 0.17)
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Systolic blood pressure
Networks of eligible comparisons for the SBP are shown in Figure 7, showing predominantly pairwise
comparisons of drugs with placebo. There were seven comparisons.
Figure 8 and Table 11 display a caterpillar plot of the MD and 95% CrIs for all comparisons for mean
change in SBP from baseline. Canagliflozin 100 mg and 300 mg, empagliflozin 25 mg, dapagliflozin 10 mg
and empagliflozin 10 mg were significantly more effective in reducing mean change in SBP from baseline
compared with placebo and sitagliptin 100 mg. Canagliflozin 300 mg gave the largest reduction in mean
change in SBP from baseline compared with placebo (–5.65 mmHg). The between-study variance was
small, suggesting no heterogeneity, but the CrIs were wide, which reflects the small number of studies
available for pairwise comparisons. Analyses based on direct versus indirect comparisons showed no
evidence of inconsistency between direct and indirect evidence in the network for SBP.
One question was whether or not canagliflozin is more potent than other SGLT2 inhibitors, due to its dual
effect on SGLT2 and SGLT1 receptors. In monotherapy, both doses of canagliflozin lowered HbA1c slightly
more than both doses of empagliflozin, which does not have a significant effect on SGLT1 receptors. Nor
does canagliflozin 100 mg. This suggests that the SGLT1 effect does not explain all the differences in
HbA1c results. It may explain some of the difference between the two doses of canagliflozin, or it may not
be clinically significant.
However, irrespective of the mechanism, one finding is that canagliflozin 300 mg does have a greater
effect on HbA1c than dapagliflozin and empagliflozin. Indeed, the 100-mg dose also has a clinically
significantly greater reduction in HbA1c than dapagliflozin 10 mg (but see caveats to follow).
Table 12 compares the effects and AEs of the two doses of canagliflozin, with effects taken from our NMA
and AEs from the published studies. Effects are compared with placebo. However, we do not know
whether the reduction seen with canagliflozin 300 mg in the trials would be as great in patients who
responded insufficiently to the 100-mg dose.
Sitagliptin 100 mg
Canagliflozin 300 mg
Canagliflozin 100 mg
Dapagliflozin 10 mgPioglitazone 15–45 mg
Linagliptin 5 mg
Empagliflozin 25 mg
Empagliflozin 10 mg
Vildagliptin 50 mg
Gliclazide
Placebo
FIGURE 5 Network plot: weight gain.
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Pairwise comparison
Compared with placebo
Canagliflozin 300 mg
Canagliflozin 100 mg
Empagliflozin 25 mg
Empagliflozin 10 mg
Dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with canagliflozin 300 mg
Canagliflozin 100 mg
Empagliflozin 25 mg
Empagliflozin 10 mg
Dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with canagliflozin 100 mg
Empagliflozin 25 mg
Empagliflozin 10 mg
Dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with empagliflozin 25 mg
Empagliflozin 10 mg
Dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with empagliflozin 10 mg
Dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with dapagliflozin 10 mg
Linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with linagliptin 5 mg
Sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with sitagliptin 100 mg
Vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with vildagliptin 50 mg
Gliclazide
Pioglitazone
Compared with gliclazide
Pioglitazone
–4
–2.91 (–3.22 to –2.59)
–2.02 (–2.41 to –1.65)
–1.89 (–2.29 to –1.49)
–1.74 (–2.15 to –1.33)
–1.58 (–2.01 to –1.14)
0.31 (–0.17 to 0.79)
0.74 (0.39 to 1.10)
1.16 (0.07 to 2.26)
1.97 (0.76 to 3.20)
3.80 (3.20 to 4.40)
–0.88 (0.57 to 1.21)
1.02 (0.51 to 1.54)
1.17 (0.67 to 1.70)
1.33 (0.80 to 1.86)
3.21 (2.64 to 3.79)
3.65 (3.18 to 4.12)
4.06 (2.92 to 5.21)
4.88 (3.63 to 6.15)
6.71 (6.03 to 7.38)
0.14 (–0.42 to 0.69)
0.28 (–0.26 to 0.85)
0.45 (–0.12 to 1.02)
2.33 (1.73 to 2.95)
2.76 (2.25 to 3.30)
3.18 (2.02 to 4.35)
3.99 (2.72 to 5.28)
5.82 (5.12 to 6.53)
0.15 (–0.27 to 0.57)
0.31 (–0.27 to 0.92)
2.20 (1.62 to 2.77)
2.63 (2.21 to 3.06)
3.05 (1.89 to 4.20)
3.86 (2.58 to 5.14)
5.69 (4.95 to 6.41)
0.16 (–0.45 to 0.76)
2.05 (1.48 to 2.62)
2.48 (2.06 to 2.91)
2.90 (1.72 to 4.06)
3.71 (2.44 to 4.98)
5.54 (4.81 to 6.26)
1.89 (1.23 to 2.53)
2.32 (1.74 to 2.88)
2.74 (1.56 to 3.92)
3.54 (2.24 to 4.86)
5.38 (4.65 to 6.11)
0.43 (–0.14 to 1.00)
0.85 (–0.36 to 2.05)
1.66 (0.33 to 2.98)
3.49 (2.74 to 4.25)
0.41 (–0.73 to 1.59)
1.22 (–0.04 to 2.50)
3.06 (2.37 to 3.75)
0.81 (0.27 to 1.36)
2.65 (1.38 to 3.87)
1.83 (0.45 to 3.17)
Effect (95% CI)
–2 0
Better than comparator Worse than comparator
2 6 84
FIGURE 6 Pairwise comparisons for weight gain.
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TABLE 10 Pairwise comparisons of all different flozins for weight gain
Pairwise comparison MD (95% CrIs)
Compared with placebo
Canagliflozin 300 mg –2.91 (–3.22 to –2.59)
Canagliflozin 100 mg –2.02 (–2.41 to –1.65)
Empagliflozin 25 mg –1.89 (–2.29 to –1.49)
Empagliflozin 10 mg –1.74 (–2.15 to –1.33)
Dapagliflozin 10 mg –1.58 (–2.01 to –1.14)
Linagliptin 5 mg 0.31 (–0.17 to 0.79)
Sitagliptin 100 mg 0.74 (0.39 to 1.10)
Vildagliptin 50 mg 1.16 (0.07 to 2.26)
Gliclazide 1.97 (0.76 to 3.20)
Pioglitazone 3.80 (3.20 to 4.40)
Compared with canagliflozin 300mg
Canagliflozin 100 mg 0.88 (0.57 to 1.21)
Empagliflozin 25 mg 1.02 (0.51 to 1.54)
Empagliflozin 10 mg 1.17 (0.67 to 1.70)
Dapagliflozin 10 mg 1.33 (0.80 to 1.86)
Linagliptin 5 mg 3.21 (2.64 to 3.79)
Sitagliptin 100 mg 3.65 (3.18 to 4.12)
Vildagliptin 50 mg 4.06 (2.92 to 5.21)
Gliclazide 4.88 (3.63 to 6.15)
Pioglitazone 6.71 (6.03 to 7.38)
Compared with canagliflozin 100mg
Empagliflozin 25 mg 0.14 (–0.42 to 0.69)
Empagliflozin 10 mg 0.28 (–0.26 to 0.85)
Dapagliflozin 10 mg 0.45 (–0.12 to 1.02)
Linagliptin 5 mg 2.33 (1.73 to 2.95)
Sitagliptin 100 mg 2.76 (2.25 to 3.30)
Vildagliptin 50 mg 3.18 (2.02 to 4.35)
Gliclazide 3.99 (2.72 to 5.28)
Pioglitazone 5.82 (5.12 to 6.53)
Compared with empagliflozin 25mg
Empagliflozin 10 mg 0.15 (–0.27 to 0.57)
Dapagliflozin 10 mg 0.31 (–0.27 to 0.92)
Linagliptin 5 mg 2.20 (1.62 to 2.77)
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TABLE 10 Pairwise comparisons of all different flozins for weight gain (continued )
Pairwise comparison MD (95% CrIs)
Sitagliptin 100 mg 2.63 (2.21 to 3.06)
Vildagliptin 50 mg 3.05 (1.89 to 4.20)
Gliclazide 3.86 (2.58 to 5.14)
Pioglitazone 5.69 (4.95 to 6.41)
Compared with empagliflozin 10mg
Dapagliflozin 10 mg 0.16 (–0.45 to 0.76)
Linagliptin 5 mg 2.05 (1.48 to 2.62)
Sitagliptin 100 mg 2.48 (2.06 to 2.91)
Vildagliptin 50 mg 2.90 (1.72 to 4.06)
Gliclazide 3.71 (2.44 to 4.98)
Pioglitazone 5.54 (4.81 to 6.26)
Compared with dapagliflozin 10mg
Linagliptin 5 mg 1.89 (1.23 to 2.53)
Sitagliptin 100 mg 2.32 (1.74 to 2.88)
Vildagliptin 50 mg 2.74 (1.56 to 3.92)
Gliclazide 3.54 (2.24 to 4.86)
Pioglitazone 5.38 (4.64 to 6.11)
Compared with linagliptin 5mg
Sitagliptin 100 mg 0.43 (–0.14 to 1.00)
Vildagliptin 50 mg 0.85 (–0.36 to 2.05)
Gliclazide 1.66 (0.33 to 2.98)
Pioglitazone 3.49 (2.74 to 4.25)
Compared with sitagliptin 100mg
Vildagliptin 50 mg 0.41 (–0.73 to 1.59)
Gliclazide 1.22 (–0.04 to 2.50)
Pioglitazone 3.06 (2.37 to 3.75)
Compared with vildagliptin 50mg
Gliclazide 0.81 (0.27 to 1.36)
Pioglitazone 2.65 (1.38 to 3.87)
Compared with gliclazide
Pioglitazone 1.83 (0.45 to 3.17)
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Canagliflozin 300 mg
Canagliflozin 100 mg
Dapagliflozin 10 mg
Empagliflozin 25 mg
Empagliflozin 10 mg
Sitagliptin 100 mg
Placebo
FIGURE 7 Network plot: SBP.
Pairwise comparison
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–4
–5.65 (–7.77 to –3.53)
–4.24 (–6.01 to –2.44)
–3.38 (–5.67 to –1.11)
–2.73 (–4.77 to –0.74)
–2.59 (–4.88 to –0.33)
0.80 (–1.47 to 3.11)
1.44 (–0.62 to 3.54)
2.27 (–0.85 to 5.42)
2.92 (0.03 to 5.85)
3.09 (–0.07 to 6.25)
6.45 (3.36 to 9.59)
0.83 (–2.07 to 3.72)
1.48 (–1.18 to 4.22)
1.64 (–1.30 to 4.53)
5.01 (2.15 to 7.89)
0.66 (–2.35 to 3.69)
0.79 (–1.50 to 3.04)
4.20 (1.94 to 6.50)
–0.16 (–2.95 to 3.12)
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3.40 (1.13 to 5.66)
Effect (95% CI)
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FIGURE 8 Pairwise comparisons for SBP.
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TABLE 11 Pairwise comparisons for SBP
Pairwise comparison MD (95% CrIs)
Compared with placebo
Canagliflozin 300 mg –5.65 (–7.77 to –3.53)
Canagliflozin 100 mg –4.24 (–6.01 to –2.44)
Empagliflozin 25 mg –3.38 (–5.67 to –1.11)
Dapagliflozin 10 mg –2.73 (–4.77 to –0.74)
Empagliflozin 10 mg –2.59 (–4.88 to –0.33)
Sitagliptin 100 mg 0.80 (–1.47 to 3.11)
Compared with canagliflozin 300mg
Canagliflozin 100 mg 1.44 (–0.62 to 3.54)
Empagliflozin 25 mg 2.27 (–0.85 to 5.42)
Dapagliflozin 10 mg 2.92 (0.03 to 5.85)
Empagliflozin 10 mg 3.09 (–0.07 to 6.25)
Sitagliptin 100 mg 6.45 (3.36 to 9.59)
Compared with canagliflozin 100mg
Empagliflozin 25 mg 0.83 (–2.07 to 3.72)
Dapagliflozin 10 mg 1.48 (–1.18 to 4.22)
Empagliflozin 10 mg 1.64 (–1.30 to 4.53)
Sitagliptin 100 mg 5.01 (2.15 to 7.89)
Compared with empagliflozin 25mg
Dapagliflozin 10 mg 0.66 (–2.35 to 3.69)
Empagliflozin 10 mg 0.79 (–1.50 to 3.04)
Sitagliptin 100 mg 4.20 (1.94 to 6.50)
Compared with dapagliflozin 10mg
Empagliflozin 10 mg 0.16 (–2.95 to 3.12)
Sitagliptin 100 mg 3.54 (0.53 to 6.55)
Compared with empagliflozin 10mg
Sitagliptin 100 mg 3.40 (1.13 to 5.66)
TABLE 12 Effects of canagliflozin dosages
Effect
Canagliflozin
Difference100mg 300mg
HbA1c reduction 0.95% 1.19% 0.26%
Weight reduction 2.02 kg 2.91 kg 0.89 kg
SBP reduction 4.2 mmHg 5.7 mmHg 1.5 mmHg
UTIs by 12 months 8.2% 7.1% No significant difference
GTIs by 12 months 9.2% 9.1%
Volume depletion AEs 1.5% 2.0%
Diuresis AEs 4.6% 7.6%
Reported hypoglycaemia by 12 months 5.1% 3.6% Placebo rate 2.6%
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If in patients in whom a SGLT2 inhibitor is considered the appropriate choice, it is considered worth trying
canagliflozin 300 mg if the 100-mg dose does not have enough effect; it would be logical to also try
canagliflozin 300 mg if dapagliflozin or empagliflozin are insufficiently effective. The licence implies that
they would have to switch to canagliflozin 100 mg first, if only briefly. However, the same caveat would
apply – the HbA1c reduction seen with canagliflozin 300 mg might be less amongst patients who have not
responded sufficiently to starting doses.
Table 13 shows that the differences in effects of the two empagliflozin doses are slight, using figures from
the Roden and Lewin trials.81–83
Again, a caveat is required. Those who do not respond to empagliflozin 10 mg may not achieve as great a
reduction in HbA1c after increasing to 25 mg daily, as in Table 13. The differences are, in any case, mostly
not clinically meaningful.
In the NMA reported here, dapagliflozin reduced HbA1c significantly less than canagliflozin 100 mg, but it
should be noted that the Kaku 2014 trial80 of dapagliflozin recruited patients with mean baseline HbA1c of
7.5%, whereas most trials had baseline HbA1c of around 8%. To summarise, the placebo-adjusted HbA1c
reductions in the trials at 24–26 weeks were, for the starting dosages:
l canagliflozin 100 mg:
¢ CANTATA84 0.91%
¢ Inagaki76 1.03%
l dapagliflozin 10 mg:
¢ Ferrannini77,78 0.66%
¢ Ji79 0.82%
¢ Kaku80 0.39%
l empagliflozin 10 mg:
¢ Roden82,83 0.74%.
Hence the Kaku trial,80 while qualifying for our NMA based on the baseline HbA1c of 7.5%, will be
reducing the mean effect of dapagliflozin.
When interpreting weight changes, the baseline BMIs need to be considered. The trials in China and Japan
recruited people with BMIs in the 25- to 26-kg/m2 range, whereas the European trials had mean BMIs
ranging from 28 to almost 34 kg/m2. The pattern of type 2 diabetes differs in East Asians, with lower BMI
TABLE 13 Effects of empagliflozin dosages
Effect
Empagliflozin
Difference10mg 25mg
HbA1c reduction 0.66% and 0.83% 0.78% and 0.95% 0.12%
Weight reduction 2.2 and 2.3 kg 2.4 and 2.5 kg 0.2 kg
SBP reduction 2.1 mmHg 3.7 mmHg 1.6 mmHg
UTIs by 12 months 16.3% 10.4% 5.9% in favour of 25 mg
GTIs by 12 months 5.2% 4.4% 0.8%
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and a more insulin-secretory defect.167 This does not apply to South Asians (Indian subcontinent) in whom
insulin resistance is more important.
Another factor to be considered in interpretation is that in the dapagliflozin trials, HbA1c fell in the placebo
groups, by 0.29%, and by 0.23% in the Ji79 and Ferrannini77 trials. In the Ferrannini trial,77 weight fell
significantly, by 2.2 kg. In the placebo groups in the canagliflozin trials, HbA1c rose by 0.29% (Inagaki76)
and 0.14% (Stenlöf, CANTATA-M84). Ferranini et al.77 (and the AstraZeneca submission, which talks of a
‘motivated placebo group’ on p. 58) suggested that the reduction in HbA1c in the placebo group might
have been due to improved adherence to lifestyle advice in that group, but as the placebo tablets matched
the dapagliflozin ones, this seems unlikely.
Problems with evidence and effect sizes for modelling
This review has encountered a number of problems.
Many trials provided data on only some of the variables which are used in the UKPDS Outcomes Model.
For example, SBP changes were often not reported. This applied more to older trials of comparators than
to the more recent trials of the SGLT2 inhibitors.
Some trials provided no data with which to calculate TC/HDL ratios. However, a more important problem is
that when TC levels were reported, they were often high, giving quite high TC/HDL–C ratios. It is likely
that greater use of statins renders such data obsolete. For our modelling, we will assume that all general
practitioners (GPs) and diabetologists follow NICE guidance and are using atorvastatin 20 mg for primary
prevention in all people with type 2 diabetes. This will produce a TC/HDL ratio of about 3.0.
Another problem is with effect sizes after intensifications. For example, there are reviews of the effects on
HbA1c and weight of sulfonylureas when added to monotherapy, but the bulk of evidence is addition to
metformin monotherapy. The weight gain after adding gliclazide to a SGLT2 inhibitor may be different – it
may only restore weight to the baseline before weight loss on the flozin. And the weight gain after adding
gliclazide to pioglitazone may be less because pioglitazone itself causes weight gain.
In passing, it is worth noting that the weight gains in trials may be greater than in routine primary care.
De Fine Olivarius et al.168 reported that 330 patients did not gain weight after starting on sulfonylureas.
They make the point that most patients with type 2 diabetes are treated in primary care and are seldom
recruited to trials, and that trials may therefore not be generalisable to all patients.
As regards reductions in adding sulfonylurea to monotherapy, some reviews report that adding a
sulfonylurea to metformin results in a reduction in HbA1c of around 1%. However, the size of the
reduction will depend on the HbA1c level on metformin alone. Genuth169 quotes a reduction of 1% from a
baseline of 8.3%. This may be a bigger reduction than would be seen in people who have just crept over
the NICE switching threshold of 7.5%.
In the same review, Genuth169 reports that pioglitazone added to metformin reduces HbA1c by 1.0%, and a
DPP-4 inhibitor does so by 0.7%.
Hirst et al.170 produced a good-quality systematic review and meta-analysis in which they examined
reductions in HbA1c after starting sulfonylureas in dual therapy. Sulfonylureas (glibenclamide, glipizide and
glimepiride) reduced HbA1c by 0.95% on average but with considerable heterogeneity – reductions ranged
from 0.47% to 1.3%. They found little variation in HbA1c reductions by baseline HbA1c but most of those
baselines were well above 8%, ranging from 7.5% to 9.5%. The only trial with baseline HbA1c under
8.4%, had starting HbA1c of 7.5%, and that was the trial by Feinglos et al.,171 which showed a reduction
of only 0.47%. This trial171 is closest to what we would expect in care as recommended by the NICE
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guideline,8 and with baseline HbA1c of 7.5%, the reduction in HbA1c of 0.47% would be sufficient to
improve HbA1c to around 7.0% and would be seen as a reasonable result.
One problem with the review by Hirst et al.170 was that most trials were short term. A very useful
observational study by Cook et al.172 used data on 2220 patients from the UK General Practice Research
Database (GPRD) to study glycaemic control over time after a sulfonylurea was added to metformin,
because of poor glycaemic control, with median HbA1c of 8.8%. There was a prompt reduction to median
of 7.3% after 6 months of sulfonylurea, but thereafter, HbA1c started rising again, by 0.32% between
months 6 and 12. Half of the patients had HbA1c of 8.0% or over by 1 year of starting sulfonylureas.
Cook et al.172 also noted that intensification of treatment was often delayed until HbA1c is over 9%.
However, their data were from 1998 to 2004 and may no longer apply. Nevertheless, the large drops
often reported after sulfonylureas are started may be because of very poor control, and we should not
expect such large reductions in HbA1c in carefully monitored patients who have only recently gone above
the NICE switching threshold of 7.5%.
In a trial comparing dapagliflozin with glipizide as add-ons to metformin, and with baseline HbA1c of about
7.7%, the reductions in HbA1c by week 52 were 0.50% on dapagliflozin and 0.48% on glipizide.173
The durability issue with sulfonylureas has been reported by several studies, of which the best known may
be the ADOPT (A Diabetes Outcome Progression Trial) trial174 in which time to monotherapy failure was
longer with rosiglitazone and metformin than with glibenclamide, with 34% of the glibenclamide patients
needing additional treatment by 5 years compared with only 15% of those on rosiglitazone.
Del Prato et al.173 looked at duration of effect of dapagliflozin and glipizide in dual therapy when added
to metformin. HbA1c fell more rapidly, and further on glipizide, but then rose again more quickly. So at
about 12 weeks, the falls were (from graph) about 0.8% on glipizide and 0.5% on dapagliflozin, but by
52 weeks the curves had met at reductions of about 0.5%, though about 20% of patients were absent
by that time point. After 52 weeks, HbA1c rose on both drugs, but more on glipizide, with a gap of 0.30%
by 208 months. However, the numbers by that time point were low – 20% of the dapagliflozin group and
18% of the glipizide group. The reductions were due to patients starting rescue therapy after HbA1c rose.
Rescue was mandatory once HbA1c reached 8.0% or more, and was at the investigator’s discretion
between 7.0% and 8.0%. So similar proportions in each group had to move to rescue therapy, implying
no difference in durability.
There is a 2015 abstract by Bacon et al.175 from Janssen, comparing time until insulin is started between
canagliflozin and dapagliflozin, when used in dual or triple therapy. It also used the ECHO-T2DM
(Economic and Health Outcomes Model for Type 2 Diabetes Mellitus) model. In triple therapy, the authors
report insulin being started on average at 5.1 years with canagliflozin (starting with 100 mg daily and
increasing as required to 300 mg) compared with 3.3 years with dapagliflozin. Insulin was started when
HbA1c exceeded 7.5%.
For the effects of adding sitagliptin we have two useful trials with HbA1c baseline 7.7% and 7.8%,
which reported reductions in HbA1c of 0.67% and 0.79% (Scott 2007,176 Nauck 2007177) giving a mean
of 0.73%.
A recent report from the Canadian Agency for Drugs and Technologies in Health (CADTH) (see appendix
of CADTH report)178 concludes that pioglitazone added to monotherapy reduces HbA1c by 0.78%. It also
gives the reduction with DPP-4 inhibitors as a mean of 0.7%.
At intensification to triple therapy, one option would be to introduce a long-acting (LA) GLP-1 analogue.
NICE has so far approved only exenatide LA for this purpose, but there are now other drugs in this group,
including dulaglutide and albiglutide.179
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
In the DURATION-1 (Diabetes Therapy Utilisation: Researching Changes in A1C, Weight and Other Factors
Through Intervention with Exenatide Once Weekly) trial, Drucker et al.180 compared exenatide LA with the
short-acting, twice-daily form. Patients were on a mixture of baseline treatments with only 38% on dual
therapy. However, reductions in HbA1c were reported to be similar across baseline treatment groups. On
exenatide LA, HbA1c fell by 1.9% from a baseline of 8.3%, with 60% of patients getting HbA1c under
6.5%. The advantages of using a GLP-1 analogue, compared with insulin, are the once-weekly injection,
weight loss (in DURATION 1 weight fell by 3.7 kg on exenatide LA), a low risk of hypoglycaemia (there
were no severe hypoglycaemia in DURATION 1 and minor hypoglycaemia was seen only in patients on
sulfonylurea) and some reduction in SBP (4.7 mmHg). Another advantage of adding a GLP-1 analogue to
treatment with a SGLT2 inhibitor is that the latter increases plasma glucagon levels, which would be
suppressed by the former, though if triple therapy includes a sulfonylurea such as gliclazide, glucagon
secretion may already be suppressed.181
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Chapter 4 Clinical effectiveness aspects of the
submissions from the manufacturers
Three submissions were received, from:
1. Janssen for canagliflozin
2. AstraZeneca for dapagliflozin
3. Boehringer Ingelheim for empagliflozin.
The submissions had three main sections:
1. a review of the evidence on clinical effectiveness and safety
2. a NMA comparing SGLT2 inhibitors with comparators
3. cost-effectiveness analysis.
Clinical effectiveness
As regards clinical effectiveness, the evidence provided by the manufacturers was very similar to that
presented earlier in this report. The same trials were presented. The submissions were of good quality and
we have very few comments.
The Janssen submission included 52-week results from an extension to the CANTATA-M study,92 which we
omitted because there was no comparison group. In brief, the 52-week data showed that the reductions
in HbA1c were largely maintained (reductions on 100 mg 0.91% at 26 weeks and 0.81% at 52 weeks;
reductions on 300 mg 1.16% at 26 weeks and 1.11% at 52 weeks). However, a little more weight was
lost by 52 weeks.
The Boehringer submission included data from a 76-week extension study, which had been published in
abstract form only.82 Almost 40% of patients dropped out, leading to extensive use of last observation
carried forward (LOCF), which is not a reliable method because people do not drop out at random. It is
likely that those who stayed in were doing better than those who dropped out.
The Boehringer submission made a useful point about adherence to therapy. This would apply not just
to diabetes medications: people with diabetes tend to have comorbidities such as hypertension and
osteoarthritis (due to excess weight) and so may be on other medications for other conditions. Donnan
et al.182 reported that the more medications were prescribed and the more complex the regimen, the
poorer the compliance. Eli Lilly now market a combination tablet with empagliflozin and linagliptin.
One omission from the AstraZeneca submission was any mention of cancer risk. The FDA were concerned
about breast, prostate and bladder cancer, even though in none of these cases was the risk statistically
significantly raised.183 In the trials, there were nine cases of bladder cancer amongst 5501 subjects in the
dapagliflozin group versus one amongst 3516 in the placebo arms. Some of these cancers appeared too
soon after the patients started dapagliflozin for credible causality, and all but one of the patients had had
microscopic haematuria, suggestive of bladder pathology, before starting the drug or within 6 months of
doing so.184 One hypothesis is that an increased UTI rate in patients on dapagliflozin leads to increased
testing or urine and hence of detection of bladder tumours, but 7 of the 10 patients diagnosed with
bladder cancer had not had UTIs.184
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Breast cancer was observed in nine patients (0.04% of female patients) in the dapagliflozin arms but in
none of the placebo groups. However, two cases were diagnosed within 6 weeks of starting dapagliflozin
so were certainly not due to the drug.
There were 10 cases of prostate cancer in the dapagliflozin arms (0.34%) versus three cases in the placebo
arms (0.16%).
Some cancers, albeit less common ones, were less common (though 95% CIs overlapped with no
difference) in the dapagliflozin groups, and overall there was no difference in rates for all cancers.
It is difficult to explain the differences in bladder and breast cancer, but it seems unlikely that dapagliflozin
is the cause.
Network meta-analyses
There were marked differences amongst the NMAs. For example, the AstraZeneca meta-analysis included
seven trials of sulfonylureas, with five trials involving glibenclamide. The Janssen meta-analysis included
nine trials of sulfonylureas, with five trials comparing glibenclamide with other sulfonylureas and two of
glibenclamide against pioglitazone. Only one trial was in both NMAs.
The Boehringer NMA included 22 trials involving sulfonylureas: glibenclamide, seven; glimepiride, six;
gliclazide, six; glipizide three; and tolbutamide, one.
Of the seven sulfonylurea trials in the AstraZeneca NMA, four were also in the Boehringer NMA. Of the
nine sulfonylurea trials in the Janssen NMA, three were also in the Boehringer NMA. Only one trial was in
all three of the manufacturers’ NMAs.
AstraZeneca
The AstraZeneca NMA starts with a major assumption with which the AG disagrees, which is that the
classes of drugs (sulfonylureas, TZDs, DPP-4 inhibitors and SLT2 inhibitors) can be grouped. In the case of
the TZDs, this does not matter because all of the trials cited include pioglitazone. However, our view is that
the sulfonylureas have different effects, and that gliclazide is the sulfonylurea of choice, as explained in
Chapter 1.
We also disagree with the assumption by AstraZeneca that when monotherapy fails, NPH insulin would be
started. This seems strange when there is such a range of oral medications that can be tried. We note that
a recommendation to introduce insulin as a second drug was one option in the consensus statement by a
group on behalf of the ADA and the European Association for the Study of Diabetes in 2006.185 However,
this consensus was strongly criticised by a larger group of experts as being based more on opinion
than evidence.186
One problem with the AstraZeneca NMA is the data reported in the forest plot (figure 4.6) for the pooled
sulfonylureas, which include glibenclamide, glimepride, glipizide and one gliclazide trial. The net effect
size in HbA1c lowering is 0.12%, which is unusually low. Two trials provide 85% of the weight in this
meta-analysis, Rosenstock 2013187 and Shihara 2011.188 In the forest plot for the Shihara trial,188
glimepiride is shown as reducing HbA1c by 0.10%, and in the Rosenstock trial187 glipizide is shown as
increasing HbA1c by 0.03%. These results are not credible.
In the Rosenstock trial,187 about half of the patients left the trial before conclusion, with 21.5% of the
glipizide group doing so because they needed additional ‘rescue’ treatment because of hyperglycaemia.
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About half of the recruits had been on glucose-lowering drugs before entry, and had a 4-week washout
period. However, the primary analysis included the rescued patients and this is reflected in the one of
the analyses, which reported a 0.09% reduction in HbA1c. (It is not clear where the rise of 0.03% in the
AstraZeneca forest plot comes from.) The baseline HbA1c in the glipizide group was 7.45%, and 33% had
baseline HbA1c of 7.0% or less. So a large reduction in HbA1c would not be expected. However, if the
rescue group is removed, those completing the trial had mean reduction in HbA1c of 0.31% (from text) or
about 0.5% (from graph).
The Shihara 2011 trial188 compared glimepiride and pioglitazone monotherapy in drug-naive Japanese
patients. Baseline HbA1c was 7.8% in the glimepiride group and it fell to 6.8% by 6 months (from graph –
reduction of 6.9% in text at 3 months). It is not clear where the 0.1% figure used in the AstraZeneca
meta-analysis comes from, though we note that the HbA1c difference between glimepiride and
pioglitazone at 3 months as 0.1%.
One other sulfonylurea trial in the forest plot is shown as having a very small reduction in HbA1c. This is
Erem 2014,158 which was used in the AG NMA. The AstraZeneca forest plot reports a reduction in HbA1c of
0.14% compared with placebo. There was no placebo group in Erem 2014158 which compared gliclazide
with pioglitazone and metformin. The HbA1c was reduced from 8.26% at baseline in the gliclazide group
to 6.92% at 6 months, so a more credible reduction against placebo might have been to use the 1.34%
before-and-after figure.
Given that these Rosenstock187 and Shihara188 trials dominate the meta-analysis, the sulfonylurea section of
it is not credible. It contains eight trials but the others are smaller and carry less weight. Apart from the
Erem trial,158 their HbA1c results in the other five are as expected from sulfonylureas, showing reductions
ranging from 0.6% to 1.8%.
However, these problems may just affect the forest plot. In appendix 8.9, the reduction attributed to
glipizide in the Rosenstock trial187 is 0.23%, still smaller than usual but more credible. The reduction stated
in this table for glimepiride in the Shihara trial188 is 1.0%. In addition, the caterpillar figure 8.9 in the
appendices looks reasonable and is followed by a reported difference for sulfonylureas versus placebo of
0.80% in table 8.21.
Table 4.4 in the AstraZeneca NMA gives a reduction in HbA1c of 0.99% with sulfonylureas, compared with
placebo. In the modelling a figure of –0.95% is used, which corresponds with both of the submitted
AstraZeneca models and table 5.3 of their submission. So the forest plot figures are a minor mishap that
does not affect the AZ modelling.
Review of statistical methods
The AstraZeneca submission estimated both fixed- and random-effects meta-analyses for the continuous
and count-based outcome measures. It used the DIC to assess model fit, with at least a 3-point change
signifying an improved model. Also, the manufacturer submission (MS) compared the posterior distribution
of between-study SDs with the prior distributions to assess whether or not it was updated by the available
evidence (i.e. the additional information had had an effect). Random-effects models were fitted first, as
they were considered a priori as the appropriate model. Fixed-effects models were selected only if they
significantly improved model fit as demonstrated by DIC and changes to the posterior distribution of
between-study SDs. Clinical and statistical heterogeneity were assessed through an evaluation of sources
and the I2-statistic for pairwise comparisons, respectively. Heterogeneity was examined through a sensitivity
analysis using meta-regression to adjust for the effects of baseline HbA1c. Consistency was also assessed
through a comparison of the direct and indirect evidence using pairwise meta-analyses of the active
treatments versus placebo for the outcome of HbA1c only. The overall modelling strategy used in the MS
seemed appropriate.
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AstraZeneca undertook Bayesian Markov chain Monte Carlo (MCMC) NMAs for continuous and count-based
outcome measures. It specifies that vague priors were used for unknown parameters; however, no details
were provided as to the distributions or link functions used in the models. Vague priors are usually specified;
however, there are occasions when other priors should be assessed to establish the possible effects on the
posterior estimates [e.g. binomial model with a logit link function or a rate model with log link function (when
a uniform prior is used for the SD) or when data are sparse and the model fails to converge (when vague
gamma priors are used for precision)]. No sensitivity analyses assessing the effects of different distributions,
link functions or priors were presented. As the treatments considered in the NMAs were assessed by class, this
may be less of a concern. The MS reports that MCMC models were run using three chains starting from
different values of the unknown parameters, used a burn-in of ≥ 20,000 iterations, an update of ≥ 100,000
iterations and a parameter thin of 10. Convergence was assessed using history plots of the chains for the
relevant parameters (overlapping histories indicating convergence) and a Monte Carlo error for each
parameter (error of ≤ 5% of posterior SD indicating convergence). No assessment is reported regarding the
influence of autocorrelation. The approach taken in the MS to MCMC models appears appropriate.
The MS reports NMAs on classes of treatments (i.e. SGLT2s, DPP-4s, SUs, TZDs) rather than comparing
individual treatments. Such ‘lumping’ of evidence is a concern as regards the assumption of consistency,
leading to heterogeneity, difficulties in interpreting results and potential conflict between the direct and
indirect evidence. The MS states that the rationale for considering the treatments as a class was due to
the limited evidence base for some treatments; that previous NICE CGs had indicated that they could be
considered as a class; and that heterogeneity among some individual studies in terms of study characteristics
within a class of treatments meant that comparison of individual studies may be affected by a risk of bias.
The MS should have considered a NMA of individual treatments as well as presenting one of class effects.
This would have shown results similar to the AG NMA, when dapagliflozin has slightly less effect than
empagliflozin 10 mg and canagliflozin 100 mg, the other starting doses. Although it is not clear which
treatment was the reference treatment in the NMAs, results are presented for comparisons of the treatment
classes with both placebo and SGLT2 only.
Continuous outcomes of mean change from baseline in HbA1c, weight and SBP (MD scale) and count-based
outcomes of proportion of patients experiencing hypoglycaemia (odds ratios) were used in the NMA.
Although data for the continuous outcomes were for ITT populations using LOCF, any missing data were
based on estimates from the primary study. Data time points ranged from 18 to 30 weeks.
Comparison of the baseline characteristics of the 32 studies showed variability. Although the MS stated
that the trials were generally similar in baseline characteristics, it identified that nine RCTs were conducted
only in Asian patients, one RCT had a higher mean age, one RCT had a higher mean baseline HbA1c, eight
RCTs had higher mean baseline weights and that average duration of diabetes and baseline BMI varied.
It should be noted that the included studies were conducted between 1994 and 2014 and study duration
ranged from 18 to 102 weeks. Although the effects of baseline HbA1c was assessed through meta-
regression and those associated with the Asian-only studies through exclusion of the studies in a sensitivity
analysis, possible heterogeneity associated with the other factors was not considered further.
The MS presents network diagrams of the decision space for the classes of treatment. The number of
RCTs linking each treatment class is not clear, and subsequent forest plots are presented for comparisons
with placebo only. It is difficult to judge whether or not sparse evidence networks or zero values were a
concern, although the ‘lumping’ of evidence into treatment classes may well have overcome this issue. It is
also unclear which treatment was used as the reference treatment.
The MS clearly specified the approach it had taken to the majority of the elements of its NMAs. It lacked
details concerning the prior distributions and link functions used; its assessment of autocorrelation in MCMC
models; and sensitivity analyses concerning the elements of the models themselves (e.g. prior distributions,
link functions and priors for parameters). Although it assessed some possible causes of heterogeneity,
others were not considered (e.g. participant characteristics, length of study follow-up). It appropriately
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examined consistency of the outcomes from the NMAs. The MS identified several limitations underlying its
analysis, including high placebo effects associated with the assessment of body weight in a dapagliflozin
monotherapy study and a study focusing on Asian patients; a lack of evidence on specific patient groups
(i.e. metformin intolerant); limited duration of follow-up; different definitions of hypoglycaemia; and
inconsistent reporting of safety outcomes. However, the key limitation that affects the NMA is the lack of
evidence on individual treatments. As a result, the MS ‘lumps’ together the evidence by treatment class.
This can cause concerns with regards to the assumption of consistency, and lead to heterogeneity,
difficulties in interpreting results and potential conflict between the direct and indirect evidence.
Boehringer Ingelheim
The Boehringer NMA is shaded as confidential. It was very complex and included 37 studies, including
some that the AG rejected for our NMA. All of the sulfonylureas trials were pooled into one node, which
we think is undesirable, given the mix of drugs from tolbutamide to gliclazide. The NMA includes both the
Saleem 2011149 and Jibran 2006151 papers with their striking similarities.
Janssen
The Janssen NMA included 40 studies, including some that the AG did not think relevant, such as
dapagliflozin 5 mg. It included four DPP-4 inhibitors and four sulfonylureas. It did not include repaglinide
but this was included in a sensitivity analysis.
Review of statistical methods
A Bayesian hierarchical model was used for the Janssen NMA. Although not explicitly stated, it is evident
that both fixed- and random-effects models were estimated. No analysis was undertaken of possible effect
modifiers using meta-regression; instead, sensitivity analyses excluded trials with different characteristics.
The MS used the DIC to assess the goodness of fit of the models, selecting the model with the lowest DIC
as the most appropriate. A threshold of 3 points on the DIC is used to judge significant change. Where a
random-effects model was selected as the base-case analysis, a fixed-effects model was estimated in a
sensitivity analysis. Given other statements in the MS, it is assumed that random-effects models may have
also been estimated as a sensitivity analysis when a fixed-effects model was the base case. When trials had
multiple arms, the MS correctly made adjustments to the statistical approach to account for the correlation
between treatment effects from the same trials. The approach taken was based on a conditional distribution
formulation of the multivariate normal distribution. The influence of heterogeneity was assessed through an
analysis of the direct pairwise comparison of treatments using Cochran’s Q test (p = 0.1), I2-statistic (threshold
> 50%), comparisons using forest plots and comparison of the characteristics of the trials. Consistency of the
direct and indirect evidence was compared using the difference in the respective point estimates and their
p-values, testing whether they differed statistically significantly from zero. As well as producing point estimates
(and CrIs) of the MD and odds ratios, the MS ranked the probability of the different treatments as being the
most effective based on the Surface Under the Cumulative Ranking (SUCRA). SUCRA produces probabilities
that range from 100%, showing the treatment ranks first, to 0%, which shows it ranks last. These rankings
formed the basis of the comparison of the different treatments, along with an assessment of the probability
that canagliflozin performed better than the other treatments. The comparative ranks were interpreted on
the basis that a treatment with > 70% was judged the best, between 30% and 70% no difference between
treatments, and < 30% the alternative treatment was considered best. Although the analysis lacked an
assessment of heterogeneity through meta-regression, the overall modelling strategy used in the MS
appeared appropriate.
For the NMAs of continuous outcomes, the MS correctly assumed that a Normal distribution and identity link
function should be used. Similarly, for binary outcomes, the MS appropriately selected a binomial distribution and
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logit link function. The MS states that it uses non-informative priors for unknown parameters. Priors for the Normal
distributions for treatment effects (0, 104) and the uniform distributions for between-trial SDs (binary outcomes
range (0,2); continuous outcomes range based on outcome scale with assessment of posterior distribution to select
prior distribution) were specified. Although the priors are considered suitable, issues concerning sparse data may
require other priors to be considered, particularly if the model fails to converge. Although not specifically stated
in the MS, this issue appears to have been considered as a sensitivity analysis on the prior distributions for
between-trial precision uses a gamma distribution (0.001, 0.001) for the random-effects model. No other prior
distributions appear to have been examined in sensitivity analyses.
The NMAs used MCMC simulation in WinBUGS, running three chains with different starting values. It assessed
convergence through history and Gelman–Rubin plots, although these are not presented. Fixed-effects NMAs
used a burn-in of 20,000 iterations, which were discarded, and a further 20,000 iterations to monitor the
parameters. Random-effects NMAs used a burn-in of 100,000 iterations (which were discarded) and monitored
parameters for a further 100,000 iterations. Where convergence was not achieved, iterations were increased
(numbers of iterations used not stated).
Treatments included in the NMA had to be in common use in the UK. The NMAs assessed both treatment-
and dose-specific outcomes in the classes of SGLT2, TZD and DPP-4, with those for sulfonylurea pooled to
reflect dose adjustments on a per-patient basis. The MS appropriately selected placebo as the reference
treatment for all of the evidence network diagrams; however, all results were compared with canagliflozin.
No comparisons were made between the other active treatments, which may reflect the sparse nature of
the evidence.
Continuous outcomes measured the change from baseline in each treatment arm for HbA1c, FPG, weight,
BMI and SBP. If data were missing, values were estimated as the difference between the final value and
the value at baseline, with the variance calculated using an approach recommended by the NICE Decision
Support Unit. Sensitivity analyses were conducted on the approach to estimating the variance of the mean
change (i.e. within-patient correlation varied from base case of 0.5 to 0.7). Binary outcomes used the
number of events and total patients in each treatment arm for calculating the proportion of patients
reaching HbA1c of < 7%, proportion of patients with one or more hypoglycaemic events and proportion
of patients reaching HbA1c of < 6.5%. Handling of missing data from binary outcomes is not discussed.
Outcomes were assessed at 26 weeks ± 4 weeks, with a sensitivity analysis of 26 weeks ± 10 weeks.
This variation may have led to heterogeneity in the outcomes reported, although the MS states that these
were based on expert clinical opinion. Additional sensitivity analyses were also conducted including studies
reporting outcomes from 16 to 21 weeks and/or 31–36 weeks.
There appeared to be some heterogeneity in the participant characteristics. Patients in the included
studies ranged in age from 48 to 72 years; the proportion of males from 11% to 80%; the proportion who
were white from 6% to 80%; and, in duration of their diabetes 1.1 years to 13 years. In many instances
studies did not report the characteristics of their participant populations. As a result, heterogeneity was
identified in the NMAs and sensitivity analyses were undertaken.
The MS presented evidence networks for the different comparisons undertaken. It was evident from the
network diagrams that some of the treatments were in parts of the network that were unconnected, and
these were excluded from the analyses. Other parts of the evidence networks were sparsely populated
with only one trial. Such limited data may have resulted in posterior distributions of the SDs that included
extreme values and the possibility of non-convergence of the model. This increased the uncertainty around
the outcome of the NMAs. Trials including binary outcomes were affected by zero events. Where this
occurred, the MS appropriately used a continuity correction (0.5 added to all cells counts of studies with at
least one arm with a zero). Trials with no event in any arm or that were considered to affect convergence
(basis of exclusion not stated) were excluded from the analysis.
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The trials included in the evidence network were assessed through sensitivity analyses that excluded trials
considered a source of heterogeneity or inconsistency; identified as lower quality (not double blind), where
it was unclear if it assessed monotherapies; assessed a single ethnic group; or published in a non-peer
reviewed journal or as part of a regulatory process. Further sensitivity analyses were conducted, which
included an unpublished trial (DIA3011) assessing canagliflozin 100 mg and canagliflozin 300 mg, and
repaglinide trials that included metformin and sulfonylurea.
The MS clearly outlined the key aspects of the NMAs. It estimated fixed- and random-effects Bayesian
hierarchical models using MCMC simulation in WinBUGS, evaluating the fit of the models through DIC.
Prior distributions and values were correctly assumed, with an alternative assessed through sensitivity
analysis to examine the effects of sparse data. The MS discussed the simulation process in terms of chains
run, iterations for burn-in and monitoring parameters, and the process for assessing convergence. The
analysis also assessed heterogeneity, inconsistency between direct and indirect meta-analyses, and made
adjustments for multiple treatment arms. The NMAs presented point estimates and CrIs for outcomes, and
ranked treatments as to which performed the best. Treatments were compared with canagliflozin, with no
comparisons of the other active treatments. Missing data were appropriately estimated for continuous
measures; however, there is no discussion of missing data for binary outcomes. Outcomes were assessed
at 26 weeks ± 4 weeks, with a sensitivity analysis at 26 weeks ± 10 weeks, which may have resulted in
some heterogeneity. It was evident that the network was sparsely populated in certain comparisons and
that there were zero values for binary outcomes. Although the zero values were handled appropriately
through a continuity correction, the effects of sparse data for the continuous variables may lead to
increased uncertainty around the estimates. The MS produced a range of sensitivity analyses to explore the
robustness of the models. Overall, the methods used in the NMAs appeared appropriate and identified
most limitations in the evidence. The sparse evidence base may influence the outcomes produced.
Comments
Despite the different approaches and inclusions, some findings from the different meta-analyses were
similar. For example, the differences in effect sizes of HbA1c of canagliflozin 100 mg and dapagliflozin
10 mg were reported as 0.33% (Janssen), 0.365% (Boehringer) and 0.36% (AG).
There appears to be a systematic difference between results of the AG NMA and the Boehringer NMA,
with effects on HbA1c being higher in the latter, with the AG results being closer to the trial results.
The Janssen figures are similar to the AG ones. This is shown in Table 14.
However, the relative differences between drugs are similar, and those are what matter in the modelling.
TABLE 14 Reductions in HbA1c at 24 weeks compared with placebo
Drug Janssena AG Trial
Dapagliflozin 10 mg 0.64 0.59 0.66 (Ferrannini 201077)
Empagliflozin 10 mg 0.74 0.76 0.74 (Roden 201482)
Empagliflozin 25 mg 0.85 0.88 0.86 (Roden 201482)
Canagliflozin 100 mg 0.97 0.95 0.91 (CANTATA-M 201384)
Canagliflozin 300 mg 1.20 1.19 1.17 (CANTATA-M 210384)
a Janssen figures derived from their figure 8.
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Chapter 5 Cost-effectiveness
Approach to modelling
There are several issues to consider in choosing sequences, including:
l The assumption that in most patients, the condition will progress, requiring intensification of therapy
by adding a second glucose-lowering agent – dual therapy – and, later, one or more others.
l Whether or not the second drug should vary according to what the first was. For example, after a
flozin as first drug, the choice of second drug includes sulfonylureas, gliptins and pioglitazone.
l Whether or not these drugs could also come in at later stages. For example, if dual therapy with
canagliflozin and gliclazide is failing, one option might be to add sitagliptin. Others include
pioglitazone, insulin and a GLP-1 analogue.
l We assume that if intensification to dual therapy is required, the doses of empagliflozin and
canagliflozin will already have been raised to 25 mg and 300 mg, respectively.
These options could create a need for a very large number of pathways which is beyond the scope of this
report. We also need to keep regimens after monotherapy as similar as possible in order to focus on the
differences arising from the initial monotherapy.
Dual therapy
The NICE guideline on type 2 diabetes envisages, for patients who cannot take metformin, dual therapy
with one of the following combinations:
l pioglitazone and a sulfonylurea
l pioglitazone and a gliptin
l sulfonylurea and a gliptin.
In the interest of simplicity, we have chosen the sulfonylurea as the second drug, except after gliclazide
monotherapy, when we use pioglitazone. The sulfonylurea was preferred to pioglitazone because of the
latter’s safety record. Pioglitazone is preferred to a DPP-4 inhibitor only on cost grounds.
We have assumed that patients are at the maximum tolerated dose of each monotherapy drug before
moving to dual therapy.
Triple therapy
Moving to triple therapy is more complicated, as after some of the dual regimens, pioglitazone and a gliptin
are still available, and the GLP-1 analogues and insulin enter the frame. It is not possible to review all options.
At this stage, the NICE guideline recommends that insulin-based treatment should be considered.16
In the interests of simplicity, our base case is therefore to bring in NPH insulin for triple therapy. We
therefore have sequences as follow:
l empagliflozin 25 mg→ empagliflozin + gliclazide→ empagliflozin + gliclazide + NPH insulin
l canagliflozin 300 mg→ canagliflozin + gliclazide→ canagliflozin + gliclazide + NPH
l dapagliflozin 10 mg→ dapagliflozin + gliclazide→ dapagliflozin + gliclazide + NPH
l sitagliptin 100 mg→ sitagliptin + gliclazide→ sitagliptin + gliclazide + NPH
l pioglitazone 45 mg→ pioglitazone + gliclazide→ pioglitazone + gliclazide + NPH
l gliclazide→ gliclazide + pioglitazone→ gliclazide + pioglitazone + NPH.
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Some patients will progress to needing short-acting insulin to control blood glucose after meals. We
assume that once patients move to a basal-bolus insulin regimen, the sulfonylurea will be stopped.
Note that we have not introduced any of the flozins beyond monotherapy, as those situations were dealt
with in the three single technology appraisals (STAs).
An alternative to bringing in insulin as third drug, is to consider the GLP-1 analogues. These are simpler for
patients to manage, involving a once-a-week injection, and a low risk of hypoglycaemia.
The National Institute for Health and Care Excellence has adopted a very restrictive position on the GLP-1
analogues, based on a minimum BMI, and stopping rules requiring both a 1% reduction in HbA1c and
3% weight loss, but that was not based on any cost-effectiveness analysis and is due for review.
Only one long-acting GLP-1 analogue has been appraised by NICE – long-acting exenatide. If we bring that
in as a third drug, basal insulin would be the fourth drug, with sequences as follow:
l empagliflozin 25 mg→ empagliflozin + gliclazide→ empagliflozin + gliclazide + exenatide LA→
empagliflozin + gliclazide + exenatide + NPH insulin
l canagliflozin 300 mg→ canagliflozin + gliclazide→ canagliflozin + gliclazide + exenatide LA→
canagliflozin + gliclazide + exenatide + NPH
l dapagliflozin→ dapagliflozin + gliclazide→ dapagliflozin + gliclazide + exenatide LA→
dapagliflozin + gliclazide + exenatide + NPH
l sitagliptin 100 mg→ sitagliptin + gliclazide→ sitagliptin + gliclazide + exenatide LA→
sitagliptin + gliclazide + exenatide + NPH
l pioglitazone 45 mg→ pioglitazone + gliclazide→ pioglitazone + gliclazide + exenatide LA→
pioglitazone + gliclazide + exenatide + NPH.
One problem with deriving effect sizes for modelling is that most trials recruit patients with rather poorer control
than would be expected amongst patients who are being followed up according to NICE type 2 guidelines that
recommend measuring HbA1c at 3–6 monthly intervals until HbA1c is stable (and presumably satisfactory).
So if the above guideline is being followed, patients whose HbA1c rises above the 7.5% intensification
threshold, should have that detected within a few months, before it has gone much higher. Their HbA1c
levels might be in the 7.5–8.0% range. Whereas most trials of intensification to dual or triple therapy
recruit patients with much higher HbA1c, often in the 8.7–9.05% range but sometimes well over 9%.
The importance of this is that reductions in HbA1c tend to be larger when baseline HbA1c is higher. So the
effect sizes in HbA1c seen in most trials will be larger than expected in management of type 2 diabetes
according to the NICE guideline, with close monitoring and prompt intensification.
So we need to be selective in the trials from which we extract data, rather than using effect sizes from
broad-spectrum meta-analysis.
The generalisability of trials to routine care has been examined by Thomsen et al.7 in Denmark. They
looked at the effects of adding a second drug to metformin in a large population-based cohort, and
concluded that the results were similar to those seen in the trials. The mean HbA1c at intensification was
8.0%. They observed reductions in median HbA1c of 1.2% with sulfonylureas, 0.8% with DPP-4 inhibitors,
1.3% with GLP-1 receptor agonists and 2.4% with insulin. However, these differences reflect different
baseline HbA1c levels, notably 9.5–10% amongst those who started insulin. Despite intensification, 41%
had not achieved HbA1c < 7.5% 6 months later.
Thomsen et al.7 also noted that the threshold for intensification had fallen over the years, from about
8.8% in 2000–3 to about 8.1% in 2010–12 (estimated from graph in supplementary material; figure 3).
If this has also occurred in the UK, it reinforces the need to be selective in extracting effect sizes for
modelling. In past studies, patients with type 2 diabetes were often left poorly controlled for several years
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before intensification,189,190 but this may be happening less nowadays, with improved control promoted by
the Quality Outcomes Framework of payments to general practices for demonstrating performance against
HbA1c control indicators,191 including DM007 for the HbA1c indicator. The three bands are now 59, 64 and
75 mmol/mol. All of them (not just the tightest) probably encourage initiation of insulin in practice.
Assessment Group cost-effectiveness literature review
Only one paper192 was identified that addressed the cost-effectiveness of flozin monotherapy in the patient
group under consideration. Neslusan et al.,192 available only in abstract, used the ECHO-T2DM model to
compare the cost-effectiveness of monotherapy canagliflozin 100 mg and canagliflozin 300 mg with
lifestyle management within the USA. Patients could intensify to sulfonylurea and then on to insulin, both
apparently with an 8.0% intensification threshold. By the 10th year the use of canagliflozin had delayed
the intensification to insulin such that 27% of the canagliflozin-100 mg group and 19% of the
canagliflozin-300 mg group were receiving insulin compared with 66% of those who started with lifestyle
management. Canagliflozin was reported to lower total costs and result in improved QoL over a 30-year
time horizon, and so dominated lifestyle management.
United Kingdom Prospective Diabetes Study and the United Kingdom
Prospective Diabetes Study Outcomes Models
By way of background, for much cost-effectiveness modelling in type 2 diabetes the results of the UKPDS
have been used. Until recently the main UKPDS publication relevant to cost-effectiveness modelling was
the UKPDS68.193 This outlines a number of equations for estimating the progression of the risk factors of
HbA1c, SBP, TC/HDL and smoking status through time. Given the evolution of these risk factors, the
UKPDS68193 also specifies a number of equations that calculate the annual risk of experiencing first
‘events’, these events being the macrovascular complications of diabetes, such as stroke, and the
microvascular complications of diabetes, such as blindness. The UKPDS68193 also permits the calculation
of annual probabilities of death. The UKPDS68193 was used by Oxford University to develop an electronic
cost-effectiveness model, the UKPDS Outcomes Model v1 (OM1).
There are 10 equations:
l equation 1: ischaemic heart disease (IHD)
l equation 2: MI
l equation 3: CHF
l equation 4: stroke
l equation 5: amputation
l equation 6: blindness
l equation 7: renal failure
l equation 8: event mortality
l equation 9: diabetes-related mortality
l equation 10: other mortality.
The UKPDS68193 has recently been partially updated by the UKPDS82,194 the latter incorporating longer
follow-up data of the UKPDS. This provides an alternative set of equations to estimate the probability of
events and deaths, and also permits the estimation of the probability of some second events: MI, stroke
and amputation. Oxford University has developed an updated electronic model, the UKPDS Outcomes
Model v2 (OM2). As far as the AG is aware, this currently relies upon the UKPDS68193 for the evolution of
the risk factors and the UKPDS82 for the probabilities of events and deaths. The AG has not had access to
the OM2 during the course of the assessment.
The UKPDS82194 provides the following table (Table 15) to outline the differences in the predicted number
of events at 10 years for patients of different ages.
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Ischaemic heart disease includes angina and consequences of procedures to relieve it, such as angioplasty
and coronary artery bypass grafting.
The OM1 predicts roughly double the number of MIs over 10 years, and the rates of IHD are also
noticeably higher. Possibly mainly as a consequence of the higher rate of MI predicted by the OM1, the
10-year death rate predicted by the OM1 is also noticeably higher. The OM1 will tend to over-predict
event rates compared with the OM2. The OM1 is now likely to overstate the benefits and cost savings
arising from any avoidance of the complications of diabetes that are associated with the more
effective treatment.
It is anticipated that the longer follow-up data of the UKPDS associated with the UKPDS82194 will result in
additional publications, one of which will update the evolution of the risk factors. The costs associated
with events have already been updated, the UKPDS84195 being an update of the UKPDS65.196 The QoL
estimates have also been updated in Alva et al.197 But the format of the analysis of Alva et al.197 is less
closely aligned with the events of the UKPDS84195 when compared with the alignment of the QoL
estimates of the UKPDS62198 with the events of the UKPDS68.193
Company submissions
There are three company submissions:
l Boehringer Ingelheim for empagliflozin
l AstraZeneca for dapagliflozin
l Janssen for canagliflozin.
An overarching summary of the companies’ and the AG’s modelling assumptions, inputs and results is
presented at the end of the economics section, permitting an easy read across. Readers may wish to work
through this overarching summary first, before turning to the more detailed summaries presented below
for more clarity around specific points of the individual modelling exercises.
TABLE 15 Table 2 of UKPDS82:194 10-year event rates (%): OM1 vs. OM2
Event
50–54 years 60–64 years 70–74 years All ages
OM1 OM2 OM1 OM2 OM1 OM2 OM1 OM2
First MI 14.9 7.5 22.5 10.3 29.6 13.3 21 9.9
Second MI n/a 0.9 n/a 1.0 n/a 1.1 n/a 1.0
Ulcer n/a 1.5 n/a 1.9 n/a 2.2 n/a 1.8
Blindness 2.2 2.2 3.5 3.1 4.9 4.0 3.3 2.9
IHD 8.6 6.9 10.3 8.3 10.5 9.0 9.5 7.8
First stroke 3.3 3.3 7.9 6.4 14.2 10.7 7.6 6.2
Second stroke n/a 0.3 n/a 0.7 n/a 1.5 n/a 0.7
Renal failure 0.9 0.3 1.4 0.6 1.6 0.8 1.3 0.5
First amputation 1.7 1.3 2.0 1.6 1.7 1.8 1.8 1.5
Second amputation n/a 0.4 n/a 0.6 n/a 0.4 n/a 0.4
Heart failure 3.0 2.5 5.9 4.3 9.9 6.4 5.7 4.0
Death 14.5 11.1 32.1 22.3 58.8 43.3 31.6 22.5
n/a, not applicable.
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All of the submissions contain modelling exercises with long-term time horizons of around 40 years, which
for the majority of patients will be a lifetime horizon. They all undertake a cost–utility analysis using the
appropriate perspectives of the NHS and Personal Social Services (PSS) for costs and the patient for
benefits, and discount costs and benefits at 3.5%.
Boehringer Ingelheim designed a front end to the UKPDS OM1 model. The Boehringer Ingelheim
submission has a great deal in common with the modelling of recent NICE CGs for type 2 diabetes, and
the AG modelling for the current assessment, both of which design a front end to the UKPDS OM1.
AstraZeneca uses the Cardiff Diabetes Model (CDM), which uses many of the UKPDS68193 equations and
so has much in common with the UKPDS OM1 model, but updates the calculation of the probabilities of
having an event to use the UKPDS82,194 which is the basis of the OM2.
Janssen differs from AstraZeneca and Boehringer Ingelheim in using the ECHO-T2DM model. Its base case
has assumptions that differ quite noticeably from those of the other two submissions. There is also
relatively little detail in the Janssen submission, with most of the detail being contained in the appendices
to the submission and the submitted electronic copy of the model.
In light of the above, the review of the company submissions below provides a reasonably in depth review
of the Janssen modelling. This is followed by shorter reviews of the Boehringer Ingelheim and the
AstraZeneca modellings, which are more in line with the AG modelling.
Janssen economic modelling
The ECHO-T2DM model is an individual patient simulation model developed by staff of the Swedish
Institute for Health Economics. It has been routinely submitted to the Mount (Mt) Hood Challenges. The
Mt Hood Challenges are intermittent events at which the main diabetes models are challenged to use a set
of real-world clinical inputs to predict the longer-term incidences of the various complications of diabetes
without having access to the actual longer-term incidences of the various complications. Their predictions
are then compared with the actuals. But the ECHO-T2DM submissions to the Mt Hood Challenges were
probably with different assumptions than those used for the Janssen submission, in particular with regard
to the evolution of HbA1c.
The model was run with a 40-year time horizon and a cycle length of 1 year. Costs and benefits were
discounted at 3.5%. The perspective was that of the patient for health impacts and of the NHS/PSS
for costs.
One thousand probabilistic sensitivity analysis (PSA) iterations were run for the base case, with each PSA
iteration modelling 2000 patients. It appears that each patient was run through the model only once,
with no internal loops to reduce Monte Carlo error. For the scenario analyses the number of patients was
reduced to 1500. The submission did not present any analysis of model convergence over the number
of patients modelled. It appears that only results of analyses performing the 1000 PSA iterations were
presented and that no deterministic analyses, that is analyses with no sampling of second order uncertainty,
were undertaken. This could have permitted more than 2,000 patients to be simulated and some analysis
of convergence of results as patient numbers were increased to be presented.
The model simulates the evolution of the severity of the microvascular complications of diabetes, based
mainly upon Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) data:
l retinopathy
l CKD
l neuropathy, this also encompassing PVD.
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Chronic kidney disease health states range from stage 1 with an eGFR of > 90 ml/minute/1.73 m2 to
end-stage renal disease (ESRD) with an eGFR of < 15 ml/minute/1.73 m2 for over 1 year.
The appendices to the Janssen submission state that four macrovascular complications are included:
l IHD
l MI
l stroke
l CHF.
The model also incorporates:
l patient weight
l severe hypoglycaemia
l non-severe hypoglycaemia
l UTIs
l GTIs
l peripheral oedema
l discontinuations.
Patient characteristics
Patient characteristics at baseline were drawn from a pooled analysis of the CANTATA-M84,92 and Japanese
canagliflozin76 studies, resulting in baseline estimates of 56 years of age, 52% male, 8.016% HbA1c,
128 mmHg SBP, 29.7 kg/m2 BMI, 200 mg/dl TC, 118 mg/dl LDL, 48 mg/dl HDL, 175 mg/dl triglycerides and
a mean eGFR of 86 ml/minute/1.73 m2. Note that the inclusion of the Japanese study76 pulls down the
mean BMI because the mean BMI was 25.6 kg/m2. Those in CANTATA-M84,92 had a higher BMI, mean
31.6 kg/m2.
Based upon the submitted electronic model input sheets, the mean disease duration was 4.6 years,
and was assumed to range uniformly between 0 years and 9.2 years. The proportion of patients with
background diabetic retinopathy (BDR) was 0.7%; microalbuminuria, 0.1%; and symptomatic neuropathy,
1.5%. The proportion of patients with IHD was 1.2%, MI 0.8%, stroke 0.1% and amputation 0.1%. The
other complication rates were zero.
Sequences modelled and treatment effectiveness
The Janssen submission modelled the following treatment sequences (Table 16).
Repaglinide was included only as a scenario analysis. For canagliflozin 100 mg it appears that two arms
were modelled: one that intensified by adding gliclazide. The other was classed as confidential. But the
Janssen submission is slightly ambiguous about this.
Clinical effectiveness estimates for the monotherapies were mainly drawn from the 26-week NMA, though
infection rates were drawn from the canagliflozin trials, with the flozins being assumed to have the same
rate as canagliflozin 100 mg and the other comparators the same rate as the placebo arm. Based upon the
electronic input sheets submitted by Janssen and the model having an annual cycle, the 26-week estimates
were assumed to apply at the end of the first cycle. Note also that the estimates of the electronic input
sheets are stated as being relative to placebo, and that there does not appear to be a placebo effect
within the electronic input sheets. As a consequence, it appears that the treatment effects relative to
placebo rather than the absolute treatment effects have been applied within the Janssen modelling.
The appendices to the submission present two NMAs: with and without repaglinide. The central estimates
of these appear to the AG to be virtually identical, with the exception of the rates of severe and non-
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severe hypoglycaemic events for pioglitazone and sitagliptin. Why these should differ between the two
analyses is not clear (Table 17).
As already noted, the definition of hypoglycaemia used a cut-off of below 4.0 mmol/l, which is above the
foot of the normal range of 3.5 mmol/l.
The submission appears to state that when a patient intensified by adding another therapy that the clinical
effectiveness estimates of that therapy were applied. When a patient intensified therapy by switching to
another therapy, rebound was assumed with the clinical effectiveness estimates of the initial therapy being
removed prior to applying the clinical effectiveness estimates of the therapy to which the patient was
switching. Rebound consequently appears to be to take the patients back to their baseline values for the
risk factors. And the clinical effectiveness of a treatment was assumed to be the same whether it was
being used as a monotherapy or was being added to other therapies.
At the progression to insulin the clinical effectiveness estimates in Table 18 were applied, the values being
taken from the copy of the electronic model input sheet that was submitted. The source of these estimates
was not clear to the AG.
Treatment intensification and discontinuation
Treatment intensification occurred if the patient breached the 7.5% HbA1c treatment intensification
threshold. Some details in the Janssen submission were classed as confidential and cannot be replicated here.
A key issue is whether or not the subset of patients who do poorly when treated with canagliflozin
100 mg will, when they switch to canagliflozin 300 mg, experience the same peak HbA1c effect as
estimated from the entire patient group in the trial, which was randomised to canagliflozin 300 mg from
the start.
Patients could also discontinue their current treatment because of adverse events and contraindications.
It is unclear to the AG whether those discontinuing one treatment were assumed to intensify to
monotherapy with another agent or to dual therapy with another agent.
The submission states that the treatment effects associated with discontinuations were immediately
reversed at discontinuation. If treatment effects were limited to, for example, one-off reductions in HbA1c it
is easy to see how this treatment effect could be reversed and rebound could occur. But treatment effects
are not limited to one-off effects. The evolution of HbA1c after the initial one-off effect is also treatment
specific so has to be counted as a treatment effect. The AG assumption is that rebound was to baseline
values, but this is not unambiguous and may have been treated differently for different risk factors, for
example HbA1c and weight.
TABLE 16 Janssen model treatment sequences
Monotherapy
Intensification
First Second Third Fourth
Flozin Flozin + SU NPH insulin NPH + aspart (insulin) None
Pioglitazone Pioglitazone + SU NPH insulin NPH + aspart None
Gliclazide Sitagliptin + SU NPH insulin NPH + aspart None
Sitagliptin Sitagliptin + SU NPH insulin NPH + aspart None
Repaglinide Pioglitazone Pioglitazone + SU NPH insulin NPH+ aspart
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The Janssen submission is ambiguous about whether or not the model handles treatment intensifications
and treatment discontinuations in the same manner. It is important to know whether or not rebound also
occurs when treatments are withdrawn at treatment intensification, particularly for the intensification from
repaglinide to pioglitazone, and for the intensification to insulin when patients are assumed to discontinue
their oral therapies. Appendix 4 to the main submission states that:
Treatment intensification algorithms triggered when biomarker threshold levels are exceeded
determine AHA and concomitant medication use (i.e. anti-hypertensive, dyslipidaemia) over time.
Each drug (or drug combination) is described by a profile that includes price, initial treatment effects,
bio-marker evolution, ‘rebound’ effects applied upon discontinuation, AE rates, non-compliance rates,
contraindications, and disutility (if any). A treatment sequence of rescue medications can be specified
by the user, including at least one line of rescue insulin therapy. Agents can be continued or
discontinued at bio-marker failure (HbA1c for AHA, SBP for anti-hypertensive agents, and any of the
cholesterol components for anti-dyslipidaemia agents).
To the AG, this suggests the intensifications, or discontinuation at biomarker failure of HbA1c in the above,
may be treated in the same manner as discontinuations and treatment switches, and have rebound applied
if specified by the user.
This raises the possibility of repaglinide rebounding at treatment failure, so adding 1.28% to the
then current 7.5% patient HbA1c. Intensifications to pioglitazone with its –0.78% effect and then the
subsequent intensification to add gliclazide and its effect of –0.59% may not reverse this rebound, given
the incorporation of annual drift. If this applied, patients on repaglinide could spend little to no time on
subsequent oral intensifications before intensifying to insulin. But the AG assumption is that rebound is to
the baseline value rather than to the baseline value plus annual drift, and that this rebound applies to all
of the risk factors and not just HbA1c.
It is not obviously reasonable to assume that there will be rebound when patients start insulin. The clinical
effectiveness estimates for insulin may reflect the overall effect of a switch to insulin including any
discontinuations of existing therapy.
TABLE 18 Janssen central clinical effectiveness estimates for insulin
Variable
Drug
NPH Aspart
HbA1c –0.9 –1.509
SBP – –
BMI 0.496 1.009
TC – –
LDL – –
HDL – –
Triglycerides – –
AEs
Severe hypoglycaemia 0.0049 0.04
Non-severe hypoglycaemia 0.67 44.95
Hypoglycaemia rates are events per patient per year.
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Glycated haemoglobin evolution
A major difference in assumptions in the Janssen submission compared with the other submissions and the
AG modelling is that rather than apply the UKPDS68193 equation to evolve HbA1c, treatment-specific linear
evolutions were assumed. The argument for this is that though most NICE assessments in diabetes have
used the UKPDS68193 equations to evolve HbA1c, these evolutions encompass treatment intensifications.
As a consequence, if treatment effects are being associated with treatment intensifications in the
modelling, using the UKPDS68193 evolution will tend to double count these treatment effects.
The values of these for the monotherapies were based upon values taken from the ADOPT trial as reported
in Kahn et al.174 The majority of the monotherapies under consideration were not used in the ADOPT trial,
which used rosiglitazone, metformin and glyburide (the North American name for glibenclamide). Janssen
assumes that values from treatments within the ADOPT trial apply to the monotherapies under
consideration in Table 19.
Applying the glibenclamide progression rate to gliclazide may be pessimistic given the 6-year difference in
start of insulin on gliclazide and glibenclamide, in favour of gliclazide.17
Given the annual rates of drift and the initial HbA1c treatment effects estimated in the NMA, it is apparent
that the annual rates of drift are likely to be as, if not more, important than the HbA1c treatment effects
estimated in the NMA. Owing to the NMA estimating HbA1c from 24-week data, half the annual drift is
added to the estimated treatment effect to provide the 52-week estimate.
At intensification, if another treatment is added the annual rate of HbA1c drift is assumed to be the
average of the HbA1c annual drifts of the two treatments being used as dual therapy (Table 20).
For those intensifying to insulin, Janssen derives an annual rate of drift of 0.15% from the UKPDS82.194
The impact of these different annual drifts in HbA1c is applied in tandem with the initial treatment effects.
For instance, at the central Janssen treatment effect estimates and a baseline value for HbA1c of 8.0% it
appears that for those who do not discontinue for other reasons the following evolutions are implied up to
the point at which HbA1c rises above 7.5% and treatment is intensified (Figure 9).
Immediately apparent is that for gliclazide (the topmost line) the treatment effect of –0.59% when
coupled with half of the annual drift, that is an increase of 0.12%, means that the patient is above 7.5%
at the end of the first cycle.
TABLE 19 Janssen annual rates of HbA1c drift by monotherapy
Monotherapy ADOPT equivalent Annual HbA1c drift (%)
Flozin Metformin 0.14
DPP-4: sitagliptin Metformin 0.14
SU: gliclazide SU: glyburide 0.24
Repaglinide SU: glyburide 0.24
Pioglitazone Rosiglitazone 0.07
TABLE 20 Janssen annual rates of HbA1c drift by dual therapy
Dual therapy Annual HbA1c drift (%)
Flozin + sulfonylurea 0.19
DPP-4+ SU 0.19
Pioglitazone + SU 0.16
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Turning to canagliflozin 100 mg (the solid line), despite its initial treatment effect of –0.97% being
somewhat less than the –1.28% of repaglinide, they both breach the 7.5% HbA1c intensification threshold
at the fourth year due to the differences in annual drift. The slower drift for canagliflozin 300 mg also
means that despite an initial treatment effect of –1.20% it breaches the 7.5% HbA1c intensification
threshold by 6 years.
Thereafter, it should be borne in mind that repaglinide is assumed to be replaced by pioglitazone. Owing
to the withdrawal of treatment the AG reading of the Janssen submission is that in the model this causes
the HbA1c to rebound to the original baseline value of 8.016%, and not to have the full rebound of the
repaglinide 1.28% treatment effect applied. The –0.59% pioglitazone effect is then applied with the
pioglitazone-specific HbA1c rate of drift applied, with a further intensification to pioglitazone plus SU after
this. In other words, in the repaglinide arm there is the initial repaglinide evolution of HbA1c in the above
example for 4 years, which is then followed by exactly the same HbA1c evolution as in the pioglitazone
arm, only with this being lagged by 4 years.
The same annual drifts apply for empagliflozin, dapagliflozin and sitagliptin as for canagliflozin. They also
intensify by adding gliclazide, and then on to insulin. Again, ignoring discontinuations for other reasons,
the linear evolution of HbA1c means that any difference in the timings of the first intensification is also
reflected in the timings of the intensification to insulin. It appears that the assumption of a linear evolution
of HbA1c will maintain absolute differences in HbA1c between treatments, at least until the patient
intensifies to insulin. Upon intensification to insulin it appears that the ECHO-T2DM model applies the
linear evolution for HbA1c, but then permits the patient to increase his/her insulin dose in order to stabilise
his/her HbA1c. The Janssen submission is not particularly clear on this point, but it appears that this means
that HbA1c may eventually converge between treatments once the patient has started insulin.
Pioglitazone benefits from a slower annual rate of drift, and continues to derive some benefit from this
source even after the intensification of adding gliclazide. At central parameter values and again ignoring
discontinuations it will have a permanent HbA1c benefit over all the other comparators with the possible
exception of canagliflozin 300 mg.
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FIGURE 9 Janssen modelled HbA1c drift by treatment at central values.
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Reconciling the above with the evolutions of HbA1c reported in the Janssen submission is difficult, given
the annual cycle of the model. But it should be borne in mind that the Janssen curves are averaged over a
large number of patients and PSA iterations, and include the effects of discontinuations for other reasons
(Figure 10).
For instance, the mean first year effect for the gliclazide arm as shown by the topmost curve is around a
0.95% reduction in HbA1c, which is somewhat greater than the –0.59% mean estimate for gliclazide.
Those discontinuing for reasons other than HbA1c apparently in effect switch to pioglitazone, the estimate
for which is –0.78%. Similarly, the reduction of around 1.4% in HbA1c for canagliflozin 300 mg, as shown
by the bottom curve, is also difficult to reconcile with its central estimate of –1.20%. Perhaps both
discontinuations and their treatment effects and intensifications and their treatment effects are included
in the year 1 estimates, though this timing could be questionable given the annual cycle of the model.
It remains difficult to reconcile the above with the central estimates for treatment effectiveness.
At central estimates around one-third of the canagliflozin 300 mg patients would be required to not
receive a boost of the –0.59% estimate for the intensification to gliclazide to achieve the reduction of
1.4% shown in the above figure. This also requires that none discontinue, rebound and receive a lesser
treatment effect from whatever alternative to which they switch. Any discontinuations in the canagliflozin
300-mg arm would seem to require an even larger boost to the 1.2% canagliflozin 300-mg treatment
effect among those not discontinuing if the reduction of around 1.4% is to be arrived at.
Even with the effects of second-order sampling, it is not clear to the AG how the above central estimates
for the evolutions of HbA1c have been arrived at. Perhaps there are additional placebo treatment effects in
addition to the treatment effects relative to placebo and the AG has not managed to identify these. In
light of the above, while having read the Janssen submission and its appendices, the AG does not really
understand how the model is implementing the changes in HbA1c and how the central estimate for
canagliflozin 300 mg is to reduce the patient HBA1c, on average, from 8.016% at baseline to around
6.63% at 1 year: a reduction of around 1.4%.
The above figure also sees the HbA1c values converge between the arms. Janssen states that this is
‘Because of differences in the timing of requirements for rescue medication, HbA1c, SBP, and lipid curves
tend to converge as patients with higher values benefit from treatment-related improvements earlier’.
To the AG this does not obviously explain the convergence, or why the curve for gliclazide converges by
essentially having zero increase from the tenth to the thirtieth year. A possible explanation might be the
intensification to insulin with patients then being permitted to increase their insulin dose in order to
stabilise their HbA1c.
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FIGURE 10 Janssen figure 13: submission reported evolutions of HbA1c.
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The argument that the UKPDS68 equation 11193 includes the effects of treatment intensifications does
have some force. But it should be borne in mind that the UKPDS68 equation 11193 explicitly includes a
parameter for whether or not the patient is in his/her second year of diagnosis. This could be viewed as a
proxy for the clinical effectiveness of the first treatment for diabetes being introduced, though the second
year of diagnosis might be a little early for some patients. As a consequence, modelling could as an
alternative apply treatment-specific effects and still apply the UKPDS68 equation 11193 thereafter, only
ignoring the parameter related to whether or not the patient is in his/her second year. For the patient
baseline characteristics outlined in the Janssen submission, the annual increases implied by the UKPDS68
equation 11193 in the years shortly after the second year are around 0.18%, which is broadly central to
the rates Janssen takes from the ADOPT study as reported in Kahn et al.174 This may be preferable to
extrapolating linear rates from the ADOPT trial, particularly as these rates are being applied to treatments
which were not used in the ADOPT trial, and to periods beyond the 5-year follow-up of the ADOPT trial,
and with some distinctly ad hoc averaging for the rates for dual therapy.
The AG has some sympathy with the argument that HbA1c drift may initially be treatment specific. A linear
evolution might even be the most reasonable functional form, particularly given the coefficients reported
by Kahn et al.174 But the AG does not view it as reasonable to assume a linear evolution of HbA1c
throughout and that there will be no convergence between treatments, or at least none until a patient
starts insulin therapy. This may artificially preserve differences between treatments, when the UKPDS68193
evolution clearly implies a convergence. The AG is also uncomfortable with the assumed linear rates of
drift that have been imputed from Kahn et al.,174 given that none of the monotherapies under consideration
was studied by Kahn et al.
A scenario analysis where the model applies the UKPDS68193 evolution of HbA1c was presented.
Evolution of other risk factors
Linear drifts were also assumed for the other biomarkers but these were not differentiated by treatment:
0.30 mmHg for SBP, 0.03 mg/dl for lipids resulting in a flat TC/HDL evolution. These annual rates of drift
were apparently derived from the UKPDS. The UKPDS was conducted largely before the use of statins, and
it can be argued that alternative evolutions to those of the UKPDS are now appropriate. But given that the
annual rates of drift were apparently derived from the UKPDS, it is unclear to the AG why the equations of
the UKPDS68193 were not applied.
For a patient’s SBP, the common annual rate of drift will tend to maintain the absolute differences
between the arms. As far as the AG can ascertain, it also appears that unlike HbA1c this absolute
difference for SBP will be maintained even after insulin therapy has been started.
Weight was associated with an annual gain of 0.1 kg. Table 12 of the submission states that weight drifts
upwards but there is no suggestion of a base-case assumption of convergence; table 13 goes on to
suggest that for the base case the patient’s weight was assumed to converge at treatment discontinuation,
with this being in line with figure 26 of the appendix. If this convergence applied, it is unclear whether it
was at the first intensification or was when the oral therapies were being discontinued and the patient
switched to insulin. A scenario analysis of a slower convergence over 2 years after treatment discontinuation
was also presented.
Treatment discontinuation: renal impairment
In accordance with the canagliflozin Summary of Product Characteristics (SmPC), canagliflozin 100 mg was
modelled as being discontinued if the eGFR fell below 45 ml/minute/1.73 m2; canagliflozin 300 mg was
modelled as being discontinued if the eGFR fell below 60 ml/minute/1.73 m2. The SmPC states that if the
eGFR falls below 60 ml/minute/1.73 m2 the patient should have his/her dose adjusted to 100 mg. Those
intensifying from canagliflozin 100 mg to canagliflozin 300 mg would have already failed on canagliflozin
100 mg. The licence states that canagliflozin 100 mg should always be used before canagliflozin 300 mg.
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So dose reduction may be of limited relevance and discontinuation of canagliflozin 300 mg may be the
appropriate assumption.
Empagliflozin has similar restrictions in its SmPC, with it being possible to increase the dose from 10 mg to
25 mg if the eGFR is more than 60 ml/minute/1.73 m2. If the eGFR falls below 60 ml/minute/1.73 m2 the
patient should have his/her dose adjusted to 10 mg, and if the eGFR falls below 45 ml/minute/1.73 m2 the
patient should discontinue empagliflozin.
The dapagliflozin SmPC has slightly different restrictions and is not recommended for patients with an
eGFR of less than 60 ml/minute/1.73 m2.
The sitagliptin SmPC does make the administered dose depend on renal impairment, requiring it to be
reduced to 50 mg in those with moderate renal impairment, and 25 mg in those with severe renal
impairment. But discontinuation does not appear to be required.
As far as the AG can see the submission does not state what assumptions, if any, have been made about
discontinuing empagliflozin and dapagliflozin based upon the patient’s eGFR. Table 12 of the submission
is explicit in its consideration of the canagliflozin SmPC for discontinuations related to renal impairment
and to the pioglitazone SmPC for discontinuations related to CHF, but makes no reference to the
empagliflozin SmPC or the dapagliflozin SmPC. Appendix 4 of the submission mentions that empagliflozin
and dapagliflozin also have treatment rules based upon eGFR. The input sheets to the electronic model
suggest that empagliflozin 10 mg, empagliflozin 25 mg and dapagliflozin are assumed to be discontinued
as per canagliflozin: if the eGFR drops below 60 ml/minute/1.73 m2. This appears to be incorrect for
empagliflozin 10 mg, and illogical for empagliflozin 25 mg.
The use of the ECHO-T2DM model was, in part, justified by Janssen on grounds of the need to properly
account for discontinuations due to renal impairment. In light of this, a scenario analysis that does not
apply these discontinuations would have been useful in order to assess the importance of attempting to
model this.
Treatment discontinuations: adverse events
Patients could discontinue treatments as a result of adverse events. It is not clear to the AG what was
assumed to happen to these patients. They may have discontinued their current treatment and switched to
whatever is next in the sequence, for example from flozins to SU and then on to NPH insulin, or they may
switch to an alternative monotherapy, or they may have switched to an alternative dual therapy.
Hypoglycaemic events
Hypoglycaemia event rates were derived from the pooled 26-week data of the two canagliflozin trials.
The NMA 26-week data provided the estimates for the other comparators with the exception of gliclazide.
No hypoglycaemia rates were available for gliclazide, and, as a consequence, rates for glimepiride were
adjusted by relative risks of 0.43 for symptomatic hypoglycaemia and 0.45 for severe hypoglycaemia.
The AG is unclear whether or not these rates were adjusted to be annual rates and so to be in line with
the annual model cycle.
Hypoglycaemia event rates were further modified by increasing the risk of hypoglycaemia for low HbA1c
values. The relationship underlying this was based upon a large data set of the Diabetes Control and
Complications Trial (DCCT) study among patients with type 1 diabetes. A 1% drop in HbA1c below the
mean value of the clinical study was associated with an increased hazard of hypoglycaemia of 1.43.
However, patients in the DCCT intensive arm were on either MDI or continuous subcutaneous insulin
infusion (CSII) via insulin pumps.
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Adverse events
The UTI and GTI event rates were derived from the pooled 26-week data of the two canagliflozin
trials. The AG is unclear whether or not these rates were adjusted to be annual rates and so to be in line
with the annual model cycle. The other flozins were assumed to have the same rates as canagliflozin
100 mg, with the other comparators being assumed to have the same rate as the pooled placebo arms of
the canagliflozin trials.
Quality of life
A systematic literature review was conducted, with Janssen preferring the CODE-2 (Cost of Diabetes in
Europe–Type 2) data of Bagust and Beale199 over the UKPDS62198 as a result of it providing greater richness
for the microvascular complications. Bagust and Beale199 is also the source for the QoL coefficient for BMI.
Janssen reports that no appropriate studies were identified for adverse events, and as a consequence a
time trade-off (TTO) study among 100 members of the UK general public was conducted to determine
the QoL impacts from UTIs and GTIs. This TTO study also explored hypoglycaemia, GI symptoms and
hypovolaemic events, but the estimates for these were disregarded (Table 21).
Based upon the references cited, these values apparently contributed to a regression analysis, which arrived
at the final QALY decrements. Unfortunately, the AG has not been able to source this regression analysis.
The health state descriptors suggest that the estimates relate to ongoing infection and are not time
limited, as is appropriate in a TTO study, but this implies that event health states need to be adjusted
by the average duration of UTIs and GTIs, as occurs in the Janssen submission. The method of this
adjustment does not appear to have been presented. At mean values, 1 week of a moderate UTI would
roughly correspond with a –0.0012 QALY decrement; 2 weeks of a severe UTI would roughly correspond
with a –0.0073 QALY decrement; and 1 week of a mycotic infection would roughly correspond with a
–0.0046 QALY decrement.
The QoL values applied for the baseline characteristics and microvascular complications are presented in
Table 22. Those for macrovascular complications, obesity, hypoglycaemic events and adverse events are
presented in the overarching summary comparison of the companies’ and AG’s inputs (see Table 22).
TABLE 21 Janssen TTO AE QoL report mean values
Condition Mean SD Disutility
Type 2 diabetes 0.92 0.10 –
and mild/moderate UTIs 0.83 0.14 0.09
and severe UTIs 0.73 0.20 0.19
and mycotic infection 0.67 0.26 0.25
and moderate hypoglycaemia 0.81 0.19 0.11
and severe hypoglycaemia 0.77 0.21 0.15
and fear of hypoglycaemia 0.77 0.17 0.15
and GI symptoms 0.68 0.24 0.24
and hypovolaemic events 0.84 0.14 0.08
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Costs
Direct drug costs were sourced from BNF 69147 and are not presented here for reasons of space. Note that
the Janssen analysis, in common with the other company analyses, applies the £608 cost for canagliflozin
300 mg as a result of the submission predating the equalisation of the canagliflozin list prices at the
canagliflozin 100 mg list price of £477.
The costs of blindness, IHD, MI, CHF and stroke were derived from the UKPDS84195 but are not presented
here again for reasons of space. Similar costs are presented within the section on the AG modelling. A
variety of other costs are sourced from a variety of NICE guidelines and other sources. Again, for reasons
of space, and because they have very little impact upon the modelling, these are not presented here. A full
table of event costs is presented in the appendices of the Janssen submission in table 33, starting on p. 69.
Costs are also summarised in the overarching comparison of the companies and AG modelling exercises.
Adverse event costs are given in Table 23.
Some additional costs for GTIs might be anticipated if a patient’s partner is also treated.
Results
The QALY losses in the model are presented in tables 42 and 43 of the appendices, which are summarised
in Table 24. The AG interpretation of this is that canagliflozin 100 mg has been taken as the reference for
survival with the absolute QALY losses associated with the various events also being presented. The net
absolute QALY difference between canagliflozin 100 mg and each of the comparators is then presented,
with the percentage contribution of the various events to this net QALY effect being presented alongside.
As the complications of diabetes other than neuropathy make little contribution to this, they have been
grouped together for reasons of space.
TABLE 22 Janssen QoL values: baseline and microvascular
State QoL Source
Baseline 1.027 CODE 2
Patient characteristics
Age (per 10 years) –0.0235 CODE 2
Female –0.0930
Duration of type 2 diabetes (per 10 years) –0.0163
Microvascular complications
Retinopathy (BDR, MO, PDR and combinations) 0.000 CODE 2
Blindness (one or both eyes, including combinations) –0.057
Gross proteinuria –0.048
ESRD –0.175
Symptomatic neuropathy –0.084
PVD –0.061
Symptomatic neuropathy and PVD –0.085
Diabetic foot ulcer –0.170
One lower-extremity amputation –0.272
Two lower-extremity amputations –0.272
PDR, proliferative diabetic retinopathy.
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The above shows that within the modelling survival differences account for a reasonable proportion of the
estimated differences in mean QALYs between the comparators: about one-quarter for the non-canagliflozin
comparators. But the direct QoL impacts of weight, hypoglycaemia and, to a lesser extent, neuropathy
account for the majority of the differences. The QALY losses from the other complications of diabetes are
relatively insignificant. A similar analysis can be presented for the cost differences (Table 25).
As can be seen from Table 25, the main differences in cost arise from different treatment costs for both
the oral drugs and insulin, with these being in part driven by the survival differences alluded to above.
The only real exceptions to this are for the comparison with pioglitazone, for which an additional £156
treatment cost for CHF is anticipated compared with canagliflozin 100 mg.
Ranking treatments in order of increasing total costs, the Janssen base-case cost-effectiveness results are
shown in Table 26. Note that the following table presents the ICERs relative to the cheapest comparator
among those being considered. Not all of these ICERs are presented by Janssen, with some having been
derived by the AG, so are subject to rounding errors (see Table 26).
Pioglitazone is the cheapest owing to its acquisition cost. As a consequence, although other treatments
are estimated to be more effective compared with pioglitazone their cost-effectiveness is poor. Both
gliclazide and sitagliptin are estimated to be dominated by it. Sitagliptin being dominated by pioglitazone
TABLE 24 Janssen base-case sources of QALY differences
Drug Loss Survival Hypoglycaemia AEs Weight Neuropathy Other
Canagliflozin 100 mg 1.258 – 0.213 0.015 0.553 0.358 0.119
Absolute QALY differences relative to canagliflozin 100mg, and proportionate contribution by source
Canagliflozin 300 mg +0.044 38% 11% 1% 42% 5% 3%
Canagliflozin 100/300 mg +0.012 49% 12% 1% 36% 2% 0%
Dapagliflozin –0.033 26% 7% 1% 51% 9% 6%
Empagliflozin 10 mg –0.029 28% 6% 1% 49% 10% 6%
Empagliflozin 25 mg –0.015 7% 8% 1% 70% 8% 6%
Pioglitazone –0.041 27% 33% 0% 36% 1% 4%
Gliclazide –0.090 27% 19% 2% 40% 8% 5%
Sitagliptin –0.058 23% 2% 3% 62% 4% 5%
TABLE 23 Janssen adverse event costs
Adverse event Cost (£) Description and reference
Non-severe hypoglycaemic event 0.00 Assumption
Severe hypoglycaemic event 380.00 Value taken from NICE draft CG
Lower UTIs (male) 93.01 One GP visit plus trimethoprim 200mg twice daily
Lower UTIs (female) 47.01 One GP visit plus trimethoprim 200mg twice daily
Upper UTIs (male) 94.02 Two GP visits plus trimethoprim 200mg twice daily
Upper UTIs (female) 94.02 Two GP visits plus trimethoprim 200mg twice daily
GTI (male) 52.86 One GP visit plus fluconazole for 7 days
GTI (female) 49.45 One GP visit plus one 500mg clotrimazole pessary
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may be due to its assumed faster rate of HbA1c drift. Canagliflozin 100 mg is estimated to have an ICER
of £79,537 per QALY compared with pioglitazone. Canagliflozin 100 mg also provides more QALYs at a
cheaper cost than empagliflozin and dapagliflozin, so dominating them. Canagliflozin 100 mg followed
by canagliflozin 300 mg has a better cost-effectiveness against pioglitazone than canagliflozin 100 mg,
so extendedly dominates canagliflozin 100 mg. But it is, in turn, extendedly dominated by canagliflozin
300 mg, which is estimated to have a cost-effectiveness compared with pioglitazone of £47,456 per QALY.
The cost-effectiveness of sitagliptin and the flozins is estimated to be more reasonable when compared
with gliclazide. But canagliflozin 100 mg extendedly dominates sitagliptin and dominates empagliflozin
and dapagliflozin.
TABLE 26 Janssen base-case cost-effectiveness estimates
Drug Cost (£) QALY
vs. Pioglitazone vs. Gliclazide vs. Sitagliptin
Δ£ ΔQALY ICER (£) Δ£ ΔQALY ICER (£) Δ£ ΔQALY ICER (£)
Pioglitazone 20,264 9.998
Gliclazide 23,220 9.949 2956 –0.049 Dom
Sitagliptin 23,443 9.981 3179 –0.017 Dom 223 0.032 6969
Canagliflozin
100 mg
23,525 10.039 3261 0.041 79,537 305 0.090 3377 82 0.058 1414
Empagliflozin
25 mg
23,528 10.024 3264 0.026 125,538 308 0.075 4107 85 0.043 1977
Empagliflozin
10 mg
23,580 10.010 3316 0.012 276,333 360 0.061 5902 137 0.029 4724
Dapagliflozin 23,594 10.006 3330 0.008 416,250 374 0.057 6561 151 0.025 6040
Canagliflozin
100/300 mg
23,669 10.051 3405 0.053 64,245 449 0.102 4402 226 0.070 3229
Canagliflozin
300 mg
24,302 10.083 4038 0.085 47,456 1082 0.134 8075 859 0.102 8422
Dom, dominated by pioglitazone.
TABLE 25 Janssen base-case sources of cost differences
Drug Total Oral treatment Insulin Hypoglycaemia AEs Neuropathy Other
Canagliflozin 100 mg £23,525 £3190 £5604 £142 £179 £6350 £8060
Absolute cost differences relative to canagliflozin 100mg, and proportionate contribution by source
Canagliflozin 300 mg £777 73% 21% 1% 0% 2% 3%
Canagliflozin 100/300 mg £144 61% 33% 0% 0% 0% 4%
Dapagliflozin £69 46% 45% 1% 0% 2% 5%
Empagliflozin 10 mg £55 47% 44% 0% 0% 3% 6%
Empagliflozin 25 mg £3 49% 43% 0% 1% 3% 5%
Pioglitazone –£3261 68% 23% 1% 1% 1% 7%
Gliclazide –£305 53% 39% 0% 1% 2% 4%
Sitagliptin –£82 49% 30% 1% 3% 2% 14%
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Across the nine comparators, the probabilistic modelling suggested that if the willingness to pay is zero,
pioglitazone has a 100% probability of being the most cost-effective treatment. This probability declined
as the willingness to pay increased, until at around a willingness to pay of £55,000 it ceased to have the
highest probability of being the most cost-effective treatment. At this point canagliflozin 300 mg overtook
it, with a probability of being the most cost-effective of around 25%.
At high willingness-to-pay values of £200,000 per QALY it appears that the probabilities of being the most
cost-effective have stabilised. Canagliflozin 300 mg remains the highest with a probability of around 33%.
The others increase their probabilities as the willingness to pay rises, but still converge only to values under
20%, with the values for empagliflozin 10 mg, dapagliflozin 10 mg, sitagliptin 100 mg and gliclazide never
rising above 10%.
Sensitivity analyses
The univariate sensitivity analyses presented by Janssen vary parameters by an arbitrary ±20% and are
consequently of limited interest. Full results of these are presented in tables 46–48 of the appendices to
the submission. The main result of interest is that the modelling is sensitive to the annual rate of HbA1c
drift that is assumed for canagliflozin: deterministic sensitivity analyses (DSAs) number 6 lower value and
upper value (6L and 6U), which, respectively, decrease and increase the base case 0.14% annual rate of
drift by 20%. The cost-effectiveness estimates under DSA 6L and DSA 6U for canagliflozin 100 mg
compared with:
l pioglitazone are £45,862 per QALY and £211,000 per QALY, respectively
l gliclazide are £593 per QALY and £8751 per QALY, respectively
l sitagliptin are dominance and £8528 per QALY, respectively.
In the opinion of the AG these changes are likely to be due more to the time spent on therapy and its
immediate effects upon treatment cost, weight, adverse events and hypoglycaemia than to any changes in
the modelled complications of diabetes. An exception to this might be the modelled rates of neuropathy.
Scenario analyses
A range of scenario analyses as summarised in table 13 on p. 52 of the Janssen submission is presented,
with summary results for all of these in tables 19 and 20 of the Janssen submission. The main points of
interest identified by the AG are summarised below.
For the comparison with empagliflozin and dapagliflozin the main scenario analyses of interest are
those that:
l revise the patient characteristics at baseline from those that Janssen pools from its trials to those of
The Health Improvement Network (THIN) database, which is the database that underlies the patient
characteristics of the modelling for the draft NICE CG: Sc5. The THIN database has anonymised patient
data from 562 general practices covering 6.2% of the population.200
l apply the UKPDS68193 HbA1c evolution equation and UKPDS62198 QoL values, while also assuming that
patients can intensify to NPH insulin but not to basal-bolus insulin: Sc6; and,
l apply the UKPDS68193 HbA1c evolution equation: Sc14.
These scenario analyses remove the dominance of canagliflozin 100 mg over empagliflozin and
dapagliflozin with the cost-effectiveness estimates typically changing to lie between £5000 and £10,000
per QALY.
Scenario analysis 14 is rather more dramatic in terms of the cost-effectiveness estimates. But it would
probably be more accurate to describe it as showing broad clinical equivalence, but additional costs from
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canagliflozin compared with dapagliflozin, empagliflozin 10 mg and empagliflozin 25 mg of £198, £150
and £65, respectively.
Including repaglinide: scenario 1
The analysis that includes repaglinide differs little from the base-case analysis, but with repaglinide being
estimated to have total costs of £22,170 and total QALYs of 9.967. As a consequence it is dominated
by pioglitazone. If pioglitazone is excluded from this analysis gliclazide is still dominated, only now by
sitagliptin. Sitagliptin with a cost-effectiveness of £79,400 per QALY compared with repaglinide is, in turn,
extendedly dominated by canagliflozin 100 mg, which has a cost-effectiveness of £21,050 per QALY
compared with repaglinide. Empagliflozin and dapagliflozin remain dominated by canagliflozin 100 mg.
Canagliflozin 100 mg followed by canagliflozin 300 mg has a cost-effectiveness estimate compared with
repaglinide of £20,816 per QALY, which is, again, extendedly dominated by canagliflozin 300 mg, which
has a cost-effectiveness of £20,200 per QALY compared with repaglinide.
Same annual glycated haemoglobin drift across the monotherapies:
scenario 2
Unfortunately, table 50 of the Janssen submission appendices does not provide the estimates for the
canagliflozin 300-mg arm. But the estimates for canagliflozin 100 mg and canagliflozin 100/300 mg are
extremely similar to those of the base case, and, as a consequence, the AG has used the estimates of the
base case for canagliflozin 300 mg for Table 27. The reported ICERs are all compared with repaglinide
(see Table 27).
If the annual HbA1c drift across the monotherapies is set equal to that of canagliflozin 100 mg, this
somewhat worsens the cost-effectiveness of pioglitazone to the extent that it is now dominated by
repaglinide. The cost-effectiveness estimate for canagliflozin 100 mg compared with pioglitazone improves
to £24,233 per QALY.
Assuming the same annual rate of HbA1c drift across the comparators improves the cost-effectiveness of
repaglinide and somewhat worsens the cost-effectiveness estimates for canagliflozin compared with
repaglinide. But the cost-effectiveness estimate for canagliflozin compared with pioglitazone improves.
TABLE 27 Janssen scenario analysis: common HbA1c annual drift
Drug Cost (£) QALY ICER
Repaglinide 20,982 10.03
Pioglitazone 21,485 9.95 Dom
Gliclazide 22,589 10.01 Dom
Sitagliptin 23,615 9.99 Dom
Canagliflozin 100 mg 23,732 10.05 £137,500
Empagliflozin 25 mg 23,732 10.03 Dom
Empagliflozin 10 mg 23,739 10.02 Dom
Dapagliflozin 23,786 10.02 Dom
Canagliflozin 100/300 mg 23,853 10.06 £95,700
Canagliflozin 300 24,594 10.09 £63,368
Dom, dominated by repaglinide
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Lower body mass index disutility: scenario 4
Revising the disutility per BMI point from 0.0061 to 0.0038 has quite a large impact upon some results,
as would be anticipated. The cost-effectiveness estimate for canagliflozin 100 mg compared with
pioglitazone worsens to £146,000 per QALY and compared with repaglinide to £26,378 per QALY. The other
cost-effectiveness estimates are not particularly affected. Canagliflozin 100 mg is still estimated to dominate
the other flozins.
UKPDS68 glycated haemoglobin evolution coupled with UKPDS62 quality of
life: scenario 6
This scenario applied the UKPDS68193 HbA1c evolution and some of the UKPDS62198 QoL values. It also
assumed that there was no intensification to basal-bolus insulin. The rationale for these grouped changes
is not obvious, and as a consequence the AG prefers scenario analysis 14.
UKPDS glycated haemoglobin evolution: scenario 14
Applying the UKPDS HbA1c evolution isolates the effects of this compared with scenario 6. The full results
for this scenario do not appear to be reported in the Janssen appendices. As already reported above,
for the comparisons with the other flozins there is broad clinical equivalence but there are additional costs
from canagliflozin 100 mg compared with dapagliflozin, empagliflozin 10 mg and empagliflozin 25 mg
of £198, £150 and £65, respectively. Similarly, there is broad clinical equivalence with gliclazide but a
rather larger incremental cost of £744. The cost-effectiveness of canagliflozin 100 mg compared with
pioglitazone improves somewhat to £31,945 per QALY.
The assumptions around the evolution of HbA1c are clearly central to the Janssen modelling. In the opinion
of the AG this is not due to the complications of diabetes being modelled as changing. In the opinion of
the AG it is likely to be mainly due to the amount of time a patient is modelled as spending on the various
oral therapies changing. This primarily affects the direct drug costs of treatment, patients’ weights,
hypoglycaemia and adverse events.
AstraZeneca economic modelling
The CDM is an individual patient-level model that has been used for previous NICE assessments. It has
been routinely submitted to the Mt Hood Challenges. But these submissions to the Mt Hood Challenges
were with different assumptions than those used for the AstraZeneca submission.
The modelling of the complications of diabetes within the CDM was previously largely based upon the
UKPDS68193 risk equations, these being the basis of the UKPDS OM1 model. For the AstraZeneca
submission, the CDM modelling of the complications of diabetes has been updated to use the UKPDS82194
risk equations, these being the basis of the UKPDS OM2 model. Note that for the probabilistic modelling
the UKPDS researchers have made available the 1000 bootstraps of the equations underlying the UKPDS
OM1 model to the Mt Hood Challenge modellers. As far as the AG is aware, the corollary of these has not
been made available for the equations underlying the UKPDS OM2 model. As a consequence, it is not
clear how the CDM of the AstraZeneca submission has implemented the probabilistic modelling.
During the STA of dapagliflozin the ERG noted various errors in the CDM implementation formulae for the
evolution of the risk factors, which were subsequently corrected during the course of the STA. The AG
assumption is that within the AstraZeneca submission these errors have been corrected.
The model was run with a 40-year time horizon and a cycle length of 6 months. Costs and benefits were
discounted at 3.5%. The perspective was that of the patient for health impacts and of the NHS/PSS
for costs.
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It appears that for a deterministic model run 30,000 patients were run. It appears that each patient was run
through the model only once, with no internal loops to reduce Monte Carlo error. Probabilistic modelling
was based upon 1000 PSA iterations, each with 30,000 patients being simulated. The submission did not
present any analysis of model convergence over the number of patients modelled. The CDM permits only
pairwise comparisons. As a consequence, the uncertainty around the cost-effectiveness estimates is not
presented across all of the comparators, but only in a pairwise fashion.
The AstraZeneca submission notes that among those receiving monotherapy, among the comparators
within the NICE scope, sulfonylurea has the largest market share of 80%. The gliptins share is stated as
being 13%, followed by 4% for the glitazones. AstraZeneca argues that the main comparator for the
flozins will be the gliptins, which, if true, would justify the concentration upon pairwise comparisons.
The CDM models the incidence of the following microvascular complications:
l amputation
l nephropathy
l blindness.
Four macrovascular complications are included:
l IHD
l MI
l stroke, and
l CHF.
The model also incorporates:
l patient weight
l severe hypoglycaemia
l UTIs
l GTI, and
l discontinuations.
Patient characteristics
Patient characteristics at baseline were mainly drawn from the NMA, resulting in baseline estimates of
55 years of age, 54.6% male, 7.5% HbA1c due to NICE CGs, though the NMA mean of 8.2% was used
as a scenario analysis, 128.3 mmHg SBP, 195 mg/dl TC, 46 mg/dl HDL and a weight of 80 kg.
The submission does not appear to state what the baseline prevalence of the complications of diabetes
was. The submitted electronic model sets these to zero.
Sequences modelled and treatment effectiveness
The comparators were grouped into their class as per the AstraZeneca NMA, for example the cost-
effectiveness of flozins as a group was estimated compared with the gliptins as a group. Note that of the
glitazones only pioglitazone was considered, rather than a class effect being applied. Repaglinide was not
considered as a comparator owing to a lack of evidence.
AstraZeneca argues that allowing the intensifications to differ between the arms would not permit a fair
assessment of the cost-effectiveness of alternative monotherapies, but would rather be a comparison of
the cost-effectiveness of alternative treatment sequences. Consequently, the AstraZeneca submission
modelled the following treatment sequences despite this not reflecting UK clinical practice (Table 28).
Intensified insulin was assumed to involve a 50% dose escalation.
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Clinical effectiveness estimates for the monotherapies were drawn mainly from the 24-week NMA.
Infection rates were not meta-analysed, but were drawn from a weighted pooled mean of incidence data
at 24 weeks from the papers included in the NMA. Clinical effectiveness estimates for insulin were drawn
from Monami et al.201 for NPH and from Waugh et al.202 for intensified NPH (Table 29). (The AG does not
know how these figures for ‘intensified NPH’ were obtained. Usually if NPH was insufficient, short-acting
insulin would be added at mealtimes.)
Treatment intensifications and discontinuations
A patient is modelled as intensifying treatment, first to NPH and then to intensified NPH, when their HbA1c
breaches the 7.5% intensification threshold. The AG assumption is that the monotherapies are withdrawn
at treatment intensification, but this is not explicit within the AstraZeneca submission.
Patients may also discontinue due to adverse events. The AG was unable to identify what was assumed for
these patients: whether they switched to an alternative monotherapy and, if so, which, or they intensified
to NPH insulin.
Glycated haemoglobin evolution
In common with the AG modelling, the evolution of HbA1c is based upon equation 11 of the UKPDS68.193
Treatment intensification occurs if a patient’s HbA1c breaches the 7.5% intensification threshold. This leads
to a sawtooth evolution of HbA1c, as described in more detail in the section on the AG modelling.
Evolution of other risk factors
The evolution of SBP and the TC/HDL ratio was also based upon equations 12 and 13 of the UKPDS68.193
The section on the AG modelling describes this in some detail so it is not further described here.
TABLE 29 AstraZeneca central clinical effectiveness estimates
Drug Flozin Gliptin Pioglitazone SU NPH Intensified NPH
HbA1c –0.74 –0.64 –0.90 –0.95 –1.10 –1.11
SBP –5.87 –1.53 –1.31 –0.65 – –
Weight (kg) –2.81 –0.13 2.61 0.07 1.08 1.90
AEs
UTI 0.092 0.022 0.153 – – –
GTI 0.074 0.002 – – – –
Severe hypoglycaemia 0.010 0.016 0.024 0.055 0.0004 0.0136
Non-severe hypoglycaemia – – – – 0.0104 0.6024
First-cycle discontinuation 0.034 0.039 0.177 0.061 – –
TABLE 28 AstraZeneca model treatment sequences
Monotherapy
Intensification
First Second
Flozin NPH insulin Intensified NPH
Gliptin NPH insulin Intensified NPH
Pioglitazone NPH insulin Intensified NPH
Sulfonylurea NPH insulin Intensified NPH
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Weight loss with the flozins is assumed to be maintained for 2 years, after which it is assumed that
patients rebound to their starting weight. A similar assumption appears to have been made for the
gliptins, though the weight loss is maintained for only 1 year. The weight increases associated with the
other treatments are assumed to be retained. Weight is also assumed to increase by 0.1 kg annually.
Quality of life
The QoL for a patient without any complications is a function of patient age, as drawn from analysis of
EuroQol-5 Dimensions (EQ-5D) data from the Health Survey for England 2003:203
QoL = 1:2066− 0:0184 × age + 0:0004 × age2 − 0:0000026 × age3. (1)
This results in a baseline QoL of 0.882, with this slowly declining over time.
Quality-of-life decrements associated with the complications of diabetes were drawn from the UKPDS62198
with the exception of that for ESRD, which was drawn from the standard UKPDS OM1 source. QoL
decrements for hypoglycaemic events were drawn from Currie et al.204 but note that it appears that the
coefficient for symptomatic event was applied to the number of symptomatic events rather than to their
logarithm. The QoL impacts of increasing BMI was drawn from Bagust and Beale.199 These sources and
values are all as per the AG modelling, so are not tabulated here for reasons of space.
Note that the submission suggests that the BMI disutility is applied for all BMI changes and is not limited in
its effects to changes in BMI when the patient BMI is greater than 25 kg/m2. If this applies it may have biased
the analysis in favour of the flozins by valuing reductions on patients’ BMI among those with a BMI of less
than 25 kg/m2. But given the mean BMI at baseline of 29.2 kg/m2 this may not be a particular concern.
A systematic literature review was conducted for UTI and GTI QoL decrements. For UTIs the average of the
values of Barry et al.205 of –0.3732 for pyelonephritis and of –0.2894 for dysuria appears to have been
coupled with an assumed duration of around 3 days to yield a QALY decrement of –0.00283 per UTI.
Apparently no values were found for GTIs and, as a consequence, these had the same disutility applied.
Costs
The direct drug costs were sourced from the BNF 69.147 For both the flozins and the gliptins, weighted
average costs based upon their UK market share were used. This resulted in a mean annual flozin cost of
£482 and a mean annual gliptin cost of £429. The annual cost of pioglitazone was £19 and the annual
sulfonylurea cost was based upon gliclazide at an annual cost of £66. The cost of gliclazide suggests to the
AG that MR gliclazide has been assumed, as the standard version would be around half of the cost that
was applied.
The costs of the complications of diabetes in the first year and for subsequent years for blindness and
amputation were based upon the UKPDS84.195 This is the same source as the AG, though the AG arrives
at somewhat lower values. There may be a suggestion that indexation by AstraZeneca was based on 2007
prices, when the UKPDS84195 is in 2012 prices. But the source of the discrepancies is unclear.
The AG calculations suggest that the UKPDS84195 average inpatient costs and outpatient costs for those
without any of the modelled complications have not been included within the AstraZeneca modelling. If
this is the case it would be a quite serious omission, and would tend to bias the analysis in favour of the
more effective treatment.
AstraZeneca may have used the UKPDS84195 bespoke costing template to derive costs for a representative
baseline patient, but this seems unlikely to be the source of the discrepancies between AstraZeneca and
the AG. The AstraZeneca mean age at baseline is 55 years, whereas the AG, in order to be able to
implement the costs probabilistically, has taken the costs example of the UKPDS82194 for a 60-year-old
man. Costs are typically increasing with age in the UKPDS84.195
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Table 5.10 of the AstraZeneca submission also does not include a cost for fatal IHD events despite these
being within the UKPDS84195 and seeming to be associated with deaths in the UKPDS82194 and the UKPDS
OM2. The UKPDS65,196 which goes along with the UKPDS68193 and the UKPDS OM1, does not itemise a cost
for fatal IHD events. But the AG understanding is that the AstraZeneca CDM modelling is based upon the
UKPDS82194 and, as a consequence, does not understand why fatal IHD events have had a zero cost assigned.
For reasons that are unclear, AstraZeneca chose to revert to the costs of the UKPDS65196 for the ongoing
costs among those with a history of IHD, CHF and stroke, and probably MI as well. This seems peculiar to
the AG, given that the UKPDS82194 and the UKPDS65196 are very similar in their format, with the UKPDS82194
also presenting cost estimates for those with a history of IHD, CHF, stroke and MI.
End-stage renal disease was costed using the estimate of Baboolal et al.206 for continuous ambulatory
peritoneal dialysis. Previous NICE assessments have also used this reference, though have also tended to
use the higher cost estimates within Baboolal et al.206 for hospital haemodialysis. AstraZeneca argued that
the use of the peritoneal dialysis cost was conservative.
Severe hypoglycaemia was costed using the Hammer et al. (2009) reference,207 which is the reference used
for the AG modelling. UTIs and GTIs were assumed to involve one GP appointment, costed at £46 using
the Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care 2014208 (Table 30).
Results
The CDM modelling for the base-case results is shown in Table 31. The AG assumption is that this is based
upon deterministic modelling, that is with no second order sampling.
Within the pairwise comparisons, compared with the sulfonylureas the flozins offer some additional benefit
of 0.027 QALYs, but there are reasonable additional costs of £1397 associated with this resulting in a
cost-effectiveness estimate of £52,047 per QALY.
The gains from the flozins compared with pioglitazone are larger at 0.095 QALYs, which may be sufficient
to justify the additional cost of £1912, which results in a cost-effectiveness estimate of £20,089 per QALY.
When compared with the gliptins, the flozins provide only a small additional gain of 0.018 QALYs, but this
is also at a relatively modest additional £106 cost, which results in a cost-effectiveness estimate of £5904
per QALY.
TABLE 30 AstraZeneca costs (£) of complications and adverse events
Event
First year
Subsequent yearsFatal Non-fatal
IHD 12,762 1395
MI 2605 7938 2177
CHF 5180 1656
Stroke 5188 11,450 1378
Amputation 13,499 4618
Blindness 6502 2307
ESRD (including dialysis) 18,776 18,776
Severe hypoglycaemia 424 424
UTI 46 46
GTI 46 46
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The probabilistic pairwise modelling suggests that the flozins have a probability of being cost-effective
(using the NICE threshold of £30,000 per QALY) compared with the gliptin of 66%, compared with
pioglitazone of 51% and compared with the sulfonylureas of 13%.
Ranking results in order of increasing cost are provided in Table 32.
As would be anticipated from the pairwise comparisons, it appears that the sulfonylureas have an
acceptable cost-effectiveness compared with pioglitazone of £7574 per QALY. The gliptins offer minimal
patient benefit compared with the sulfonylureas, 0.009 QALYs or the equivalent of around an additional
4 days’ survival, but with a reasonable increase in costs of £1291 and a cost-effectiveness estimate of
£143,000 per QALY. As already noted, the flozins cost-effectiveness estimate compared with the gliptins is
good at £5904 per QALY, but is poor against the sulfonylureas at £52,047 per QALY.
A variety of univariate sensitivity analyses were presented, which varied the clinical effectiveness estimates
to their upper and lower CI limits, the disutilities for BMI changes to their upper and lower CI limits; the
disutilities for complications by ±10%; and the total non-drug costs by ±25%.
Only the changes to the BMI disutility had any marked impact, with these impacts being mainly for the
comparisons with pioglitazone and sulfonylurea. The lower confidence limit for the disutility of weight
gains improved the cost-effectiveness estimate compared with pioglitazone from £20,089 per QALY to
£14,626 per QALY, whereas the upper confidence limit worsened it to £32,065 per QALY. The lower
confidence limit for the utility of weight losses worsened the cost-effectiveness compared with the
sulfonylureas from £52,047 per QALY to £62,810 per QALY, whereas the upper confidence limit improved
it to £4434 per QALY.
Owing to the CDM of AstraZeneca modelling only pairwise comparisons, the probabilistic modelling is
presented only for the pairwise comparisons.
TABLE 31 AstraZeneca base-case results: pairwise comparisons
Costs Flozins Gliptins Net Pioglitazone Net SU Net
Drug £5638 £5449 £190 £4066 £1572 £4128 £1510
Macrovascular complications £9179 £9251 –£72 £9319 –£140 £9226 –£47
Microvascular complications £12,924 £12,938 –£14 £12,433 £491 £12,935 –£11
Hypoglycaemia £175 £184 –£9 £197 –£22 £244 –£69
Other AE £63 £51 £12 £53 £10 £49 £14
Total £27,979 £27,873 £106 £26,067 £1912 £26,582 £1397
QALYs 13.206 13.188 0.018 13.111 0.095 13.179 0.027
ICER £5904 £20,089 £52,047
TABLE 32 AstraZeneca base-case results
Drug Cost (£) Net (£) QALY Net ICER (£)
Pioglitazone 26,067 13.111
SU 26,582 515 13.179 0.068 7574
Gliptins 27,873 1291 13.188 0.009 143,444
Flozins 27,979 106 13.206 0.018 5904
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Compared with the gliptins, at willingness-to-pay values of £0, £20,000 and £30,000 per QALY the flozins
are estimated to have a probability of being the most cost-effective of around 42%, 65% and 68%, with the
cost-effectiveness acceptability curve (CEAC) converging to a little over 70% at high willingness-to-pay values.
Compared with pioglitazone, at willingness-to-pay values of £0, £20,000 and £30,000 per QALY the
flozins are estimated to have a probability of being the most cost-effective of around 0%, 50% and 80%,
with the CEAC converging to a little over 95% at high willingness-to-pay values.
Compared with sulfonylurea, at willingness-to-pay values of £0, £20,000 and £30,000 per QALY the
flozins are estimated to have a probability of being the most cost-effective of around 0%, 12% and 26%,
with the CEAC still slowly increasing to a little over 60% at a willingness to pay of £100,000 per QALY.
Scenario analyses
A range of scenario analyses were undertaken, mainly varying the HbA1c values at baseline and HbA1c
thresholds for intensifying treatment, altering the assumptions around maintenance of weight effects and
the drug costs that were applied (Table 33).
The scenario analyses around adverse events and discontinuations for the comparison with pioglitazone
were reported as having the same values as the corresponding analyses for sitagliptin, so appear to be
typographical errors.
Less stringent thresholds for intensification of therapy tended to worsen the cost-effectiveness estimates.
This seems likely to be mainly due to patients remaining on their monotherapy for longer and the associated
increase in the direct drug costs, and not due to differences in the modelled complications of diabetes.
TABLE 33 AstraZeneca scenario analyses: cost-effectiveness estimates for the flozins
Scenario
vs. Gliptins vs. Pioglitazone vs. SUs
Δ£ ΔQALY ICER Δ£ ΔQALY ICER Δ£ ΔQALY ICER
HbA1c baseline 7.5%, threshold
8.0%
£225 0.021 £10,799 £3059 0.106 £28,970 £2335 0.037 £63,783
HbA1c baseline 8.19%, threshold
8.19%
£198 0.023 £8694 £3327 0.101 £32,982 £1846 0.021 £88,934
HbA1c baseline 7.5%, threshold
7.5%, 8.0%
£100 0.020 £4977 £1902 0.101 £18,884 £1382 0.026 £53,057
Flozin weight maintenance
1 year
£22 0.014 £1583 £1828 0.091 £20,077 £1313 0.023 £57,839
Comparator weight
maintenance 2 years
£115 0.014 £8137 £1913 0.101 £19,032 £1435 0.028 £51,166
Flozin and pioglitazone weight
convergence at final switch
– – – £1818 0.048 £38,199 – – –
No discontinuations £69 0.023 £3035 NA NA NA £1431 0.028 £51,718
No AE disutility £106 0.019 £5685 NA NA NA £1397 0.028 £50,456
Canagliflozin 100 mg and 300
market share 10%
£137 0.018 £7585 £1943 0.095 £20,407 £1427 0.027 £53,176
Sitagliptin price £90 0.018 £4996 – – – – – –
Alogliptin price £410 0.018 £22,756 – – – – – –
20-year time horizon £100 0.020 £5093 £1841 0.089 £20,611 £1399 0.028 £49,275
NA, not available.
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Weight convergence between the flozins and pioglitazone somewhat worsens the cost-effectiveness
estimate, because of this removing the weight gains associated with pioglitazone. Note that this
convergence is imposed only at around the seventh or eighth year of the modelling.
Results compared with the gliptins are not particularly sensitive to whether the sitagliptin price is applied
rather than the gliptins’ prices weighted by their market shares, due to AstraZeneca estimating sitagliptin
to have a market share of the gliptin monotherapy of 56% with the similarly prices saxagliptin and
linagliptin having market shares of 16% and 25%, respectively. Alogliptin is notably cheaper but is
estimated to have less than a 1% market share.
Boehringer Ingelheim economic modelling
Boehringer Ingelheim presented the results of two modelling exercises: model A and model B. However,
much of their NMA and cost-effectiveness analysis was classed as confidential, so what follows is mainly
methods with no results.
Model A simulated the effects of 1 year of treatment. Thereafter, the path of the patient was determined
by the UKPDS OM1. This appears to have limited the direct treatment effects for elements such as
treatment cost and the direct treatment effects upon adverse events and the QoL impact of weight
changes to 1 year’s duration. At the end of the first year the AG assumption is that the treatment effects
upon HbA1c, SBP, the TC/HDL ratio and weight were fed into the UKPDS OM1 to model the lifetime
impact of the monotherapy. But the AG has not been able to identify how the model A does this and this
assumption is based upon the written Boehringer Ingelheim submission, which states that ‘Model A . . .
approach . . . patients undergo different comparator therapies for a year . . . the UKPDS model then
undergoes a full 40 year . . . run’.
The AG understanding, which may not be correct, is that, in effect, this assumed that the patient remained
on the monotherapy for the patient lifetime. And that it also assumed that the direct treatment costs,
adverse events and direct QoL impacts from weight changes would apply only during the first year.
Model B was somewhat more involved, and took a similar modelling approach to that of the modelling for
the draft NICE CG for type 2 diabetes and the AG modelling for the current assessment. A Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA) front end was designed for the UKPDS OM1, which
modelled the initial treatment effects and then used the UKPDS risk equations to model the evolution of
the risk factors and the complications of diabetes. When patients’ HbA1c breached the 7.5% intensification
threshold they could first intensify by adding another oral drug, with a second intensification to NPH
insulin also being possible. The survival curve of the OM1 coupled with the timing of intensifications
permitted model B to calculate treatment-specific treatment costs, adverse event rates and QoL impacts
from weight changes to add to the outputs of the OM1 model.
Boehringer Ingelheim noted that model B ran the OM1 1 year at a time, and that this can lead to an
underestimation of the total costs and total QALYs over the 40-year time horizon. Boehringer Ingelheim
suggested that this will tend to have underestimated the cost-effectiveness of empagliflozin. Note that the
AG approach was to run the OM1 model over the 40-year time horizon for each patient simulated.
Patient characteristics
Patient characteristics were drawn from patients within the Clinical Practice Research Datalink (CPRD).
This identified 9211 UK patients who started their first oral antidiabetic treatment in 2014. Although not
all of the codes used for the search appear to have been specific to type 2 diabetes, for example diabetes
mellitus, the minimum age at diagnosis was 23 years, with a mean of 60 years and a SD of 12 years, and
the requirement to be starting an oral therapy should have restricted the sample to patients with type
2 diabetes.
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The average duration of diabetes was 2.9 years, 57% being male. The mean HbA1c was 8.49%, SBP
134 mmHg, HDL 1.2 mmol/l and LDL 4.0 mmol/l. The mean BMI was 31 kg/m2.
The presence of existing complications was included: 6.63% for atrial fibrillation, 3.18% for PVD, 2.21%
for MI, 1.92% for CHF, 1.62% for stroke, 6.13% for IHD, 0.29% for amputation, 0.23% for blindness
and 0.05% for renal failure.
Sequences modelled and treatment effectiveness
Model A considers only the first year of treatment with monotherapy and then adds the UKPDS costs and
complications to this.
Model B considers the treatment sequences in Tables 34 and 35 with patients intensifying to the next line
of therapy when their HbA1c breaches the 7.5% intensification threshold.
Pioglitazone 45 mg was chosen because of it being the most commonly prescribed dose. The differences in
cost between pioglitazone 30 mg and pioglitazone 45 mg are minimal.
Note that if repaglinide was insufficient, it would be replaced, as for dual use it is licensed only with
metformin. So it would not be logical to add gliclazide to repaglinide since they act largely on the same
receptors. Note also that 1 mg is a small dose of repaglinide.
Clinical effectiveness data were based upon 52-week data where available, though this was apparently not
available for canagliflozin or dapagliflozin. Sitagliptin clinical effectiveness estimates were apparently based
upon 24-week data, though the submission does not state that 52-week data were not available.
TABLE 34 Boehringer Ingelheim sequences modelled: 52-week data
Monotherapy
Intensification
First Second
Repaglinide 1 mg +Gliclazide + NPH insulin
Gliclazide + Sitagliptin
Pioglitazone 45mg +Gliclazide
Sitagliptin 100 mg +Gliclazide
Empagliflozin 10 mg +Gliclazide
Empagliflozin 25 mg +Gliclazide
TABLE 35 Boehringer Ingelheim sequences modelled: 24-week data
Monotherapy
Intensification
First Second
Dapagliflozin 5 mg +Gliclazide + NPH insulin
Dapagliflozin 10 mg +Gliclazide
Canagliflozin 100 mg +Gliclazide
Canagliflozin 300 mg +Gliclazide
Empagliflozin 10 mg +Gliclazide
Empagliflozin 25 mg +Gliclazide
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The effect upon SBP and rates of UTIs were also based upon 24-week data because of 52-week data not
being available.
Hypoglycaemia rates were based upon the sulfonylurea 16.4% annual rate from the NMA (for pooled
sulfonylureas) coupled with odds ratios for each of the comparators against sulfonylurea. A ratio of
non-severe to severe hypoglycaemia event rate of 17.2 was based upon the 0.009 annual rate of severe
hypoglycaemia event rates of Leese et al.,18 coupled with the overall rates of hypoglycaemia in the NMA.
Urinary tract infection event rates were based upon the annual placebo rates of 3.5% from the NMA
coupled with odds ratios for each of the comparators.
Treatment intensifications and discontinuations
Within model A there are no treatment intensifications. Treatment with the monotherapies is for 1 year
only, after which it appears that the UKPDS OM1 model is appended to this.
Within model B, treatment is intensified when a patient is modelled as breaching the 7.5%
HbA1c threshold.
It appears that discontinuations of therapy for reasons other than breaching the HbA1c threshold of 7.5%
have not been modelled.
Glycated haemoglobin evolution
The evolution of HbA1c is based upon equation 11 of the UKPDS68.193
Within model A it appears that the patient’s baseline HbA1c has the treatment effect of the initial
monotherapy applied, with the UKPDS OM1 and hence relevant equation of the UKPDS68193 being used
to model its evolution thereafter. But, as stated in the introduction, the AG has not been able to identify
how model A interacts with the UKPDS OM1.
Within model B it appears that the patient’s baseline HbA1c has the treatment effect of the initial
monotherapy applied. Equation 11 of the UKPDS68193 is then used to model the evolution of the patient’s
HbA1c until it breaches the 7.5% intensification threshold, at which point the treatment effect of the first
intensification is applied. Equation 11 of the UKPDS68193 is then applied until the second intensification
occurs with the associated treatment effect. HbA1c is then modelled as progressing as per equation 11 of
the UKPDS68.193
Evolution of the other risk factors
The evolution of SBP and the TC/HDL is based on the UKPDS OM1 and hence on the relevant equation of
the UKPDS68.193
Within model A, it appears that the patient’s baseline SBP had the treatment effect of the initial therapy
applied, with equation 12 of the UKPDS68193 being used to model its evolution thereafter. For the TC/HDL
ratio, as a result of there being no treatment effects estimated, it appears that equation 13 of the
UKPDS68193 was used to model the evolution throughout. But, again, as stated in the introduction, the AG
has not been able to identify how model A interacts with the UKPDS OM1.
Within model A the direct impacts of weight changes upon QoL were evaluated only during the first year.
For the UKPDS modelling it appears that weight losses were assumed to rebound to baseline after 1 year,
whereas weight gains were assumed to remain indefinitely.
Within model B it appears that the patient’s baseline SBP had the treatment effect of the initial therapy
applied, with equation 12 of the UKPDS68193 being used to model its evolution except for when a
treatment intensification took place at which point the treatment effect of the intensification was applied.
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For the TC/HDL ratio, as a result of there being no treatment effects estimated, it appears that equation 13
of the UKPDS68193 was used to model the evolution throughout.
Within model B, weight losses from treatment were assumed to apply at 52 weeks and then to rebound to
baseline at 104 weeks. Weight gains from treatment were assumed to be maintained indefinitely. A 0.1-kg
annual weight gain from natural history was also applied.
Quality of life
The QoL at baseline and the QoL decrements associated with the complications of diabetes were drawn
from the recent paper by Alva et al.,197 which reanalysed the updated UKPDS data set and in some sense
updated the values of the UKPDS62,198 which is the paper that the AG modelling relies upon. The values
and a commentary upon this are presented later in the comparison of modelling inputs used by the
companies and the AG.
In common with the other companies, the QoL impact of hypoglycaemic events was drawn from Currie
et al.204 Similarly, the QoL decrement of –0.0061 per BMI point above 25 kg/m2 was drawn from Bagust
and Beale.199
The QoL decrement of –0.00283 per UTI was based upon the estimates of Barry et al.205
Costs
Treatment costs were based upon the March 2015 Monthly Index of Medical Specialities (MIMS).
The costs of diabetes without complications and the costs of the complications of diabetes were taken
from the UKPDS84.195 Boehringer Ingelheim appears to have applied only the inpatient costs of the
UKPDS84195 and ignored the outpatient costs.
A cost of £380 per severe hypoglycaemic event was drawn from the draft NICE CG for type 2 diabetes,
which is similar to that of the other company submissions and AG value.
Urinary tract infections were associated with a £36 cost, based upon the ERG report52 for the previous STA
of dapagliflozin for type 2 diabetes combination therapy.
Note that the UKPDS costs of model B that are reported in Tables 36 and 37 are around half of those of
model A. The reason for these discrepancies is far from obvious.
TABLE 36 Boehringer Ingelheim results: model B costs (£), 52-week analysis
Effect
Table 71 Table 72
UKPDS Tx Severe hypoglycaemia UTI Total Total
Empagliflozin 25 mg 7774 3890 108 13 11,785 11,664
Empagliflozin 10 mg 7772 3894 214 26 11,907 11,667
Pioglitazone 45mg 7836 994 311 38 9180 8830
Repaglinide 1 mg 7816 1649 463 50 9978 9465
Sitagliptin 100 mg 7809 3525 578 61 11,972 11,334
Gliclazide 7819 2538 666 77 11,100 10,357
Tx, treatment.
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Assessment Group economic modelling
Model
The protocol specified that either the UKPDS OM1 or the UKPDS OM2 would be used by the AG. For
some of its outputs the OM1 is quite different from the OM2 in its predictions. But the OM2 was not
made available to the AG in time for the assessment and so, as specified in the protocol, the OM1 has
been used.
As already noted, the OM1 predicts roughly double the number of MIs over 10 years, and the rates of IHD
are also noticeably higher than those of the OM2. The 10-year mortality is also higher with the OM1.
Compared with the OM2, the OM1 will tend to overpredict event rates and so overstate the benefits and
cost savings arising from any avoidance of the complications of diabetes that are associated with the more
effective treatment. Being more recent and more reflective of current practice, the OM2 would consequently
have been much preferable had it been available to the AG.
The OM1 was used for the modelling that underlies the NICE CG for diabetes. During its development the
Guideline Development Group (GDG) reviewed in detail 10 type 2 diabetes cost-effectiveness models.
These included the JADE209 and CORE210 models, but not the ECHO-T2DM model. Based upon validation
and consistency with the NICE reference case, the GDG very much preferred the OM1, in no small part
because of it being based upon a single RCT rather than drawing a range of modelling inputs from
disparate sources.
The AG has developed a front and back end to the OM1. Briefly, for each patient and treatment strategy
that is simulated the AG front end models the patient’s progression from monotherapy through the various
treatment intensifications over a 40-year time horizon in annual cycles. This, in turn, introduces the patient’s
evolutions of HbA1c, SBP, TC/HDL, BMI, hypoglycaemia event rates, adverse events and treatment costs.
The evolutions of the patient’s HbA1c, SBP and TC/HDL are then fed into the OM1, which models the
complications of diabetes and patient lifespan, and outputs the costs and QoL impacts of living with diabetes
and the patient’s survival curve. The AG back end takes the OM1 survival curve and uses this to condition
the evolutions of the patient’s BMI, hypoglycaemia event rates, adverse events and treatment costs. The cost
and QoL impacts of these are then summed with the cost and QoL impacts outputted by the OM1.
In slightly more detail, patients start on monotherapy but intensify their treatment if their HbA1c is
modelled as breaching the 7.5% threshold. Intensifications typically add another treatment to a patient’s
existing treatment(s). This permits treatment sequences to be modelled, starting with monotherapy but
with subsequent treatment intensifications, these intensifications eventually leading to first basal insulin
and then basal-bolus insulin. Each treatment within a sequence is associated with treatment costs, weight
changes, hypoglycaemic events and adverse events. The AG modelling also permits treatments to be
TABLE 37 Boehringer Ingelheim results: model B costs (£), 24-week analysis
Drug
Table 71 Table 72
UKPDS Tx Severe hypoglycaemia UTI Total Total
Empagliflozin 25 mg 7769 3811 120 13 11,713 11,580
Empagliflozin 10 mg 7773 3830 236 26 11,864 11,602
Canagliflozin 300 mg 7752 4753 346 40 12,891 12,504
Canagliflozin 100 mg 7764 3772 475 57 12,068 11,536
Dapagliflozin 10 mg 7776 3758 597 72 12,204 11,534
Dapagliflozin 5 mg 7771 3806 712 91 12,380 11,577
Tx, treatment.
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associated with a discontinuation rate in their first year, with patients who discontinue being assumed to
switch to another treatment at the same line of therapy.
For each patient who is modelled, the modelled treatment sequences lead to a modelled evolution of
HbA1c, SBP and TC/HDL ratio. These, together with the patient’s baseline characteristics, are fed into the
OM1. The OM1 then models the rates of the complications of diabetes, such as CHF, and the patient
survival, which results in estimates for the discounted costs and QALY impacts of the complications of
diabetes over the modelled lifetime of the patient. A survival curve is also drawn from the OM1 model.
Owing to the model being an individual patient simulation, any given patient is run through the model
many times, say 1000 inner loops, in order to reduce Monte Carlo sampling error. In effect this is the
same as running a cohort of 1000 identical patients through the model. The OM1 survival curve is the
proportion of this cohort, or 1000 inner loops, that is modelled as surviving. This survival curve conditions
the AG front end evolutions of treatment sequences and the cost and QALY impacts of their treatment
costs, weight changes, hypoglycaemic events and adverse events.
For the deterministic model run, the OM1 correctly outputs the relevant survival curve. Unfortunately, for
the PSA iterations it appears that the OM1 does not output the relevant survival curve. As a consequence,
the relevant survival curve has had to be imputed from the OM1 annual discounted QALY estimates by
an initial run of the model with the baseline QoL set equal to unity and the QoL decrements of the
complications all set to zero. The resulting annual discounted QALYs were then undiscounted to arrive at
the patient-specific survival curve. (For the PSA each patient was run with 100 inner loops, and, as a
consequence, the imputed survival curve had a granularity of 1%.) But this also meant that the PSA had to
run the OM1 model twice for each strategy for a given patient, for a given PSA iteration. This also required
that the same random number seed be used for each of these model runs in order for the imputed survival
curve to be consistent with the second run of the model that estimated the strategy’s costs and benefits.
The OM1 permits the random number seed to be only 1 of 100 values. The AG model randomly assigned
this value during the PSA, keeping this value constant between the two model runs for a given patient, for
a given PSA iteration. Having to run the model twice for a given patient for a given PSA iteration also
significantly increased the time it took to run the PSA.
An element that the OM1 cannot address is the requirement for patients receiving a flozin to have their
dose of it reduced or discontinued based upon renal function and eGFR rates. Although the AG has a
number of issues with the Janssen modelling, the use of the ECHO-T2DM model did permit this to be
explored, though the AG has not reviewed the implementation of this in any detail. It would be interesting
to know the impact that turning off these discontinuations would have upon the cost-effectiveness estimates
of the Janssen modelling. If this is significant enough to affect the conclusions that would be drawn from
the Janssen modelling it could suggest additional modelling uncertainty from the AG use of the OM1.
The AG visual basic modelling has the advantage of permitting up to 12 treatment strategies to be
simultaneously compared with one another, with the correlation between treatments’ effects being
properly taken into account. Each PSA iteration also uses the same set of parameter values and random
number seed across all of the treatment strategies being modelled. This, in turn, permits the correct
characterisation of uncertainty within the probabilistic modelling.
Model runs
The NICE CG group for type 2 diabetes concluded after a number of model runs that with a patient cohort
of 35,000 or more there was little to be gained from running more than 100 inner loops to reduce Monte
Carlo sampling error. As a consequence, probabilistic results were based upon 1000 PSA iterations, each
with a patient cohort of 50,000 with 100 inner loops. For deterministic model runs, that is those without
any second order sampling, the modelling for the CG increased the number of inner loops to 1000, as
recommended within the OM1 manual.
The AG has adopted the same approach.
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Probabilistic sampling
The risk factor evolution parameters of equations 11–13 of the UKPDS68193 were received as 1000
bootstrap samples from the UKPDS group (Professor Alastair Gray, University of Oxford, June 2015,
personal communication). The UKPDS OM1 also permits only 1000 bootstraps.
The other parameters within the modelling were sampled by the AG. Clinical effectiveness was sampled
within the NMA, with this outputting 10,000 look-up values for the various clinical effectiveness
parameters. But as a result of the OM1 permitting only 1000 bootstraps and the time taken to run the
PSA, a subset of 1000 was sampled from the 10,000 look-up values of the NMA. It was checked that
these subsets had means that were similar to the central estimates of the NMA.
Other parameters were sampled by the AG using the distributions outlined below.
Patient characteristics at baseline
The patient characteristics at baseline are taken from the draft NICE CG for diabetes. This undertook
extensive analysis of the THIN database, supported by some additional data from the Health Survey for
England (Table 38).
These were sampled once for the modelling using the full variance–covariance between the characteristics,
as per the modelling for the current draft NICE CG for diabetes.
TABLE 38 National Institute for Health and Care Excellence CG baseline risk factors and baseline complication rates
Risk factors
Age 59.8 years
Duration of diabetes 2.0 years
Male 57%
BMI 31.9 kg/m2
HbA1c 8.40%
SBP 137.5 mmHg
TC 4.96 mmol/l
HDL 1.18 mmol/l
Complication rates (%)
Current smoker 18.1
Past smoker 34.0
Atrial fibrillation 0.81
PVD 0.51
MI 0.80
CHF 0.50
Stroke 0.50
IHD 2.70
Amputation 0.10
Blindness 0.40
Renal failure 0.20
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The AG has adopted these values with the exception of the baseline the baseline TC/HDL ratio. TC/HDL
has been assumed to be 3.0 owing to NICE guidelines on atorvastatin use in people with diabetes. This
change in therapy may be partly the cause of the differences between the OM1 and the OM2. A scenario
analysis applies the values of the NICE CG and evolves these according to the UKPDS68193 equation 13.
AstraZeneca argued that the baseline HbA1c should be 7.5% in order to be in line with NICE guidelines.
But the patients modelled are starting their first drug treatment after, on average, having been diagnosed
with diabetes for 2.0 years. The mean HbA1c at diagnosis was estimated to be 8.2%. It seems unlikely that
most patients will have successfully controlled their diabetes through diet and exercise and got below
7.5% if they were above it at diagnosis, only to subsequently lose this control. As a consequence, the base
case will apply the baseline HbA1c values as estimated within the draft NICE CG. A scenario analysis applies
a common 7.5% HbA1c at baseline across the 50,000 patients simulated.
Sequences modelled
As outlined in the assessment protocol, in line with NICE guidelines patients will intensify their treatment if
their HbA1c breaches the 7.5% intensification threshold. As a consequence, the modelling needs to take
into account the clinical effects and costs of these intensifications. Based upon expert opinion the AG has
modelled the treatment sequences in Table 39.
Clinical effectiveness
The clinical effectiveness estimates are drawn from the Warwick AG NMA as presented in the clinical
effectiveness section and from a review of the literature. Events rates are annual unless otherwise stated
(Tables 40 and 41).
For the flozins the UTI rates and GTI rates are half-yearly.
TABLE 39 Assessment Group treatment sequences modelled
Monotherapy
Intensification
First Second Third
Repaglinide – Repaglinide + NPH insulin –Gliclazide
+ Pioglitazone + Bolus insulin
+Gliclazide
Gliclazide + Pioglitazone + NPH insulin –Gliclazide
+ Bolus insulin
Pioglitazone +Gliclazide + NPH insulin –Gliclazide
+ Bolus insulin
Sitagliptin +Gliclazide + NPH insulin –Gliclazide
+ Bolus insulin
Dapagliflozin +Gliclazide + NPH insulin –Gliclazide
+ Bolus insulin
Empagliflozin +Gliclazide + NPH insulin –Gliclazide
+ Bolus insulin
Canagliflozin 100 mg +Gliclazide + NPH insulin –Gliclazide
+ Bolus insulin
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For the intensifications, because of a lack of data the addition of a treatment is assumed to have the same
clinical effectiveness regardless of what it is being added to (Tables 42 and 43).
Adjusting the glycated haemoglobin effect for a patient’s baseline
glycated haemoglobin
The NICE CG modelling estimated two alternative models for the change at 1 year in HbA1c. The first
corresponded to the base-case approach of the AG, though metformin was the reference treatment in the
NICE CG NMA rather than placebo, as in the AG NMA.
l Estimate a reference treatment’s absolute change in HbA1c from baseline, t0, to the end of the first
cycle, t1: Δabs.
l Estimate the difference between the reference treatment and the other treatments at the end of the
first cycle: ΔTxrel.
l H1 = H0 + Δabs + ΔTxrel.
For instance, suppose that the change between t0 and t1 for metformin Δabs = –1.49 and that the difference
between metformin and canagliflozin at t1 was ΔTxrel = –0.51. A patient with a baseline H0 = 9.00 would be
TABLE 40 Assessment Group monotherapy clinical effectiveness estimates: non-flozins
Variable
Gliclazide Pioglitazone Repaglinide Sitagliptin
µ SE µ SE µ SE µ SE
HbA1c –1.301 0.014 –1.200 0.011 –1.200 0.360 –0.723 0.019
SBP –0.600 0.520 –1.400 0.500 –1.000 0.000 0.394 0.048
Weight 1.397 0.013 2.962 0.009 0.100 0.670 –0.003 0.275
Severe hypoglycaemia 0.10% 0.04% 0.00% 0.00% 2.00% 0.70% 0.00% 0.00%
Symptomatic hypoglycaemia 1.30% 0.40% 0.00% 0.00% 13.00% 1.70% 0.00% 0.00%
UTI 4.00% 1.00% 4.00% 1.00% 4.00% 1.00% 4.00% 1.00%
GTI 1.00% 0.49% 1.00% 0.49% 1.00% 0.49% 1.00% 0.49%
Discontinuation 3.30% 0.82% 9.00% 0.74% 5.00% 3.00% 4.00% 1.30%
Note
The rates of hypoglycaemia, UTIs and GTIs are annual.
TABLE 41 Assessment Group monotherapy clinical effectiveness estimates: flozins
Variable
Dapagliflozin 10mg Empagliflozin 25mg Canagliflozin 300mg
µ SE µ SE µ SE
HbA1c –0.704 0.016 –0.870 0.016 –1.153 0.032
SBP –2.931 0.024 –3.743 0.054 –1.338 0.048
Weight –2.457 0.006 –2.471 0.008 –3.577 0.012
Severe hypoglycaemia 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Symptomatic hypoglycaemia 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
UTI 5.50% 1.97% 5.40% 1.50% 6.60% 1.80%
GTI 4.50% 1.80% 3.60% 0.64% 5.00% 2.00%
Discontinuation 3.00% 1.50% 1.80% 0.91% 2.00% 1.00%
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estimated to have H1 = 9.00 – 1.49 – 0.51 = 7.00, whereas a patient with a baseline H0 = 7.00 would be
estimated to have H1 = 7.00 – 1.49 – 0.51 = 5.00.
But a strong correlation was observed between the trials’ metformin absolute effect between t0 and t1 and
their mean baseline HbA1c. As a consequence the NICE CG explored adding an additional term to Δabs to
make the change also a function of the baseline HbA1c, H0. This led to the following adjusted model for
the HbA1c at the end of the first cycle:
H1 = H0 + (Δabs+ β (H0−7:5)) + ΔTxrel, (2)
with ΔTxrel being taken from the NICE CG NMA.
The Δabs and β were not estimated during the NMA, but were separately estimated using the same data
for metformin as was used in the NMA. The adjusted model simplifies to the unadjusted model by setting
β = 0. This resulted in the following coefficients (Table 44), and the following unadjusted and adjusted
treatment effects for metformin (Figure 11).
In essence, the adjusted function adds the difference between the two intercepts –1.49 and –0.78, or a
constant 0.71, and the β (H0 –7.5) to the unadjusted H1. In other words for a given baseline H0, the H1 of
the adjusted function is a constant difference from the H1 of the unadjusted function, regardless of the
treatment effect relative to metformin ΔTxrel. As β = –0.50 is negative, the reduction in HbA1c between t0
TABLE 42 Assessment Group first intensification clinical effectiveness estimates
Variable
+ Pioglitazone +Gliclazide – Repaglinide, + gliclazide, + pioglitazone
µ SE µ SE µ SE
HbA1c –1.200 0.011 –1.010 0.011 –1.200 0.011
SBP –1.400 0.500 –0.600 0.520 –1.400 0.500
Weight 2.800 0.160 1.300 0.070 2.800 0.160
Severe hypoglycaemia 0.00% 0.00% 0.00% 0.00% 0.10% 0.18%
Symptomatic hypoglycaemia 10.70% 1.80% 11.20% 2.10% 10.70% 1.80%
GMI 4.0% 1.0% 4.0% 1.0% 4.0% 1.0%
UTI 1.0% 0.5% 1.0% 0.5% 1.0% 0.5%
TABLE 43 Assessment Group second and third intensification clinical effectiveness estimates
Variable
+NPH + Bolus
µ SE µ SE
HbA1c –1.200 0.300 –0.660 0.060
SBP –0.500 1.200 0.000 0.000
Weight 3.600 0.500 0.800 0.200
Severe hypoglycaemia 0.40% 0.17% 0.7% 0.5%
Symptomatic hypoglycaemia 14.0% 5.1% 38.0% 2.9%
UTI 0.0% 0.0% 6.0% 1.4%
GTI 0.0% 0.0% 0.0% 0.0%
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and t1 is larger for those with a high baseline H0. The application of the adjusted function means that more
patients will see a treatment reduce their HbA1c to below the NICE treatment intensification threshold of
7.5%. It also prevents patients with a low baseline H0 being modelled as falling to perhaps unrealistically
low values of HbA1c.
The adjusted function was preferred for the NICE CG because of a superior information criterion and
because the influence of β was judged to be significant with its 95% CrI all lying below zero.
For the patient with a baseline H0 = 9.00, the adjusted model estimates that under canagliflozin his/her
H1 = 9.00 – 0.78 – 0.50 × (9.00 – 7.50) – 0.51 = 6.96 in contrast to the estimate of H1 = 7.00 of the
unadjusted model. Similarly, for the patient with a baseline H0 = 7. 00, the adjusted model estimates that
under canagliflozin their H1 = 7.00 – 0.78 – 0.50 × (7.00 – 7.50) – 0.51 = 5.96 in contrast with the estimate
of H1 = 5.00 of the unadjusted model.
The NICE CG function is for metformin monotherapy. It was also estimated using a very different data
set than the current AG NMA. Any read across from it to the current assessment is consequently almost
submerged in caveats. But if a hypothetical placebo in the monotherapy metformin trials would have a
reasonably constant relative effect, Txrel, at t1 compared with metformin, and this placebo effect could
reasonably be read across to the current patient group, it would be reasonable to explore the impact
of the above relationship in the current assessment. For a deterministic analysis this simply requires
0.71 – 0.50 (H0 – 7.5) to be added to the overall unadjusted H1 treatment effect estimated for each of the
active treatments within the AG NMA. This will be explored as a scenario analysis.
TABLE 44 National Institute for Health and Care Excellence CG adjustment to reference treatment HbA1c effect by
baseline HbA1c
Variable Unadjusted (95% CrI) Adjusted (95% CrI)
Δabs –1.49 (–2.16 to –0.90) –0.78 (–1.65 to 0.03)
β – –0.50 (–0.78 to –0.21)
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FIGURE 11 National Institute for Health and Care Excellence CG adjustment to reference treatment HbA1c effect by
baseline HbA1c.
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Treatment discontinuations
Those discontinuing in the first year for reasons other than their HbA1c not falling below the 7.5%
threshold are assumed to switch to another monotherapy:
l From:
¢ flozins to gliclazide
¢ sitagliptin to gliclazide
¢ pioglitazone to gliclazide
¢ gliclazide to pioglitazone
¢ repaglinide to pioglitazone.
Note that those discontinuing are in effect assumed to switch to the alternative monotherapy, and its
associated subsequent sequence of treatments. These sequences were retained in part due to data
availability and in part due to a desire not to introduce new sequences with a different number of possible
intensification steps.
But these subsequent sequences may also contain the treatment that the patient was intolerant of as a
monotherapy. This affects only those discontinuing from pioglitazone and those discontinuing from
gliclazide. In light of this, a scenario analysis will be undertaken, whereby, among those discontinuing and
switching treatment, the intensification step to a treatment, to which the patient was intolerant as a
monotherapy, is omitted.
The modelling of the evolution of the risk factors
For HbA1c the base case applies the treatment effect in the first year of therapy. HbA1c is then evolved
according to the UKPDS68193 equation 11. But this is with the proviso of the UKPDS68193 equation 11
parameter for a patient being in their second year at diagnosis not being applied. Given the average
patient duration of 2 years since diagnosis, the AG is of the opinion that including the UKPDS68193
equation 11 parameter for a patient being in their second year since diagnosis would tend to double count
the treatment effect of starting a monotherapy. HbA1c is evolved according to the UKPDS68193 equation 11
until the treatment intensification threshold of 7.5% is breached.
At this point, the patient intensifies treatment and receives the associated treatment effect. HbA1c is then
once more evolved according to the UKPDS68193 equation 11 until the treatment intensification threshold
of 7.5% is breached, at which point another treatment intensification occurs. When the patient is on
the last line of treatment, HbA1c evolves according to the UKPDS68193 equation 11 with no further
treatment intensifications.
Should a patient discontinue and move on to an alternative treatment at the same line of therapy, the
treatment effect of the first line of therapy of the first year is removed, 1 year’s evolution according to the
UKPDS68193 equation 11 added, and the treatment effect of the alternative treatment applied.
The paragraphs that follow are purely for illustration. The data are hypothetical and bear no relation to the
actual inputs used in the AG modelling.
Figure 12a shows how this results in a sawtooth evolution of HbA1c. It applies to a patient aged 40 years
with a current baseline HbA1c of 7.6%, who at diagnosis was aged 30 years and had a HbA1c of 7.0%.
It assumes four strategies, with initial reductions in HbA1c of 1.8%, 1.6%, 1.4% and 1.2% for strategies
1–4, respectively. It also assumes that two further treatment intensifications are possible, these having the
reductions in HbA1c of 2.0% and 1.5% across the four strategies.
The modelled evolution of strategies 2–4 are very similar, with the first treatment intensification at year 6.
The slightly greater initial reduction in HbA1c of strategy 1 is sufficient for HbA1c not to breach the
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treatment intensification threshold of 7.5% until 1 year later, and, as a consequence, the first treatment
intensification does not occur until year 7.
Figure 12b illustrates how a discontinuation could affect the modelled evolution of HbA1c for strategy 1.
This still assumes a reduction in HbA1c from the original treatment of 1.8%, but from the alternative
treatment that the patient discontinues, a reduction of only 0.5%. As before, this also assumes that two
further treatment intensifications are possible, with reductions in HbA1c of –2.0% and –1.5% in the
sequence to which the patient has discontinued.
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FIGURE 12 Example of the modelled evolution of HbA1c: UKPDS68.193
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In light of the Janssen submission, the model has been constructed to permit a scenario analysis of HbA1c
having a linear increase and for the annual rate of increase to be treatment specific. The following
illustrates the same initial treatment effects for strategies 1–4, but for the annual linear increase while on
first-line treatment to be 0.1%, 0.2%, 0.3% and 0.4%, respectively. For those discontinuing from strategy 1,
the annual linear increase while on the first-line treatment is assumed to be 0.05%. Subsequent to treatment
intensification, the evolution of HbA1c is assumed to revert to the UKPDS68193 equation 11, but the model
has the facility to impose treatment-specific annual linear increases in HbA1c at any or all treatment lines
(Figure 13).
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FIGURE 13 Example of the modelled evolution of HbA1c: linear evolution.
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A similar approach is taken for the modelling of the evolution of SBP and can be for the TC/HDL ratio,
though the base case holds the TC/HDL ratio constant at 3.0. The UKPDS68193 specifies equations 12 and
13, respectively. Treatment intensifications are still determined by the modelled HbA1c.
Figure 14 illustrates the modelled evolution of SBP for the same patient as before, with HbA1c being modelled
to evolve according to the UKPDS68193 equation 11, with a SBP at baseline of 130 mmHg and at diagnosis of
120 mmHg. It assumes initial treatment effects of –20mmHg, –15mmHg, –10mmHg and –5 mmHg for
strategies 1–4, respectively. The intensifications result in treatment effects of –15mmHg and –10 mmHg. For
the patient modelled as discontinuing during strategy 1, the alternative treatment effect is –5 mmHg.
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FIGURE 14 Example of the modelled evolution of SBP.
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Figure 15 illustrates the UKPDS modelled evolution of the TC/HDL ratio for the same patient as before,
with HbA1c being modelled to evolve according to the UKPDS68193 equation 11, with a TC/HDL ratio at
baseline of 4.0 and a ratio at diagnosis of 3.5. It assumes initial treatment effects of –1.0, –0.8, –0.6 and
–0.4 for strategies 1–4 respectively. The intensifications result in treatment effects of –0.8 and –0.6. For
the patient modelled as discontinuing during strategy 1, the alternative treatment effect is –0.4.
The modelled evolution of HBA1c, SBP and the TC/HDL ratio for a range of inputted patient characteristics was
cross-checked with that modelled by the UKPDS OM1 at central UKPDS68193 parameter values. The modelled
evolutions values were typically around 99.99% of the values simulated by the UKPDS OM1 model.
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FIGURE 15 Example of the modelled evolution of the TC/HDL ratio.
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The evolution of the patient BMI is based upon a mean annual increase in weight of 0.1 kg, as has
typically been used in previous NICE assessments of treatments for diabetes, and is apparently originally
sourced from the 2006 NICE CG on obesity.211 Over the course of NICE assessments and guidelines
development for treatments for type 2 diabetes, quite a lot of discussion has focused upon what is
reasonable to assume about the duration of weight effects. There has been some argument that initial
weight losses associated with treatment may tend to be transient, whereas initial weight gains associated
with treatment may tend to be more permanent. In light of this, five scenarios are modelled:
l treatment weight changes maintained, with no rebound to natural history
l treatment weight gains maintained, weight losses rebound to natural history after 1 year
l treatment weight gains maintained, weight losses rebound to natural history at intensification
l treatment weight changes rebound to natural history after 1 year
l treatment weight changes rebound to natural history at intensification.
Figures 16 and 17 illustrate weight changes being maintained for a patient of 85 kg at baseline. Initial
hypothetical treatment effects are 5 kg, –5 kg, 10 kg and –4 kg for strategies 1–4, respectively. The
intensifications result in treatment effects of 3 kg and 7 kg. For the patient modelled as discontinuing
during strategy 1, the alternative treatment effect is 4 kg, with the additional weight gains in the
alternative sequence thereafter being assumed to be the same as in the original sequence.
The above is largely self-explanatory. Within the evolution of weight for the patient under strategy 1 who
discontinues, there is a drop in weight between year 1 and year 2. This arises as a result of the patient
being assumed to come off his/her original treatment, which would have increased his/her weight by 5 kg
and to move on to the alternative treatment which increases his/her weight by only 4 kg. Quite when the
patient would discontinue, and, as a consequence, quite what the balance would be, in practice, between
the 5-kg increase and the 4-kg increase during the first line of treatment, is a moot point.
Body mass index scenarios 2 and 3, which have weight losses rebounding to natural history, do not affect
strategies 1 and 2, as they incur only weight gains.
Body mass index scenario 2 sees weight losses rebound to natural history after 1 year. So at year 2 both
strategies 2 and 4 have rebounded to natural history and 85.2-kg weight. Thereafter, they follow the same
weight profile, as their treatment intensifications also occur at the same time: years 6 and 11.
Body mass index scenario 3 sees weight losses rebound to natural history at treatment intensification. To
model this, the rebound to natural history that would have applied in the previous year is first calculated –
85.5 kg – to which the intensification treatment effect of 3.0 kg is added to give a weight of 88.5 kg at
year 6. An alternative way of looking at this is to view the intensification treatment effect of 3.0 kg being
composed of two parts: 0.1 kg for natural history and 2.9 kg for additional treatment effect.
Body mass index scenario 4 sees all weight changes rebound to natural history after 1 year. The figure is
largely self-explanatory, with all initial treatment effects being removed at year 2. Thereafter, strategies 2–4
intensify treatment at years 6 and 11, and see the weight gains associated with intensifications rebound to
natural history at years 7 and 12. Strategy 1 intensifies later at years 7 and 12, hence the later rebounds to
natural history.
Body mass index scenario 5 sees all weight changes rebound to natural history at treatment change.
Strategies 2–4 intensify treatment at years 6 and 11, so rebound to natural history the following year. But
the weight gains associated with the intensifications are then added to where the patients rebound. As a
result, after the first intensification at year 6 the patient weight is 88.5 kg for strategies 2–4. For strategy 1
the intensification is 1 year later, with it joining the other strategies at a weight of 88.6 kg in year 7. Much
the same happens at the subsequent intensification.
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Note that the BMI scenarios 4 and 5 may be felt to be literally unrealistic, with weight gains rebounding to
natural history after 1 year or at the next treatment change. But they may be better thought of as causing
weight to converge between strategies either after 1 year or at treatment change. In terms of the
modelling of the impact of BMI upon QoL this will not be exactly arithmetically correct because of the floor
of 25 kg/m2 on the BMI QoL coefficient of –0.0061. Given the baseline BMI of 31.6 kg/m2 (SD 6.0 kg/m2),
around 13% of patients are modelled as having a BMI of less than 25 kg/m2. For some of these patients,
the rebounds of scenarios 4 and 5 may not be exactly equivalent in their QoL impacts to weight
converging between the strategies by some other means, for example at the value of strategy with the
higher BMI. But the AG is of the opinion that any differences are likely to be minor.
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FIGURE 16 Example of the modelled evolution of patient weight: no rebound.
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Note that there is a minor error within the implementation of weight in the AG modelling. The
UKPDS68193 requires that the BMI at diagnosis is used and this has been implemented correctly. But the
AG modelling assumes that the BMI at diagnosis also applies at baseline. It can be argued that the BMI at
baseline should be the BMI at diagnosis plus the natural history increase that would be implied by the
duration at baseline. But as the mean duration of diabetes at baseline is estimated to be 2.0 years, and
that this adjustment would affect results for only the subset of patients during the cycles they bordered,
the 25 kg/m2 threshold, this error will have negligible effects upon net results.
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FIGURE 17 Example of the modelled evolution of patient weight: rebound scenarios. Tx, treatment. (continued )
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Diabetic ketoacidosis
There has been some suggestion that the flozins may increase the risk of DKA. But rates are low in
absolute terms, with the EMA reporting 101 cases over about 500,000 patient-years of flozins use.
The Diabetics With Eating Disorders surveyed England’s primary care trusts (PCTs) in 2010.212 Among the
45 PCTs that responded, the mean cost per DKA event was £1438, or £1552 in 2014 prices. But given an
event rate of 1 per 5000 patient-years, the average increase in costs associated with this is minimal:
around 30p per year of treatment. The typical duration of DKA events is also quite short, certainly less than
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FIGURE 17 Example of the modelled evolution of patient weight: rebound scenarios. Tx, treatment.
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1 week, though there may be recurrence. But even with quite a large QoL decrement, given the absolute
event rate and the short duration any overall average QALY impact will also be minimal.
There remains the possibility of an increased mortality with DKA among those with type 2 diabetes. This
could have more of an impact upon the modelled average QALY in the flozin arms. But there is no simple
means of incorporating this mortality into the OM1 modelling, this being a black box to the AG.
For the above reasons, DKA has not been incorporated into the economic modelling.
Quality of life: diabetes and the complications of diabetes
Given the use of the OM1 model, the AG draws the QoL value for those without any complications and
QoL impacts for the complications of diabetes from the UKPDS62198 (Table 45). A value for renal failure is
not given in the UKPDS62198 and, as a consequence, the AG has used the OM1 default value of –0.263 as
drawn from Kiberd and Jindal.213
Quality of life: weight
In common with most NICE assessments of treatment for type 2 diabetes and the draft NICE type 2
diabetes CG, the AG applies the utility decrement of –0.0061 (SE 0.001) of Bagust and Beale.199 Within
Bagust and Beale,199 this decrement applies if the patient BMI is above 25 kg/m2.
The mean BMI within the UKPDS RCT was 27.7 kg/m2, and it is from here that the mean baseline utility
of 0.785 is drawn. As a consequence, as the modelling applies the –0.0061 QoL decrement when the
patient BMI rises above 25 kg/m2, it can be argued that the baseline utility of 0.785 should have
0.0061 × 2.7 = 0.0165 added to it. This modification is adopted for the AG base case.
Quality of life: treatment discontinuations
Treatment discontinuations were assigned a QALY decrement associated with nausea as drawn from
Matza et al.214 The with- and without-nausea QoL values of 0.85 and 0.89 were taken to apply yielding a
mean decrement of 0.04, which the GDG thought a 6-week duration would be most reasonable estimate,
this yielding a mean QALY decrement of –0.00462.
Quality of life: adverse events
The 2012 NICE CG on infection, CG139,215 undertook a systematic review of the literature for studies of
the QoL impacts of symptomatic UTIs. This identified 11 studies, but a number of these are of limited
relevance to the current assessment because, for example, being among patients with spinal cord injuries.
Of the 11 studies, five appear most relevant to the current assessment.
TABLE 45 Quality-of-life values for OM1 complications
Complication Mean SE Distribution
No complications 0.785 0.005 Beta
MI –0.055 0.006 Log-normal
IHD –0.090 0.018 Log-normal
Stroke –0.164 0.030 Log-normal
CHF –0.108 0.031 Log-normal
Amputation –0.280 0.056 Log-normal
Blindness –0.074 0.033 Log-normal
Renal failure –0.263 0.020 Log-normal
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Clinical guideline 139215 also undertook economic modelling of treatments for UTIs. But as a result of the
available clinical effectiveness estimates being largely limited to those with spinal cord injury, the QoL
values applied are of limited relevance to the current assessment. This modelling also considered
progression from symptomatic UTIs through to first-line drug resistance and multidrug resistance, with
these causing increased costs and mortality.
The AG modelling for the current assessment only considers the QoL and cost impacts of treating UTIs and
GTIs, with the assumption that none will progress to a more serious condition. So there are caveats around
these estimates, and for a given set of inputs they could be seen as being biased and on the low side.
Barry et al.205 used the Index of Wellbeing (IWB) to estimate QoL among young women with UTIs. The IWB
is a generic QoL instrument. The mapping function from the IWB to QoL values was apparently based
upon 62 American nurses and non-medical graduate students ranking health states on a 16-point scale.
Barry et al.205 report that the IWB includes hospitalisation, self-care and ambulatory status, and permits the
inclusion of the following symptoms: pain; bleeding; itching discharge from sexual organs; painful burning
or frequent urination; burning or itching rash on large areas of the body; taking medication; fever or chills
with aching all over; and pain in the chest, stomach, sides, back or hips. But Barry et al.205 do not describe
quite how the QoL values for the health states for their model have been derived. It appears to be based
upon an index patient with a set of symptoms; that is expert opinion linked to the IWB. They estimated
disutilities of 0.3732 for pyelonephritis, and 0.2894 for vaginitis and persistent dysuria. Their duration was
estimated to be 10 days, 5 days and 5 days, respectively.
Gold et al.216 catalogued 130 health states using the Health and Activity Limitation Index (HALex), with
the score being based upon the answers to two questions of the US National Health Interview Survey.
A multiattribute utility model resulted in QoL estimates of 1.00 for perfect health, and 0.73 for bladder
infection and 0.66 for kidney infection. The derivation of these weights is not particularly clear within
the paper.
Ackerman et al.217 used the standard gamble to estimate QoL values among 13 men with moderate to
severe benign prostatic hyperplasia. A variety of health states were described, with the QoL impacts of
severe UTIs being estimated among these. The six risk-averse men reported an average value of 0.972
for a severe UTI, whereas the seven non-risk-averse men reported an average value of 0.893. Over the
13 respondents this suggests an average disutility per severe UTI of 0.071.
Ellis and Verma218 measured the impact of UTIs among 118 otherwise healthy Canadian women through a
case-controlled analysis using the Short Form questionnaire-36 items (SF-36) with a recall period of 1 day.
The mapping from the SF-36 to the EQ-5D QoL values based upon the algorithm of Ara and Brazier219
appears to have been undertaken by the NICE CG, as Ellis and Verma218 report only the mean values for
the eight main elements of the SF-36. This resulted in those with no UTI having a mean QoL of 0.922
compared with 0.724 for those with a UTI.
Ernst et al.220 used the Quality of Wellbeing (QWB) to estimate the QoL among 146 American women who
were diagnosed with acute cystitis, and the effect of treatment upon QoL. Those with type 2 diabetes
were excluded from the study. The QWB was administered 3, 7, 14 and 28 days after the initial visit. The
QoL at baseline was 0.68 (SD 0.03) compared with 0.81 (SD 0.11) at the 28-day point. QoL among those
cured compared with those not cured was statistically significantly different at the 5% level at days 3, 7
and 14, with respective QWB scores of 0.77 vs. 0.72, 0.82 vs. 0.71 and 0.83 vs. 0.76 (Table 46).
Of the above papers, Ackerman et al.217 could be argued as coming closest to the NICE reference case. But
the usefulness of these estimates is compromised by the small sample size. As a consequence, the AG will
use the results of the Janssen TTO study for the base case of QoL impact of –0.19 for a UTI and –0.25 for
a GTI. Nicolle et al.98 estimated median durations of UTIs of between 11.0 days and 12.5 days, and, as a
consequence, the base case will assume 2 weeks’ average duration.
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Quality of life: hypoglycaemia
Following the lead of the draft NICE CG for type 2 diabetes, the source for the base case for the QoL
decrements associated with hypoglycaemia events will be Currie et al.204 This used two separate
3-month recall surveys among patients with diabetes (n = 408 and n = 897), undertaken at different time
points, though 145 patients responded to both surveys.
The first survey was used to estimate a relationship between a patient’s score on the Hypoglycaemic Fear
Survey (HFS) and the number of non-severe and severe hypoglycaemic episodes with coefficients of 1.773
(SE 0.230) and 5.881 (SE 1.553), respectively. The second survey was used to estimate the relationship
between the HFS and the EQ-5D QoL with a coefficient of –0.008 (SE 0.001).
Given the 3-month recall period, the mapping between non-severe hypoglycaemia event rates and the
patient’s score on the HFS requires that rates be converted to 3-monthly rates before the 1.773 HFS
coefficient can be applied to arrive at the correct QALY decrement.
The authors of the draft NICE CG for type 2 diabetes also point out that the table 4 coefficient of Currie
et al.204 for non-severe hypoglycaemia events is based upon the natural logarithm of the event rate rather
than the event rate. As such it is non-linear. To account for this the AG has followed the method of the
authors of the draft NICE CG for type 2 diabetes and applied a Poisson distribution to give the spread of
possible patient event rates prior to applying the coefficients of Currie et al.204
The 5.881 HFS coefficient of table 4 of Currie et al.204 for severe hypoglycaemic events was derived on a
dichotomous basis, equal to 1 if there were any events reported during the previous 3 months and equal
to 0 if there were none reported. The draft NICE CG gives a quite complicated formula for accounting for
this using a binomial distribution, but this apparently simplifies to the quarterly probability times the utility
decrement (Gabriel Rogers, NICE, 17 August 2015, personal communication).
Table 47 presents a range of estimates based upon this method.
TABLE 46 Quality-of-life estimates for infections
Source Barry 1997205 Gold 1998216 Ackerman
2000217
Ellis and
Verma 2000218
Ernst 2005220
Year 1997 1998 2000 2000 2005
Country USA USA USA Canada USA
N NA NA 13 men 118 women 146 women
Method IWB HALex SG SF-36 QWB
Condition Pyelonephritis Vaginitis/dysuria Bladder Kidney UTIs UTIs Cystitis
Disutility 0.3732 0.2894 0.27 0.33 0.028–0.107 0.198 0.05–0.13
NA, not available; SG, standard gamble.
TABLE 47 Assessment Group QALY decrements by hypoglycaemia event rates
Scenario Severe Non-severe
Annual 1.00 10 20 30 40 50 60
Quarterly 0.22 2.50 5.00 7.50 10.00 12.50 15.00
HFS 1.30 1.39 2.65 3.44 3.98 4.40 4.74
Annual QALY loss –0.010 –0.011 –0.021 –0.032 –0.035 –0.038 –0.040
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But the values of Currie et al.204 come with some major caveats. As Currie et al.204 note regarding the
two data sources, ‘These studies were commissioned by the pharmaceutical industry to inform drug
developments around new treatments for diabetes that were found to reduce the frequency of
hypoglycaemia’. The paper authorship also includes staff of Novo Nordisk and Sanofi-Aventis.
The values are based on results from two surveys, with a response rate of 31%. The hypoglycaemic
episodes were recent events and perhaps therefore fresh in the memory. Forty-five per cent of respondents
were on insulin. Respondents might have been more likely to have been concerned about hypoglycaemia
than non-respondents.
Around one-third of respondents had type 1 diabetes mellitus (T1DM) with around two-thirds of respondents
having type 2 diabetes. Quite what covariates were considered and quite how the paper arrived at the final
regressions is not entirely explicit. Patient data from the first survey were removed if the patient also
responded to the second survey, reducing the sample to 57% of the original, though the reasons for this and
impacts of doing so are not clear. Similarly, the grouping of complications was also possibly subjective.
The 5.881 coefficient for severe hypoglycaemia episodes was also based on whether patients had had any
severe hypoglycaemia events during the recall period. If, within this group, the mean number of severe
hypoglycaemic episodes was more than one, it seems likely that the coefficient somewhat overestimates
the impact of having one severe hypoglycaemia events within a quarter.
The patient number and demographics reported by Currie et al.204 for the first survey are based upon the
full 408 patients of this survey. But for the analysis, 175 of these patients were excluded because of also
being in the second survey. As a consequence the demographics and events rates that were used when
analysing the data subset of the first survey cannot be determined.
For the full 408 patients of the first survey, only 2.3% (n = 9) reported experiencing at least one severe
hypoglycaemic event during the previous 3 months. This was somewhat less than the 8.6% (n = 77)
proportion who reported experiencing at least one severe hypoglycaemic event during the previous
3 months in the second survey.
For severe hypoglycaemic event rates, Currie et al.204 state that within the surveys ‘very few people > 1
event’ and they report a mean rate of ‘1.47 events per patient-year’. It seems likely that this mean rate
was the average across the two surveys. It would have been useful to have known the mean rate for each
survey, and for the small subset of the first survey that was actually analysed.
The relationship between having experienced at least one severe hypoglycaemic event in the last 3 months
and the HFS index, that is the 5.881 coefficient, consequently appears to have been based upon, at most,
nine patients reporting. The restriction of the subset analysed to 57% of the total sample of the first
survey suggests that this number is likely to have been somewhat less than nine patients. This gives rise to
the possibility of an outlier patient within this small subset having an unreasonable impact upon results.
The construction of the subset was at investigator discretion.
The AG cannot further interrogate the data underlying the estimates of Currie et al.,204 and it is possible
that they may be overestimates. Note that in common with previous analyses, the method of the table
above in effect assumes that a patient experiences at most one severe hypoglycaemic event per quarter.
There may be an argument for dividing the QALY decrement associated with severe hypoglycaemic events
by 1.47, the mean event rate reported in Currie et al.204
Costs: direct drug costs
Treatment costs are based upon the NHS drug tariff, and upon list prices for which there are no entries in
the NHS drug tariff. Daily doses are assumed to be 60 mg for gliclazide MR, 45 mg for pioglitazone, 6.0 mg
for repaglinide, 100 mg for sitagliptin, 10 mg for dapagliflozin, 25 mg for empagliflozin and 300 mg for
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canagliflozin. Insulins costs are based upon a requirement of 0.3 IU/kg when starting NPH, with this rising to
0.55 IU/kg when adding bolus which itself is required at 0.2 IU/kg.
The AG expert opinion also suggests that those receiving pioglitazone should have their BNP measured,
perhaps initially 6-monthly but annually thereafter. A marginal cost of £21 has been taken from Craig
et al.45 and inflated to 2014 prices using a 1.25 multiplier from the PSSRU Unit Costs of Health and Social
Care index. This has also been assumed to require a dedicated GP appointment, costed at £46 using the
PSSRU Unit Costs of Health and Social Care 2014.208
This results in the following treatment costs for the oral therapies (Table 48).
The AG modelled sequences differ from those of the company submissions in that patients add NPH
insulin rather than switch to it and as a consequence the cost differences between the sequences are
maintained over the horizon of the modelling. In light of this, a scenario analysis is undertaken, which
withdraws the initial monotherapies when patients switch to NPH insulin. Note that this affects only the
direct drug costs and not the clinical effectiveness estimates.
Costs: treatment intensifications and switches
Treatment intensifications due to breaching the 7.5% HbA1c threshold and treatment switches due to
intolerance are assumed to involve one 12-minute GP appointment. This is costed using the PSSRU Unit
Costs of Health and Social Care 2014 at £46.208
Costs: adverse events
The AG treatment assumptions are broadly in line with those of the Janssen submission (Table 49), with
this resource use being confirmed by AG expert opinion. Medication for UTIs is assumed to be 7 days of
trimethoprim 200 mg twice daily, for male GTIs fluconazole 200 mg and female GTIs three 200-mg
clotrizamole pessaries (see Table 49).
These costs are largely based upon assumption and have consequently been treated deterministically
within the probabilistic modelling.
Costs: hypoglycaemic events
The AG have followed the draft NICE CG when costing severe hypoglycaemic events.
Hammer et al.,207 in an industry-sponsored study, surveyed 147 UK patients with type 2 diabetes using
insulin, with 19 reporting at least one severe hypoglycaemic episode in the previous year, with 10 of these
being treated by the NHS. Hammer et al.207 acknowledge the non-random selection of their patient
sample, but provide few details about it other than to note that it was predominantly through health-care
professionals. Patients were surveyed using a structured questionnaire about the resource use associated
with their events.
Patients were divided into three groups: those who had their severe hypoglycaemic event treated by family
members; by medical practitioners in the community; and, in hospital. The mean direct costs by type, in
2007 prices, were £33 for those treated by family members, due to NHS follow-up costs; £231 for those
treated by the NHS in the community; and £862 for those treated in hospital. Owing to the non-random
sample selection, there is no definitive means to translate these into a weighted average cost. But the
GDG of the draft NICE CG was reportedly happy to use the sample proportion treated by family members
(9/19), coupled with an assumption that, of the remainder, 65% would be treated in hospital.
This results in a mean cost per severe hypoglycaemic event of £353 in 2007 prices, which, when uplifted
by a 1.16 multiplier from the PSSRU Unit Costs of Health and Social Care 2014,208 results in an estimate
of £411.
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TABLE 48 Assessment Group sequences annual drug and administration costs (£)
Strategy Monotherapy Cost
First
intensification Cost
Second
intensification Cost
Third
intensification Cost
S1 Empagliflozin 476.98 Gliclazide MR 62.18 Gliclazide MR 62.18
Empagliflozin 476.98 Empagliflozin 476.98 Empagliflozin 476.98
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S1 total cost 476.98 539.16 730.63 947.88
S2 Canagliflozin 476.93 Gliclazide MR 62.18 Gliclazide MR 62.18
Canagliflozin 476.93 Canagliflozin 476.93 Canagliflozin 476.93
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S2 total cost 476.93 539.11 730.58 947.83
S3 Dapagliflozin 476.98 Gliclazide MR 62.18 Gliclazide MR 62.18
Dapagliflozin 476.98 Dapagliflozin 476.98 Dapagliflozin 476.98
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S3 total cost 476.98 539.16 730.63 947.88
S4 Sitagliptin 433.57 Gliclazide MR 62.18 gliclazide MR 62.18
Sitagliptin 433.57 Sitagliptin 433.57 Sitagliptin 433.57
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S4 total cost 433.57 495.75 687.22 904.47
S5 Pioglitazone 93.25 Gliclazide MR 62.18 Gliclazide MR 62.18
Pioglitazone 93.25 Pioglitazone 93.25 Pioglitazone 93.25
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S5 total cost 93.25 155.43 346.90 564.15
S6 Gliclazide MR 62.18 Gliclazide MR 62.18 Gliclazide MR 62.18
Pioglitazone 93.25 Pioglitazone 93.25 Pioglitazone 93.25
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S6 total cost 62.18 155.43 346.90 564.15
S7 Repaglinide 71.91 Gliclazide MR 62.18 Gliclazide MR 62.18
Pioglitazone 93.25 Pioglitazone 93.25 Pioglitazone 93.25
INS 140.38 Int. INS 351.36
SMBG 51.09 SMBG 119.54
S7 total cost 71.91 155.43 346.90 564.15
Int. INS, intensive insulin.
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Costs: diabetes and the complications of diabetes
The costs of diabetes and the complications of diabetes are taken from the UKPDS84195 tables, and
uprated for inflation using a multiplier of 1.03 from the PSSRU Hospital and Community Health Services
index208 (Table 50).
It should be noted that these costs are for a representative 60-year-old male patient, and are for a patient
with only one complication. Costs are to a degree a function of age. There are interactions between
complications within the UKPDS82,194 which mean that those with more than one complication do not
necessarily incur a simple sum of the individual complication costs. Only one set of the costs of
complications can be fed into the OM1. As a consequence, it has not been possible to take these effects
into account, but they are not particularly marked.
The UKPDS84195 does not provide a costing for renal disease. In common with the draft NICE CG for
diabetes, these have been drawn from Lamping et al.221 with the inpatient cost in 1996 prices of £20,802
(SE £613) being uprated for inflation using a multiplier of 1.75 from the PSSRU HCSC index.
Assessment Group sensitivity analyses
All scenario analyses have been run deterministically with a cohort of 50,000 patients and 1000 inner
loops to reduce Monte Carlo error. The sensitivity analyses around the –0.0061 QoL decrement per BMI
point above 25 kg/m2 and the rebound of treatments’ effect upon weight are presented for all analyses:
l BMI 1 Natural history progression with no rebound
l BMI 2 Natural history progression with weight losses rebounding after 1 year
l BMI 3 Natural history progression with weight losses rebounding at treatment change
l BMI 4 Natural history progression with weight rebounding after 1 year
l BMI 5 Natural history progression with weight rebounding at treatment change.
The AG has also undertaken the following sensitivity analyses.
l SA01 At the third intensification patients switch to insulin plus gliclazide, and cease their
other treatments.
l SA02 Applying the UTI and GTI rates to all cycles of the model.
l SA03 Assuming that all patients when starting monotherapy have a HbA1c of 7.5%.
l SA04 Adjusting the HbA1c treatment effect for patients’ baseline HbA1c values as in the NICE CG.
l SA05 Not applying the discontinuation rates.
l SA06 Applying the NICE CG baseline TC/HDL values and the UKPDS68193 TC/HDL progression.
TABLE 49 Assessment Group resource use and costs of UTIs and GTIs
Infection GP visits
Unit
cost (£) Cost (£)
Drug
tariff (£) Cost/day (£) Days Cost (£)
Total
cost (£)
UTI
Male 2 46 92 1.87 0.62 7 4.36 96
Female 1 46 46 1.87 0.62 7 4.36 50
Total UTI cost 73
GTI
Male 1 46 46 6.23 0.89 7 6.23 52
Female 1 46 46 3.10 – – 3.10 49
Total GTI cost 51
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l SA07 Applying the UKPDS68193 year 2 parameter for the evolution of HbA1c.
l SA08 Intensifying when adding gliclazide having a –0.47% HbA1c effect.
l SA09 Applying the Janssen linear evolutions of HbA1c for all treatments.
l SA10 Assuming that those discontinuing from a treatment omit any subsequent intensification step
that reapplies this treatment.
l SA11 SA01 and SA08 combined.
Assessment Group base-case results
The disaggregate costs of the base case provided in Table 51.
The UKPDS costs for all the flozins are similar, with slightly lower costs than sitagliptin due, in part, to the
latter having little impact upon SBP, whereas the flozins reduce it.
Pioglitazone, gliclazide and repaglinide are estimated to have similar or slightly lower UKPDS OM1 costs
than the flozins, which is in line with the estimates of them having slightly larger effects upon HbA1c.
Treatment costs are the main source of the differences in costs, as would be anticipated. The flozins are of
similar cost, but canagliflozin is a reasonable amount cheaper. This arises due to the greater HbA1c effect
of canagliflozin meaning that patients will tend to intensify to the more expensive subsequent lines of
treatment slightly later.
For the base case, with the exception of repaglinide, and to a lesser extent gliclazide, patients remain on
their initial monotherapy throughout, adding treatments to it when they intensify. As a consequence, the
TABLE 50 Costs of diabetes and its complications
Event
Inpatient costs (£) Outpatient costs (£)
Total, mean (£)Mean SE Distribution Mean SE Distribution
No event 472 33 Gamma 547 23 Gamma 1019
Event year
Fatal MI 1564 531 Gamma 1564
Fatal IHD 3873 1250 Gamma 3873
Fatal stroke 4066 1158 Gamma 4066
MI 6560 1062 Gamma 990 95 Gamma 7550
IHD 10,044 1484 Gamma 888 78 Gamma 10,932
Stroke 6998 1685 Gamma 1122 191 Gamma 8120
Heart failure 3281 846 Gamma 1007 167 Gamma 4288
Amputation 9816 1849 Gamma 2775 713 Gamma 12,592
Blindness in one eye 1393 588 Gamma 1841 571 Gamma 3234
Subsequent years
MI 1187 158 Gamma 690 49 Gamma 1877
IHD 1249 153 Gamma 673 42 Gamma 1922
Stroke 1157 234 Gamma 777 89 Gamma 1934
Heart failure 1515 347 Gamma 1001 98 Gamma 2515
Amputation 1843 494 Gamma 1657 242 Gamma 3499
Blindness in one eye 466 99 Gamma 759 89 Gamma 1225
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annual treatment costs difference between sitagliptin and the flozins is maintained over the time horizon
of the model and the sitagliptin treatment costs are noticeably lower than those of the flozins. This
outweighs the slightly higher UKPDS OM1 costs for sitagliptin, and its total costs are a reasonable amount
less than those of the flozins.
Pioglitazone, gliclazide and repaglinide treatment costs are considerably lower than those of the flozins
and sitagliptin. Treatment costs cause the total costs of pioglitazone, gliclazide and repaglinide to be
considerably less than those of the flozins and sitagliptin.
The disaggregate QoL impacts of the base case provided in Table 52. Within this, the total QALYs
estimated under the UKPDS OM1 model and those associated with treatment switching, hypoglycaemic
events and UTIs and GTIs, are summed to give a subtotal. This subtotal corresponds to the sensitivity
analysis of assuming that a patent’s BMI has no impact upon the patient’s QoL. The QALY impacts from
assuming a –0.0061 QoL decrement for each BMI point above 25 kg/m2 are then presented for each of the
five weight progression scenarios that are modelled (see Table 52).
TABLE 51 Assessment Group base case: disaggregate costs (£)
Quantity
Empagliflozin
25mg
Canagliflozin
300mg
Dapagliflozin
10mg
Sitagliptin
100mg Pioglitazone Gliclazide Repaglinide
OM1 costs 22,880 22,925 22,926 23,039 22,905 22,876 22,871
Tx costs 9768 9624 9811 9199 4521 4323 4401
Tx change 95 92 96 96 94 91 92
Hypoglycaemic
episodes
20 20 21 21 19 20 46
UTI 8 10 8 3 3 3 3
GTI 4 5 5 1 1 1 1
Total costs £32,775 £32,676 £32,866 £32,358 £27,543 £27,314 £27,413
Tx, treatment.
TABLE 52 Assessment Group base case: disaggregate QALYs
Quantity
Empagliflozin
25mg
Canagliflozin
300mg
Dapagliflozin
10mg
Sitagliptin
100mg Pioglitazone Gliclazide Repaglinide
OM1 QALYs 10.380 10.382 10.369 10.355 10.385 10.393 10.390
Tx switch 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Hypoglycaemic
episodes
–0.001 –0.000 –0.000 –0.000 –0.000 –0.000 –0.001
UTI and GTI –0.001 –0.002 –0.002 –0.000 –0.000 –0.000 –0.000
Subtotal 10.378 10.380 10.367 10.355 10.384 10.392 10.389
BMI 1 –0.631 –0.600 –0.633 –0.697 –0.772 –0.759 –0.726
BMI 2 –0.694 –0.689 –0.696 –0.700 –0.772 –0.759 –0.726
BMI 3 –0.684 –0.673 –0.686 –0.699 –0.772 –0.759 –0.726
BMI 4 –0.612 –0.610 –0.612 –0.616 –0.622 –0.622 –0.619
BMI 5 –0.622 –0.613 –0.623 –0.636 –0.656 –0.653 –0.645
Tx, treatment.
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The QALY estimates are driven by the UKPDS OM1 outputs, and the BMI QoL decrements if these are
applied. The other elements have little impact, though it should be borne in mind that the base case
applies the UTI rates and GTI rates only during the first year.
The QALY losses associated with the –0.0061 QoL decrement for each BMI point above 25 kg/m2 may
appear large, at around 6% of the total QALYs. But the baseline QoL of 0.801 in the absence of
complications, the QoL impacts of complications and the baseline mean BMI of 31.9 kg/m2 should be
borne in mind. The baseline mean BMI of 31.9 kg/m2, when coupled with the –0.0061 QoL decrement per
BMI point above 25 kg/m2, reduces the baseline QoL of 0.801 in the absence of complications by around
4.5% by itself.
A summary of the total costs and QALYs with treatments ranked from the least expensive to the most
expensive is presented in Table 53.
These quantities can be subtracted from one another to present how much more costly and effective each
treatment is compared with the least costly treatment (Table 54).
There is a large step in total costs when moving from pioglitazone to sitagliptin driven by treatment costs.
There is a reasonable step in total costs when moving from sitagliptin to canagliflozin.
Pioglitazone is estimated to be both more costly and less effective than repaglinide under all of the BMI
scenarios. Similarly, empagliflozin and dapagliflozin are estimated to be more costly and less effective than
canagliflozin under all BMI scenarios, though the differences are not particularly large. This dominance is
reflected in the estimates of cost-effectiveness as tabulated (Table 55). Note that the following ICERs are
not relative to the least costly treatment, but are relative to the next least-costly treatment that is not
dominated. In other words for BMI 1 the cost-effectiveness of repaglinide compared with gliclazide is
£3331 per QALY and the cost-effectiveness of canagliflozin relative to repaglinide is £44,994 per QALY.
If the effects of BMI upon QoL are ignored or assumed not to apply then gliclazide is estimated to be both
the cheapest and the most effective treatment. It is cheaper than sitagliptin and the flozins by quite a large
amount, though the differences in the total lifetime QALYs are less marked.
For the scenarios of BMI progressing with natural history and the –0.0061 BMI QoL impact applying, if
there is no rebound of treatment weight effects or only weight losses rebound the weight gain associated
with gliclazide reduces its relative effectiveness. The smaller weight gain associated with repaglinide means
that it is estimated to have a cost-effectiveness of £3331 per QALY compared with repaglinide under
these scenarios.
TABLE 53 Assessment Group base case: lifetime total costs and QALYs
Treatment Total costs (£)
Total QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,314 10.392 9.633 9.633 9.633 9.771 9.739
Repaglinide 27,413 10.389 9.663 9.663 9.663 9.770 9.744
Pioglitazone 27,543 10.384 9.612 9.612 9.612 9.762 9.728
Sitagliptin 100 mg 32,358 10.355 9.657 9.655 9.655 9.739 9.719
Canagliflozin 300 mg 32,676 10.380 9.780 9.691 9.707 9.770 9.767
Empagliflozin 25 mg 32,775 10.378 9.747 9.683 9.694 9.766 9.756
Dapagliflozin 10 mg 32,866 10.367 9.734 9.671 9.681 9.756 9.745
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The scenarios of both weight gains and weight losses rebounding may be felt to be unrealistic. But these
are better seen as scenarios that explore when weight might tend to converge between the alternative
treatments. If this happens after only 1 year the differences in weight between gliclazide and repaglinide
are not maintained long enough for the BMI QALY effects to outweigh the QALYs estimated under the
UKPDS OM1 and repaglinide remains dominated. Maintaining the difference for a longer period up until
treatment change is sufficient for repaglinide to confer more QALYs and yields a cost-effectiveness
estimate of £18,507 per QALY.
Pioglitazone is estimated to yield slightly fewer QALYs under the UKPDS OM1 than gliclazide, and its larger
weight gain than gliclazide further hampers it. It remains dominated by gliclazide under all scenarios. But
this should not obscure the fact that the UKPDS OM1 estimates pioglitazone to be more effective than
sitagliptin and marginally more effective than the flozins. Pioglitazone is also considerably cheaper than
sitagliptin and the flozins. Without the QoL impacts of weight changes pioglitazone is formally estimated to
dominate sitagliptin and the flozins. Even with the QoL impacts of weight changes the cost-effectiveness
estimates for sitagliptin and the flozins compared with pioglitazone are poor and well above conventional
thresholds. Only canagliflozin and empagliflozin show any reasonable cost-effectiveness estimates compared
with pioglitazone, and these occur only if treatment weight changes and the resulting differences in weight
between treatments are assumed to be maintained over the patient lifetime. The BMI 1 scenario results in
cost-effectiveness estimates for canagliflozin and empagliflozin compared with pioglitazone of £30,537 per
QALY and £38,889 per QALY, respectively.
TABLE 54 Assessment Group base case: lifetime net costs and QALYs vs. the least costly treatment
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – – –
Repaglinide 100 –0.003 0.030 0.030 0.030 –0.001 0.005
Pioglitazone 230 –0.008 –0.021 –0.021 –0.021 –0.008 –0.011
Sitagliptin 100 mg 5045 –0.037 0.024 0.022 0.022 –0.031 –0.020
Canagliflozin 300 mg 5362 –0.012 0.147 0.057 0.074 0.000 0.028
Empagliflozin 25 mg 5461 –0.015 0.113 0.050 0.061 –0.005 0.017
Dapagliflozin 10 mg 5553 –0.025 0.101 0.038 0.048 –0.015 0.006
TABLE 55 Assessment Group base case: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom 3331 3331 3331 Dom 18,507
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 44,994 192,000 119,000 Dom 235,000
Empagliflozin 25 mg Dom Dom Dom Dom Dom Dom
Dapagliflozin 10 mg Dom Dom Dom Dom Dom Dom
Dom, dominated – i.e. more costly and less effective than another treatment.
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The UKPDS OM1 estimates sitagliptin to be slightly less effective than gliclazide. Being weight neutral,
its weight profile is superior to gliclazide, but this is insufficient to render it cost-effective at conventional
thresholds under any of the BMI scenarios when compared with gliclazide. Sitagliptin is dominated by
gliclazide if there are no direct QoL impacts from weight, and for the BMI scenarios 4 and 5. For the BMI
scenarios 1–3 the cost-effectiveness estimates for sitagliptin compared with gliclazide are £207,000,
£231,000 and £227,000 per QALY.
The UKPDS OM1 estimates canagliflozin to be slightly less effective than both gliclazide and repaglinide.
Its superior weight profile means that applying the –0.0061 QoL impact per BMI point, canagliflozin is
estimated to provide more benefits than both gliclazide and repaglinide, except for the scenario of all
weight changes rebounding after 1 year. The cost-effectiveness of canagliflozin compared with repaglinide
is £44,994 per QALY if weight changes are maintained indefinitely. But for the other scenarios the
cost-effectiveness estimates are well into six figures.
If the main comparator of the flozins is sitagliptin, this eliminates the much less costly alternatives. The net
quantities relative to sitagliptin are provided in Table 56.
The cost-effectiveness estimates for the flozins compared with sitagliptin is outlined in Table 57.
Even without their superior weight profiles, canagliflozin and empagliflozin are estimated to have
reasonable cost-effectiveness estimates compared with sitagliptin of £12,623 per QALY and £18,341 per
QALY, respectively. Factoring in the weight profiles, and assuming that the –0.0061 QoL decrement
applies, improves these cost-effectiveness estimates. The picture for dapagliflozin is more mixed, in part
due to the estimate of its impact upon HbA1c being similar to that of sitagliptin.
The central cost-effectiveness estimates of the probabilistic modelling are much the same as the
corresponding deterministic estimates. Given previous assessments in the area, the likelihood of different
treatments being cost-effective are presented for only the BMI 2 and BMI 3 scenarios. The full results of
the probabilistic modelling are presented in Appendix 7.
TABLE 56 Assessment Group base case: flozin cost-effectiveness estimates relative to sitagliptin
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Sitagliptin 100 mg – – – – – – –
Canagliflozin 300 mg 318 0.025 0.123 0.036 0.052 0.031 0.048
Empagliflozin 25 mg 416 0.023 0.089 0.028 0.038 0.026 0.037
Dapagliflozin 10 mg 508 0.013 0.077 0.017 0.026 0.017 0.026
TABLE 57 Assessment Group base case: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 12,623 2590 8913 6111 10,256 6627
Empagliflozin 25 mg 18,341 4676 14,716 10,841 15,734 11,300
Dapagliflozin 10 mg 40,383 6632 30,710 19,787 30,487 19,679
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For the BMI 2 scenario, if all comparators are included the probabilities of the flozins being cost-effective
are zero for willingness-to-pay values up to £50,000 per QALY. If the flozins are compared only with
sitagliptin, at a willingness to pay of £20,000 per QALY canagliflozin 300 mg is estimated to have the
highest likelihood of being cost-effective at 61%, followed by empagliflozin 25 mg at 24%, sitagliptin at
11% and dapagliflozin 10 mg at 4%. Increasing the willingness to pay to £30,000 per QALY revises these
probabilities to 64% for canagliflozin 300 mg, 27% for empagliflozin 25 mg, 5% for sitagliptin and 4%
for dapagliflozin.
For the BMI 3 scenario, if all comparators are included again up to a willingness to pay of £50,000 per
QALY there is effectively no probability of the flozins being cost-effective, though canagliflozin 300 mg is
estimated to have a 2% probability of being cost-effective at a willingness to pay of £50,000 per QALY. If
the flozins are compared only with sitagliptin then canagliflozin 300 mg is estimated to have the highest
likelihood of being cost-effective at 74%, followed by empagliflozin 25 mg at 19%, sitagliptin at 3%
and dapagliflozin 10 mg at 3%. Increasing the willingness to pay to £30,000 per QALY revises these
probabilities to 77% for canagliflozin 300 mg, 20% for empagliflozin 25 mg, 1% for sitagliptin and 3%
for dapagliflozin.
Assessment Group sensitivity analyses results
SA01: Patients switch to insulin plus gliclazide and drop other therapies
Applying the same cost for the insulin-containing regimes across the treatment arms results in the flozins
changing their ordering when ranked by increasing total cost. Canagliflozin 300 mg is now slightly more
expensive than the other flozins. This is probably due to the larger HbA1c effect of canagliflozin meaning
that patients, on average, switch to insulin slightly later than the other flozins (Table 58).
Total costs have fallen. As would be expected they have fallen furthest for the flozins and by almost as
much for sitagliptin when compared with the base case (Table 59). As only the treatment costs are
changing, there is no difference in QALYs.
Owing to the reordering of the treatments by total costs, empagliflozin is no longer dominated (Table 60).
The cost-effectiveness of repaglinide compared with gliclazide improves slightly for the BMI 1–3 scenarios
to £3026 per QALY and for the BMI 5 scenario to £16,814 per QALY.
The flozins remain dominated if there are no direct QoL impacts from weight changes. For the BMI
scenarios 1–3 the cost-effectiveness of empagliflozin compared with repaglinide is £27,230 per QALY,
TABLE 58 Assessment Group SA01: total costs and QALYs
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 26,628 10.392 9.633 9.633 9.633 9.771 9.739
Repaglinide 26,719 10.389 9.663 9.663 9.663 9.770 9.744
Pioglitazone 26,835 10.384 9.612 9.612 9.612 9.762 9.728
Sitagliptin 100 mg 28,875 10.355 9.657 9.655 9.655 9.739 9.719
Empagliflozin 25 mg 28,990 10.378 9.747 9.683 9.694 9.766 9.756
Dapagliflozin 10 mg 29,010 10.367 9.734 9.671 9.681 9.756 9.745
Canagliflozin 300 mg 29,040 10.380 9.780 9.691 9.707 9.770 9.767
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£113,000 per QALY and £74,209 per QALY, respectively, whereas for the BMI scenario 5 it is £201,000
per QALY. But these cost-effectiveness estimates for empagliflozin are extendedly dominated by
canagliflozin, which has cost-effectiveness estimates compared with repaglinide of £19,850 per QALY,
£84,634 per QALY and £52,571 per QALY for the BMI scenarios 1–3, and £104,000 per QALY for the BMI
scenario 5.
For the cost-effectiveness of the flozins compared with sitagliptin the estimates improve quite considerably
because of the greater cost reductions for the flozins (Table 61).
TABLE 59 Assessment Group SA01: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide –685 0.000 0.000 0.000 0.000 0.000 0.000
Repaglinide –694 0.000 0.000 0.000 0.000 0.000 0.000
Pioglitazone –709 0.000 0.000 0.000 0.000 0.000 0.000
Sitagliptin 100 mg –3483 0.000 0.000 0.000 0.000 0.000 0.000
Empagliflozin 25 mg –3785 0.000 0.000 0.000 0.000 0.000 0.000
Dapagliflozin 10 mg –3856 0.000 0.000 0.000 0.000 0.000 0.000
Canagliflozin 300 mg –3635 0.000 0.000 0.000 0.000 0.000 0.000
TABLE 60 Assessment Group SA01: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom 3026 3026 3026 Dom 16,814
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Empagliflozin 25 mg Dom 27,230 112,991 74,209 Dom 201,000
Dapagliflozin 10 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 1504 6882 3722 Dom 4559
Dom, dominated – i.e. more costly and less effective than another treatment.
TABLE 61 Assessment Group SA01: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 6567 1347 4637 3179 5335 3447
Empagliflozin 25 mg 5054 1288 4055 2987 4335 3114
Dapagliflozin 10 mg 10,739 1764 8166 5262 8107 5233
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SA02: Urinary tract infection and genital tract infection rates applied to all
model cycles
If the UTI and GTI rates are applied to all model cycles this has a slightly larger impact upon the flozins
than the other treatments. Compared with the values of the base case the following changes occur
(Table 62).
The pattern of dominated strategies is as for the base case. Given the similarity of changes for both
gliclazide and repaglinide the cost-effectiveness estimates for repaglinide compared with gliclazide are little
different from those of the base case.
Owing to the flozins being slightly worse affected by this, the cost-effectiveness estimates for canagliflozin
compared with repaglinide for BMI scenarios 1–3 and 5 worsen slightly to £46,721 per QALY, £223,000
per QALY, £131,000 per QALY and £283,000 per QALY, respectively. There is also some worsening in the
cost-effectiveness estimates for the flozins compared with sitagliptin (Table 63).
SA03: A common baseline HbA1c of 7.5%
The common baseline HbA1c of 7.5% does not change the ordering of treatments by their total costs, with
the aggregate outcomes being as shown in Table 64.
Total costs have fallen and the total QALYs have increased compared with the base case as outlined in
Table 65.
Although the effects are reasonably similar across all the treatments, they appear to be larger for sitagliptin
and in some instances for the flozins too. Whereas the differences in total QALYs are sometimes slight for
TABLE 62 Assessment Group SA02: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 65 –0.007 –0.007 –0.007 –0.007 –0.007 –0.007
Repaglinide 65 –0.007 –0.007 –0.007 –0.007 –0.007 –0.007
Pioglitazone 66 –0.007 –0.007 –0.007 –0.007 –0.007 –0.007
Sitagliptin 100 mg 68 –0.007 –0.007 –0.007 –0.007 –0.007 –0.007
Canagliflozin 300 mg 93 –0.010 –0.010 –0.010 –0.010 –0.010 –0.010
Empagliflozin 25 mg 84 –0.009 –0.009 –0.009 –0.009 –0.009 –0.009
Dapagliflozin 10 mg 86 –0.009 –0.009 –0.009 –0.009 –0.009 –0.009
TABLE 63 Assessment Group SA02: Flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 15,805 2875 10,656 7065 12,465 7709
Empagliflozin 25 mg 21,167 4987 16,622 11,973 17,878 12,513
Dapagliflozin 10 mg 52,010 7093 37,364 22,660 37,046 22,523
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sitagliptin compared with the cheaper alternatives, there is always a cheaper alternative that offers slightly
more QALYs. The cost differences remain large and as a consequence sitagliptin remains dominated.
For BMI scenarios 1–3 the cost-effectiveness of repaglinide compared with gliclazide rises slightly to £3911
per QALY. For BMI scenarios 1–3 and 5 the cost-effectiveness of canagliflozin worsen slightly to £45,968,
£207,000, £107,000 and £173,000, respectively.
For the cost-effectiveness of the flozins compared with sitagliptin the estimates worsen as a result of the
relative improvement of sitagliptin (Table 66).
TABLE 64 Assessment Group SA03: total costs and QALYs
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 26,593 10.432 9.687 9.687 9.687 9.810 9.776
Repaglinide 26,710 10.429 9.717 9.717 9.717 9.810 9.784
Pioglitazone 26,814 10.425 9.665 9.665 9.665 9.802 9.763
Sitagliptin 100 mg 31,501 10.404 9.716 9.714 9.714 9.787 9.767
Canagliflozin 300 mg 31,925 10.421 9.831 9.742 9.766 9.810 9.815
Empagliflozin 25 mg 32,003 10.420 9.800 9.737 9.752 9.808 9.803
Dapagliflozin 10 mg 32,044 10.414 9.789 9.728 9.742 9.801 9.794
TABLE 65 Assessment Group SA03: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide –721 0.040 0.054 0.054 0.054 0.039 0.037
Repaglinide –703 0.041 0.054 0.054 0.054 0.040 0.040
Pioglitazone –730 0.041 0.053 0.053 0.053 0.040 0.035
Sitagliptin 100 mg –858 0.049 0.059 0.059 0.059 0.048 0.048
Canagliflozin 300 mg –751 0.041 0.050 0.052 0.059 0.040 0.048
Empagliflozin 25 mg –772 0.043 0.053 0.054 0.058 0.042 0.047
Dapagliflozin 10 –822 0.046 0.055 0.057 0.061 0.045 0.049
TABLE 66 Assessment Group SA03: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 24,939 3717 14,961 8237 18,309 8880
Empagliflozin 25 mg 30,150 6042 21,643 13,310 24,300 13,972
Dapagliflozin 10 mg 54,863 7442 38,256 19,902 38,725 20,011
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SA04: Initial glycated haemoglobin treatment effect a function of baseline
glycated haemoglobin
If the monotherapies’ treatment effects upon HbA1c are made a function of patients’ baseline HbA1c, as
derived from the NICE CG modelling, which implies a larger effect for those with a higher baseline value,
the following applies (Table 67).
And the following changes from the baseline values (Table 68):
This does not change the treatments that are modelled as being dominated. The cost-effectiveness
estimates for repaglinide compared with gliclazide are little changed at £3747 per QALY for the BMI
scenarios 1–3 but the cost-effectiveness estimate for the BMI scenario 5 worsens to £34,225 per QALY
due to the similarity in effectiveness between the two treatments.
For the BMI scenarios 1–3 and 5 the cost-effectiveness estimates for canagliflozin compared with
repaglinide are broadly similar to those of the base case at £44,115 per QALY, £179,000 per QALY,
£127,000 per QALY, and £272,000 per QALY, respectively.
The cost-effectiveness estimates for the flozins compared with sitagliptin are typically slightly better than
those of the base case (Table 69).
SA05: No discontinuation rates
Not applying the treatment discontinuation rates results in the following (Tables 70 and 71).
TABLE 67 Assessment Group SA04: total costs and QALYs
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,410 10.393 9.629 9.629 9.629 9.771 9.738
Repaglinide 27,518 10.389 9.658 9.658 9.658 9.770 9.741
Pioglitazone 27,650 10.384 9.608 9.608 9.608 9.762 9.729
Sitagliptin 100 mg 32,588 10.358 9.654 9.651 9.652 9.742 9.718
Canagliflozin 300 mg 32,782 10.381 9.777 9.687 9.700 9.771 9.760
Empagliflozin 25 mg 32,953 10.380 9.744 9.680 9.687 9.768 9.751
Dapagliflozin 10 mg 33,100 10.371 9.732 9.669 9.674 9.759 9.740
TABLE 68 Assessment Group SA04: total costs and QALYs compared with the base case
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 97 0.001 –0.004 –0.004 –0.004 0.001 –0.001
Repaglinide 105 0.000 –0.005 –0.005 –0.005 0.000 –0.003
Pioglitazone 106 0.000 –0.004 –0.004 –0.004 0.000 0.001
Sitagliptin 100 mg 230 0.003 –0.003 –0.004 –0.004 0.002 –0.001
Canagliflozin 300 mg 106 0.001 –0.003 –0.003 –0.008 0.001 –0.006
Empagliflozin 25 mg 179 0.003 –0.003 –0.003 –0.007 0.002 –0.005
Dapagliflozin 10 mg 234 0.004 –0.002 –0.003 –0.007 0.003 –0.004
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Repaglinide increases in cost slightly, but the small increases in the total QALYs are proportionally slightly
greater and there is a minor improvement in the cost-effectiveness estimates for repaglinide compared
with gliclazide compared with those of the base case for the BMI scenarios 1–3 and 5.
The costs for sitagliptin and the flozins increase slightly with minimal impact upon the total QALYs associated
with them. Compared with the cost-effectiveness estimate of the base case, the cost-effectiveness estimates
for canagliflozin compared with repaglinide for the BMI scenarios 1–3 and 5 worsen slightly, but the effect
is small.
TABLE 69 Assessment Group SA04: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 8314 1570 5367 4037 6636 4570
Empagliflozin 25 mg 16,222 4063 12,671 10,411 13,894 11,064
Dapagliflozin 10 mg 37,733 6582 29,767 23,093 29,242 22,808
TABLE 70 Assessment Group SA05: total costs and QALYs
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,320 10.393 9.634 9.634 9.634 9.771 9.739
Repaglinide 27,421 10.389 9.665 9.665 9.665 9.770 9.745
Pioglitazone 27,571 10.383 9.610 9.610 9.610 9.761 9.727
Sitagliptin 100 mg 32,456 10.354 9.658 9.655 9.656 9.739 9.718
Canagliflozin 300 mg 32,735 10.379 9.781 9.690 9.707 9.769 9.766
Empagliflozin 25 mg 32,826 10.377 9.747 9.683 9.694 9.765 9.755
Dapagliflozin 10 mg 32,944 10.367 9.735 9.671 9.681 9.755 9.744
TABLE 71 Assessment Group SA05: total costs and QALYs compared with the base case
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 6 0.000 0.001 0.001 0.001 0.000 0.000
Repaglinide 7 0.000 0.002 0.002 0.002 0.000 0.001
Pioglitazone 28 –0.001 –0.002 –0.002 –0.002 –0.001 –0.001
Sitagliptin 100 mg 98 –0.001 0.000 0.000 0.000 –0.001 0.000
Canagliflozin 300 mg 59 –0.001 0.001 0.000 0.000 –0.001 0.000
Empagliflozin 25 mg 52 0.000 0.001 0.000 0.000 0.000 0.000
Dapagliflozin 10 mg 78 –0.001 0.001 0.000 0.000 –0.001 0.000
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SA06: National Institute for Health and Care clinical guideline baseline TC/HDL
values and UKPDS68 progression
If the NICE CG baseline TC/HDL values are applied and the TC/HDL ratio is evolved as per the UKPDS68193
equation 13 the patient outcomes worsen and costs rise, as shown in Tables 72 and 73.
The cost-effectiveness estimates for repaglinide compared with gliclazide are little different from those of
the base case.
The cost-effectiveness estimates for canagliflozin compared with repaglinide for the BMI scenarios 1–3 and
5, of £46,562 per QALY, £129,000 per QALY, £223,000 per QALY and £272,000 per QALY respectively,
are broadly similar to those of the base case.
The cost-effectiveness estimates of the flozins compared with sitagliptin show some improvements
compared with the base-case estimates (Table 74).
SA07: Applying the UKPDS68 year 2 parameter for the evolution of
glycated haemoglobin
Applying the UKPDS68193 year 2 parameter of equation 11 for the evolution of HbA1c has little impact
upon results compared with the base case in absolute terms (Table 75).
TABLE 72 Assessment Group SA06: total costs and QALYs
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,783 10.006 9.273 9.273 9.273 9.404 9.373
Repaglinide 27,884 10.003 9.302 9.302 9.302 9.404 9.379
Pioglitazone 27,996 9.997 9.251 9.251 9.251 9.394 9.361
Sitagliptin 100 mg 32,676 9.963 9.289 9.287 9.287 9.367 9.348
Canagliflozin 300 mg 32,968 9.990 9.411 9.325 9.341 9.400 9.398
Empagliflozin 25 mg 33,057 9.989 9.379 9.318 9.329 9.397 9.387
Dapagliflozin 10 mg 33,154 9.977 9.366 9.305 9.315 9.385 9.375
TABLE 73 Assessment Group SA06: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 469 –0.386 –0.361 –0.361 –0.361 –0.367 –0.366
Repaglinide 470 –0.386 –0.361 –0.361 –0.361 –0.366 –0.365
Pioglitazone 452 –0.388 –0.362 –0.362 –0.362 –0.368 –0.367
Sitagliptin 100 mg 318 –0.392 –0.368 –0.368 –0.368 –0.372 –0.371
Canagliflozin 300 mg 292 –0.390 –0.369 –0.366 –0.366 –0.370 –0.369
Empagliflozin 25 mg 283 –0.389 –0.367 –0.365 –0.365 –0.369 –0.368
Dapagliflozin 10 mg 288 –0.390 –0.369 –0.366 –0.366 –0.370 –0.370
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The cost-effectiveness estimates for the treatments that are not dominated are little different from those of
the base case. The cost-effectiveness estimates compared with sitagliptin are similar to those of the base
case (Table 76).
SA08: Intensifying by adding gliclazide has a –0.47% glycated haemoglobin reduction
If the intensification of adding gliclazide to a monotherapy results in only a –0.47% reduction in HbA1c,
then this has very little impact upon those who had gliclazide and repaglinide monotherapy, as a result of
this affecting only the small percentage who discontinue because of adverse events. But the impact upon
the other treatments is quite marked. For these, the change affects the vast majority of patients. They have
an overall smaller clinical effect applied, which is, in itself, harmful, and will also tend to progress through
to insulin more quickly than the base case (Table 77).
This results in the following differences in costs and QALYs compared with the base case (Table 78).
And the following cost-effectiveness estimates (Table 79).
TABLE 74 Assessment Group SA06: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 10,601 2403 7748 5420 8807 5845
Empagliflozin 25 mg 14,657 4237 12,152 9208 12,873 9552
Dapagliflozin 10 mg 33,394 6284 26,373 17,585 26,173 17,486
TABLE 75 Assessment Group SA07: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide –7 0.001 0.001 0.001 0.001 0.001 0.001
Repaglinide 3 0.001 0.001 0.001 0.001 0.001 0.001
Pioglitazone –4 0.000 0.000 0.000 0.000 0.000 0.000
Sitagliptin 100 mg –5 0.001 0.001 0.001 0.001 0.001 0.001
Canagliflozin 300 mg –16 0.000 0.000 0.000 0.000 0.000 0.000
Empagliflozin 25 mg –12 0.000 0.000 0.000 0.001 0.000 0.000
Dapagliflozin 10 mg –8 0.001 0.001 0.001 0.001 0.001 0.001
TABLE 76 Assessment Group SA07: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 12,919 2527 8936 6036 10,356 6563
Empagliflozin 25 mg 18,616 4635 14,818 10,825 15,879 11,294
Dapagliflozin 10 mg 41,268 6630 31,255 19,911 31,026 19,801
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If second-line gliclazide is less effective, and crucially is less effective than the second-line pioglitazone in
the gliclazide and repaglinide arms, this considerably worsens the cost-effectiveness estimates for the
flozins compared with gliclazide and repaglinide. It also worsens their cost-effectiveness estimates
compared with pioglitazone.
TABLE 77 Assessment Group SA08: total costs and QALYs
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,320 10.393 9.634 9.634 9.634 9.771 9.739
Repaglinide 27,421 10.389 9.665 9.665 9.665 9.770 9.745
Pioglitazone 27,571 10.383 9.610 9.610 9.610 9.761 9.727
Sitagliptin 100 mg 32,456 10.354 9.658 9.655 9.656 9.739 9.718
Canagliflozin 300 mg 32,735 10.379 9.781 9.690 9.707 9.769 9.766
Empagliflozin 25 mg 32,826 10.377 9.747 9.683 9.694 9.765 9.755
Dapagliflozin 10 mg 32,944 10.367 9.735 9.671 9.681 9.755 9.744
TABLE 78 Assessment Group SA08: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 5 0.000 0.000 0.000 0.000 0.000 0.000
Repaglinide 13 0.000 0.000 0.000 0.000 0.000 0.000
Pioglitazone 273 –0.016 –0.020 –0.020 –0.020 –0.016 –0.016
Sitagliptin 100 mg 299 –0.019 –0.023 –0.023 –0.023 –0.018 –0.018
Canagliflozin 300 mg 266 –0.018 –0.023 –0.023 –0.023 –0.018 –0.018
Empagliflozin 25 mg 281 –0.018 –0.022 –0.022 –0.022 –0.018 –0.017
Dapagliflozin 10 mg 286 –0.020 –0.024 –0.024 –0.024 –0.020 –0.019
TABLE 79 Assessment Group SA08: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom 3604 3604 3604 Dom 19,784
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 58,292 1.1M £254,000 Dom £1.1M
Empagliflozin 25 mg Dom Dom Dom Dom Dom Dom
Dapagliflozin 10 mg Dom Dom Dom Dom Dom Dom
Dom, dominated – i.e. more costly and less effective than another treatment.
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For the comparisons with sitagliptin the cost-effectiveness estimates for the flozins are provided in
Table 80.
The flozins continue to show reasonable cost-effectiveness estimates compared with sitagliptin, though,
again, the picture is more mixed for dapagliflozin.
SA09: Applying the Janssen linear evolutions of glycated haemoglobin
Applying the Janssen linear evolutions for treatments causes pioglitazone to become the cheapest as
shown in Table 81.
Compared with the base case, costs have fallen considerably for all treatments, and total QALYs have risen
(Table 82).
TABLE 81 Assessment Group SA09: total costs and QALYs
Treatment Costs (£)
QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Pioglitazone 25,818 10.486 9.740 9.740 9.740 9.861 9.811
Gliclazide 25,986 10.476 9.734 9.734 9.734 9.852 9.807
Repaglinide 26,139 10.470 9.761 9.761 9.761 9.849 9.812
Sitagliptin 100 mg 31,303 10.426 9.741 9.738 9.739 9.808 9.782
Canagliflozin 300 mg 31,385 10.465 9.882 9.793 9.821 9.853 9.857
Empagliflozin 25 mg 31,643 10.453 9.836 9.773 9.790 9.840 9.831
Dapagliflozin 10 mg 31,836 10.438 9.817 9.754 9.769 9.825 9.813
TABLE 80 Assessment Group SA08: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 11,125 2311 7903 5435 9065 5909
Empagliflozin 25 mg 17,003 4442 13,784 10,214 14,676 10,638
Dapagliflozin 10 43,173 6551 32,025 20,133 31,759 19,999
TABLE 82 Assessment Group SA09: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Pioglitazone –1725 0.101 0.128 0.128 0.128 0.099 0.082
Gliclazide –1328 0.084 0.101 0.101 0.101 0.082 0.069
Repaglinide –1275 0.081 0.098 0.098 0.098 0.079 0.067
Sitagliptin 100 mg –1055 0.071 0.083 0.083 0.083 0.069 0.063
Canagliflozin 300 mg –1291 0.085 0.102 0.102 0.114 0.083 0.091
Empagliflozin 25 mg –1131 0.076 0.090 0.090 0.096 0.074 0.075
Dapagliflozin 10 mg –1030 0.071 0.083 0.083 0.088 0.069 0.068
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Gliclazide is now dominated by pioglitazone, though the pattern of dominance of the base case has not
otherwise changed.
The cost-effectiveness estimates for repaglinide compared with pioglitazone are somewhat worse than the
corollaries for repaglinide compared with gliclazide of the base case. The cost-effectiveness estimates for
canagliflozin compared with repaglinide are surprisingly similar, though the estimates for BMI scenario 5,
and to a lesser extent scenario 3, have improved (Table 83).
Despite the quite radical change in the evolution of HbA1c, the cost-effectiveness estimates for the flozins
compared with sitagliptin are not radically different from those of the base case, but have improved
somewhat for canagliflozin and empagliflozin (Table 84). The picture for dapagliflozin remains mixed.
SA10: Those discontinuing a treatment omit the intensification step that
applies this treatment
This sensitivity analysis has little impact upon results and does not affect the ordering of treatments by
their total costs. The pattern of dominated treatments is also not affected.
The cost-effectiveness of repaglinide compared with gliclazide is estimated to improve for the BMI
scenarios 1–3 to £2744 per QALY, and for BMI scenario 5 to £14,190 per QALY.
The cost-effectiveness estimates of canagliflozin compared with repaglinide are little affected, being
£45,679 per QALY, £206,000 per QALY, £124,000 per QALY and £257 per QALY for the BMI scenarios
1–3 and 5, respectively.
The cost-effectiveness estimates for the flozins compared with sitagliptin are essentially those of the
base case.
TABLE 84 Assessment Group SA09: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 11,125 2311 7903 5435 9065 5909
Empagliflozin 25 mg 17,003 4442 13,784 10,214 14,676 10,638
Dapagliflozin 10 mg 43,173 6551 32,025 20,133 31,759 19,999
TABLE 83 Assessment Group SA09: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Pioglitazone – – – – – –
Gliclazide Dom Dom Dom Dom Dom Dom
Repaglinide Dom 15,633 15,633 15,633 Dom 343,000
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 43,246 163,000 86,862 Dom 115,000
Empagliflozin 25 mg Dom Dom Dom Dom Dom Dom
Dapagliflozin 10 Dom Dom Dom Dom Dom Dom
Dom, dominated – i.e. more costly and less effective than another treatment.
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SA11: SA01 and SA08 combined
If intensifying from monotherapy, by adding gliclazide only, results in a –0.47% reduction in patients
HbA1c, and, when switching to insulin, patients receive only insulin and gliclazide, the combined effects of
this are as shown in Table 85. As for SA01, canagliflozin is now estimated to be the most expensive
treatment (see Table 85).
The pattern of changes in cost is much as per SA01, whereas the pattern of changes in QALYs is as per
SA08 (Table 86).
Owing to the reordering of the treatments by total costs, empagliflozin is no longer dominated.
Note that the erratic pattern for canagliflozin as the BMI scenarios are worked across is due to it being compared
with empagliflozin for the BMI scenarios 1, 3 and 5, but to repaglinide for the BMI scenarios 2 and 4 (Table 87).
The flozins remain dominated if there are no direct QoL impacts from weight changes. For the BMI
scenarios 1 and 3 the cost-effectiveness of empagliflozin compared with repaglinide is £36,837 per QALY
and £268,000 per QALY, respectively. But these cost-effectiveness estimates for empagliflozin are
extendedly dominated by canagliflozin, which has cost-effectiveness estimates compared with repaglinide
of £24,226 per QALY and £105,000 per QALY, respectively, for the BMI scenarios 1 and 3.
For the cost-effectiveness of the flozins compared with sitagliptin the estimates improve quite considerably
because of the greater cost reductions for the flozins and sitagliptin seeing similar falls in total QALYs as
the flozins (Table 88).
TABLE 86 Assessment Group SA11: total costs and QALYs compared with the base case
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide –682 0.000 0.000 0.000 0.000 0.000 0.000
Repaglinide –684 0.000 0.000 0.000 0.000 0.000 0.000
Pioglitazone –489 –0.016 –0.020 –0.020 –0.020 –0.016 –0.016
Sitagliptin 100 mg –3437 –0.019 –0.023 –0.023 –0.023 –0.018 –0.018
Empagliflozin 25 mg –3787 –0.018 –0.022 –0.022 –0.022 –0.018 –0.017
Dapagliflozin 10 mg –3848 –0.020 –0.024 –0.024 –0.024 –0.020 –0.019
Canagliflozin 300 mg –3654 –0.018 –0.023 –0.023 –0.023 –0.018 –0.018
TABLE 85 Assessment Group SA11: total costs and QALYs
Treatment Net costs (£)
Net QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 26,631 10.392 9.633 9.633 9.633 9.770 9.739
Repaglinide 26,730 10.389 9.663 9.663 9.663 9.770 9.744
Pioglitazone 27,054 10.368 9.592 9.592 9.592 9.746 9.713
Sitagliptin 100 mg 28,922 10.336 9.634 9.632 9.632 9.721 9.701
Empagliflozin 25 mg 28,988 10.359 9.724 9.661 9.671 9.748 9.738
Dapagliflozin 10 mg 29,018 10.347 9.710 9.647 9.657 9.736 9.726
Canagliflozin 300 mg 29,022 10.361 9.758 9.668 9.685 9.752 9.749
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Canagliflozin 300 mg systolic blood pressure effect
The AG cost-effectiveness modelling provided to NICE relied upon the results of the AG NMA, which had
an incorrect figure of 0.5 mmHg for canagliflozin, whereas the correct figure was 5 mmHg. Correcting this,
a revised estimate for the SBP effect of canagliflozin 300 mg improves its net cost and QALY estimates as
shown in Table 89 for the pairwise comparisons with gliclazide, pioglitazone and sitagliptin.
These changes, in turn, yield the following cost-effectiveness estimates in Table 90.
TABLE 87 Assessment Group SA11: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom 3278 3278 3278 Dom 17,994
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Empagliflozin 25 mg Dom 36,837 Dom 268,000 Dom Dom
Dapagliflozin 10 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 1030 460,000 2581 Dom 470,000
Dom, dominated – i.e. more costly and less effective than another treatment.
TABLE 88 Assessment Group SA11: flozin cost-effectiveness estimates relative to sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 3927 816 2789 1918 3199 2085
Empagliflozin 25 mg 2818 736 2285 1693 2432 1763
Dapagliflozin 10 mg 8399 1274 6230 3917 6178 3891
TABLE 89 Revised canagliflozin 300mg SBP effect and pairwise net cost and QALYs
Comparison Net cost (£) No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
vs. Gliclazide 5224 0.005 0.163 0.074 0.090 0.016 0.044
vs. Pioglitazone 4991 0.013 0.185 0.095 0.112 0.025 0.055
vs. Sitagliptin 187 0.042 0.139 0.052 0.068 0.048 0.064
TABLE 90 Revised canagliflozin 300mg SBP effect and pairwise ICERs (£)
Comparison No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
vs. Gliclazide 1.1M 32,015 71,038 57,865 330,000 118,000
vs. Pioglitazone 385,000 27,003 52,432 44,590 201,000 90,653
vs. Sitagliptin 4401 1341 3586 2729 3929 2896
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Summary of the Assessment Group modelling
The AG modelling base case estimates that the lifetime QALYs arising from diabetes, its complications and
adverse events are highest for gliclazide at 10.392 QALYs, with repaglinide having a similar estimate of
10.389 QALYs. Pioglitazone accrues slightly fewer at 10.384 QALYs. The flozins lie a little below this, with
canagliflozin being estimated to yield 10.380 QALYs, empagliflozin 10.378 QALYs and dapagliflozin
10.367 QALYS. Sitagliptin fares worse at 10.355 QALYs. Gliclazide is estimated to be superior to the
flozins by 0.012 QALYs compared with canagliflozin, 0.015 QALYs compared with empagliflozin, and
0.025 QALYs compared with dapagliflozin. Adverse events contribute relatively little to these estimates,
and even less to the estimates of the differences between treatments. To place these amounts in context,
at the baseline QoL of 0.801 they would be equivalent to survival gains of around 6 days compared with
canagliflozin, 7 days compared with empagliflozin and 11 days compared with dapagliflozin.
But these amounts ignore the direct QoL effects of weight changes. The flozins have a superior weight
profile, with canagliflozin providing the largest weight losses. If the monotherapy weight changes are
retained over the patient lifetime then canagliflozin is estimated to yield an additional 0.147 QALYs
compared with gliclazide: equivalent to 67 days’ additional survival at the baseline QoL of 0.801. These
gains are reduced if it is assumed that weight losses rebound after 1 year to only 0.057 QALYs, and
rebound at treatment change to 0.074 QALYs.
The flozins and, to a slightly lesser extent sitagliptin, are estimated to be considerably more expensive than
gliclazide, repaglinide and pioglitazone, with the increases in lifetime costs ranging between £5000
and £5500.
In light of the above, if there are no direct QoL effects from weight changes, the flozins are estimated to
be dominated. But if there are direct QoL impacts from weight changes, and the monotherapy weight
changes persist throughout the patient lifetime, the flozins are no longer dominated. Repaglinide remains
more expensive than gliclazide, but now yields slightly more QALYs and has a cost-effectiveness estimate
compared with gliclazide of £3331 per QALY. Canagliflozin has a cost-effectiveness estimate of £44,994
per QALY compared with repaglinide. Although canagliflozin formally dominates the other flozins, the
cost-effectiveness estimates for empagliflozin and for dapagliflozin compared with gliclazide are £48,169
per QALY and £55,000 per QALY, respectively.
It may be unrealistic to expect the monotherapies’ weight changes, and the differences they imply
between treatments, to persist indefinitely. If weight losses rebound after 1 year the cost-effectiveness of
canagliflozin compared with repaglinide worsens considerably to £192,000 per QALY; if they persist until
treatment intensification then the cost-effectiveness estimate for canagliflozin compared with repaglinide
worsens to £119,000 per QALY.
The companies argue that the main comparator for the flozins is sitagliptin. The flozins are estimated to
provide slightly greater total QALYs from the modelling of diabetes, its complications and the adverse
events associated with treatments. The flozins are also associated with somewhat larger weight losses than
sitagliptin, which is broadly weight neutral. Total costs are higher than sitagliptin by £318 for canagliflozin,
£416 for empagliflozin and £508 for dapagliflozin. Even without the direct QoL effects of weight changes,
canagliflozin has a reasonable cost-effectiveness compared with sitagliptin of £12,623 per QALY, as does
empagliflozin at £18,341 per QALY. Dapagliflozin fares worse with a cost-effectiveness estimate of
£40,383 per QALY.
With the direct QoL effects of weight changes and weight changes being assumed to persist over the
patient lifetime the cost-effectiveness of the flozins compared with sitagliptin improves considerably.
Canagliflozin has an estimate of £2590 per QALY, empagliflozin has an estimate of £4676 per QALY and
dapagliflozin has an estimate of £6632 per QALY. If weight changes are assumed to rebound either after
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1 year or at treatment change, the cost-effectiveness estimates for the flozins generally remain within
conventional thresholds. The exception to this is dapagliflozin, for which if weight rebounds after 1 year
the cost-effectiveness estimates go slightly above the £30,000 threshold.
A key difference between the AG modelling and that of the companies is that the AG has assumed that
patients remain on their monotherapy and add treatments to it. When patients intensify to insulin, they
do so by adding it to their existing regime, for example they intensify from canagliflozin plus gliclazide
to canagliflozin plus gliclazide plus insulin. Retaining the original monotherapy increases the total costs,
and, in particular, increases the total cost for the flozins and, to a slightly lesser extent, sitagliptin. If it is
assumed that the monotherapies are discontinued when the patients intensify to insulin then the net costs
fall to be within the range of £2362–2412 for the flozins and to £2247 for sitagliptin.
The flozins remain dominated if the direct QoL impact of weight changes are not included, but applying
them, and assuming that weight changes persist indefinitely, improves the cost-effectiveness estimates
for the flozins compared with repaglinide to £19,850 per QALY for canagliflozin, £27,230 per QALY for
empagliflozin and £32,288 per QALY for dapagliflozin. Weight losses rebounding after 1 year cause these
estimates to worsen to £84,634 per QALY, £112,000 per QALY and £274,000 per QALY, respectively,
whereas weight losses rebounding at change of treatment cause these estimates to worsen to £52,571
per QALY, £74,209 per QALY and £128k per QALY, respectively.
This sensitivity analysis also sees the flozins being estimated to be cost-effective relative to sitagliptin under
all of the weight-change scenarios including that of no direct QoL impact from weight changes.
The base case applied the baseline HbA1c values for those starting a monotherapy of the NICE CG, which
had a mean of 8.4% (SD 1.8%). This differs from some of the companies’ modelling, which assumed a
common baseline HbA1c of 7.5%. As would be expected, this both improved patient outcomes and
lowered total costs. It did not alter the patterns of dominance, and, although the cost-effectiveness
estimates for the flozins compared with repaglinide worsened, the effect was not major.
Of more interest was that the cost-effectiveness estimates of the flozins compared with sitagliptin
worsened. With no direct QoL impacts from weight these worsened to £24,939 per QALY for
canagliflozin, £30,150 per QALY for empagliflozin and £54,863 per QALY for dapagliflozin. With the
monotherapy BMI effects persisting for the patient lifetime, these cost-effectiveness estimates improve to
£3717 per QALY, £6042 per QALY and £7442 per QALY, respectively. Weight loss rebound after 1 year
reduces the improvements to £14,961 per QALY, £21,643 per QALY and £38,256 per QALY, whereas
weight loss rebound at treatment change reduces the improvements to £8237 per QALY, £13,310 per
QALY, and £19,902 per QALY, respectively.
Making the HbA1c treatment effect a function of patients’ baseline HbA1c had little practical impact upon
the cost-effectiveness estimates for the flozins compared with gliclazide, repaglinide and pioglitazone.
But it improved the cost-effectiveness estimates for canagliflozin compared with sitagliptin by around
one-third. The impact for empagliflozin is less, and there was little impact for dapagliflozin. This is as
would be expected, given the greater HbA1c effect for canagliflozin compared with sitagliptin, the slightly
greater effect for empagliflozin, and broad equivalence between dapagliflozin and sitagliptin.
Janssen applied linear evolutions of HbA1c with the annual rate of change being treatment specific.
Applying the same annual rates of change within the AG modelling reduced total costs and increased total
QALYs quite considerably. It also caused pioglitazone to be estimated as the cheapest treatment, with it
dominating gliclazide. Pioglitazone also dominated repaglinide if there were no direct QoL impacts from
weight changes. Including these with no rebound for weight gains caused the cost-effectiveness of
repaglinide compared with pioglitazone to improve to £15,633 per QALY. The pattern of dominance was
not otherwise altered.
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The linear HbA1c evolutions still saw the flozins dominated unless there were direct QoL impacts from
weight changes. Given these, the cost-effectiveness estimates for canagliflozin compared with repaglinide
were surprisingly similar to those of the base case, though the higher cost-effectiveness estimates varied
more because of the divisions by small net QALY gains.
Assuming that adding gliclazide at the first intensification causes only a –0.47% reduction in HbA1c
compared with the –1.01% reduction of the base case has little to no impact for gliclazide and
repaglinide, as patients will not use this intensification. But it increases costs and reduces QALYs in the
other arms, so worsening the cost-effectiveness estimates for the flozins. The cost-effectiveness estimates
for the flozins compared with sitagliptin are not particularly affected, though those for dapagliflozin do
worsen slightly.
Assuming that the UTI and GTI rates apply throughout the modelling, rather than just for the first cycle,
has little practical impact upon results.
Summary: a comparison of the modelling exercises’
assumptions and inputs
National Institute for Health and Care Excellence checklist
The modelling exercises and their data sources can be assessed against the NICE reference case checklist
(Table 91).
Modelling assumptions
In terms of the main assumptions and data sources, the companies and the AG have used the assumptions
in Table 92. These represent a simplification. For instance, the Janssen submission has a large number of
health states associated with eGFR levels, which also have ongoing costs associated with them. These are
not sourced from the UKPDS84.195 The ECHO-T2DM model used by Janssen has been submitted to the Mt
Hood Challenges. But the Janssen implementation of the ECHO-T2DM and base-case assumptions is likely
to have differed quite considerably from that submitted to the Mt Hood Challenges.
But Table 92 does help highlight the main differences between the submissions and the AG modelling.
Janssen is the outlier in terms of its approach, both in terms of the modelling of its complications and its
assumptions about the linearity of the evolution of HbA1c and SBP. AstraZeneca and Boehringer Ingelheim
use the UKPDS68193 to model the evolution of HbA1c, SBP and the TC/HDL ratio. The AG does as well with
the exception of the TC/HDL ratio which is assumed to be constant for the base case, but is evolved using
the UKPDS68193 in a sensitivity analysis. Janssen argues that the evolutions of the UKPDS include the
effects of treatment intensifications so cannot be used when the modelling is separately accounting for the
treatment intensifications. There is some force to this argument. But it then has to be asked whether or
not the alternative of linear evolutions is preferable. The treatment-specific linear evolutions of HbA1c
within the Janssen submission are not obviously related to the treatments under consideration. There are
also concerns with linear evolutions maintaining absolute differences indefinitely when the UKPDS clearly
suggests convergence.
As already discussed, the UKPDS OM2, which is based upon the UKPDS82,194 was not available to the AG.
As a consequence, in line with the modelling of Boehringer Ingelheim, the older OM1 was used to model
the complications of diabetes, this being based upon the UKPDS68.193 The AstraZeneca modelling was
based upon the UKPDS68193 for the evolution of the risk factors, and the UKPDS82194 for the calculation of
event probabilities, as implemented within the CDM. As far as the AG is aware, this version of the CDM
has not been previously used; submitted to the Mt Hood Challenges; and independently interrogated
or validated.
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TABLE 91 National Institute for Health and Care Excellence reference case checklist: companies and AG
Factor Janssen AstraZeneca
Boehringer
Ingelheim AG
Comparator(s) The individual flozins
were assessed
alongside sitagliptin
100 mg, pioglitazone
and SU
The flozins were
grouped into a class
effect, as are the
gliptins, with
pioglitazone and SU
also being considered
The main analysis
compared
empagliflozin 10 mg,
empagliflozin 25 mg,
sitagliptin 100 mg,
pioglitazone, SU and
repaglinide
Canagliflozin 100 mg,
dapagliflozin 10 mg,
empagliflozin 10 mg,
empagliflozin 25 mg,
sitagliptin 100 mg,
pioglitazone and SU
Patient group Adult patients with type 2 diabetes, unable to take metformin starting monotherapy
Perspective: costs NHS and PSS
Perspective: benefits patient
Analysis Cost utility
Time horizon 40 years
Clinical evidence Own NMA Own NMA Own NMA Own NMA
Outcome measure QALYs
Health states
generic QoL
Other
than UTIs
and GTIs
Yes, EQ-5D Yes, EQ-5D Yes, EQ-5D Yes, EQ-5D
UTIs and
GTIs
No IWB IWB No
Benefit
valuation
Other
than UTIs
and GTIs
TTO TTO TTO TTO
UTIs and
GTIs
Janssen TTO Ranking scale Ranking scale Janssen TTO
Health-
related QoL
preference
data
Other
than UTIs
and GTIs
UK tariff UK tariff UK tariff UK tariff
UTIs and
GTIs
100 UK Public 62 US PubMed
search
62 US PubMed
search
100 UK Public
Discount rates 3.5% for both costs and benefits
Equity Equal QALY regardless of patient characteristics
Probabilistic modelling Yes Yes No (model B) Yes
Sensitivity analyses Yes Yes No Yes
TABLE 92 Main assumptions: companies and AG
Variable Janssen AstraZeneca Boehringer Ingelheim AG
HbA1c Linear UKPDS68
193 UKPDS68193 UKPDS68193
SBP Linear UKPDS68193 UKPDS68193 UKPDS68193
TC/HDL Linear UKPDS68193 UKPDS68193 UKPDS68193
Weight Linear Linear Linear Linear
Complications modelling Variety UKPDS82194 UKPDS68193 UKPDS68193
QoL main source CODE-2 UKPDS62198 Alva 2014197 UKPDS62198
Costs main source UKPDS84195 UKPDS65196/84195 UKPDS84195 UKPDS84195
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A concern with the Janssen and the AstraZeneca models is that there has been little presented on model
convergence. The AG has relied upon the work of the draft NICE CG for diabetes, which resulted in
deterministic model runs having 50,000 patients simulated with 1000 inner loops for each patient to
reduce the Monte Carlo error. The draft NICE CG for diabetes could be read as suggesting that only 100
inner loops are necessary for convergence, but even this seems to be somewhat more model runs that any
of the company submissions. As a consequence, the AG is uncertain whether the company models have
reliably converged. Boehringer Ingelheim did present some work on convergence and concluded that
results of the OM1 stabilised after 1000 inner loops for each patient had been run, choosing to run the
model with 10,000 inner loops though only for 9211 patients so around 92 million model runs:
approximately double the 50 million of the AG.
Monotherapies modelled and sequences compared
The companies and the AG considered the following monotherapies (Table 93).
Note that Janssen considered repaglinide in a scenario analysis.
AstraZeneca pooled the flozins into a single-treatment group, with pooled treatment effect estimates and
weighted average direct drug costs. The gliptins were similarly pooled.
The following treatment intensifications were assumed for the base cases, with treatment intensifications
occurring when a patient’s HbA1c was modelled as breaching the 7.5% intensification threshold (Table 94).
Within the Boehringer Ingelheim submission all but gliclazide had a first intensification of adding gliclazide to
the existing monotherapy. Those on gliclazide monotherapy had a first intensification of adding sitagliptin.
Similarly, for the first intensification within the AG modelling all but gliclazide added gliclazide to the
existing monotherapy. Those on gliclazide monotherapy had a first intensification of adding pioglitazone.
The repaglinide monotherapy arm stands out, having repaglinide withdrawn and both pioglitazone and
gliclazide added. For the second intensification all strategies intensify by adding NPH insulin. The third
intensification adds bolus insulin and withdraws gliclazide.
TABLE 93 Base-case comparators considered: companies and AG
Janssen AstraZeneca Boehringer Ingelheim AG
Base analysis Base analysis 24-week analysis 52-week analysis Base analysis
Flozin
Canagliflozin 100 mg Canagliflozin 100 mg
Canagliflozin 300 mg Canagliflozin 300 mg Canagliflozin 300 mg
Dapagliflozin 5 mg
Dapagliflozin 10 mg Dapagliflozin 10 mg Dapagliflozin 10 mg
Empagliflozin 10 mg Empagliflozin 10 mg Empagliflozin 10 mg
Empagliflozin 25 mg Empagliflozin 25 mg Empagliflozin 25 mg Empagliflozin 25 mg
Gliptin
Sitagliptin 100 mg Sitagliptin 100 mg Sitagliptin 100 mg
Pioglitazone Pioglitazone Pioglitazone Pioglitazone
Sulfonylurea Sulfonylurea Sulfonylurea Gliclazide
Repaglinide Repaglinide
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The AG modelled sequences differ from those of the company submissions in that patients add NPH
insulin rather than switch to it. The retention of the monotherapies in the AG triple therapy combinations
with gliclazide and NPH means that the differences in costs between the monotherapies are retained
throughout the AG base-case modelling. In light of this, a scenario analysis was undertaken, which
withdraws the initial monotherapies when patients now, in effect, switch to NPH insulin, although this
affected only the direct drug costs and not the clinical effectiveness estimates.
Patient characteristics and complications prevalences at baseline
The patient baseline characteristics are shown in Table 95.
Note that the baseline HbA1c of 7.5% of AstraZeneca is based upon the treatment intensification threshold
rather than the AstraZeneca NMA, which had a mean of 8.2%. The AstraZeneca proportion of patients
who smoke has been taken from the electronic model, where it is ambiguous whether this is the
proportion at diagnosis, the proportion at baseline, or both.
The mean baseline age differs quite a lot across the companies’ and AG’s estimates, with the AG’s
estimate lying somewhere in the middle. Baseline age is likely to affect results, as this determines the
amount of time left for the longer-term impacts of clinical effects to be realised. Perhaps more pertinently,
it will also affect the amount of time that the direct QoL impacts of weight changes apply if weight
changes are modelled as being maintained into the long term.
TABLE 94 Base-case intensifications: companies and AG
Intensification Janssen AstraZeneca Boehringer Ingelheim AG
First +Gliclazide Switch to NPH + SU; or + sitagliptin –Repaglinide, + pioglitazone;
and/or + gliclazide
Second Switch to NPH Intensify NPH Switch to NPH + NPH
Third + Aspart None None –Gliclazide, + bolus
TABLE 95 Main baseline risk factors: companies and AG
Variable Janssen AstraZeneca Boehringer Ingelheim AG
Source Canagliflozin trials NMA CPRD THIN/Health Survey
for England
Age, years 56.2 55.0 63.1 59.8
Duration diabetes, years 4.7 3.6 2.9 2.0
Male, % 53 55 57 57
BMI, kg/m2 29.7 28.9 31.1 31.9
Male – 31.0 –
Female – 32.0 –
HbA1c, % 8.02 7.50 8.49 8.40
SBP, mmHg 127.7 128.3 134.7 137.5
TC, mmol/l 5.17 5.07 – 4.96
HDL, mmol/l 1.25 1.20 1.20 1.18
LDL, mmol/l 3.06 3.32 4.02 –
Current smoker, % 9.0 36.90 16.7 18.1
Past smoker, % – – 36.5 34.0
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The proportion modelled as smoking is unclear within the Janssen submission, but it seems likely to have
been somewhat lower than the other exercises; within the AstraZeneca submission it is somewhat higher,
though there is some ambiguity about this. The AG assumption, given the electronic copy of the CDM that
was submitted, is that the 36.9% is the proportion at both diagnosis and at baseline, as only one value for
smoking could be found.
The prevalences of the complications of diabetes at baseline were as shown in Table 96.
Given the recentness of the diagnosis of diabetes, the companies and the AG all suggest low prevalences
of complications at baseline. But AstraZeneca assumes these to be zero. As the CDM models the instances
of initial events, and some secondary events, this will slightly bias the analysis of AstraZeneca towards the
more effective treatment.
Again, the above does some disservice to the Janssen submission, which modelled a range of other
microvascular conditions.
Clinical effectiveness estimates
The main clinical effect estimates are as shown in Tables 97–99. The Janssen NMA is for BMI rather than
for weight in kilograms. To aid comparison with the other estimates, the Janssen estimates have been
converted to kilograms, assuming a patient weight of 85 kg and a patient BMI of 30 kg/m2. The Janssen
BMI estimates are presented within parentheses (see Table 99). No Boehringer Ingelheim figures are shown
because they classed their NMA as confidential.
The estimates for the HbA1c changes are broadly in line for the flozins and sitagliptin. Among the flozins,
all sources that provide individual estimates suggest that canagliflozin 300 mg provides that largest
reduction, though the practical clinical differences between these estimates is a moot point. The AG
estimates for pioglitazone and sulfonylurea are larger than those of the companies – to the extent that
these are estimated to be more effective than canagliflozin 300 mg (see Table 97).
Table 98 shows SBP estimates.
Although not perfectly aligned, the estimates of weight changes are similar across the sources. The AG
suggests slightly larger reductions in weight than the companies’ estimates for dapagliflozin 10 mg and
empagliflozin 25 mg, with the AG also suggesting that sitagliptin is broadly weight neutral.
TABLE 96 Prevalence (%) of main complications at baseline: companies and AG
Complication Janssen AstraZeneca Boehringer Ingelheim AG
Atrial fibrillation – 0.00 6.63 0.81
PVD 0.00 0.00 3.18 0.51
MI 0.80 0.00 2.21 0.80
CHF 0.00 0.00 1.92 0.50
Stroke 0.10 0.00 1.62 0.50
IHD 1.20 0.00 6.13 2.70
Amputation 0.10 0.00 0.29 0.10
Blindness 0.00 0.00 0.23 0.40
Renal failure 0.00 0.00 0.05 0.20
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Quality-of-life values
Turning to the main QoL values, these are as follows, though again the presentation is slightly biased
against the Janssen submission because of the number of health states within the ECHO-T2DM model and
these not being particularly aligned with those of the other modelling (Table 100).
Janssen is unusual in selecting the CODE-2 data set as its main source of QoL estimates. But this is a
respected publication, and, as Janssen is using the ECHO-T2DM model, the health states of their model
are not so obviously aligned with the health states of the UKPDS OM1 and UKPDS OM2 for which UKPDS
TABLE 97 Central clinical effectiveness estimates: companies and AG – HbA1c (%)
Treatment
Janssen AstraZeneca AG
Base Base Base
Flozins pooled – 0.74
Canagliflozin 100 mg – 0.97
Canagliflozin 300 mg – 1.20 – 1.153
Dapagliflozin 5 mg
Dapagliflozin 10 mg – 0.64 – 0.704
Empagliflozin 10 mg – 0.73
Empagliflozin 25 mg – 0.85 – 0.870
Gliptins pooled – 0.64
Sitagliptin 100 mg – 0.72 – 0.723
Pioglitazone – 0.78 – 0.90 – 1.200
Sulfonylurea – 0.59 – 0.95 – 1.301
Repaglinide – 1.28 – 1.200
TABLE 98 Central clinical effectiveness estimates: companies and AG – SBP (mmHg)
Treatment
Janssen AstraZeneca AG
Base Base Base
Flozins pooled –5.87
Canagliflozin 100 mg –3.71 –4.2
Canagliflozin 300 mg –5.41 –5.7
Dapagliflozin 5 mg
Dapagliflozin 10 mg –3.21 –2.931
Empagliflozin 10 mg –2.60
Empagliflozin 25 mg –3.40 –3.743
Gliptins pooled –1.53
Sitagliptin 100 mg +0.80 +0.394
Pioglitazone +0.88 –1.31 –1.400
Sulfonylurea +0.19 –0.65 –0.600
Repaglinide +0.19 –1.000
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QoL estimates are available. AstraZeneca, Boehringer Ingelheim and the AG all use models based upon the
UKPDS, and, as a consequence, QoL estimates from the UKPDS are a natural choice.
For QoL, Boehringer Ingelheim draws most of its values from the fixed-effects estimates of Alva et al.
(2014),197 which is an analysis of the updated UKPDS data set with Alva et al.197 expressing a clear
preference for the fixed-effects estimates over their ordinary least squares (OLS) estimates. This explicitly
analyses the data longitudinally in order to estimate the QoL pre and post and event and the impact of
events upon an individual, rather than comparing patients cross-sectionally. This has obvious attractions,
TABLE 99 Central clinical effectiveness estimates: companies and AG – weight (kg)
Treatment
Janssen AstraZeneca AG
Base (BMI) Base Base
Flozins pooled – 2.81
Canagliflozin 100 mg –2.40 (–0.85)
Canagliflozin 300 mg –3.42 (–1.21) –3.577
Dapagliflozin 5 mg
Dapagliflozin 10 mg –1.61 (–0.57) –2.457
Empagliflozin 10 mg –1.72 (–0.61)
Empagliflozin 25 mg –1.84 (–0.65) –2.471
Gliptins pooled –0.13
Sitagliptin 100 mg +0.82 (+0.29) –0.003
Pioglitazone +2.35 (+0.83) +2.61 +2.962
Sulfonylurea +0.62 (+0.22) +0.07 +1.397
Repaglinide +0.62 (+0.22) +0.100*
TABLE 100 Main health state QoL values: companies and AG
Health state Janssen AstraZeneca Boehringer Ingelheim AG
No complications 0.843 0.882 0.720 0.801
MI year –0.028 –0.055 –0.065 –0.055
MI history –0.028 –0.055 0.008 –0.055
IHD –0.028 –0.090 –0.028 –0.090
Stroke –0.115 –0.164 –0.165 –0.164
CHF –0.028 –0.108 –0.101 –0.108
Amputation –0.272 –0.280 –0.172 –0.280
Blindness –0.057 –0.074 0.033 –0.074
ESRD –0.175 –0.263 –0.263 –0.263
Per BMI > 25 kg/m2 –0.0061 –0.0061 –0.0061 –0.0061
Severe hypoglycaemia –0.0470 –0.0470 –0.0470 –0.0470
Non-severe hypoglycaemia –0.0142 –0.0142 –0.0142 –0.0142
UTI (QALY) –0.0043 –0.0028 –0.0028 –0.0073
GTI (QALY) –0.0046 –0.0028 – –0.0096
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but there may be some difficulty when applying these estimates in that the coefficients for blindness and
a history of MI are positive. Within Alva et al.,197 these coefficients and that for IHD are not statistically
significant, so it could be argued that these could or should be set to zero. But if these are set to zero, it
would obviously be preferable for the coefficients to have been further explored or excluded within the
analysis of Alva et al.,197 in order to explore the impact that this would have upon the estimates of the
other coefficients. But, given its choice of Alva et al.197 as the source of its QoL estimates, this option was
not available to Boehringer Ingelheim.
The AG is not as familiar with the Alva et al.197 estimates as with those from the UKPDS62.198 It seems likely
that there is an age effect within the estimates of Alva et al.197 as well, due to the mean age at completion
of the first questionnaire being 62 compared with a mean age of 71 years for the seventh, coupled with
negative and statistically significant coefficients for the questionnaires. Whether it is reasonable to apply the
mean value of the EQ-5D in the absence of complications of 0.72 or it would be better to estimate it from
the fixed-effects model is a moot point, but it can be noted that the constant for the fixed-effects model
was somewhat higher at 0.807. But the values of Alva et al.197 are reasonable to apply.
All of the analyses have used the CODE-2 QoL decrement for BMI above 25 kg/m2. AstraZeneca may not
have restricted this to when the patient BMI is above 25 kg/m2, but, given baseline BMIs, the impact of this
will not have been large. All of the analyses also rely upon the estimates of Currie et al. (2006)204 for the
QoL impacts of hypoglycaemic events, though again it appears that AstraZeneca may have applied the
coefficient for non-severe hypoglycaemia to the event rate rather than to its logarithm.
And all analyses apply fairly similar absolute QALY decrements per UTI and per GTI: they are small. Those
of the AG are slightly higher, this probably being due to the assumption of 2 weeks’ duration as drawn
from Nicolle et al. (2014)98 who estimated median durations of UTIs of between 11.0 days and 12.5 days.
Costs
Turning to the main costs, these are as follows, though again the presentation is slightly biased against the
Janssen submission. The Janssen submission has a number of health states associated with a patient’s
eGFR and the cost in the absence of complications will not have been zero. But it is difficult to identify
quite what the cost in the absence of complications was. In the opinion of the AG, it is likely to have been
quite small (Table 101).
TABLE 101 Monotherapy direct drug costs (£): companies and AG
Drug Janssen AZ Boehringer Ingelheim AG
Empagliflozin 10 mg 477.30 476.98 477.98 476.98
Empagliflozin 25 mg 477.30 476.98 477.98 476.98
Dapagliflozin 5 mg – – 477.98 –
Dapagliflozin 10 mg 477.30 476.92 477.98 476.98
Canagliflozin 100 mg 477.26 476.93 477.98 476.93
Canagliflozin 300 mg 608.63 608.21 476.93
Flozin average – 481.79 – –
SU (gliclazide MR) 25.81 65.70 68.36 62.18
Pioglitazone 20.48 19.03 24.25 20.99
Repaglinide 6 mg 71.10 – 93.40 71.91
Sitagliptin 100 mg 433.86 433.57 433.86 433.57
Gliptin average – 429.13 – –
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It seems likely that Janssen assumed the costs for gliclazide rather than the costs for gliclazide MR. The
company submissions also predated the recent change to the canagliflozin 300 mg cost.
Note that the AG adds an additional £72.26 to the cost of pioglitazone for BNP monitoring: £26.26 for
the test itself and £46.00 for a dedicated GP appointment (Tables 102 and 103).
For Janssen the first-year costs of events appear to be broadly in line with those of the AG. But the costs
for those with a history of events are somewhat lower. It appears that these costs may not have included
the outpatient costs.
For AstraZeneca the costs of all events are somewhat higher than those of the AG. The AG cannot
definitively identify the source of these discrepancies, and any error may well be on the side of the AG. But
it seems possible that AstraZeneca may have indexed the UKPDS84195 costs from 2007 rather than from
2012. AstraZeneca also assumed zero costs in the absence of complications, which is not in line with the
UKPDS84.195 This will have tended to exaggerate the differences between treatments’ total costs.
TABLE 103 Main health state costs (£): history of event: companies and AG
Event Janssen AstraZeneca Boehringer Ingelheim AG
MI 875 2177 1154 1877
IHD 920 1395 1215 1922
Stroke 934 1378 1125 1934
CHF 1527 1656 1473 2515
Amputation 2531 4618 1792 3499
Blindness 215 2307 453 1225
ESRD 26,152 18,776 35,631 36,801
TABLE 102 Main health state costs (£): year of event: companies and AG
Event Janssen AstraZeneca Boehringer Ingelheim AG
No complications 0 0 459 1019
Complications first year
Fatal MI 1566 2605 1521 1564
Fatal IHD 3818 0 3766 3873
Fatal stroke 4255 5188 3954 4066
Fatal CHF 3366 0 3191 NA
Non-fatal MI 6665 7938 6379 7550
Non-fatal IHD 10,116 12,762 9767 10,932
Non-fatal stroke 7247 11,450 6805 8120
Non-fatal CHF 3337 5180 3191 4288
Amputation 11,810 13,499 9546 12,592
Blindness 2260 6502 1355 3234
ESRD 26,297 18,776 35,715 36,801
NA, not available.
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Boehringer Ingelheim appear to have applied only the inpatient costs of the UKPDS84,195 and to have
ignored the outpatient costs (Table 104).
In the above presentation the Janssen costs for UTIs are a simple mean of the Janssen costs of upper UTIs
and lower UTIs, but the Janssen modelling explicitly accounts for this.
Summary and conclusions: a comparison of the modelling exercises’ results
All of the company submissions apply the old £608 annual cost for canagliflozin 300 mg, rather than the
recently revised list price that equalises this with the £477 annual canagliflozin 100 mg. As a consequence,
the summary of cost-effectiveness results of the companies concentrates upon the canagliflozin
100 mg results.
Owing in part to the assumed slow rate of HbA1c drift for pioglitazone, Janssen estimates that it has the
lowest total costs of £20,264 and yields and average 9.998 QALYs. Gliclazide is estimated to be somewhat
more expensive than pioglitazone with total costs of £2956 and to yield 9.949 QALYs so is dominated by
pioglitazone. Sitagliptin is also more expensive with a total cost of £23,442 and yields a total of 9.981 per
QALY so is dominated by pioglitazone, though has a cost-effectiveness estimate compared with gliclazide
of £6969 per QALY.
Janssen estimates that canagliflozin 100 mg has total costs of £23,525 and yields 10.039 QALYs, which
implies a cost-effectiveness estimate of £79,537 per QALY compared with pioglitazone. The cost-
effectiveness estimate compared with gliclazide is £3377 per QALY, this being largely due to the higher
costs in the gliclazide arm compared with pioglitazone. Canagliflozin 100 mg is estimated to dominate
empagliflozin 10 mg, empagliflozin 25 mg and dapagliflozin 10 mg.
The Janssen cost-effectiveness estimates for the flozins compared with sitagliptin are £1414 per QALY for
canagliflozin 100 mg, £1977 per QALY for empagliflozin 25 mg, £4724 per QALY for empagliflozin 10 mg,
and £6040 per QALY for sitagliptin.
If that annual rate of increase in HbA1c is equalised between the treatments and repaglinide is included as
a comparator, it appears that this worsens the cost-effectiveness estimate for canagliflozin compared with
repaglinide to £189,000 per QALY. The cost-effectiveness estimates for canagliflozin 100 mg compared
with gliclazide and sitagliptin worsen to £21,580 per QALY and £21,470 per QALY, respectively. Applying
the UKPDS68193 evolution of HbA1c results in broad clinical equivalence between canagliflozin 100 mg and
gliclazide, but the costs of canagliflozin 100 mg are £744 greater.
AstraZeneca pooled the flozins into a class effect. Given this pioglitazone was estimated to be the least
costly with total costs of £26,067 and to yield 13.111 QALYs. The sulfonylureas were estimated to have a
total cost of £26,582 so £515 higher than pioglitazone, and to yield 13.179 QALYs so have a cost-
effectiveness estimate of £7574 per QALY compared with pioglitazone. The gliptins were estimated to
have a total cost of £27,873 and to yield 13.188 QALYs or only 0.009 QALYs more than the sulfonylureas,
TABLE 104 Main health state costs (£): adverse events: companies and AG
Adverse event Janssen AstraZeneca Boehringer Ingelheim AG
Severe hypoglycaemia 380 424 380 411
Non-severe hypoglycaemia 0 0 0 0
UTI 82 46 36 73
GTI 51 46 NA 51
NA, not available.
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hence have a cost-effectiveness compared with the sulfonylureas of £143,000 per QALY. The flozins
were only £106 more expensive than the gliptins and yielded an additional 0.018 QALYs, so had a
cost-effectiveness compared with the gliptins of £5904 per QALY. But the flozins cost-effectiveness
compared with the sulfonylureas was poor, at £52,047 per QALY.
AstraZeneca sensitivity analyses showed results were sensitive to the HbA1c intensification threshold and to
the assumptions around the evolution of weight.
The AG modelling suggests that gliclazide is the least expensive, with total costs of £27,314. Repaglinide
and pioglitazone have similar total costs of £27,413 and £27,543, respectively. The increased costs for
pioglitazone are due in part to the AG including a £72 allowance for annual BNP monitoring. Costs
increase quite markedly with sitagliptin at a total cost of £32,358, and increase further with the flozins
being clustered between £32,676 and £32,866. Sitagliptin is estimated to be £5045 more expensive than
gliclazide, and the flozins between £5362 and £5553 more expensive than gliclazide.
If there are no direct QoL impacts from weight changes, gliclazide is estimated to yield 10.392 QALYs.
This is the highest total QALYs for this scenario and, as a consequence, gliclazide dominates all of the
other treatments.
Including direct QoL impacts from weight changes and assuming that the weight changes associated with
the monotherapies persist indefinitely results in repaglinide now being superior to gliclazide by 0.030
QALYs and so having a cost-effectiveness estimate of £3331 per QALY. Repaglinide formally dominates
pioglitazone and sitagliptin, but canagliflozin yields an additional 0.177 QALYs at an additional cost of
£5262 so has a cost-effectiveness estimate of £44,994 per QALY compared with repaglinide. If weight
losses associated with treatment tend to rebound at either 1 year or at treatment intensification the
cost-effectiveness estimate for canagliflozin compared with repaglinide worsens to £192,000 per QALY
and £119,000 per QALY, respectively.
Canagliflozin is estimated to be around £100 less expensive than empagliflozin and £200 less expensive
than dapagliflozin. With no direct QoL effects from weight changes it is estimated to be marginally more
effective than empagliflozin by 0.002 QALYs and 0.013 QALYs more effective than dapagliflozin. Including
the effects of weight upon QoL increases these net gains to 0.034 QALYs and 0.046 QALYs if weight
changes persist indefinitely. If they rebound after 1 year these gains fall to 0.007 QALYs and 0.019 QALYs,
whereas if they rebound at treatment change they fall to 0.014 QALYs and 0.026 QALYs.
Both canagliflozin and empagliflozin have reasonable cost-effectiveness estimates compared with
sitagliptin of £12,623 per QALY and £18,341 per QALY even if there are no QoL impacts from weight
changes. Including these effects improves their cost-effectiveness estimates compared with sitagliptin.
Dapagliflozin fares slightly worse compared with sitagliptin. It costs an additional £508 but yields only an
additional 0.013 QALYs if there are no direct QoL impacts from weight changes, so has a cost-effectiveness
estimate of £40,383 per QALY compared with sitagliptin. This improves to £6632 per QALY if weight
changes have a QoL impact and are assumed to persist indefinitely. If they only persist for 1 year the
cost-effectiveness estimate worsens to a little over £30,000 per QALY, but if they persist until treatment
change the cost-effectiveness estimate worsens but only to a little under £20,000 per QALY.
The AG results showed some sensitivity to whether patients add insulin to their existing treatments or
switch to it, the application of a common 7.5% HbA1c baseline and applying a reduced –0.47% HbA1c
effect for gliclazide as recently reviewed above.
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Chapter 6 Discussion and research needs
Principal findings
The key findings are:
l Canagliflozin, dapagliflozin and empagliflozin are clinically effective in improving glycaemic control
when used in monotherapy.
l They also provide modest reductions in SBP and promote weight loss.
l The main AEs are urinary tract and genital area infections.
l There are concerns following reports of DKA and bone loss. DKA appears rare – about 1 per 3000
patient-years. Fractures were not increased after 3 years of empagliflozin treatment in the empagliflozin
outcomes trial.
l The AG modelling results suggest that dapagliflozin, canagliflozin and empagliflozin are not cost-
effective compared with gliclazide or pioglitazone, nor probably to repaglinide, though the evidence
base for repaglinide is poorer.
l However, if patients cannot take one of the older drugs, both canagliflozin and dapagliflozin are
cost-effective compared with sitagliptin.
l Dapagliflozin is cost-effective compared with sitagliptin if direct utility gains from weight loss
are accepted.
Limitations
l There are no head-to-head comparisons amongst the flozins so relative effects have to be drawn from
NMAs. In these there is a problem because in some dapagliflozin trials HbA1c improved in the placebo
groups, reducing the placebo-adjusted improvement after dapagliflozin treatment. In the canagliflozin
trials, HbA1c rose in placebo groups.
l Patients in one dapagliflozin trial had a low baseline HbA1c, and hence less chance of a large reduction.
l Patients randomised to 300 mg of canagliflozin, started on that dose. In routine care adhering to the
licence, patients would start on 100 mg and change to the higher dose only if it was insufficiently
effective. Those who do not respond well to 100 mg may have a lower effect from 300 mg than the
trial patients did.
l The above features would make it unwise to conclude that any one flozin is better than the others.
l Some trials were conducted in East Asian populations with a much lower baseline BMI than in
European populations.
l In the trials, HbA1c was usually above 8%. The higher the baseline HbA1c, the greater the likely
reduction. Their results may not apply if the NICE guidelines are followed, with close monitoring of
glycaemic control and prompt intervention once HbA1c rises above 7.5%.
l Cost-effectiveness analysis requires extrapolating from short-term results to long-term outcomes.
l Some QALY differences were very small, making ICERs unstable.
Other options
The NICE scope did not include all possible comparators. Five not included were:
l intensive lifestyle interventions
l bariatric surgery, which is covered by other guidance
l early intensive treatment
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l very-low-calorie diets
l other non-pharmacological interventions.
Intensive lifestyle interventions
The work of Aas et al.222 has been reported in previous reviews for NICE. Aas et al.222 carried out a trial in
38 diabetic subjects poorly controlled (HbA1c 8–10.5%; mean 9.0%) on oral drugs and being considered
for insulin treatment. They were randomised to insulin treatment or to an intensive lifestyle intervention
based on exercise and diet, or both. After 12 months, HbA1c improved by 1.2% in the lifestyle arm and by
1.5% in the insulin (NPH twice daily, with short-acting at mealtimes if required) arm. Weight fell by 3 kg in
the lifestyle arm, but rose 4.9 kg in the insulin arm. The lifestyle intervention comprised 14 sessions of
dietary advice, two individual sessions and 1 hour of exercise of moderate intensity twice a week, including
group aerobics, walking and swimming. Unfortunately, a year after the intervention had finished, HbA1c
and weight rose again in the lifestyle group.
Coppell et al. from Otago223 carried out a randomised trial of an intensive nutritional intervention (seven
individual sessions with a dietitian, one group session and telephone calls) compared with standard care
(GP or hospital clinic). After 6 months, the intensive group recorded reductions in HbA1c (0.5%), weight
(2.1 kg), waist circumferences (3.5 cm), SBP (4.1 mmHg) and TC (0.24 mmol/l), whereas HDL-C was
unchanged. The control group showed little change and none in HbA1c.
Bariatric surgery
The NICE guidance on bariatric surgery224 includes a section specific to type 2 diabetes, reproduced in
Box 4.
Early intensive treatment
The use of intensive treatment at diagnosis was first reported by a Chinese study in 2004.225 Two weeks of
intensive insulin treatment (with CSII) improved beta cell function, after which 47% remained well controlled
on diet alone for 12 months and 42% for 2 years. A later trial randomised 410 Chinese patients to intensive
insulin or oral agents (metformin or gliclazide, or both). Once patients had been normoglycaemic for 2 weeks,
the drugs were stopped. After insulin, 51% of the CSII group and 45% of the MDI group remained in good
glycaemic control a year later, compared with 27% of those on oral agents, suggesting that how the
normoglycaemia is achieved is important (Yang and Weng226).
A systematic review published in 2013 by Kramer et al.227 found seven studies of short-term intensive
insulin therapy at diagnosis of type 2 diabetes. Two were RCTs and five were case series from China.
BOX 4 National Institute for Health and Care Excellence guidance on bariatric surgery for type 2 diabetes
1.11 Bariatric surgery for people with recent-onset type 2 diabetes
1.11.1 Offer an expedited assessment for bariatric surgery to people with a BMI of 35 or over who have
recent-onset type 2 diabetes as long as they are also receiving or will receive assessment in a tier 3 service
(or equivalent).
1.11.2 Consider an assessment for bariatric surgery for people with a BMI of 30–34.9 who have recent-onset
type 2 diabetes as long as they are also receiving or will receive assessment in a tier 3 service (or equivalent).
1.11.3 Consider an assessment for bariatric surgery for people of Asian family origin who have recent-onset
type 2 diabetes at a lower BMI than other populations (see recommendation 1.2.8) as long as they are also
receiving or will receive assessment in a tier 3 service (or equivalent).
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When considering data from China, we need to bear in mind that Chinese people with type 2 diabetes
have a more insulin-deficient, and less insulin-resistant, pattern.
Two small studies in white populations were not included in the Kramer review. Ilkova et al.228 from Turkey
and Israel treated 13 patients with newly diagnosed type 2 diabetes not responding to 3–6 weeks of diet
and physical activity with CSII for 2 weeks. Most (9/13) responded and three had 3–5 years’ remission of
diabetes. In five patients control deteriorated after 9–36 months but good control was restored after a
second fortnight of CSII. Ryan229 in Canada treated 16 people newly diagnosed with type 2 diabetes with
MDI for 2–3 weeks, and a year later seven people were on no glucose-lowering agents.
Introducing metformin earlier after diagnosis has been advocated by Brown et al.230 They noted that in a
cohort of 1799 patients that had metformin as first ever glucose-lowering drug, those who started it less
than 3 months after diagnosis of diabetes had a lower failure rate (12.2% a year) than those who started
metformin 12 or more months after diagnosis (about 20% a year).
Another form of early intensive treatment is triple therapy from diagnosis. Abdul-Ghani et al.231 report the
results of the EDICT (Efficacy and Durability of Initial Combination Therapy for type 2 diabetes) in which
patients were treated from diagnosis with metformin, pioglitazone and exenatide, and compared with a
control arm that had a more standard approach of starting with metformin followed by addition of
sulfonylurea then glargine as required. The hypothesis behind the trial combination was to have a
combination of drugs to improve both insulin secretion and sensitivity. The triple therapy group had lower
HbA1c (by 0.55%), far less hypoglycaemia, and 1.2-kg weight loss compared with 4-kg gain on the
standard sequence.
Very-low-calorie diets
Taylor et al.232 from Newcastle have challenged the consensus that diabetes is a progressive irreversible
disease, by showing that very-low-calorie diets (600 kcal/day for 8 weeks) can reverse type 2 diabetes by
restoring beta cell function and hepatic insulin sensitivity. They did this first for relatively recent-onset cases
in the Counterpoint Study,233 but then showed that about half of people with long-standing diabetes
could return to normal glucose levels and stop their glucose-lowering medications. This was achieved by
weight loss averaging 14–15 kg. The 8-week time period was too short to show full effect on HbA1c but
even by then it fell by 1.15 in the short duration group and by an average of 0.6% in the long-duration
group. Steven and Taylor (2015)232 report that e-mail feedback from people who lost weight and kept it
off have continued to have normal glucose levels for up to 3 years, so far. So it appears that as long as
weight loss is maintained, they remain non-diabetic.
Non-pharmacological interventions
A very large number of trials reporting effects of different drugs are mentioned in this report and the
industry submissions. Research into the management of type 2 diabetes is very pharmacocentric, partly
because the manufacturers of the drug have to carry out such trials for licensing purposes. There is no
such pressure on developers of lifestyle interventions, nor guaranteed funding.
However, lifestyle interventions should also be considered. Type 2 diabetes is strongly associated with
overweight and obesity, and physical inactivity, and lifestyle change can be effective.
The problem with lifestyle interventions is adherence. A previous health technology assessment on
prevention of diabetes in people with impaired glucose tolerance noted the tendency for gains after
lifestyle interventions to be lost once the intervention was stopped, with the exception of the Finnish
Diabetes Prevention Study234 in which the intervention continued for 4 years.
However, ways of improving adherence have been researched. Perri et al.235 randomised 379 adults to
walking at different speeds, and found that increasing the frequency of exercise achieved better adherence
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than increasing the intensity. Their study was prompted by awareness of a public perception that health
benefits would be achieved only by frequent high-intensity exercise.
Hansen et al.236 from Belgium and the Netherlands also reported that prolonged low-to-moderate exercise
was almost as effective as more intense exercise. Their participants had three sessions a week of supervised
walking, cycling or cross-country ski-type exercise for 6 months. In the moderate intensity group, HbA1c fell
from 7.4% at baseline to 7.2% at 6 months. There were modest improvements in weight (91.1 kg) and
TC. The higher-intensity group did better, with HbA1c reduction of 0.5% and weight loss of 1.8 kg. The
authors note that participants are more likely to drop out of high-intensity physical activity, partly because
people with long-standing type diabetes often have comorbidities that restrict such exercise.
Walking supported by pedometer use has been reported to be effective in a 12-month trial from
Leicester.237 However, arguments to the contrary have appeared in recent years, suggesting that
short-duration, high-intensity exercise may be effective, with the brevity improving adherence.238
Snowling and Hopkins239 carried out a meta-analysis of the effects of different forms of exercise (aerobic,
resistance, mixed) in type 2 diabetes. They reported an improvement in HbA1c of 0.8%, which is as great
as many drugs achieve.
A full review of the benefits of physical activity in type 2 diabetes is beyond the scope of this report.
Reviews of exercise therapy in type 2 diabetes and the mechanisms are provided by Praet and van Loon240
and Zanuso et al.241
The NICE Public Health Guidance on weight management242 noted that even modest weight loss could be
cost-effective if sufficient and maintained. An Australian review of six interventions to promote physical
activity also concluded that most would be cost-effective.243
A review by Fujioka244 also concluded that in type 2 diabetes, weight loss of 1–4 kg improved metabolic
control and cardiovascular risk, though greater weight loss achieved greater benefit. Wing et al.245 reported
from the Look AHEAD trial (Action for Health in Diabetes) that modest weight loss (5–10% body weight,
7.25 kg) improved glycaemic control (HbA1c reduced by 0.5%), BP (6 mmHg) and HDL-C, but even minor
weight loss (2–5%) showed some benefit (HbA1c reduced by about 0.25%, SBP by about 4 mmHg).
A full review of the benefits of weight loss in type 2 diabetes is outwith the scope of the this report, and
others have reviewed the subject.246 The cost-effectiveness of lifestyle interventions was reviewed by
Jacobs-van der Bruggen et al.,247 who concluded that short-term results showed that they were
cost-effective. However, they noted a lack of long-term maintenance of benefit.
In summary, there is a range of effective lifestyle interventions, but the main problems are adherence and
long-term maintenance.
Research needs
The clinical effectiveness of the SGLT2 inhibitors for at least 2 years is not in doubt, and we now need data
on long-term effectiveness and safety. The empagliflozin cardiovascular outcomes trial136 has reported,
though some clarifications are required. The equivalent studies for canagliflozin [CANVAS129 (CANagliflozin
cardioVascular Assessment Study)] and dapagliflozin [DECLARE130 (Multicenter Trial to Evaluate the Effect
of Dapagliflozin on the Incidence of Cardiovascular Events)] are under way. Continued monitoring for DKA
and fractures is required.
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One of the anonymous National Institute for Health Research referees suggested two subgroups for which
research is required.
1. The first is individuals with type 2 diabetes diagnosed at < 40 years old. This population of type 2
diabetes is rising very quickly. Phenotypically, they are different from the conventional ‘late-onset’
type 2 diabetes, because they are associated with more aggressive CVD; they are hypertensive, obese
and insulin resistant; and they are at risk of progression of diabetic nephropathy.
2. The second is elderly patients with type 2 diabetes. Elderly patients are more at risk of fractures,
hypoglycaemia and falls. This may be relevant when comparing different glucose-lowering therapies,
because of recognised side effects of currently available agents.
The first trials of the SGLT2 in type 1 diabetes are emerging, and because of their insulin-independent
mode of action, they would be expected to be useful there. However, the DKA risk would be more of a
concern than in type 2 diabetes.
Conclusions
The SGLT2 inhibitors are effective in improving glycaemic control, promoting weight loss and reducing
BP – the first oral drugs for diabetes to do so. Their safety record remains to be established, but the only
common AEs are small increases in the frequency of urinary and GTIs, seldom serious. However, they are
much more expensive than older drugs such as gliclazide and pioglitazone.
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155

Acknowledgements
We thank Emma Loveman for checking data extractions. The authors are indebted to Gabriel Rogersand Steven Ward who provided advice on the economics and without whom the probabilistic
modelling would not have been possible.
Norman Waugh is guarantor for this report.
Contributions of authors
Pamela Royle did literature searches, generated the list of references, and edited and formatted the
final report.
Christine Clar, Rachel Court, Bee Kang Tan and Saran Shantikumar extracted data from the trials in
Chapter 2. Christine Clar drafted the clinical effectiveness section. Bee Kang Tan drafted the section on
UTIs and GTIs.
Christine Clar and Jill Colquitt extracted data for the NMA, which was carried out by Olakan Uthman.
Andrew Clegg provided a technical critique of the methods of the manufacturers’ NMAs.
Rhona Johnston and Ewen Cummins wrote additions to the UKPDS Outcomes Model and carried out
the economic modelling.
Norman Waugh drafted Chapters 1 and 6, wrote various other sections, and edited the final report.
David McGrane, J Paul O’Hare and Tim Holt provided clinical advice.
Data sharing statement
There are no further data to share.
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157

References
1. Public Health England. Diabetes Prevalence Model (APHO). 2014. URL: www.yhpho.org.uk/
resource/view.aspx?RID=81090 (accessed 4 September 2015).
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1
and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity
costs. Diabet Med 2012;29:855–62. https://doi.org/10.1111/j.1464-5491.2012.03698.x
3. Health and Social Care Information Centre. Prescribing for Diabetes: England 2005–06 to
2013–14. 2014. URL: www.hscic.gov.uk/catalogue/PUB14681/pres-diab-eng-200506-201314-rep.
pdf (accessed 4 September 2014).
4. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview
of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58.
https://doi.org/10.2337/diab.44.11.1249
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or
insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies
(UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12.
https://doi.org/10.1001/jama.281.21.2005
6. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled
diabetes in general practice: cross sectional survey. Lancet 2004;364:423–8. http://dx.doi.org/
10.1016/S0140-6736(04)16765-2
7. Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, et al. Early glycaemic
control in metformin users receiving their first add-on therapy: a population-based study of
4,734 people with type 2 diabetes. Diabetologia 2015;58:2247–53. http://dx.doi.org/10.1007/
s00125-015-3698-1
8. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes: The Management
of Type 2 Diabetes. NICE guidelines [CG87]. 2009. URL: www.nice.org.uk/guidance/cg87
(accessed September 2015).
9. National Institute for Health and Care Excellence (NICE). Dapagliflozin in Combination
Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA288]. 2013.
URL: www.nice.org.uk/guidance/ta288 (accessed 29 September 2015).
10. National Institute for Health and Care Excellence (NICE). Canagliflozin in Combination
Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA315]. 2014.
URL: www.nice.org.uk/guidance/ta315 (accessed 29 September 2015).
11. National Institute for Health and Care Excellence (NICE). Empagliflozin in Combination
Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA336]. 2015.
URL: www.nice.org.uk/guidance/ta336 (accessed 29 September 2015).
12. European Medicines Agency (EMA). Trulicity (dulaglutide): Summary of Product Characteristics.
2014. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
human/002825/WC500179470.pdf (accessed 29 July 2015).
13. European Medicines Agency (EMA). Eperzan (albiglutide): Summary of Product Characteristics.
2014. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
human/002735/WC500165117.pdf (accessed 29 September 2015).
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
159
14. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on
heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open
2013;3:e001986. http://dx.doi.org/10.1136/bmjopen-2012-001986
15. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for
type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD004654. https://doi.org/10.1002/
14651858.cd004654.pub2
16. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management.
NG28, December 2015. URL: www.nice.org.uk/guidance/ng28 (accessed January 2016).
17. Satoh J, Takahashi K, Takizawa Y, Ishihara H, Hirai M, Katagiri H, et al. Secondary sulfonylurea
failure: comparison of period until insulin treatment between diabetic patients treated with
gliclazide and glibenclamide. Diabetes Res Clin Pract 2005;70:291–7. http://dx.doi.org/10.1016/
j.diabres.2005.04.002
18. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe
hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based
study of health service resource use. Diabetes Care 2003;26:1176–80. https://doi.org/10.2337/
diacare.26.4.1176
19. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence
of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with
sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:11–22.
http://dx.doi.org/10.1002/dmrr.2470
20. Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the
hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2
diabetes. Diabetes Obes Metab 2014;16:833–40. http://dx.doi.org/10.1111/dom.12287
21. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study:
double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Eur J Clin Invest 2004;34:535–42. http://dx.doi.org/10.1111/j.1365-2362.2004.01381.x
22. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and
cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–28.
http://dx.doi.org/10.1056/NEJMoa1203858
23. Zoungas S, Chalmers J, Kengne AP, Pillai A, Billot L, de Galan B, et al. The efficacy of lowering
glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering
regimen in the ADVANCE trial. Diabetes Res Clin Pract 2010;89:126–33. http://dx.doi.org/
10.1016/j.diabres.2010.05.012
24. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of
treatment modalities and their duration. Diabetologia 2007;50:1140–7. https://doi.org/10.1007/
s00125-007-0599-y
25. Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, et al. Safety and
efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of
randomized trials. PLOS ONE 2014;9:e82880. http://dx.doi.org/10.1371/journal.pone.0082880
26. Schrijnders D, Houweling ST, Landman GW. Comment on Genuth. Should sulfonylureas remain
an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s
time to move on! Diabetes Care 2015;38:170–5. https://doi.org/10.2337/dc15-0293
27. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk
among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol
2015;3:43–51. http://dx.doi.org/10.1016/S2213-8587(14)70213-X
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
160
28. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and
cardiovascular risk associated with different insulin secretagogues compared with metformin in
type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J
2011;32:1900–8. http://dx.doi.org/10.1093/eurheartj/ehr077
29. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. Guideline no. 116.
2010. URL: www.sign.ac.uk/guidelines/fulltext/116/index.html (accessed 4 September 2015).
30. American Diabetes Association (ADA). (7) Approaches to glycemic treatment. Diabetes Care
2015;38(Suppl. 1):41–8. https://doi.org/10.2337/dc15-S010
31. Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a
double-blind, randomized, multinational study. J Diabetes Complicat 2000;14:185–91. https://doi.org/
10.1016/S1056-8727(00)00086-6
32. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2
diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet
Diabetes Endocrinol 2015;3:105–13. https://doi.org/10.1016/S2213-8587(14)70219-0
33. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of
macular edema among patients with type 2 diabetes. Arch Intern Med 2012;172:1005–11.
https://doi.org/10.1001/archinternmed.2012.1938
34. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease
and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs:
retrospective cohort study using UK General Practice Research Database. BMJ 2009;339:b4731.
http://dx.doi.org/10.1136/bmj.b4731
35. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, et al. Hospitalised hip
fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Diabetologia 2012;55:2929–37. http://dx.doi.org/10.1007/s00125-012-2668-0
36. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone
and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ
2012;344:e3645. http://dx.doi.org/10.1136/bmj.e3645
37. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder
cancer among diabetic patients in France: a population-based cohort study. Diabetologia
2012;55:1953–62. http://dx.doi.org/10.1007/s00125-012-2538-9
38. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use
and risk of bladder cancer and other common cancers in persons with diabetes. JAMA
2015;314:265–77. http://dx.doi.org/10.1001/jama.2015.7996
39. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular
benefit. Diabet Med 2015;32:305–13. http://dx.doi.org/10.1111/dme.12627
40. Gale EA. Pioglitazone: are rumours of its death exaggerated? Diabet Med 2015;32:431–7.
http://dx.doi.org/10.1111/dme.12708
41. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder
cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia
2015;58:493–504. http://dx.doi.org/10.1007/s00125-014-3456-9
42. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes
mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 2013;13:310.
http://dx.doi.org/10.1186/1471-2407-13-310
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
161
43. European Medicines Agency (EMA). European Medicines Agency Clarifies Opinion on Pioglitazone
and the Risk of Bladder Cancer; 2011. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/
news_and_events/news/2011/10/news_detail_001368.jsp&mid=WC0b01ac058004d5c1
(accessed 4 September 2015).
44. Medicines and Healthcare products Regulatory Agency (MHRA). Pioglitazone: Risk of bladder
Cancer. 2011. URL: www.gov.uk/drug-safety-update/pioglitazone-risk-of-bladder-cancer (accessed
4 September 2015).
45. Craig J, Bradbury I, Cummins E, Downie S, Foster L, Stout A. The Use of B-type Natriuretic
Peptides (BNP and NT-proBNP) in the Investigation of Patients with Suspected Heart Failure.
Health Technology Assessment Report 6, Health Technology Board for Scotland. 2005.
URL: www.healthcareimprovementscotland.org/previous_resources/hta_report/hta_6.aspx
(accessed 9 September 2015).
46. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala
variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/
alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006;91:3446–50.
https://doi.org/10.1210/jc.2006-0590
47. Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in
the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess
2011;15(38). http://dx.doi.org/10.3310/hta15380
48. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis
of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873–82.
https://doi.org/10.1097/01.ASN.0000092790.89332.D2
49. Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196–8.
http://dx.doi.org/10.1016/S0140-6736(10)60749-0
50. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin,
a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol
Ther 2009;85:520–6. http://dx.doi.org/10.1038/clpt.2008.251
51. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose
reabsorption in humans? Diabetes 2012;61:2199–204. http://dx.doi.org/10.2337/db12-0052
52. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel,
selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes
mellitus. Clin Pharmacol Ther 2009;85:513–19. http://dx.doi.org/10.1038/clpt.2008.250
53. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers
postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing
urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care
2013;36:2154–61. http://dx.doi.org/10.2337/dc12-2391
54. Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, et al. Canagliflozin, a sodium glucose
co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes
by a non-renal mechanism: results of a randomized trial. Metab Clin Exp 2014;63:1296–303.
http://dx.doi.org/10.1016/j.metabol.2014.07.003
55. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-
glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
J Am Soc Hypertens 2014;8:262–75.e9. http://dx.doi.org/10.1016/j.jash.2014.01.007
56. NHS Business Services Authority. Electronic Drug Tariff. 2015. URL: www.nhsbsa.nhs.uk/
PrescriptionServices/4940.aspx (accessed 4 September 2015).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
57. National Institute for Health and Care Excellence (NICE). Canagliflozin, Dapagliflozin and
Empagliflozin monotherapy for Treating Type 2 Diabetes. Final Scope. 2015. URL: www.nice.org.
uk/guidance/TA390/documents/diabetes-type-2-canagliflozin-dapagliflozin-and-empagliflozin-
monotherapy-id756-final-scope2 (accessed April 2015).
58. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574–9. http://dx.doi.org/10.1056/
NEJM199602293340906
59. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes:
results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491–7.
https://doi.org/10.1016/S0002-9343(97)00254-4
60. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent
diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–9.
http://dx.doi.org/10.1056/NEJM199508313330902
61. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of
extended-release metformin tablets compared to immediate-release metformin tablets: results of
a retrospective cohort study. Curr Med Res Opin 2004;20:565–72. http://dx.doi.org/10.1185/
030079904125003278
62. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab
2003;29:6S36–43.
63. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal
motility in type 2 diabetes mellitus. Diabet Med 1998;15:651–6. http://dx.doi.org/10.1002/
(SICI)1096-9136(199808)15:8%3C651::AID-DIA628%3E3.0.CO;2-A
64. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD, DARTS/MEMO Collaboration.
Contraindications to metformin therapy in patients with Type 2 diabetes: a population-based
study of adherence to prescribing guidelines. Diabet Med 2001;18:483–8. https://doi.org/
10.1046/j.1464-5491.2001.00509.x
65. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with
metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD002967.
http://dx.doi.org/10.1002/14651858.CD002967.pub4
66. Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, Yamamoto M, et al. The evaluation of risk
factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol
Pharm Bull 2012;35:933–7. https://doi.org/10.1248/bpb.35.933
67. American Diabetes Association (ADA). (6) Glycemic targets. Diabetes Care 2015;38(Suppl. 1):33–40.
https://doi.org/10.2337/dc15-S009
68. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive
glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial
sequential analysis of randomised clinical trials. BMJ 2011;343:d6898. http://dx.doi.org/10.1136/
bmj.d6898
69. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of complications in patients with type 2
diabetes (UKPDS 33). Lancet 1998;352:837–53. https://doi.org/10.1016/S0140-6736(98)07019-6
70. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose
control in type 2 diabetes. N Engl J Med 2008;359:1577–89. http://dx.doi.org/10.1056/
NEJMoa0806470
71. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive
glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. http://dx.doi.org/
10.1056/NEJMoa0802743
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
163
72. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose
control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
http://dx.doi.org/10.1056/NEJMoa0802987
73. Boussageon R, Bejan-Angoulvan T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al.
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and
microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ
2011;343:d4169. https://doi.org/10.1136/bmj.d4169
74. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients’ risks and preferences on health
gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med
2014;174:1227–34. http://dx.doi.org/10.1001/jamainternmed.2014.2894
75. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.
2011. URL: http://handbook.cochrane.org/ (accessed 24 September 2105).
76. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of
canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with
diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Expert Opin Pharmacother 2014;15:1501–15. http://dx.doi.org/10.1517/14656566.2014.935764
77. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic
patients with inadequate glycemic control by diet and exercise: a randomized, double-blind,
placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217–24. http://dx.doi.org/10.2337/
dc10-0612
78. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of
dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-
controlled 102-week trial. Diabet Med 2015;32:531–41. http://dx.doi.org/10.1111/dme.12624
79. Ji L, Ma J, Li H, Mansfield TA, T’joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in
drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective
phase III study. Clin Ther 2014;36:84–100.e9. http://dx.doi.org/10.1016/j.clinthera.2013.11.002
80. Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM. Efficacy and safety of
dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by
diet and exercise. Diabetes Obes Metab 2014;16:1102–10. http://dx.doi.org/10.1111/dom.12325
81. Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Initial combination of
empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394–402.
[Erratum published in Diabetes Care 2015;38:1173]. http://dx.doi.org/10.2337/dc14-2365
82. Roden M, Weng J, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin (EMPA)
monotherapy for >76 weeks in drug-naive patients with type 2 diabetes (type 2 diabetes).
Diabetes 2014;63(Suppl.):A69.
83. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC, EMPA-REGMONO trial
investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with
type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes
Endocrinol 2013;1:208–19. http://dx.doi.org/10.1016/S2213-8587(13)70084-6
84. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of
canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with
diet and exercise. Diabetes Obes Metab 2013;15:372–82. http://dx.doi.org/10.1111/dom.12054
85. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with SGLT2
inhibition. Diabetes Obes Metab 2016;18:125–34. https://doi.org/10.1111/dom.12578
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
164
86. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance after sodium-
glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730–5. http://dx.doi.org/10.2337/
dc15-0355
87. Amiel SA. It’s all in the name: what exactly is hypoglycemia? Diabetic Hypoglycemia 2013;5:15–18.
88. Plowman R, Graves N, Esquivel J, Roberts JA. An economic model to assess the cost and benefits
of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract
infections in catheterized patients. J Hosp Infect 2001;48:33–42. http://dx.doi.org/10.1053/
jhin.2001.0938
89. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in
diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract
2014;103:373–81. http://dx.doi.org/10.1016/j.diabres.2013.12.052
90. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med
2013;125:33–46. http://dx.doi.org/10.3810/pgm.2013.05.2650
91. Grandy S, Fox KM, Hardy E. Prevalence and recurrence of urinary tract and genital infections
among adults with and without type 2 diabetes mellitus in the general population: a longitudinal
cohort study. J Diab Res Clin Met 2013;2:1. https://doi.org/10.7243/2050-0866-2-5
92. Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficacy and safety of
canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and
exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014;30:163–75.
http://dx.doi.org/10.1185/03007995.2013.850066
93. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2
diabetes on background metformin monotherapy: a randomised trial. Diabetologia
2013;56:2582–92. http://dx.doi.org/10.1007/s00125-013-3039-1
94. Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on
to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week
open-label study. J Diabetes Investig 2015;6:210–18. http://dx.doi.org/10.1111/jdi.12266
95. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable
glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients
with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care
2015;38:355–64. http://dx.doi.org/10.2337/dc13-2762
96. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al. Efficacy and safety of
canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with
insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403–11. http://dx.doi.org/
10.2337/dc14-1237
97. Davies M, Kushner P, Vijapurkar U, Meininger G. Incidence of genital mycotic infections decreases
over time in older patients with type 2 diabetes mellitus treated with canagliflozin. J Gen Intern
Med 2015;30:S61–2.
98. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies
of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7–17.
http://dx.doi.org/10.3810/pgm.2014.01.2720
99. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections
with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes
mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109–19.
http://dx.doi.org/10.1185/03007995.2014.890925
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
165
100. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to
metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-
blind, placebo-controlled 102-week trial. BMC Med 2013;11:43. http://dx.doi.org/10.1186/
1741-7015-11-43
101. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in
patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473–8.
102. Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T, et al. Dapagliflozin as
monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label
study. Diabetes Ther 2014;5:415–33. http://dx.doi.org/10.1007/s13300-014-0086-7
103. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes
who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-
controlled trial. Lancet 2010;375:2223–33. http://dx.doi.org/10.1016/S0140-6736(10)60407-2
104. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group. Dapagliflozin
improves glycemic control and reduces body weight as add-on therapy to metformin plus
sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015;38:365–72.
http://dx.doi.org/10.2337/dc14-0666
105. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2
diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of
saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to
metformin. Diabetes Care 2015;38:376–83. http://dx.doi.org/10.2337/dc14-1142
106. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of
dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare
events. Drug Saf 2014;37:815–29. http://dx.doi.org/10.1007/s40264-014-0213-4
107. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy
improves glucose control in drug-naive patients with type 2 diabetes (type 2 diabetes). Diabetes
2013;62:A280.
108. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG RENAL
trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment
in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind,
placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369–84. http://dx.doi.org/10.1016/
S2213-8587(13)70208-0
109. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of
empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately
controlled on metformin. Diabetes Care 2015;38:384–93. [Erratum published in Diabetes Care
2015;38:1173.] http://dx.doi.org/10.2337/dc14-2364
110. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, EMPA-REG MDI Trial
Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased
hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese
inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815–23. http://dx.doi.org/
10.2337/dc13-3055
111. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, EMPA-REG BASALTM trial
investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately
controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab 2015;17:936–48. http://dx.doi.org/10.1111/dom.12503
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
166
112. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC,
EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in
patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes Care 2013;36:3396–404. http://dx.doi.org/10.2337/dc12-2673
113. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, EMPA-
REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2
diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care
2014;37:1650–9. http://dx.doi.org/10.2337/dc13-2105
114. Haring HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin (EMPA) for
>76 weeks as add-on to metformin plus sulfonylurea (SU) in patients with type 2 diabetes (type 2
diabetes). Diabetes 2014;63:A280.
115. Merker L, Haring HU, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to
metformin in people with Type 2 diabetes. Diabet. Med 2015;32:1555–67. https://doi.org/
10.1111/dme.12814
116. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial
investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients
with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Lancet Diabetes Endocrinol 2014;2:691–700. http://dx.doi.org/10.1016/S2213-8587(14)70120-2
117. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™
trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to
pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week,
randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147–58. http://dx.doi.org/
10.1111/dom.12188
118. Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as Add-on
Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Clin Ther 2015;37:1773–88.e1. http://dx.doi.org/10.1016/j.clinthera.2015.05.511
119. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin
versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic
control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority
trial. Diabetes Care 2011;34:2015–22. https://doi.org/10.2337/dc11-0606
120. Gangal NS, Kelton C, Heaton PC. Urinary tract infection among the SGLT 2 Inhibitors: a meta-
Analysis of 19 randomized controlled trials. Value Health 2015;18:A52. https://doi.org/10.1016/
j.jval.2015.03.308
121. European Medicines Agency (EMA). Review of Diabetes Medicines Called SGLT2 Inhibitors
Started. 2015. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/
SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f (accessed
4 September 2015).
122. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA Warns that
SGLT2 Inhibitors for Diabetes may Result in a Serious Condition of Too Much Acid in the Blood.
2015. URL: www.fda.gov/drugs/drugsafety/ucm446845.htm (accessed 4 September 2015).
123. Erondu N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the
Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–6. http://dx.doi.org/
10.2337/dc15-1251
124. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and
preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638–42.
https://doi.org/10.2337/dc15-1380
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
125. Srivali N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Acute pancreatitis in the use of
canagliflozin: a rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin
Pharm 2015;6:101–2. http://dx.doi.org/10.4103/0976-0105.160753
126. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with
canagliflozin. Endocrinol Diabetes Metab Case Rep 2015;150042. http://dx.doi.org/10.1530/
EDM-15-0042
127. US Food and Drug Administration (FDA). MedWatch: The FDA Safety Information and Adverse
Event Reporting Program. 2015. URL: www.fda.gov/Drugs/DrugSafety/ucm459579.htm (accessed
4 September 2015).
128. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications
and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metab Clin Exp
2014;63:1228–37. http://dx.doi.org/10.1016/j.metabol.2014.06.018
129. Janssen Research & Development LLC. CANVAS – CANagliflozin cardioVascular Assessment Study;
2015. URL: https://clinicaltrials.gov/ct2/show/NCT01032629 (accessed 4 September 2015).
130. AstraZeneca. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of
Cardiovascular Events (DECLARE-TIMI58). 2015. URL: https://clinicaltrials.gov/ct2/show/
NCT01730534 (accessed 4 September 2015).
131. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes
Endocrinol 2013;1:140–51. http://dx.doi.org/10.1016/S2213-8587(13)70050-0
132. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA Revises Label of
Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and
New Information on Decreased Bone Mineral Density; 2015. URL: www.fda.gov/Drugs/
DrugSafety/ucm461449.htm (accessed 27 September 2015).
133. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and
moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does
not improve glycemic control. Kidney Int 2014;85:962–71. https://doi.org/10.1038/ki.2013.356
134. Kwon H, US Food and Drug Administration (FDA). Canagliflozin: Clinical Efficacy and Safety.
2013. URL: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/
endocrinologicandmetabolicdrugsadvisorycommittee/ucm336234.pdf (accessed August 2005).
135. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors may predispose to ketoacidosis. J Clin Endocrinol
Metab 2015;100:2849–52. http://dx.doi.org/10.1210/jc.2015-1884
136. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin,
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
http://dx.doi.org/10.1056/NEJMoa1504720
137. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and
baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of
empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014;13:102. http://dx.doi.org/
10.1186/1475-2840-13-102
138. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular
and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–13. https://doi.
org/10.1136/bmj.317.7160.703
139. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–53. http://dx.doi.org/
10.1056/NEJM200001203420301
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
168
140. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
2013;369:1317–26. http://dx.doi.org/10.1056/NEJMoa1307684
141. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after
acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–35.
http://dx.doi.org/10.1056/NEJMoa1305889
142. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–42. http://dx.doi.org/
10.1056/NEJMoa1501352
143. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from
cardiovascular causes. N Engl J Med 2007;356:2457–71. http://dx.doi.org/10.1056/NEJMoa072761
144. Hirshberg B, Katz A. Insights from cardiovascular outcome trials with novel antidiabetes agents:
what have we learned? An industry perspective. Curr Diab Rep 2015;15:87. http://dx.doi.org/
10.1007/s11892-015-0663-9
145. Indianapolis Business Journal. Analyst: Lilly’s Jardiance Diabetes Pill could be a $6 Billion-a-year
Blockbuster. 2015. URL: www.ibj.com/blogs/12-the-dose/post/54957-analyst-lillys-jardiance-
diabetes-pill-could-be-a-6-billion-a-year-blockbuster (accessed 25 September 2015).
146. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma
glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67:235–40.
http://dx.doi.org/10.1212/01.wnl.0000224760.22802.e8
147. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and
Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 1 August 2015).
148. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes:
a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000;40:49–57. https://doi.org/
10.1177/00912700022008694
149. Saleem K, Yasin MA, Asrar A, Qamar S. Comparison of repaglinide with glibenclamide in the
reduction of 13 HbA1C of type 2 diabetic patients. Pak J Med Health Sci 2011;5:23–6.
150. Shah ZH, Saleem K, Mahboob F, Jibran R. A comparative study of repaglinide and glibenclamide
in type 2 diabetic patients. Pak J Med Health Sci 2011;5:476–9.
151. Jibran R, Suliman M, Qureshi F, Ahmed M. Safety and efficacy of repaglinide compared with
glibenclamide in the management of type 2 diabetic Pakistani patients. Pak J Med Sci
2006;22:385–90.
152. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and
glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind
assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003;25:472–84.
https://doi.org/10.1016/S0149-2918(03)80090-5
153. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year
comparison trial. Diabetes Res Clin Pract 1999;43:155–66. https://doi.org/10.1016/S0168-8227
(99)00002-9
154. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study
021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic
control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7. http://dx.doi.org/
10.2337/dc06-0703
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
169
155. Chen Y, Ning G, Wang C, Gong Y, Patel S, Zhang C, et al. Efficacy and safety of linagliptin
monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a multinational,
24-week, randomized, clinical trial. J Diabetes Investig 2015;6:692–8. http://dx.doi.org/10.1111/
jdi.12346
156. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes:
a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res
2007;39:218–23. https://doi.org/10.1055/s-2007-970422
157. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin
monotherapy on glycaemic control and markers of β-cell function in patients with inadequately
controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258–67.
http://dx.doi.org/10.1111/j.1463-1326.2010.01350.x
158. Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. Comparison of effects of gliclazide,
metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in
patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes
2014;122:295–302. http://dx.doi.org/10.1055/s-0034-1370989
159. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and
the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2
diabetes. Horm Metab Res 2009;41:905–9. http://dx.doi.org/10.1055/s-0029-1234042
160. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of
linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-
blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565–74. http://dx.doi.org/
10.1111/j.1463-1326.2012.01590.x
161. Kikuchi M, Kaku K, Odawara M, Momomura S, Ishii R. Efficacy and tolerability of rosiglitazone
and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind,
28 weeks’ treatment, comparative study. Curr Med Res Opin 2012;28:1007–16. http://dx.doi.org/
10.1185/03007995.2012.694361
162. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and
metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early
type 2 diabetes. Diabetes Care 2004;27:41–6. https://doi.org/10.2337/diacare.27.1.41
163. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity
and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517–23.
164. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of
interventions. Int J Epidemiol 2013;42:332–45. http://dx.doi.org/10.1093/ije/dys222
165. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison
meta-analysis. Stat Med 2010;29:932–44. http://dx.doi.org/10.1002/sim.3767
166. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations.
J Comp Graph Stat 1998;7:434–5.
167. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy
of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and
meta-analysis. Diabetologia 2013;56:696–708. http://dx.doi.org/10.1007/s00125-012-2827-3
168. De Fine Olivarius N, Andreasen AH, Siersma V, Richelsen B, Beck-Nielsen H. Changes in patient
weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes
mellitus. Diabetologia 2006;49:2058–67. https://doi.org/10.1007/s00125-006-0328-y
169. Genuth S. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line
add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on! Diabetes
Care 2015;38:170–5. Diabetes Care 2015;38:e95. http://dx.doi.org/10.2337/dc15-0519
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
170. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on
HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56:973–84.
http://dx.doi.org/10.1007/s00125-013-2856-6
171. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al. Effect on glycemic control
of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin
Pract 2005;68:167–75. http://dx.doi.org/10.1016/j.diabres.2004.09.002
172. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to
deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
Diabetes Care 2005;28:995–1000. https://doi.org/10.2337/diacare.28.5.995
173. Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S. Long-term
glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to
metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17:581–90.
http://dx.doi.org/10.1111/dom.12459
174. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability
of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43.
http://dx.doi.org/10.1056/NEJMoa066224
175. Bacon T, Willis M, Johansen P, Neslusan C. Time until insulin initiation for canagliflozin (CANA)
versus dapagliflozin (DAPA) in dual and triple therapy for type 2 diabetes mellitus (T2DM) in
Ireland. Value Health 2015;18:A55. https://doi.org/10.1016/j.jval.2015.03.324
176. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing
metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959–69.
https://doi.org/10.1111/j.1463-1326.2007.00839.x
177. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl
peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2
diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority
trial. Diabetes Obes Metab 2007;9:194–205. https://doi.org/10.1111/j.1463-1326.2006.00704.x
178. Canadian Agency for Drugs and Technologies in Health (CADTH). Second- and Third-Line
Pharmacotherapy for Type 2 Diabetes. Update: CADTH Optimal Use Report, No. 3.1. 2013.
URL: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0061000 (accessed 7 September 2015).
179. National Institute for Health and Care Excellence (NICE). Exenatide Prolonged-release Suspension
for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes.
TA248, 2012. URL: www.nice.org.uk/guidance/ta248 (accessed August 2015).
180. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study
Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a
randomised, open-label, non-inferiority study. Lancet 2008;372:1240–50. http://dx.doi.org/
10.1016/S0140-6736(08)61206-4
181. Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med
2015;373:974–6. http://dx.doi.org/10.1056/NEJMcibr1506573
182. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication
in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med
2002;19:279–84. https://doi.org/10.1046/j.1464-5491.2002.00689.x
183. US Food and Drug Administration (FDA). NDA 202293 Dapagliflozin Tablets, 5 and 10 mg.
FDA Briefing Document. 2011. URL: www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/
COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORY
COMMITTEE/UCM262994.PDF (accessed 2 October 2015).
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
171
184. Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K. Assessing Bladder
Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a
‘case study’. Diabetes Ther 2015;6:357–75. http://dx.doi.org/10.1007/s13300-015-0128-9
185. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American
Diabetes Association (ADA). Medical management of hyperglycaemia in type 2 diabetes mellitus:
a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from
the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia 2009;52:17–30. http://dx.doi.org/10.1007/s00125-008-1157-y
186. Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, et al. Is the
ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence
or opinion? A critical analysis. Diabetologia 2010;53:1258–69. http://dx.doi.org/10.1007/
s00125-010-1702-3
187. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes
mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Diabetes Obes Metab 2013;15:906–14. http://dx.doi.org/10.1111/dom.12102
188. Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J, et al. Randomized controlled
trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes:
a comparative study. J Diabetes Investig 2011;2:391–8. http://dx.doi.org/10.1111/
j.2040-1124.2011.00115.x
189. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral
hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract
2007;57:455–60.
190. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin
therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a
population-based analysis in the UK. Diabet Med 2007;24:1412–18. http://dx.doi.org/10.1111/
j.1464-5491.2007.02279.x
191. Health and Social Care Information Centre. Quality and Outcomes Framework (QOF). 2015.
URL: http://qof.hscic.gov.uk/ (accessed 27 September 2015).
192. Neslusan C, Johansen P, Willis M, Martin S. A health economic analysis of the long-term benefits
and associated cost offsets of canagliflozin monotherapy in the U.S. Diabetes 2013;62:A322.
193. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the
lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective
Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59.
https://doi.org/10.1007/s00125-004-1527-z
194. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a
model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data
from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia
2013;56:1925–33. http://dx.doi.org/10.1007/s00125-013-2940-y
195. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications
on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med 2015;32:459–66.
http://dx.doi.org/10.1111/dme.12647
196. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on
healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study no. 65).
Diabet Med 2003;20:442–50. https://doi.org/10.1046/j.1464-5491.2003.00972.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
197. Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related
quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ
2014;23:487–500. http://dx.doi.org/10.1002/hec.2930
198. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients
using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9. https://doi.org/10.1177/
027298902400448902
199. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from
CODE-2 data. Health Econ 2005;14:217–30. http://dx.doi.org/10.1002/hec.910
200. University College London. THIN Database. URL: www.ucl.ac.uk/pcph/research-groups-themes/
thin-pub/database (accessed 2 December 2016).
201. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in
type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372–8. http://dx.doi.org/
10.1111/j.1463-1326.2008.00976.x
202. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Newer agents for blood
glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol
Assess 2010;14(36). http://dx.doi.org/10.3310/hta14360
203. Department of Health (DH). Health Survey for England 2003. 2004. URL: http://webarchive.
nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstatistics/publications/
publicationsstatistics/dh_4098712 (accessed 1 October 2015).
204. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of
health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin
2006;22:1523–34. https://doi.org/10.1185/030079906X115757
205. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory
women: a cost-utility analysis of office-based strategies. J Fam Pract 1997;44:49–60.
206. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal
dialysis in a UK setting: a multicentre study. Nephrol Dial Transplant 2008;23:1982–9.
http://dx.doi.org/10.1093/ndt/gfm870
207. Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia
in three European countries. J Med Econ 2009;12:281–90. http://dx.doi.org/10.3111/
13696990903336597
208. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2014.
URL: www.pssru.ac.uk/project-pages/unit-costs/2014/ (accessed 21 September 2015).
209. Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model:
with application to assessing alternative treatment intensification strategies on survival and
diabetes-related complications. Diabetes Obes Metab 2008;10:33–42. https://doi.org/10.1111/
j.1463-1326.2008.00885.x
210. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM. The CORE Diabetes Model:
Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes
mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res
Opin 2004;20(Suppl. 1):5–26. https://doi.org/10.1185/030079904X1980
211. National Institute for Health and Care Excellence (NICE). Obesity Prevention. CG43, December
2006. URL: www.nice.org.uk/guidance/cg43 (accessed 1 August 2015).
212. Diabetics With Eating Disorders (DWED). Diabetes and DKA in England’s Primary Care Trusts.
2010. URL: http://dwed.org.uk/sites/default/files/DwedReportDKAPCT.pdf (accessed
20 September 2015).
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
213. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an
economic evaluation. BMJ 1995;311:1595–9. https://doi.org/10.1136/bmj.311.7020.1595
214. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL. Utilities and
disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251–65.
https://doi.org/10.1007/s11136-007-9226-0
215. National Institute for Health and Care Excellence (NICE). Infection: Prevention and Control of
Healthcare-associated Infections in Primary and Community care. NICE guidelines [CG139]. 2012.
URL: www.nice.org.uk/guidance/cg139/documents (accessed 21 September 2015).
216. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using
national measures to create condition-specific values. Med Care 1998;36:778–92. https://doi.org/
10.1097/00005650-199806000-00002
217. Ackerman SJ, Rein AL, Blute M, Beusterien K, Sullivan EM, Tanio CP, et al. Cost effectiveness of
microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology
2000;56:972–80. https://doi.org/10.1016/S0090-4295(00)00828-1
218. Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a
misnomer? J Am Board Fam Pract 2000;13:392–7. https://doi.org/10.3122/15572625-13-6-392
219. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a
mean EQ-5D preference-based score from published studies (where patient level data are not
available). Value Health 2008;11:1131–43. http://dx.doi.org/10.1111/j.1524-4733.2008.00352.x
220. Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women’s quality of life is decreased by acute cystitis
and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005;3:45.
http://dx.doi.org/10.1186/1477-7525-3-45
221. Lamping DL, Constantinovici N, Roderick P, Normand C, Henderson L, Harris S, et al. Clinical
outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on
dialysis: a prospective cohort study. Lancet 2000;356:1543–50. https://doi.org/10.1016/S0140-
6736(00)03123-8
222. Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI. An intensified lifestyle
intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic
patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 2005;22:316–22.
http://dx.doi.org/10.1111/j.1464-5491.2005.01421.x
223. Coppell KJ, Kataoka M, Williams SM, Chisholm AW, Vorgers SM, Mann JI. Nutritional intervention
in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment –
Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ
2010;341:c3337. http://dx.doi.org/10.1136/bmj.c3337
224. National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and
Management of Overweight and Obesity in ChIldren, Young People and Adults. NICE guidelines
[CG189]. URL: www.nice.org.uk/guidance/cg189 (accessed 2 October 2015).
225. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in
newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
Diabetes Care 2004;27:2597–602. https://doi.org/10.2337/diacare.27.11.2597
226. Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol
2014;2:992–1002. http://dx.doi.org/10.1016/S2213-8587(14)70136-6
227. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes
mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28–34.
http://dx.doi.org/10.1016/S2213-8587(13)70006-8
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
228. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycemic control in
newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care
1997;20:1353–6. https://doi.org/10.2337/diacare.20.9.1353
229. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2
diabetes. Diabetes Care 2004;27:1028–32. https://doi.org/10.2337/diacare.27.5.1028
230. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice.
Diabetes Care 2010;33:501–6. http://dx.doi.org/10.2337/dc09-1749
231. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial
combination therapy with metformin, pioglitazone and exenatide is more effective than
sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and
Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes
Obes Metab 2015;17:268–75. http://dx.doi.org/10.1111/dom.12417
232. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2
diabetes: normalisation of beta cell function in association with decreased pancreas and liver
triacylglycerol. Diabetologia 2011;54:2506–14. http://dx.doi.org/10.1007/s00125-011-2204-7
233. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and
short-duration type 2 diabetes. Diabet Med 2015;32:1149–55. http://dx.doi.org/10.1111/dme.12722
234. Gillett M, Royle P, Snaith A, Scotland G, Poobalan A, Imamura M, et al. Non-pharmacological
interventions to reduce the risk of diabetes in people with impaired glucose regulation: a
systematic review and economic evaluation. Health Technol Assess 2012;16(33). http://dx.doi.org/
10.3310/hta16330
235. Perri MG, Anton SD, Durning PE, Ketterson TU, Sydeman SJ, Berlant NE, et al. Adherence to
exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and
frequency. Health Psychol 2002;21:452–8. https://doi.org/10.1037/0278-6133.21.5.452
236. Hansen D, Dendale P, Jonkers RA, Beelen M, Manders RJ, Corluy L, et al. Continuous low- to
moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training
at lowering blood HbA(1c) in obese type 2 diabetes patients. Diabetologia 2009;52:1789–97.
http://dx.doi.org/10.1007/s00125-009-1354-3
237. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education program
designed to promote walking activity in individuals with impaired glucose tolerance: a randomized
controlled trial. Diabetes Care 2009;32:1404–10. http://dx.doi.org/10.2337/dc09-0130
238. Hawley JA, Gibala MJ. Exercise intensity and insulin sensitivity: how low can you go? Diabetologia
2009;52:1709–13. http://dx.doi.org/10.1007/s00125-009-1425-5
239. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and
risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care
2006;29:2518–27. https://doi.org/10.2337/dc06-1317
240. Praet SF, van Loon LJ. Exercise therapy in type 2 diabetes. Acta Diabetol 2009;46:263–78.
http://dx.doi.org/10.1007/s00592-009-0129-0
241. Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S. Exercise for the management of type 2
diabetes: a review of the evidence. Acta Diabetol 2010;47:15–22. http://dx.doi.org/10.1007/
s00592-009-0126-3
242. National Institute for Health and Care Excellence (NICE). Weight Management: Lifestyle Services
for Overweight or Obese Adults. NICE guidelines [PH53]. 2014. URL: www.nice.org.uk/guidance/
ph53 (accessed 2 October 2015).
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
175
243. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a
modelling study. PLOS Med 2009;6:e1000110. http://dx.doi.org/10.1371/journal.pmed.1000110
244. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes
Metab 2010;12:186–94. http://dx.doi.org/10.1111/j.1463-1326.2009.01155.x
245. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest
weight loss in improving cardiovascular risk factors in overweight and obese individuals with
type 2 diabetes. Diabetes Care 2011;34:1481–6. http://dx.doi.org/10.2337/dc10-2415
246. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes:
review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331–9. https://doi.org/
10.1080/07315724.2003.10719316
247. Jacobs-van der Bruggen MA, van Baal PH, Hoogenveen RT, Feenstra TL, Briggs AH, Lawson K, et al.
Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care 2009;32:1453–8.
http://dx.doi.org/10.2337/dc09-0363
248. Bailey CJ, Iqbal N, T’joen C, List JF. Dapagliflozin monotherapy in drug-naïve patients with
diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951–9.
http://dx.doi.org/10.1111/j.1463-1326.2012.01659.x
249. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes
mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord
2013;13:58. http://dx.doi.org/10.1186/1472-6823-13-58
250. Blüher M, Schweizer A, Bader G, Foley JE. Changes in body weight after 24 weeks of vildagliptin
therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk
Manag 2014;10:661–4. http://dx.doi.org/10.2147/VHRM.S73608
251. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ. Pharmacokinetics of empagliflozin, a
sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy
volunteers. Adv Ther 2012;29:889–99. http://dx.doi.org/10.1007/s12325-012-0055-3
252. Escudero Vilaplana B, Almodóvar Carretón MJ, Herrero Hernández S. [Dapagliflozin, a novel oral
antidiabetic with an uncertain future.] Farm Hosp 2014;38:468–74. http://dx.doi.org/10.7399/
fh.2014.38.6.7963
253. Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and
efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group,
randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care
2013;36:4015–21. http://dx.doi.org/10.2337/dc13-0663
254. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH. Dapagliflozin
compared with other oral anti-diabetes treatments when added to metformin monotherapy:
a systematic review and network meta-analysis. Diabetes Obes Metab 2014;16:433–42.
http://dx.doi.org/10.1111/dom.12239
255. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin,
metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Int J Clin Pract 2012;66:446–56. http://dx.doi.org/10.1111/j.1742-1241.2012.02911.x
256. Hussey EK, Kapur A, O’Connor-Semmes R, Tao W, Rafferty B, Polli JW, et al. Safety,
pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor,
and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol
Toxicol 2013;14:25. http://dx.doi.org/10.1186/2050-6511-14-25
257. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in
patients with diabetes treated with dapagliflozin. J Diabetes Complicat 2013;27:479–84.
http://dx.doi.org/10.1016/j.jdiacomp.2013.04.012
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
258. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, et al. Empagliflozin
monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week,
double-blind, placebo-controlled, phase II trial. Adv Ther 2014;31:621–38. http://dx.doi.org/
10.1007/s12325-014-0126-8
259. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, et al. Efficacy and safety of
monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese
patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-
controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
http://dx.doi.org/10.1186/1475-2840-13-65
260. Lutz SZ, Staiger H, Fritsche A, Häring HU. Antihyperglycaemic therapies and cancer risk. Diab Vasc
Dis Res 2014;11:371–89. http://dx.doi.org/10.1177/1479164114549553
261. Matthaei S. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus.] Dtsch
Med Wochenschr 2014;139(Suppl. 2):59–64. https://doi.org/10.1055/s-0033-1359992
262. Nauck M, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. [Dapagliflozin
versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic
control with metformin.] Dtsch Med Wochenschr 2013;138(Suppl. 1):6–15. http://dx.doi.org/
10.1055/s-0032-1305283
263. Orme M, Fenici P, Lomon ID, Wygant G, Townsend R, Roudaut M. A systematic review and
mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with
type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab
Syndr 2014;6:73. http://dx.doi.org/10.1186/1758-5996-6-73
264. Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother
2014;15:1197–201. http://dx.doi.org/10.1517/14656566.2014.916278
265. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of
type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab
2014;16:410–17. http://dx.doi.org/10.1111/dom.12233
266. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289–312.
http://dx.doi.org/10.2165/11209910-000000000-00000
267. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs
2014;74:807–24. http://dx.doi.org/10.1007/s40265-014-0225-5
268. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor,
improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia
2014;57:891–901. http://dx.doi.org/10.1007/s00125-014-3196-x
269. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2
diabetes mellitus. Diabetes Metab Res Rev 2013;29:347–56. https://doi.org/10.1002/dmrr.2403
270. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of
canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232–8. http://dx.doi.org/10.2337/dc11-1926
271. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA
(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled
on pioglitazone monotherapy. Diabetes Care 2012;35:1473–8. http://dx.doi.org/10.2337/
dc11-1693
272. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of
empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2
diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154–60. http://dx.doi.org/
10.1111/dom.12185
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
273. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2
(SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33–59.
http://dx.doi.org/10.1007/s40265-014-0337-y
274. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin
monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized,
placebo-controlled, phase II study. Curr Med Res Opin 2014;30:1219–30. https://doi.org/10.1185/
03007995.2014.901943
275. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of
luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized,
double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245–55.
http://dx.doi.org/10.1185/03007995.2014.912983
276. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of
luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-
blind, placebo-controlled, phase II study. Curr Med Res Opin 2014;30:1231–44. http://dx.doi.org/
10.1185/03007995.2014.909390
277. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients
with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized,
24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928–38.
https://doi.org/10.1111/j.1463-1326.2011.01434.x
278. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. [Effect of dapagliflozin in patients
with type 2 diabetes who have inadequate glycaemic control with glimepiride.] Dtsch Med
Wochenschr 2013;138(Suppl. 1):16–26. http://dx.doi.org/10.1055/s-0032-1305277
279. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride
in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a
randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014;5:267–83.
http://dx.doi.org/10.1007/s13300-014-0072-0
280. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in
patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med
2014;126:16–34. http://dx.doi.org/10.3810/pgm.2014.05.2753
281. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of
ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding
study. Diabetes Obes Metab 2013;15:403–9. http://dx.doi.org/10.1111/dom.12038
282. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with
type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:1149–58.
http://dx.doi.org/10.1007/s00228-014-1730-x
283. Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, et al. Effects of LX4211, a dual
SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2
diabetes. Clin Ther 2013;35:273–85.e7. http://dx.doi.org/10.1016/j.clinthera.2013.01.010
284. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a
systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev
2014;30:204–21. https://doi.org/10.1002/dmrr.2479
285. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone
hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2
diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001
Study Group. Diabetes Care 2000;23:1605–11. https://doi.org/10.2337/diacare.23.11.1605
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
178
286. Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Linagliptin
monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week
randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled
extension. Diabetes Obes Metab 2012;14:1145–54. http://dx.doi.org/10.1111/dom.12011
287. Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, et al. Efficacy and
tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized,
double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049–58. http://dx.doi.org/
10.1185/03007995.2011.568059
288. Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, Pfützner A. A 26-week, placebo- and
pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.
Diabetes Obes Metab 2012;14:1000–9. http://dx.doi.org/10.1111/j.1463-1326.2012.01631.x
289. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study
Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor,
and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care
2007;30:1979–87. http://dx.doi.org/10.2337/dc07-0627
290. Kamel AN, Cetinarslan B, Uysal AR, Baskal N, Corapcioglu D, Tonyukuk V. Efficacy of
monotherapy with acarbose, glibenclamide, gliclazide, metformin or placebo in NIDDM patients.
Diabetologia 1997;40:A138.
291. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in
the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract
2009;83:106–16. http://dx.doi.org/10.1016/j.diabres.2008.10.009
292. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide
addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care 1999;22:119–24. https://doi.org/10.2337/diacare.22.1.119
293. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with
repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care
2001;24:11–15. https://doi.org/10.2337/diacare.24.1.11
294. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Sitagliptin Study 023 Group.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients
with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71. https://doi.org/10.1007/
s00125-006-0416-z
295. Scherbaum WA, Göke B, German Pioglitazone Study Group. Metabolic efficacy and safety
of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind,
placebo-controlled study. Horm Metab Res 2002;34:589–95. http://dx.doi.org/10.1055/
s-2002-35421
DOI: 10.3310/hta21020 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 2
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179

Appendix 1 Search strategy
Clinical effectiveness searches
Searches for journal articles
Search strategy for Ovid MEDLINE (1946–February 16, 2015) and Ovid
EMBASE (1974–February 16 2015)
1. (empagliflozin or canagliflozin or dapagliflozin or sodium glucose cotransporter 2 inhibitor* or sodium
glucose co-transporter 2 inhibitor* or SGLT2 inhibitor* or SGLT-2 inhibitor*).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier]
2. randomized controlled trial.pt.
3. random*.tw.
4. 2 or 3
5. 1 and 4
164 retrieved in MEDLINE and 239 in EMBASE.
There were no restrictions by language.
Weekly auto-alerts of both searches were then run from February 2015 until the end of August 2015 in
MEDLINE, EMBASE and PubMed to check for newly emerging studies.
A total of 403 records were downloaded into EndNote, and after removal of duplicates, 246 unique
records remained, of which 195 were excluded on the basis of title and abstract on the first screening. The
full text of the 51 records remaining was obtained and a second screening was performed. Seven trials
(eight full-text articles) were included in clinical effectiveness.
Appendix 2 gives reasons for exclusion for full-text studies.
Search for meeting abstracts
Search strategy for Ovid EMBASE (1947 to 2015 Week 12)
1. (empagliflozin or canagliflozin or dapagliflozin).m_titl.
2. conference.pt.
3. 1 and 2
400 retrieved.
Search strategy for Web of Science Core Collection (from inception to
February 2015)
TITLE field: (empagliflozin or canagliflozin or dapagliflozin); Refined by: Document Types: (MEETING ABSTRACT)
239 retrieved.
A total of 636 meeting abstracts were downloaded into EndNote (version 7; Thomson Reuters, CA, USA)
and, after removing duplicates, there were 372 unique records. These were screened on the basis of title
(and abstract if available) and 46 were selected for further scrutiny, of which one was selected for inclusion.
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Cost-effectiveness searches
Ovid MEDLINE (1946 to July Week 1 2015, Ovid MEDLINE® In-Process &
Other Non-Indexed Citations July 13, 2015)
1. exp Economics/
2. exp “Costs and Cost Analysis”/
3. Health Status/
4. exp “Quality of Life”/
5. exp Quality-Adjusted Life Years/
6. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
7. (health state* or health status).tw.
8. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D
or SF6D or HUI).tw.
9. (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw.
10. (quality adj2 life).tw.
11. (decision adj2 model).tw.
12. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing*
adj2 pay)).tw.
13. “resource use”.tw.
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. (empagliflozin or canagliflozin or dapagliflozin).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier]
16. (sodium glucose cotransporter 2 or sodium glucose co-transporter 2 or SGLT2* or SGLT-2*).m_titl.
17. 15 or 16
18. 14 and 17
29 retrieved.
Ovid EMBASE 1974 to 2015 July 13
1. exp health economics/
2. exp health status/
3. exp “quality of life”/
4. exp quality adjusted life year/
5. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
6. (health state* or health status).tw.
7. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form or SF-12 or SF12 or
SF-36 or SF36 or SF-6D or SF6D or HUI).tw.
8. (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit* or net
benefit or contingent valuation).tw.
9. (quality adj2 life).tw.
10. (decision adj2 model).tw.
11. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing*
adj2 pay)).tw.
12. (resource* or quality of well-being or qwb).tw.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. (empagliflozin or canagliflozin or dapagliflozin).mp.
15. (sodium glucose cotransporter 2 or sodium glucose co-transporter 2 or SGLT2* or SGLT-2*).m_titl.
16. 14 or 15
17. 13 and 16
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18. (monotherap* or placebo).mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
19. 17 and 18
136 retrieved.
The Cochrane Library: NHS Economic Evaluation Database in July 2015
l (empagliflozin or canagliflozin or dapagliflozin) in Title, Abstract or Keywords
2 retrieved.
The EndNote database had 167 references. Retained 43 for a second viewing; the full text of six were retrieved.
Searches for trials of gliclazide in monotherapy lasting 24–26 weeks,
versus placebo
Search strategy in Ovid MEDLINE (1946–April 7 2005)
1. gliclazide.mp. or exp Gliclazide/
2. randomized controlled trial.pt.
3. 1 and 2
142 retrieved.
Search strategy in Ovid EMBASE
1. gliclazide.mp. or gliclazide/
2. (placebo or monotherapy).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword]
3. 1 and 2
4. random*.mp.
5. 3 and 4
6. randomized controlled trial/
7. 5 and 6
153 retrieved.
In total, 295 in EndNote; 230 after removing duplicates; 138 selected in first screening and 58 in the
second screening of 11 full text requested.
Searches for systematic reviews of sulfonylureas and gliclazide
Search strategy for Ovid MEDLINE 1946 – April 7 – then updated September
Week 1, 2015
1. (sulfonylurea* or sulphonylurea* or gliclazide).tw.
2. meta-analysis.pt.
3. (systematic review or meta-analysis).tw.
4. 2 or 3
5. 1 and 4
143 retrieved.
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Ovid EMBASE 1974 – September 14, 2015
1. (sulfonylurea* or sulphonylurea* or gliclazide).tw.
2. (systematic review or meta-analysis).tw.
3. 1 and 2
263 retrieved.
Total of 406 combined; after removal of duplicates it was 301. After a first screening, 34 were selected for
a second screening and 15 full text were selected.
Records identified through
database searching
(n = 1039)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 628)
Id
en
ti
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Records screened
(n = 628)
Records excluded
(n = 532)
Full-text articles and
meeting abstracts
assessed for eligibility
(n = 96)
Full-text articles
excluded, with reasons
(n = 42)
• Review, n = 17
• Not monotherapy, n = 13
• Drug not included in our
   protocol, n = 3
• Short duration, n = 3
• Comparator not included
   in our protocol, n = 2
• Not a licensed dose of
   dapagliflozin used, n = 1
• Outcome not included
   in our protocol, n = 1
• Protocol only, n = 1
• Patients did not have
   diabetes, n = 1
Studies included in
quantitative synthesis
(meta-analysis)
(n = 7)
Studies included in
qualitative synthesis 
[n = 7 (9 articles)]
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Appendix 2 Reasons for exclusions
Study ID Reason for exclusion
Bailey 2012248 Not a licensed dose of dapagliflozina used
Berhan 2013249 Review
Bluher 2014250 Review
Brand 2012251 Patients did not have diabetes
Escudero Vilaplana 2014252 Review
Ferrannini 2013253 Not monotherapy
Goring 2014254 Not monotherapy
Henry 2012255 Comparator not included in our protocol
Hussey 2013256 Short duration
Johnsson 2013101 Review
Johnsson 2013257 Review
Kadowaki 2014258 Short duration
Kaku 2014259 Comparator not included in our protocol
Lavalle-Gonzalez 201393 Not monotherapy
Lutz 2014260 Review
Matthaei 2014261 Review
Nauck 2011119 Not monotherapy
Nauck 2013262 Not monotherapy
Orme 2014263 Not monotherapy
Pafili 2014264 Review
Phung 2014265 Review
Plosker 2012266 Review
Plosker 2014267 Review
Polidori 2014268 Outcome not included in our protocol
Raskin 2013269 Review
Rosenstock 2012270 Not monotherapy
Rosenstock 2012271 Not monotherapy
Rosenstock 2013272 Not monotherapy
Scheen 2015273 Review
Seino 2014274 Drug not included in our protocol
Seino 2014275 Drug not included in our protocol
Seino 2014276 Drug not included in our protocol
Strojek 2011277 Not monotherapy
Strojek 2013278 Not monotherapy
Strojek 2014279 Not monotherapy
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Study ID Reason for exclusion
Tahrani 2013131 Review
Usiskin 2014280 Review
Wilding 2013281 Not monotherapy
Yang 2014282 Review
Zambrowicz 2013283 Short duration
Zhang 2014284 Review
Zinman 2014137 Protocol only
a Farxiga, Bristol-Myers Squibb, Luton, UK.
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Appendix 3 Study characteristics
Study Participants and baseline data Intervention/outcomes
Canagliflozin (Invokana, Janssen, High Wycombe, UK)
CANTATA-M (Stenlöf 2013)84
Setting: multicentre (n= NR);
17 countries (USA, Austria,
Colombia, Estonia, Guatemala,
Iceland, India, Korea, Republic
of, Lithuania, Malaysia, Mexico,
Philippines, Poland, Puerto Rico,
Romania, South Africa, Spain
and Sweden)
Design: phase III RCT,
double-blind, placebo controlled
Duration: 26 weeks
Extension: 26-week extension,
replacing placebo with
sitagliptin
Sponsor: Janssen Research &
Development, LLC
N: 584 (172/195 completers in the
cana100 group, 175/197 in the cana300
group, 160/192 in the placebo group;
152/170 completed extension in cana100
group, 165/170 in cana300 group,
135/155 in placebo group); 91 in the
high-glycaemic substudy (40/47 completers
in the cana100 group, 40/44 in the
cana300 group)
Inclusion criteria: age 18–80 years, type
2 diabetes inadequately controlled with
diet and exercise or on AHAs, who
underwent washout of the agent; HbA1c
for participants not on AHAs ≥ 7.0% to
≤ 10.0%; HbA1c for participants on AHA
monotherapy or SU plus metformin
≥ 6.5% and ≤ 9.5% at screening and
≥ 7.0% and ≤ 10% and FPG < 15mmol/l
at –2 weeks; substudy conducted for
participants with HbA1c > 10.0% and
≤ 12.0% at screening or –1 weeks and
FPG ≤ 19.4 mmol/l at –1 weeks
Exclusion criteria: repeated FPG
repeatedly > 15.0 mmol/l during
pretreatment (or > 19.4 mmol/l for the
high-glycaemic substudy); history of type 1
diabetes, hereditary glucose/galactose
malabsorption, primary renal glucosuria or
CVD; treatment with a PPARGagonist,
insulin, another SGLT2 inhibitor or any
other AHA except as specified in the
inclusion criteria within 12 weeks before
screening; eGFR < 50ml/minute/1.73 m2
at screening
Age (years): cana100: 55.1 (SD 10.8);
cana300: 55.3 (SD 10.2); placebo: 55.7
(SD 10.9); cana100 high HbA1c: 49.7 (SD
11.1); cana300 high HbA1c: 48.8 (SD 10.8)
Sex (% women): cana100: 58.5%;
cana300: 54.8%; placebo: 54.2%;
cana100 high HbA1c: 51.1%; cana300
high HbA1c: 56%
Ethnicity: cana100: 63.6% White,
9.2% Black, 13.8% Asian, 13.3% other;
cana300: 69.5% White, 7.1% Black,
14.7% Asian, 8.6% other; placebo:
69.8% White, 4.7% Black, 15.1% Asian,
10.4% other; cana100 high HbA1c: 53.2%
White, 6.4% Black, 23.4% Asian, 17.0%
other; cana300 high HbA1c: 68.2% White,
2.3% Black, 15.9% Asian, 13.6% other
Intervention
cana100 (n= 195): 100mg/day
canagliflozin
cana300 (n= 197): 300mg/day
canagliflozin
cana100 high HbA1c (n= 47): 100mg/
day canagliflozin in participants with
HbA1c > 10.0% and ≤ 12.0%
cana300 high HbA1c (n= 44): 300mg/
day canagliflozin in participants with
HbA1c > 10.0% and ≤ 12.0%
Control (n= 192): placebo
Run-in: 8 weeks and diet and exercise
and washout period for participants on
AHA, followed by a 2-week single-blind
placebo run-in period; participants not
on AHA directly entered the 2-week
placebo run-in period; participants in
the high-glycaemic substudy entered a
1-week, single-blind placebo run-in period
Extension: after 26 weeks, the placebo
group received double-blind sitagliptin
(100mg/day)
All groups: rescue therapy with
metformin was initiated if FPG was
> 15.0 mmol/l after day 1 to week 6,
> 13.3 mmol/l after week 6 to week 12
and > 11.1 mmol/l after week 12 to
week 26; HbA1c > 8% after week 26
Outcomes
Primary outcome: change in HbA1c from
baseline to week 26
Secondary outcomes: proportion
achieving HbA1c < 7.0%, FPG, 2-hour
postprandial glucose, HOMA, SBP, HDL-C,
triglycerides, body weight
Other outcomes: LDL-C, non-HDL-C,
apolipoprotein B, DBP, safety assessments
(including laboratory, vital signs,
hypoglycaemia)
Note: the main outcomes for the
extension period were reported only for
the canagliflozin groups (not considered
in the data extraction); safety parameters
for all groups
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Study Participants and baseline data Intervention/outcomes
Diabetes duration (years): cana100: 4.5
(SD 4.4); cana300: 4.3 (SD 4.7); placebo:
4.2 (SD 4.1); cana100 high HbA1c: 4.6 (SD
4.6); cana300 high HbA1c: 5.2 (SD 4.8)
HbA1c (%): cana100: 8.1 (SD 1.0);
cana300: 8.0 (SD 1.0); placebo: 8.0 (SD
1.0; cana100 high HbA1c: 10.6 (SD 0.9);
cana300 high HbA1c: 10.6 (SD 0.6)
BMI (kg/m2): cana100: 31.3 (SD 6.6);
cana300: 31.7 (SD 6.0); placebo: 31.8 (SD
6.2); cana100 high HbA1c: 30.4 (SD 7.1);
cana300 high HbA1c: 30.5 (SD 5.5)
Baseline medication: patients on AHA at
screening: cana100: 48.2%; cana300:
48.2%; placebo: 47.9%; cana100 high
HbA1c: 23.4%; cana300 high HbA1c:
22.7%
Inagaki 201476
Setting: multicentre (n= 31);
Japan
Design: phase III RCT, double
blind, parallel group, placebo
controlled
Duration: 24 weeks
Follow-up: 2 weeks’
post-intervention follow-up
Sponsors: Mitsubishi, Tanabe
Pharma Corp
N: 183 in relevant comparison groups
(84/90 completers in the cana100 group,
74/93 in the placebo group)
Inclusion criteria: age ≥ 20 years, type 2
diabetes mellitus diagnosed ≥ 3 months
before run-in, HbA1c 7.0% to 10%, on
diet and exercise therapy for ≥ 55 days;
patients on antihyperglycaemic treatment
had to start a washout period of ≥ 55 days
before starting run-in
Exclusion criteria: non-type 2 diabetes,
current or history of severe diabetic
complications, FPG > 270mg/dl, indication
for insulin therapy, hereditary glucose/
galactose malabsorption or renal
glycosuria, inadequately controlled thyroid
abnormality, anorexia or bulimia, current
or history of urinary tract/genital infection
< 1 year before run-in, triglyceride
≥ 6.72 mmol/l, BP ≥ 160/≥ 100mmHg
during run-in or patients with known
hypertension immediately requiring the
addition/modification of antihypertensive
therapy, heart disease, serious liver
disease, serious kidney disease, eGFR
< 50ml/minute/1.73 m2; urinary albumin/
creatinine ratio ≥ 300mg/g creatinine,
history of malignancy, neuropsychiatric
disorder likely to hinder study evaluations;
history of drug-related shock or
anaphylactic symptoms; unwilling to use
contraception; pregnant or breast feeding
women, prior use of canagliflozin
Age (years): cana100: 58.4 (SD 10.4);
placebo: 58.2 (SD 11.0)
Sex (% women): cana100: 34.4%;
placebo: 35.5%
Ethnicity: 100% Japanese
Intervention
cana100 (n= 90): 100 mg/day
canagliflozin, once daily before breakfast
Control (n = 93): placebo, once daily
Note: the trial also included a 200-mg
group, this was not considered here
Run-in: 4-week, single-blind placebo
lead-in
All groups: patients were instructed to
continue diet and exercise therapy as
before
Outcomes
Primary outcome: change in HbA1c from
baseline to week 24
Secondary outcomes: FPG, body
weight, proportion achieving HbA1c
< 7%, 2-hour postprandial glucose, waist
circumference, lipids, BP, HOMA,
proinsulin, C-peptide
Other outcomes: safety assessments
(including laboratory, vital signs,
hypoglycaemia)
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Study Participants and baseline data Intervention/outcomes
Diabetes duration (years): cana100:
4.72 (SD 4.59); placebo: 5.63 (SD 5.76)
HbA1c (%): cana100: 7.98 (SD 0.73);
placebo: 8.04 (SD 0.70)
BMI (kg/m2): cana100: 25.59 (SD 4.20);
placebo: 25.85 (SD 4.39)
Comorbidities: NR
Baseline medication: cana100: 22.2%
previously on OADs; placebo: 25.8%
previously on OADs
Study Participants and baseline data Intervention/outcomes
Dapagliflozin (Farxiga, Bristol-Myers Squibb, Luton, UK)
Ferrannini 2010/Bailey 201577,78
Setting: multicentre (n= 85);
USA, Canada, Mexico and
Russia
Design: phase III RCT, double
blind, parallel group, placebo
controlled
Duration: 24 weeks
Extension: 78 weeks (Bailey
201578), double-blind
Sponsors: Bristol-Myers Squibb;
AstraZeneca
N: 260 in relevant comparison groups
(156/185 completers in the dapa10
groups, 63/75 in the placebo group;
42/56 completed extension in dapa10
AM group, 42/62 in placebo group)
Inclusion criteria: age 18–77 years,
type 2 diabetes mellitus inadequately
controlled with diet and exercise, naive
to treatment, BMI ≤ 45 kg/m2, fasting
C-peptide ≥ 1.0 ng/ml
Exclusion criteria: type 1 diabetes,
serum creatinine ≥ 133 µmol/l (men) or
≥ 124 µmol/l (women), urine albumin/
creatinine ratio > 200mg/mmol, aspartate
transaminase and/or alanine transaminase
> 3 times the upper limits of normal,
creatine kinase ≥ 3 times the upper limit
of normal, symptoms of severely
uncontrolled diabetes (including marked
polyuria and polydipsia with > 10%
weight loss during last 3 months before
enrolment); significant renal, hepatic,
haematological, oncological, endocrine,
psychiatric, or rheumatic diseases,
cardiovascular event within 6 months of
enrolment, severe uncontrolled BP
(systolic ≥ 180mmHg and/or diastolic
≥ 110mmHg)
Age (years): dapa10 AM: 50.6 (SD 10.0);
dapa10 PM: 50.7 (SD 9.7); dapa10 high
HbA1c: 47.9 (SD 12.1); placebo: 52.7
(SD 10.3)
Sex (% women): dapa10 AM: 51.4%;
dapa10 PM: 48.7%; dapa10 high HbA1c:
41.0%; placebo: 58.7%
Intervention
l dapa10 AM (n= 70): 10mg/day
dapagliflozin, administered once daily
in the morning in people with
HbA1c 7–10%
l dapa10 PM (n= 76): 10mg/day
dapagliflozin, administered once daily
in the evening in people with
HbA1c 7–10%
l dapa10 high HbA1c (n= 39): 10 mg/
day dapagliflozin, administered once
daily in the morning in people with
HbA1c 10.1–12%
Control (n= 75): placebo, once daily in
people with HbA1c 7–10%
Note: the trial also included 2.5- and
5-mg groups – these were not considered
here
Run-in: 2-week diet/exercise placebo
lead-in (1 week for patients with HbA1c
10.1–12.0%)
Extension: after 24 weeks, the placebo
group received low-dose metformin
(500mg/day) and the dapa groups
received matching placebo; results only
reported for main dapa AM groups vs.
placebo
All groups: if fasting FPG was > 270mg/dl
at week 4, > 240mg/dl at week 8 or
> 200mg/dl at weeks 12 to 24, patients
were eligible for open-label rescue
medication (500mg metformin, titrated
as needed up to 2000mg); patients with
HbA1c > 8.0% for 12 weeks despite
maximum tolerated metformin dose were
discontinued; the strategy for rescue
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Study Participants and baseline data Intervention/outcomes
Ethnicity: dapa10 AM: 90% White,
2.9% Black, 4.3% Asian, 2.9% other;
placebo: 94.7% White, 2.7% Black,
2.7% Asian
Diabetes duration (years, median,
IQR): dapa10 AM: 0.45 (0.1–3.4); dapa10
PM: 0.40 (0.1–2.45); dapa10 high HbA1c:
1.4 (0.2–3.5); placebo: 0.5 (0.1–3.4)
HbA1c (%): dapa10 AM: 8.01 (SD 0.96);
dapa10 PM: 7.99 (SD 1.05); dapa10 high
HbA1c: 10.73 (SD 0.85); placebo: 7.84
(SD 0.87)
BMI (kg/m2): dapa10 AM: 33.6 (SD 5.4);
dapa10 PM: 33.3 (SD 5.6); dapa10 high
HbA1c: 31.1 (SD 5.9; placebo: 32.3
(SD 5.5)
Comorbidities: dapa10 AM: 1.4%
diabetic neuropathy, 1.4%
microalbuminuria, 41.4% hypertension;
placebo: 8% diabetic neuropathy,
1.3% diabetic neuropathy, 1.3%
microalbuminuria, 52% hypertension
Baseline medication: no OAD; dapa10
AM: 41.4% on antihypertensives;
placebo: 41.3% on antihypertensives
medication based on HbA1c was continued
during the extension period. Patients
received diet/exercise counselling
according to ADA recommendations
throughout the study
Outcomes
Primary outcome: change from baseline
in HbA1c at week 24 in the dapa10 AM
group
Secondary outcomes: FPG, body weight
Other outcomes: safety assessments and
adverse events (including laboratory, vital
signs, urinary tract and genital infections,
hypoglycaemia)
Ji 201479
Setting: multicentre (n= 40);
China, Korea, Taiwan and India
Design: phase III RCT, double-
blind, parallel group, placebo
controlled
Duration: 24 weeks
Follow-up: 28 days post
intervention (not reported)
Sponsors: Bristol-Myers Squibb;
AstraZeneca
N: 265 in relevant comparison groups
(117/133 completers in the dapa10
group, 113/132 in the placebo group)
Inclusion criteria: aged ≥ 18 years,
inadequately controlled type 2 diabetes
mellitus (HbA1c ≥ 7.5% and ≤ 10.5% at
enrolment and ≥ 7.0% and ≤ 10.5%
during lead-in), drug naive, BMI
≤ 45 kg/m2, C-peptide ≥ 1.0 ng/ml
Exclusion criteria: aspartate
aminotransferase and/or alanine
aminotransferase levels > 3 times
upper limit of normal, serum total
bilirubin > 34.2 µmol/l, serum
creatinine ≥ 132.6 µmol/l for men or
≥ 123.8 µmol/l for women, haemoglobin
≤ 110 g/l for men and ≤ 100 g/l for women,
creatine kinase ≥ 3 times the upper limit of
normal, urine albumin/creatinine ratio
> 1800mg/g, severe hypertriglyceridaemia
(triglyceride > 9.3 mmol/l), urinary
excretion of N-acetyl-β-d-glucosaminidase
> 84 µmol/hour per millimole of creatinine,
urinary excretion of α1 microglobulin
> 28mg/g creatinine, parathyroid hormone
value > 1.5 times the upper limit of normal,
calcium or serum phosphate values outside
the normal reference range, abnormal free
thyroxine levels, positive hepatitis B surface
antigen or positive anti-hepatitis C
antibodies; currently unstable or serious
vascular, renal, hepatic, haematological,
oncologic, endocrine, psychiatric, or
rheumatic diseases
Intervention
l dapa10 (n= 133): 10 mg/day
dapagliflozin, taken once daily before
the first meal of the day
l control (n= 132): placebo, once daily
Note: the trial also included a 5-mg
group – this was not considered here
Run-in: 6-week single-blind placebo
run-in with diet and exercise counselling
consistent with China Diabetes Society
recommendations
All groups: open-label rescue therapy
with metformin (500mg daily, titrated to
2000 mg if necessary) could be given if
glycaemic control was inadequate (during
weeks 4–12, FPG > 13.3 mmol/l; during
weeks 12–24, FPG level > 11.1 mmol/l);
patients with FPG values consistently
greater than protocol-specified values for
12 weeks despite a maximum tolerated
dose of metformin were discontinued
from the study
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Study Participants and baseline data Intervention/outcomes
Age (years): dapa10: 51.2 (SD 9.9);
placebo: 49.9 (SD 10.9)
Sex (% women): dapa10: 35.3%;
placebo: 34.1%
Ethnicity: dapa10: 88.7% Chinese, 6.8%
Asian Indian, 3.8% Korean, 0.8% other
Asian; placebo: 88.6% Chinese, 6.1%
Asian Indian, 3.8% Korean, 0.8%
Japanese, 0.8% other Asian
Diabetes duration (years): dapa10:
1.67 (SD 2.8) (range 0–13); placebo: 1.3
(SD 2.0) (range 0–9.9)
HbA1c (%): dapa10: 8.28 (SD 0.95);
placebo: 8.35 (SD 0.95)
BMI (kg/m2): dapa10: 25.76 (SD 3.43);
placebo: 25.93 (SD 3.64)
Comorbidities: dapa10: 42.9%
history of dyslipidaemia, 37.6% history
of hypertension; placebo: 40.2% history
of dyslipidaemia, 40.9% history of
hypertension
Baseline medication: no OAD; others
not reported
Outcomes
Primary outcome: change in HbA1c from
baseline to week 24
Secondary outcomes: FPG, 2-hour
postprandial glucose, proportion
achieving HbA1c < 7%, body weight
Other outcomes: beta cell function and
insulin resistance, waist circumference,
lipids, proportion of patients with ≥ 3%
or ≥ 5% reduction in total weight, fasting
urinary glucose/creatinine ratio, safety and
tolerability (including laboratory, vital
signs, hypoglycaemia)
Kaku 201480
Setting: multicentre (n= NR);
Japan
Design: phase III RCT, double
blind, parallel group, placebo
controlled
Duration: 24 weeks
Follow-up: 3-week post-
intervention follow-up
Sponsors: Bristol-Myers Squibb,
AstraZeneca
N: 175 in relevant comparison groups
(79/88 completers in the dapa10 group,
79/87 in the placebo group)
Inclusion criteria: age ≥ 20 years, type 2
diabetes mellitus inadequately controlled
with diet and exercise, naive to drug
treatment or on antihyperglycaemic
treatment (the latter underwent a
washout period before study began),
HbA1c ≥ 6.5% and ≤ 10% for drug-naive
patients and ≤ 8% for patients on
ongoing treatment
Exclusion criteria: type 1 diabetes,
FPG > 13.3 mmol/l, creatinine kinase
> 3 times upper limit of normal, eGFR
< 45ml/minute or serum creatinine
> 133 µmol/l for men and > 124 µmol/l
for women; severe hepatic insufficiency
and/or significant abnormal liver function
(aspartate aminotransferase > 3 times
upper limit of normal and/or alanine
aminotransferase > 3 times upper limit of
normal; New York Heart Association class IV
CHF; unstable or acute CHF; treatment
with TZDs < 6 months before enrolment;
pregnant or breastfeeding women
Age (years): dapa10: 57.5 (SD 9.3);
placebo: 60.4 (SD 9.7)
Sex (% women): dapa10: 39.8%;
placebo: 40.2%
Ethnicity: 100% Japanese
Intervention
l dapa10 (n= 88): 10 mg/day
dapagliflozin, administered once daily
l control (n = 87): placebo, once daily
Note: the trial also included a 5-mg
group – this was not considered here
Run-in: 2-week screening period and
4-week single-blind placebo lead-in
Follow-up: post-intervention follow-up
mainly used for safety monitoring – no
further results reported
All groups: no further information
Outcomes
Primary outcome: change in HbA1c from
baseline to week 24
Secondary outcomes: FPG, body weight
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Study Participants and baseline data Intervention/outcomes
Diabetes duration (years): dapa10: 4.93
(SD 4.52); placebo: 5.29 (SD 6.17)
HbA1c (%): dapa10: 7.46 (SD 0.61)
(21.6% < 7%); placebo: 7.50 (SD 0.63)
(24.1% < 7%)
BMI (kg/m2): dapa10: 26.06 (SD 4.52);
placebo: 25.22 (SD 4.39)
Comorbidities: dapa10: 50% history of
CVD, 40.9% hypertension only; placebo:
42.5% history of CVD, 35.6%
hypertension only, 2.3% CHF; most
patients in both groups had mild to
moderate renal impairment (69% stage 1
or mild CKD, 28% stage 2 or moderate
CKD)
Baseline medication: NR
Other outcomes: body weight in
patients with BMI ≥ 25 kg/m2, fasting
insulin and C-peptide, SBP, blood lipids,
proportion achieving HbA1c < 7%; safety
assessments (including laboratory, vital
signs, hypoglycaemia)
Empagliflozin (Jardiance, Merck and Co, Darmstadt, Germany)
Lewin 201581
Setting: multicentre (n= 197);
22 countries (no UK sites)
Design: phase III RCT, double
blind, parallel group
Duration: 52 weeks, primary
end point at 24 weeks
Follow-up: follow-up visit
4 weeks after the last dose of
study drug
Sponsors: Boehringer Ingelheim;
Eli Lilly
N: 404 in relevant comparison groups
(398 with on treatment measurements)
(114/133 completers in the empa25
group, 110/132 in the empa10 group,
116/133 in the lina5 group)
Inclusion criteria: age ≥ 18 years, type 2
diabetes mellitus inadequately controlled
with diet and exercise, no therapy with
OAD, GLP1-analogue or insulin for
≥ 12 weeks prior to randomisation, BMI
≤ 45 kg/m2, HbA1c > 7% and ≤ 10.5%
Exclusion criteria: uncontrolled
hyperglycaemia (FPG > 13.3. mmol/l);
eGFR < 60ml/minute/1.73 m2; acute
coronary syndrome, stroke, or transient
ischaemic attack within 3 months prior to
consent; bariatric surgery in the past
2 years; treatment with anti-obesity drugs
within 3 months prior to consent
Age (years): empa25: 56.0 (SD 9.3);
empa10: 53.9 (SD 10.5); lina5: 53.8
(SD 11.5)
Sex (% women): empa25: 42.1%;
empa10: 51.5%; lina5: 43.6%
Intervention
l empa25 (n= 133): 25 mg/day
empagliflozin, taken once daily in
the morning
l empa10 (n= 132): 10 mg/day
empagliflozin, taken once daily in
the morning
l lina5 (n= 133): 5 mg/day linagliptin,
taken once daily in the morning
Note: the trial also included fixed
combination empagliflozin 25 mg/
linagliptin 5-mg and empagliflozin 10 mg/
linagliptin 5-mg groups – these were not
considered here
Run-in: 2-week placebo run-in
All groups: rescue medication initiated if
blood glucose > 240mg/dl after overnight
fast between weeks 1 and 12, blood
glucose > 200mg/dl after overnight fast
between weeks 12 and 24, or blood
glucose > 180mg/dl or HbA1c > 8% after
overnight fast between weeks 24 and 52
(initiation, choice and dosage of rescue
medication at the discretion of the
investigator but use of DPP-4 inhibitors,
GLP-1 analogues, SGLT2 inhibitors not
permitted); in cases of hypoglycaemia,
rescue medication was to be reduced in
dose or discontinued; if hyper- or
hypoglycaemia could not be controlled,
participant was discontinued from the
trial
Outcomes
Primary outcome: change in HbA1c from
baseline to week 24
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Study Participants and baseline data Intervention/outcomes
Ethnicity: empa25: 69.9% White, 14.3%
Asian, 15.8% other; empa10: 75.0%
White, 9.8% Asian, 15.2% other; lina5:
77.4% White, 12.8% Asian, 9.8% other;
Asians were from Malaysia, the
Philippines, Taiwan; no South Asian
recruits; other mainly Hispanic
Diabetes duration (time since
diagnosis): empa25: 36.1% ≤ 1 year,
36.1% > 1–5 years, 18.8% > 5–10 years,
9.0% > 10 years; empa10: 32.6%
≤ 1 year, 45.5% > 1–5 years, 11.4%
> 5–10 years, 10.6% > 10 years; lina5:
37.6% ≤ 1 year, 42.9% > 1–5 years,
16.5% > 5–10 years, 3.0% > 10 years
HbA1c (%): empa25: 7.99 (SD 0.97
(27.1% ≥ 8.5%); empa10: 8.05 (SD 1.03
(28.8% ≥ 8.5%); lina5: 8.05 (SD 0.89
(25.6% ≥ 8.5%)
BMI (kg/m2): empa25: 31.2 (SD 5.7);
empa10: 31.5 (SD 5.7); lina5: 31.9
(SD 5.9)
Comorbidities: empa25: n= 20 (15%)
microalbuminuria, n= 0 macroalbuminuria;
empa10: n= 21 (16%) microalbuminuria,
n= 3 (2%) macroalbuminuria; lina5: n= 16
(12%) microalbuminuria, n= 2 (1.5%)
macroalbuminuria
Baseline medication: no
antihyperglycaemic medication
Secondary outcomes: FPG, body
weight, proportion achieving HbA1c < 7%
(of participants with HbA1c ≥ 7%)
Other outcomes: SBP, DBP, blood lipids,
safety assessments (including laboratory,
vital signs, hypoglycaemia)
Roden 2013/1482,83
Setting: multicentre (n= 124);
nine countries (Belgium,
Canada, China, Germany, India,
Ireland, Japan, Switzerland and
USA)
Design: phase III RCT, placebo
controlled, double blind, parallel
group
Duration: 24 weeks
Extension: 76-week extension
trial
Sponsors: Boehringer Ingelheim
and Eli Lilly
N: 986 (899 randomised, 87 in open-label
empagliflozin) in relevant comparison
groups (187/228 completed control,
206/224 completed empa10, 204/224
completed empa25, 206/223 completed
sita100, 78/87 completed empa25open)
Inclusion criteria: previously untreated
type 2 diabetes (no oral or injected
anti-diabetes treatment for 12 weeks
before randomisation or start of
open-label treatment), aged ≥ 18 years
(≥ 20 years in Japan, 18–65 years in
India), BMI ≤ 45 kg/m2, and insufficient
glycaemic control despite diet/exercise
regimen [HbA1c 7.0–10.0% (or 7.0–9.0%
in Germany)] at screening for patients
eligible for randomised treatment, or
> 10.0% for those eligible for the
open-label treatment group (this arm
not included in Germany or Ireland)
Exclusion criteria: uncontrolled
hyperglycaemia (PG > 13.3 mmol/l after
overnight fast during placebo run-in
phase and confirmed by second
measurement), eGFR (estimated using
modification of diet in renal disease
equation) < 50ml/minute/1.73m2
(or < 60ml/minute/1.73 m2 in China),
any contraindications to sitagliptin
Intervention
l empa10 (n= 224): empagliflozin
10 mg/day in people with
HbA1c 7–10%
l empa25 (n= 224): empagliflozin
25 mg/day in people with
HbA1c 7–10%
l sita100 (n= 223): sitagliptin 100mg/day
in people with HbA1c 7–10%
l empa25open (n= 87): empagliflozin
25mg/day in people with HbA1c > 10%
l control (n = 228): placebo once a day
in people with HbA1c 7–10%
Run-in: 2-week, open-label placebo run-in
Extension: 68.4% of the 899 patients
continued in a double-blind extension
(numbers in each group not given) for
≥ 52 weeks
All groups: All received diet/exercise
counselling according to local
recommendations; rescue medication was
started at FPG > 13.3 mmol/l between
weeks 1 and 12 or FPG > 11.1 mmol/l
between weeks 12 and 24 (drug of choice
at the discretion of the investigator, but
GLP-1 agonists and DPP-4 inhibitors were
not permitted)
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Study Participants and baseline data Intervention/outcomes
according to local label, treatment with
anti-obesity drugs within 3 months before
informed consent, treatment with systemic
steroids at time of informed consent,
change in thyroid hormone dose within
6 weeks before informed consent, any
uncontrolled endocrine disorder apart from
type 2 diabetes
Age (years): empa10: 56.2 (SD 11.6),
empa25: 53.8 (SD 11.6), sita100: 55.1
(SD 9.9), empa25open: 50.2 (SD 11.3),
placebo: 54.9 (SD 10.9)
Sex (% women): empa10: 37%,
empa25: 35%, sita100: 37%,
empa25open: 26%, placebo: 46%
Ethnicity: empa10: 64% Asian, 34%
White, 1% Black/African American,
< 1% Hawaiian/Pacific Islander; empa25:
64% Asian, 33% White, 3% Black/African
American; sita100: 64% Asian, 34%
White, 1% Black/African American,
< 1% American Indian/Alaska Native;
empa25open: 61% Asian, 33% White,
2% Black/African American, 2% American
Indian/Alaska Native, 1% information not
available, placebo: 64% Asian, 33%
White, 3% Black/African American
Diabetes duration: empa10: 39%
≤ 1 year, 41% 1–5 years, 13%
5–10 years, 7% > 10 years; empa25:
41% ≤ 1 year, 37% 1–5 years, 17%
5–10 years, 6% > 10 years; sita100:
42% ≤ 1 year, 39% 1–5 years, 14%
5–10 years, 5% > 10 years; empa25open:
52% ≤ 1 year, 25% 1–5 years, 14%
5–10 years, 8% > 10 years; placebo: 32%
≤ 1 year, 46% 1–5 years, 15% 5–10 years,
8% > 10 years
HbA1c (%): empa10: 7.87 (SD 0.88),
empa25: 7.86 (SD 0.85), sita100: 7.85
(SD 0.79), empa25open: 11.50 (SD 1.39),
placebo: 7.91 (SD 0.78)
BMI (kg/m2): empa10: 28.3 (SD 5.5),
empa25: 28.2 (SD 5.5), sita100: 28.2
(SD 5.2), empa25open: 28.2 (SD 5.5),
placebo: 28.7 (SD 6.2)
Baseline medication: no oral/injectable
anti-diabetic drug
Outcomes
Primary outcome: change from baseline
HbA1c at week 24
Secondary outcomes: weight, systolic
and DBP
Other outcomes: percentage achieving
HbA1c < 7.0% (of those with HbA1c
> 7.0% at baseline), FPG, percentage with
> 5.0% reduction in body weight, waist
circumference, percentage of patients
with previously uncontrolled hypertension
who achieved controlled BP (< 130mmHg
systolic, < 80mmHg diastolic); use of
rescue therapy, safety end points (vital
signs, clinical laboratory parameters, adverse
events, e.g. hypoglycaemic episodes, urinary
tract and genital infections)
HOMA, homeostatic model assessment (for insulin sensitivity); IQR, interquartile range; NR, not reported; OAD, oral
antidiabetic drug.
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Appendix 4 Quality assessment
Rate as: adequate, inadequate, unclear, not reported.
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Appendix 5 Cochrane risk of bias table:
EMPA-REG OUTCOME
Overall, the trial scores well, and it is likely that the unclear items are just failure to report the processesrather than causing a high risk of bias.
Entry Judgement Support for judgement
Random sequence generation (selection bias) Low risk Computerised randomisation
Allocation concealment (selection bias) Low risk Paper reports that a computerised randomisation
system was used
Blinding of participants and personnel
(performance bias)
Unclear No information on appearance of placebo and
empagliflozin tablets
Blinding of outcome assessment (detection
bias) (patient-reported outcomes)
Unclear Paper says ‘All CV outcome events and deaths are
being prospectively adjudicated by the Clinical
Events Committee (one for cardiac events and one
for neurological events), as recommended in FDA
guidelines’ but gives no detail as to whether or not
the assessors are blinded to allocation
Blinding of outcome assessment (detection
bias) (mortality)
Unclear As above. But death from any cause 8.3% in
placebo group and 5.7% in empagliflozin group
Incomplete outcome data addressed (attrition
bias) [short-term outcomes (2–6 weeks)]
NA Outcomes long term
Incomplete outcome data addressed (attrition
bias) [longer-term outcomes (> 6 weeks)]
Low risk Very good retention of participants, with around
97% completing the study
Selective reporting (reporting bias) Low risk
NA, not applicable.
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Appendix 6 Trials excluded in network
meta-analysis
Trial Drug Comparator Notes
Abbatecola 2006146 Repaglinide Glibenclamide Baseline HbA1c 7.2%
Aronoff 2000285 Pioglitazone Placebo High dropout rate and mean baseline HbA1c high
Barnett 2012286 Linagliptin Placebo then
glimepiride
18 weeks vs. placebo
Barzilai 2011287 Sitagliptin 50 or 100a Placebo High dropout rate. Some not new to drug
treatment. Mixed doses according to renal
function
Chou 2012288 Pioglitazone Placebo Dropout rate
Goldstein 2007289 Sitagliptin Placebo High dropout rate and entry HbA1c up to 11%
Jovanovic 2000148 Repaglinide Placebo High dropout rate
Kamel 1997290 Glibenclamide, gliclazide,
metformin, acarbose
Placebo Abstract only, and only 43 patients across five
arms
Mohan 2009291 Sitagliptin Placebo Only 18 weeks
Moses 1999292 Repaglinide with/without
metformin
Metformin All failed on metformin monotherapy and 25%
HbA1c > 9%
Duration
Moses 2001293 Repaglinide Placebo 16 weeks
Raz 2006294 Sitagliptin Placebo Only 18 weeks
Saleem 2011,149
Shah 2011,150
Jibran 2006151
Repaglinide Glibenclamide Wrong comparator and quality issues. The Jibran
2006151 and Saleem 2011149 papers are very
similar but have no authors in common. They are
reported to be from different time periods but
almost all figures are identical
Scherbaum 2002295 Pioglitazone Placebo Dropout rate
a Januvia, Boehringer Ingelheim, Bracknell, UK.
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Appendix 7 Probabilistic modelling
The model was run probabilistically over 996 iterations for each of the BMI scenarios:
l No BMI direct effect upon QoL
l BMI 1: natural history progression with no rebound
l BMI 2: natural history progression with weight losses rebounding after 1 year
l BMI 3: natural history progression with weight losses rebounding at treatment change
l BMI 4: natural history progression with weight rebounding after 1 year
l BMI 5: natural history progression with weight rebounding at treatment change.
The central estimates for these are as shown in Tables 105 and 106.
This suggests the following cost-effectiveness estimates.
The patterns of dominance are the same across the deterministic results with the exception of the BMI
scenario 2 in which sitagliptin is no longer inferior to repaglinide, but is now slightly superior to it. This
results in a cost-effectiveness estimate for sitagliptin compared with repaglinide of £34M per QALY. But,
given a cost-effectiveness estimate for canagliflozin compared with repaglinide of £153,000 per QALY,
sitagliptin is extendedly dominated.
TABLE 105 Probabilistic central estimates of total costs and total QALYs
Drug Costs (£) No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 28,222 10.649 9.850 9.850 9.850 9.996 9.963
Repaglinide 28,338 10.645 9.880 9.873 9.875 9.995 9.968
Pioglitazone 28,456 10.640 9.827 9.827 9.827 9.987 9.952
Sitagliptin 33,472 10.612 9.878 9.874 9.874 9.966 9.944
Canagliflozin 33,813 10.635 10.005 9.909 9.927 9.995 9.991
Empagliflozin 33,922 10.634 9.972 9.903 9.915 9.992 9.982
Dapagliflozin 34,023 10.624 9.956 9.891 9.900 9.981 9.969
TABLE 106 Probabilistic central cost-effectiveness estimates
Drug No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom £3858 £4949 £4708 Dom £22,679
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin Dom Dom £34M Dom Dom Dom
Canagliflozin Dom £43,952 £9583 £105,000 Dom £242,000
Empagliflozin Dom Dom Dom Dom Dom Dom
Dapagliflozin Dom Dom Dom Dom Dom Dom
Dom, dominated.
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The cost-effectiveness estimates for repaglinide compared with gliclazide of £3858 per QALY, £4949 per
QALY and £4708 per QALY for BMI scenarios 1–3, and £22,679 per QALY for the BMI scenario 5 are
reasonably similar to the £3331 per QALY for BMI scenarios 1–3 and £18,507 per QALY for BMI scenario 5
of the deterministic analysis. In the opinion of the AG, the differences between the probabilistic analyses
and the deterministic analyses are unlikely to be the result differences in the simulated complications of
diabetes, hypoglycaemic events and adverse events. The most likely explanation is that the sampling of
weight changes results in around 40% of the PSA iterations for repaglinide having a weight loss, but 0%
of the PSA iterations for gliclazide. Apart from the scenario of weight changes having no impact upon
QoL, these repaglinide weight losses rebound under the various BMI scenarios. For the 40% of iterations
with a repaglinide weight loss the cost-effectiveness estimate for repaglinide compared with gliclazide
worsens. As a consequence, the central estimate for the cost-effectiveness estimate for repaglinide
compared with gliclazide worsens.
The cost-effectiveness estimates for canagliflozin compared with repaglinide are similar to those of the
deterministic model, though for the BMI scenario 2 it has improved from the £192,000 per QALY of the
deterministic modelling to £153,000 per QALY. The issue around 40% of repaglinide iterations being
associated with weight losses appears to have less of an impact due to the larger absolute QALY
differences between canagliflozin and repaglinide compared with the differences between repaglinide
and gliclazide.
The probabilistic cost-effectiveness estimates of the individual flozins compared with sitagliptin are shown
in Table 107.
The probabilistic central estimates for the cost-effectiveness of the flozins compared with sitagliptin are
much as per the deterministic estimates. Although those for dapagliflozin have worsened slightly, they are
qualitatively the same.
In the figures that follow, the ordering of the legends helps to identify the curves. The topmost curve in
the legend is the curve of the treatment which is the most likely to be cost-effective at a willingness to pay
of £0 per QALY, that is at the vertical axis. As the willingness to pay is £0 per QALY only costs are of
interest, so this point depicts which treatment has the highest likelihood of being cost saving. The curve
below this in the legend is the curve for the treatment that, as the willingness to pay is increased, next
becomes the most likely to be cost-effective. And so on down the legend until the frontier is specified.
The curves within the legend that lie below the entry for the frontier in the legend are those that do not
achieve the frontier at any willingness to pay in the range of £0–50,000 per QALY. When a curve is
mentioned in the legend but is not visible in the figure it coincides with the horizontal axis, that is
estimated to have no probability of being cost-effective over the willingness-to-pay range of £0–50,000
per QALY.
Also note that the frontier has been arbitrarily lifted by 0.5% in all figures so that it does not overlay the
treatment curve to which it corresponds in order to ease identification of the relevant treatment curve.
TABLE 107 Probabilistic ICERs (£) for the flozins compared with sitagliptin
Drug No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Sitagliptin – – – – – –
Canagliflozin 14,714 2704 9583 6532 11,685 7305
Empagliflozin 20,040 4795 15,051 11,168 17,021 12,048
Dapagliflozin 47,766 7110 32,372 21,194 35,379 22,208
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Scenario: no body mass index – body mass index has no impact
upon QoL
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FIGURE 18 Body mass index no QoL effect: cost-effectiveness acceptability frontier (CEAF) across all comparators.
TABLE 108 Body mass index no QoL effect: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 4 61 35
20,000 0 0 0 0 5 59 36
30,000 0 0 0 0 5 58 37
40,000 0 0 0 0 6 56 38
50,000 0 0 0 0 6 55 39
WTP, willingness to pay.
The probabilistic analysis suggests that the flozins and sitagliptin have no real probability of being
cost-effective. The main uncertainty is around whether glicalazide or repaglinide is the most cost-effective,
with it becoming more finely balanced between the two as the willingness to pay approaches £50,000
per QALY.
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FIGURE 19 Body mass index no QoL effect: acceptability frontier for flozins and sitagliptin.
TABLE 109 Body mass index effect: probability of cost-effectiveness for flozins and sitagliptin
WTP (£) Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 10 30 2 58
20,000 26 45 4 26
30,000 33 49 5 13
40,000 36 51 5 8
50,000 38 51 5 5
WTP, willingness to pay.
At low values of willingness to pay, the additional cost of the flozins is not warranted. Sitagliptin is
estimated to be the most likely to be cost-effective up to a willingness to pay of around £15,000.
Thereafter, canagliflozin becomes the most likely to be cost-effective, though the probability of
empagliflozin being the most cost-effective is not that far behind. Dapagliflozin fares worse, with there
being little likelihood of it being the most cost-effective at any willingness-to-pay value.
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Scenario: body mass index 1 – body mass index changes
retained indefinitely
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FIGURE 20 Body mass index scenario 1: cost-effectiveness acceptability frontier (CEAF) across all comparators.
TABLE 110 Body mass index scenario 1: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 1 35 65
20,000 0 0 0 0 0 25 74
30,000 0 6 0 0 0 20 74
40,000 1 32 0 0 0 9 58
50,000 2 60 0 0 0 4 35
WTP, willingness to pay.
With weight changes being retained indefinitely, gliclazide is soon overtaken by repaglinide due to the
greater weight gain with gliclazide. But canagliflozin is associated with the largest weight losses of the
treatments. As the willingness to pay rises to around £45,000 per QALY, canagliflozin has the highest
likelihood of being cost-effective. This £45,000 per QALY is broadly in line with the cost-effectiveness
estimate for canagliflozin of both the deterministic and the probabilistic modelling.
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FIGURE 21 Body mass index scenario 1: cost-effectiveness acceptability frontier (CEAF) for flozins and sitagliptin.
TABLE 111 Body mass index scenario 1: probability of cost-effectiveness for flozins and sitagliptin
WTP (£) Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 8 91 1 0
20,000 6 93 0 0
30,000 5 94 1 0
40,000 5 95 1 0
50,000 5 95 1 0
WTP, willingness to pay.
Given the greater weight changes associated with canagliflozin, if weight changes are retained indefinitely
canagliflozin is estimated to have the greatest likelihood of being cost-effective at all but low willingness to
pay values and there is little uncertainty around this.
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Scenario: body mass index 2 – body mass index weight loss
rebounds after 1 year
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FIGURE 22 Body mass index scenario 2: cost-effectiveness acceptability frontier (CEAF) across all comparators.
TABLE 112 Body mass index scenario 2: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 1 39 61
20,000 0 0 0 0 0 30 70
30,000 0 0 0 0 1 26 74
40,000 0 0 0 0 1 24 76
50,000 0 0 0 0 1 23 77
WTP, willingness to pay.
If weight changes are only retained for 1 year compared with them being retained indefinitely there is little
impact upon where gliclazide and repaglinide cross over. The main impact is that canagliflozin no longer
shows a probability of being cost-effective as the willingness to pay increases further towards £50,000
per QALY.
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FIGURE 23 Body mass index scenario 2: cost-effectiveness acceptability frontier (CEAF) for flozins and sitagliptin.
TABLE 113 Body mass index scenario 2: probability of cost-effectiveness for flozins and sitagliptin
WTP (£) Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 12 43 2 43
20,000 24 61 4 11
30,000 27 64 4 5
40,000 28 65 4 3
50,000 29 64 4 2
WTP, willingness to pay.
Compared with the scenario of weight changes being retained indefinitely, the shorter retention of the
larger weight gain from canagliflozin compared with empagliflozin means that there is greater uncertainty
as to which is the most cost-effective treatment. At a willingness to pay of £30,000 per QALY, the
probability of canagliflozin being the most cost-effective treatment is now only double that of empagliflozin.
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Scenario: body mass index 3 – body mass index weight loss
rebounds at treatment change
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FIGURE 24 Body mass index scenario 3: cost-effectiveness acceptability frontier (CEAF) across all comparators.
TABLE 114 Body mass index scenario 3: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 1 38 61
20,000 0 0 0 0 0 29 71
30,000 0 0 0 0 1 25 75
40,000 0 0 0 0 1 23 76
50,000 0 2 0 0 1 21 77
WTP, willingness to pay.
The scenario of weight losses rebounding at treatment change is a half-way house. But this half-way
house is still insufficient for canagliflozin to be modelled as having any real probability of being the most
cost-effective treatment. This requires weight changes to be modelled as being retained indefinitely.
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FIGURE 25 Body mass index scenario 3: cost-effectiveness acceptability frontier (CEAF) for flozins and sitagliptin.
TABLE 115 Body mass index scenario 3: probability of cost-effectiveness for flozins and sitagliptin
WTP (£) Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 13 62 3 22
20,000 19 74 3 3
30,000 20 77 3 1
40,000 20 77 3 0
50,000 19 78 3 0
WTP, willingness to pay.
The longer retention of weight changes compared with BMI scenario 2 means that the greater weight loss
with canagliflozin compared with empagliflozin increases the likelihood of canagliflozin being the most
cost-effective and reduces that of empagliflozin.
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Scenario: body mass index 4 – body mass index weight changes
rebound after 1 year
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FIGURE 26 Body mass index scenario 4: cost-effectiveness acceptability frontier (CEAF) across all comparators.
TABLE 116 Body mass index scenario 4: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 4 58 38
20,000 0 0 0 0 4 55 41
30,000 0 0 0 0 4 53 42
40,000 0 0 0 0 5 52 44
50,000 0 0 0 0 5 51 44
WTP, willingness to pay.
As would be expected given the short duration of weight changes, the cost-effectiveness acceptability
frontier (CEAF) is little different from that of the scenario where BMI has no impact upon QoL, though by a
willingness to pay of £50,000 per QALY the curves for gliclazide and repaglinide show a slightly greater
convergence.
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FIGURE 27 Body mass index scenario 4: CEAF for flozins and sitagliptin.
TABLE 117 Body mass index scenario 4: probability of cost-effectiveness for flozins and sitagliptin
WTP Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 11 36 2 51
20,000 24 55 4 17
30,000 30 58 4 7
40,000 33 59 4 4
50,000 34 59 5 3
WTP, willingness to pay.
Comparing weight changes being retained for 1 year to weight changes having no direct QoL impact, the
difference between the probability of canagliflozin being the most cost compared with that of empagliflozin
is slightly greater. This increases as the willingness to pay increases.
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Scenario: body mass index 5 – body mass index weight changes
rebound at treatment change
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FIGURE 28 Body mass index scenario 5: CEAF across all comparators.
TABLE 118 Body mass index scenario 5: probability of cost-effectiveness across all comparators
WTP
(£)
Empagliflozin
(%)
Canagliflozin
(%)
Dapagliflozin
(%)
Sitagliptin
(%)
Pioglitazone
(%)
Gliclazide
(%)
Repaglinide
(%)
0 0 0 0 0 2 66 31
10,000 0 0 0 0 3 53 44
20,000 0 0 0 0 3 49 49
30,000 0 0 0 0 3 46 51
40,000 0 0 0 0 3 43 54
50,000 0 0 0 0 2 41 56
WTP, willingness to pay.
If weight changes are retained until treatment change the probabilities of being the most cost-effective for
gliclazide and for repaglinide are roughly equal at a willingness to pay of £20,000 per QALY, and have
diverged only slightly at a willingness to pay of £30,000 per QALY.
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FIGURE 29 Body mass index scenario 5: CEAF for flozins and sitagliptin.
TABLE 119 Body mass index scenario 5: probability of cost-effectiveness for flozins and sitagliptin
WTP (£) Empagliflozin (%) Canagliflozin (%) Dapagliflozin (%) Sitagliptin (%)
0 0 4 0 96
10,000 13 57 3 27
20,000 21 72 3 4
30,000 23 73 3 1
40,000 22 74 3 0
50,000 23 74 3 0
WTP, willingness to pay.
Sitagliptin and canagliflozin have the highest estimates for their probabilities of being cost-effective, with
canagliflozin having the highest estimate at conventional NICE willingness to pay thresholds. Empagliflozin
has some probability of being cost-effective but it is only around one-third of that of canagliflozin.
Erratum
The AG modelling did not apply a baseline prevalence of 2.7% IHD. Applying the 2.7% baseline IHD
prevalence results in very small differences, as outlined in Tables 120–122.
The pattern of dominance is unchanged compared with the base case of the AG report, with the
exception of the BMI scenario 4, in which repaglinide has changed from being modelled as being
marginally inferior to being marginally superior compared with gliclazide.
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The cost-effectiveness estimates for canagliflozin compared with repaglinide are essentially the same as
those of the AG report base case, though those in six figures show greater absolute changes due to the
very small divisor.
The cost-effectiveness estimates for the flozins compared with sitagliptin are similarly close to those of the
AG report base case, though those for the scenario of weight having no direct QoL impact show some
improvement for empagliflozin and dapagliflozin. There has been a marginal improvement in those for
dapagliflozin, such that the cost-effectiveness ratios that were previously estimated as being slightly above
£30,000 per QALY are now slightly below £30,000 per QALY.
TABLE 122 The 2.7% IHD baseline prevalence: flozin cost-effectiveness estimates vs. sitagliptin
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Canagliflozin 300 mg 12,034 2467 8494 5820 9777 6312
Empagliflozin 25 mg 17,278 4471 13,917 10,294 14,864 10,724
Dapagliflozin 10 mg 37,871 6542 29,341 19,172 29,116 19,062
TABLE 120 The 2.7% IHD baseline prevalence: lifetime total costs and QALYs
Treatment Total costs (£)
Total QALYs
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide 27,600 10.376 9.618 9.618 9.618 9.755 9.723
Repaglinide 27,704 10.374 9.649 9.649 9.649 9.755 9.730
Pioglitazone 27,827 10.367 9.596 9.596 9.596 9.746 9.712
Sitagliptin 100 mg 32,631 10.337 9.641 9.638 9.639 9.723 9.702
Canagliflozin 300 mg 32,933 10.362 9.763 9.674 9.691 9.753 9.750
Empagliflozin 25 mg 33,031 10.360 9.730 9.667 9.678 9.749 9.739
Dapagliflozin 10 mg 33,136 10.350 9.718 9.656 9.665 9.740 9.729
TABLE 121 The 2.7% IHD baseline prevalence: cost-effectiveness estimates
Treatment
ICERs (£)
No BMI BMI 1 BMI 2 BMI 3 BMI 4 BMI 5
Gliclazide – – – – – –
Repaglinide Dom 3388 3388 3388 434,000 16,413
Pioglitazone Dom Dom Dom Dom Dom Dom
Sitagliptin 100 mg Dom Dom Dom Dom Dom Dom
Canagliflozin 300 mg Dom 45,641 207,000 124,000 Dom 259,000
Empagliflozin 25 mg Dom Dom Dom Dom Dom Dom
Dapagliflozin 10 mg Dom Dom Dom Dom Dom Dom
Dom, Dominated – i.e. more costly and less effective than another treatment.
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